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DiOH-CBZ 10,11-dihydro- 10,11-trans-dihydroxy-carbamazepine 
DMSO  dimethyl sulfoxide 
DPT  drug provovation testing 
DRESS  drug reaction with eosinophilia and systemic symptoms 
EDTA  ethylenediaminetetraacetic acid 
ELISpot enzyme-linked immunosorbent spot assay 
ESI  electrospray ionisation 
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FDR  false discovery rate 
FOCE  first-order conditional estimation 
GAG  glycosaminoglycan 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GSEA  gene set enrichment analysis 
GSH  glutathione 
GSTP  glutathione S-transferase pi 
HBSS  Hank’s balanced salt solution 
HHV  human herpes virus 
His-GSTP hexahistidine-tagged human glutathione S-transferase pi 
HIV  human immunodeficiency virus 
HLM  human liver microsomes 
HPLC  high performance liquid chromatography 
HSA  human serum albumin 
HSS  hypersensitivity syndrome 
Ig  immunoglobulin 
IL  interleukin 
IFN-γ  interferon gamma 
IPA  Ingenuity pathway analysis 
IS  internal standard  
LLOQ  lower limit of quantitation 
LTT  lymphocyte transformation test 
mEH  microsomal epoxide hydrolase 
MHC  major histocompatibility complex 
miRNA  micro ribonucleic acid 
MPE  maculopapular exanthema 
MRM  multiple reaction monitoring 
mRNA  messenger ribonucleic acid 
MS/MS tandem mass spectrometry 
NAPQI  N-acetyl-p-benzoquinone imine 
NES  normalised enrichment score 
NONMEM non-linear mixed effects modelling 
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NSAIDs non-steroidal anti-inflammatory drugs 
OFV  objective function value 
PARP9  poly (ADP-ribose) polymerase 
PBMCs  peripheral blood mononuclear cells 
PBS  phosphate buffered saline 
PBPK  physiologically based pharmacokinetic 
PCR  polymerase chain reaction 
PE  phycoerythrin 
PG  prostaglandin 
P-gp  P-glycoprotein 
PHA  phytohaemoagglutinin 
PI  direct pharmacological interaction of drugs with immune receptors 
PICME I Pharmacokinetic Investigation into the formation of CBZ Metabolites 
and CBZ-protein conjugates in healthy volunteers 
PICME II Pharmacokinetic Investigation into the formation of CBZ Metabolites 
and CBZ-protein conjugates in Epilepsy patients 
PK pharmacokinetics 
PPD  p-phenylenediamine 
PXR  pregnane X receptor 
QC  quality control 
Rt  retention time 
RIN  RNA integrity number 
SD  standard deviation 
SNP  single nucleotide polymorphism 
SI  stimulation index 
SJS  Stevens-Johnson syndrome 
SMX-NO nitroso-sulfamethoxazole 
TCC  T cell clone 
TCR  T cell receptor 
TDM  therapeutic drug monitoring 
TEN  toxic epidermal necrolysis 
TFA  trifluoroacetic acid 
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TT  tetanus toxoid 
UGT  uridine diphosphate glucuronosyltransferase 
Vd  volume of distribution 
VPCs  visual predictive checks 
VZV  varicella zoster virus 
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Abstract 
Carbamazepine (CBZ) is an effective antiepileptic drug but has been associated with 
hypersensitivity reactions in up to 10% of patients. These reactions range from mild 
maculopapular exanthema to life-threatening conditions such as Stevens-Johnson 
syndrome and toxic epidermal necrolysis. The identification of CBZ-specific T cells 
and strong associations with specific human leukocyte antigen alleles provide 
evidence for immunological involvement. CBZ is extensively metabolised and forms 
several reactive metabolites. The aim of this thesis was to investigate the complex 
relationships between CBZ, its metabolism, the immune system, and genomics.  
Direct and microsomal incubations demonstrated that carbamazepine 10,11-
epoxide (CBZE), the major metabolite of CBZ, formed a protein conjugate with 
human serum albumin (HSA) at His146. The same CBZE-modified HSA was also 
detected in patients tolerant of CBZ therapy. A second His146 CBZ-modified HSA 
adduct was identified in microsomal incubations, formed as a product of arene 
oxide providing the first chemical evidence that reactive metabolites of CBZ can 
modify soluble proteins.  
Healthy volunteers (n=8) and patients prescribed CBZ therapy (n=72) were recruited 
to investigate the influence of genetic variation on CBZ metabolism. Patient 
demographics and a mixture of rich and sparse pharmacokinetic (PK) samples were 
collected. Plasma levels of CBZ and four major metabolites were measured using a 
novel high performance liquid chromatography tandem mass spectrometric assay. 
There was significant variation in observed plasma concentrations of CBZ (14-fold) 
and its metabolites (approximately 30-fold). 
A population PK model was developed with nonlinear mixed effects modelling using 
the PK and clinical data collected from patients. Completion of autoinduction, total 
daily dosage and concomitant therapy with phenytoin were significant covariates 
that influenced the CBZ PK. Analysis of variance demonstrated that two single 
nucleotide polymorphisms (SNPs) in the gene ABCB1 and a single SNP in EPHX1 
were significantly associated with altered plasma concentrations of CBZE. 
T cell clones (TCCs) were generated to CBZ and CBZE from two patients with a 
history of hypersensitivity to CBZ. All TCCs were CD4+ and secreted the cytokines 
IFN-γ, IL-13, granzyme B and perforin. TCC activation was MHC class II restricted and 
all TCCs were stimulated when CBZ was freshly added into the incubation mixture 
indicative of direct activation. A single TCC was activated when antigen presenting 
cells (APCs) were pulsed with CBZ indicative of a hapten mechanism. 
Transcriptomic analysis of peripheral blood mononuclear cells (PBMCs) from 
patients with a known history of CBZ hypersensitivity identified 9 CBZ/CBZE-specific 
mRNA and 39 CBZ/CBZE- miRNA transcripts. Pathway analysis mRNA and miRNA 
changes showed that antiviral response, psoriasis and inflammation were the most 
significant functions associated with exposure of cells from cases to CBZ and CBZE. 
In conclusion, these studies show that CBZ is transformed to stable and reactive 
metabolites, and these metabolites together with the parent drug, lead in 
susceptible individuals to an orchestrated response which involves transcriptional 
and immunological activation.  
 25 
 
 
Chapter 1  
General Introduction  
 26 
 
1.1 Adverse Drug Reactions 
 
1.1.1 Definition 
Adverse drug reactions (ADR) are defined as “an appreciably harmful or unpleasant 
reaction resulting from an intervention related to the use of a medicinal product; 
adverse effects usually predict hazard from future administration and warrant 
prevention, or specific treatment, or alteration of the dosage regimen, or 
withdrawal of the product” (Aronson and Ferner 2005). 
 
1.1.2 Epidemiology 
ADRs are common and account for 6.5% of all hospital admissions and occur in 15% 
of inpatients increasing healthcare and societal costs. In the US, ADRs are between 
the fourth and sixth most common cause of mortality and responsible for > 100,000 
deaths with similar estimates for the UK (Lazarou et al. 1998; Pirmohamed et al. 
2004). In the UK, ADRs extend hospital admission by approximately eight days and 
account for 4% of the total capacity of hospital beds costing the NHS £466m each 
year (Pirmohamed et al. 2004). ADRs are also a major problem in drug development 
and a report by the FDA revealed that 28 drugs had been withdrawn from the US 
market between 1978 and 2005 because of safety issues and include high profile 
drugs such as cyclooxygenase (COX) II inhibitors (FDA Centre for Drug Evaluation 
and Research 2005). This has huge implications for the pharmaceutical industry. 
 
1.1.3 Classification 
ADRs were originally classified by Rawlins and Thompson into type A and type B 
(Rawlins 1981). Type A (augmented) reactions are predictable, typically dose 
dependent, and based on an exaggerated response to the known primary and/or 
secondary pharmacological action of the drug. This type of reaction is illustrated by 
hyperkalaemia with potassium sparing diuretics (Acker et al. 1998) or bleeding with 
warfarin therapy (Witt et al. 2016). In contrast type B (bizarre) reactions are 
unpredictable, totally aberrant effects that are unexpected from the known 
pharmacology of the drug when given at normal therapeutic doses to a patient 
whose body processes the drug in the normal way. An example of a type B reaction 
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would include Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) 
in response to antiepileptic drugs (AEDs) (Ordonez et al. 2015). However, as 
knowledge of the mechanisms underlying ADRs increase it is hoped that type B 
reactions will become predictable in future. The original classification of ADRs was 
later expanded to include types C, D, E and F ADRs (Table 1.1) (Edwards and 
Aronson 2000).  
 
Table 1.1 Classification of adverse drug reactions [adapted from Edwards and 
Aronson (2000)] 
Type of Reaction Mechanism Example 
Type A 
(augmented) 
Predictable from known 
pharmacology of the 
drug; dose-dependent 
Bleeding with warfarin therapy 
Type B 
(bizarre or idiosyncratic) 
Not predictable from 
pharmacological action 
of the drug; dose-
independent 
Stevens-Johnson syndrome with 
antiepileptic therapy 
Type C 
(chemical or chronic) 
Related to the chemical 
structure or a 
metabolite of the drug 
Osteonecrosis of the jaw with 
bisphosphonates 
Type D 
(delayed) 
Develops years after 
drug therapy 
Leucopaenia six weeks after a dose 
of lomustine 
Type E 
(end of treatment) 
Appear after drug 
withdrawal especially if 
stopped abruptly 
Insomnia, anxiety and perceptual 
disturbances following withdrawal 
of benzodiazepines 
Type F  
(failure) 
Often caused by drug 
interactions 
Failure of contraceptive during 
antibiotic therapy 
 
More recently an alternative classification system for ADRs was developed based on 
dose relatedness, timing and patient susceptibility (DoTS) (Aronson and Ferner 
2003). The new system incorporates not only the properties of the drug but 
includes characteristics of the reaction and individual patient susceptibility factors 
(Table 1.2). Neither classification system is perfect but both serve as important 
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guidance for pharmacovigilance in clinical practice and drug development whilst 
providing insights into the mechanisms of ADRs. 
 
Table 1.2 DoTS classification criteria for adverse drug reactions 
 Variable Classification 
Do Dose relatedness Supratherapeutic 
Standard therapeutic 
Subtherapeutic 
T Timing Time independent 
Time dependent 
S Susceptibility Age 
Gender 
Pathology 
Physiology 
Environmental 
 
 
1.2 Drug Hypersensitivity Reactions  
 
1.2.1 Epidemiology and Classification 
Drug hypersensitivity reactions (DHRs) are idiosyncratic ADRs that result from 
inappropriate activation of the immune system by the offending drug or metabolite 
leading to heterogeneous clinical manifestations that affect multiple organ systems 
(Wheatley et al. 2015). DHRs are estimated to account for approximately 20% of all 
ADRs (Dodiuk-Gad et al. 2014). However, epidemiological studies in DHRs are 
complex because of the variable clinical presentation, absence of definitive 
diagnostic tests and lack of consensus on diagnostic criteria (Wheatley et al. 2015).  
 
Classification of DHRs is challenging because for many drugs and clinical 
presentations, the underlying pathophysiological mechanisms are poorly 
understood. Clinically, DHRs are classified as immediate or delayed (Demoly et al. 
2014). Immediate reactions are those that occur within 1 to 6 hours after the last 
drug administration and typically present with symptoms that can include uritcaria, 
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angioedema, bronchospasm and anaphylactic shock. Delayed DHRs commonly 
occur after multiple days of treatment and can present as maculopapular 
exanthema (MPE), hypersensitivity syndrome (HSS) and SJS amongst others (Bircher 
and Scherer Hofmeier 2012). Delayed DHRs are typically mediated by drug-specific T 
cells (Pichler 2003). Mechanistically, DHRs were originally  classified into four main 
categories according to criteria originally devised by Gell and Coombs (Gell 1963) 
and subsequently expanded by Pichler (Pichler 2003) (Table 1.3). The most common 
DHRs are immunoglobulin (Ig) E- and T-cell mediated reactions (Demoly et al. 2014). 
In immediate DHRs, also known as type I reactions, IgE is produced by antigen 
specific B lymphocytes in response to drug-hapten complexes. IgE activates mast 
cells and basophils resulting in the release of preformed mediators (e.g. histamine 
and tryptase) and production of new mediators (e.g. leukotrienes and kinins). The 
preformed mediators lead to immediate symptoms whilst the inflammatory 
component occurs several hours later when the new mediators have been 
synthesised (Blanca et al. 2009). Some drugs such as beta-lactam antibiotics can 
cause both immediate and delayed hypersensitivity whilst AEDs typically cause 
mainly T-cell mediated reactions (Blanca et al. 2009; Ye et al. 2014). 
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Table 1.3 Mechanistic classification of drug hypersensitivity reactions [adapted 
from Demoly et al. (2014)] 
Type Immune 
Response 
Effector 
Mechanism 
Clinical 
Presentation 
Reaction 
Time 
Examples of 
Implicated Drugs 
I IgE Mast cell and 
basophil 
degranulation 
Anaphylaxis, 
angioedema, 
urticaria 
Within 1 - 
6 h  
Penicillins, 
cephalosporins  
II IgG and 
complement 
IgG and 
complement 
dependent 
cytotoxicity 
Cytopaenia 5 - 15 
days  
Penicillin, 
quinidine 
III IgM or IgG 
and 
complement 
or FcR 
Immune 
complex 
deposition 
Serum 
sickness, 
urticarial 
vasculitis 
7 - 21 
days  
Penicillin, 
tetracyclines 
IVa Th1: IFN-γ Monocytic 
inflammation 
Eczema 1 -21 
days  
p-
phenylenediamine 
IVb Th2: IL-4 and 
IL-5 
Eosinophilic 
inflammation 
MPE, HSS 1 – 42 
days  
Anticonvulsants 
IVc Cytotoxic T 
cells (perforin, 
granzyme B, 
Fas ligand) 
Keratinocyte 
death 
mediated by 
CD4 and CD8 
MPE, SJS/TEN 1 – 28 
days  
Anticonvulsants 
IVd T cells (IL-
8/CXCL8) 
Neutrophilic 
inflammation 
AGEP Within 7 
days 
Antibiotics, 
carbamazepine 
AGEP: acute generalised exanthematous pustulosis, FcR: Fc receptor, HSS: 
hypersensitivity syndrome, Ig: immunoglobulin, IL: interleukin, MPE: maculopapular 
exanthema, SJS: Stevens-Johnson syndrome, TEN: toxic epidermal necrolysis  
 
  
 31 
 
1.2.2 Mechanisms of T Cell Activation by Drugs 
The ability to recognise and respond to antigens is the fundamental basis of the 
immune system. An antigen is any molecule that can bind with high affinity to 
immunological receptors (Uetrecht and Naisbitt 2013). Antigens (bacterium, virus, 
drug-modified proteins) activate the innate immune system by stimulating pattern 
recognition receptors such as toll-like receptors and dendritic cells (DCs). The 
activated DCs act as antigen presenting cells (APCs) by taking up and processing the 
antigen into peptides. In lymphoid organs, such as lymph nodes, the DCs present 
these peptides on the cell surface in association with major histocompatibility 
complex (MHC) to T cell receptors (TCRs) on naive T cells. The DCs also secrete 
cytokines and express costimulatory receptors that contribute to polarisation of the 
immune response (e.g. Th1, Th2) (Uetrecht and Naisbitt 2013).  
 
The interaction between the MHC, peptide and TCR determines the nature of the T 
cell response. In humans, the MHC encodes for human leukocyte antigens (HLA). 
Class I MHC consists of HLA-A, -B and -C whilst MHC class II is divided into HLA-DR, 
DQ and DP (The M. H. C. sequencing consortium 1999). MHC class I molecules are 
expressed by all nucleated cells and present peptides derived from intracellular 
compartments to CD8+ T cells (Neefjes et al. 2011). In contrast MHC class II 
expression is restricted to professional APCs but can also be induced in other cell 
types, including keratinocytes, by inflammatory processes such as psoriasis 
(Schonefuss et al. 2010). MHC class II molecules present peptides derived from 
extracellular compartments (Neefjes et al. 2011). Before entering the MHC class II 
processing pathway external proteins are internalised by phagocytosis and fused 
with lysosomes that contain proteases (Uetrecht and Naisbitt 2013). Type IV DHRs 
are characterised by activation of T cells by drugs or reactive metabolites (Pichler 
2003). The hapten hypothesis, direct pharmacological interaction of drugs with 
immune receptors (PI) concept and the altered peptide repertoire model have been 
proposed as potential mechanisms for activation of T cells by drugs.  
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1.2.2.1 Hapten/Prohapten Hypothesis 
The hapten hypothesis was originally outlined in the 1930s (Landsteiner and Jacobs 
1935) and states that chemically reactive small molecules (including drugs and 
reactive metabolites) can act as a hapten and bind irreversibly to self proteins 
(Figure 1.1). The modified protein is recognised as an antigen and processed by 
APCs leading to generation of a pool of chemically modified peptides. These 
peptides are presented in association with MHC to TCRs which results in activation 
of the immune system (Park et al. 2001). Prohaptens are assumed to be chemically 
inactive and require bioactivation to chemically reactive compounds by metabolism 
(Knowles et al. 2000). Using mass spectrometry, immunogenic β-lactam-albumin 
and piperacillin-albumin conjugates (Whitaker et al. 2011) were characterised from 
patient plasma and found to activate drug-specific T cell responses from patients 
with known allergies (El-Ghaiesh et al. 2012; Jenkins et al. 2013).  
 
 
Figure 1.1 Prohapten/hapten model of T cell activation. The hapten hypothesis 
postulates that a drug or its metabolite (yellow star) is able to bind covalently with 
self-proteins (blue square). The hapten-protein complex is recognised as foreign by 
APCs which take up and process the hapten-protein complex producing a pool of 
drug modified peptides (yellow triangle and blue triangle).  The drug modified 
peptide is presented in association with MHC and is recognised by the TCR as a 
neoantigen and activates the immune response.  
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1.2.2.2 Pharmacological Interaction of Drugs with Immune Receptors Concept 
According to the PI model inert small molecules, such as drugs, are able to bind 
directly (non-covalently) to either the MHC or TCR (Figure 1.2). Provided that there 
is interaction between the TCR and MHC-peptide complex then the direct binding of 
drug to immune receptors is able to activate T cells (Pichler et al. 2006). Studies 
using lymphocytes from patients with CBZ and sulfamethoxazole hypersensitivity 
have revealed that these two drugs are able to directly activate lymphocytes 
without the need for processing and presentation by APC providing evidence for PI 
mechanism of DHR (Naisbitt et al. 2003; Castrejon et al. 2010).    
 
1.2.2.3 Altered Peptide Repertoire Model 
The altered peptide repertoire model states that low molecular weight drugs are 
able to bind noncovalently to regions within the antigen-binding cleft of HLA class I 
molecules. Binding of the drug changes the shape of the antigen-binding cleft 
resulting in alteration of the repertoire of peptides that are presented, which may 
now include self-peptides (Ostrov et al. 2012; Illing et al. 2012). A T cell response 
will be initiated if the patient is not tolerant to the new repertoire of peptides that 
are presented (Figure 1.2). Evidence for the altered peptide repertoire model has 
been derived from studies with abacavir (Norcross et al. 2012; Ostrov et al. 2012; 
Illing et al. 2012). Abacavir, an antiretroviral drug, is known to cause hypersensitivity 
reactions in patients positive for HLA-B*57:01 (Hetherington et al. 2002). Abacavir 
binds to a specific pocket of the HLA-B*57:01 molecule which alters its ability to 
bind large aromatic residues thereby leading to altered preference for peptides that 
bind to the HLA molecule. T cells from abacavir hypersensitive patients were able to 
recognise the altered peptide-HLA complexes (Norcross et al. 2012; Ostrov et al. 
2012; Illing et al. 2012). 
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Figure 1.2 The PI and altered self-peptide repertoire models of T cell activation by 
small molecules. A. In the PI model the drug (yellow star) is able to bind 
noncovalently to either the TCR or MHC leading to activation of the immune 
system. B. In the altered self-peptide repertoire model the drug (yellow star) binds 
to the antigen binding cleft of the MHC. This results in presentation of novel 
peptides (green triangle) to the TCR and activation of the immune system. 
 
1.2.3 Clinical Presentation of Type IV Drug Hypersensitivity Reactions 
Type IV or delayed DHRs can affect many organ systems including the liver, kidneys, 
blood vessels and skin (Demoly et al. 2014). The focus of this thesis is cutaneous 
manifestations of delayed DHRs. Typically the skin is the most commonly affected 
organ because of its large surface area, extensive blood supply and fully competent 
immune system which usually helps to protect the body from harmful external 
pathogens (Bangert et al. 2011). The severity of cutaneous manifestations of type IV 
DHRs can range from mild self-limiting MPE to severe and life threatening 
conditions such as HSS, SJS, TEN and acute generalised exanthematous pustulosis 
(AGEP) (Pirmohamed et al. 2011). 
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1.2.3.1 Maculopapular Exanthema 
Maculopapular rashes are the most common type of drug-induced skin rash and 
account for more than 90% of all cutaneous ADRs (Hunziker et al. 1997). The time to 
onset is typically 1-2 weeks after starting treatment and in the absence of other 
clinical symptoms, these drug rashes are not serious, and can resolve even if the 
drug is continued (Valeyrie-Allanore et al. 2007).  However, it is important to 
remember that mild rashes such as MPE may progress to more severe conditions 
such as SJS or TEN and at present it is not possible to predict progression. Current 
clinical practice is to recommend withdrawal of drug that causes rash as this leads 
to better outcomes (Garcia-Doval et al. 2000). 
 
1.2.3.2 Hypersensitivity Syndrome 
HSS is a severe ADR with considerable morbidity and mortality that affects multiple 
organs including the kidney, liver, lung, gastrointestinal tract, central nervous and 
lymphoid systems. Because of its variable clinical presentation it has been hard to 
classify and phenotype patients. HSS has also been called drug-induced 
hypersensitivity syndrome (DIHS), drug reaction with eosinophilia and systemic 
symptoms (DRESS) and drug-induced delayed multiorgan hypersensitivity syndrome 
(Pirmohamed et al. 2011). Patients typically present within 3 months of starting 
treatment and skin rash is the most commonly reported feature along with fever, 
hypereosinophilia, liver involvement and lymphadenopathy (Cacoub et al. 2011). 
Anticonvulsants are the most common trigger for HSS accounting for about one 
third of cases followed by allopurinol and antibiotics (Kardaun et al. 2013). Several 
viral infections including Human Immunodeficiency Virus (HIV), Human Herpes Virus 
(HHV), Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) have been identified as 
risk factors for development of HSS (Dodiuk-Gad et al. 2014). The incidence of HSS 
secondary to phenytoin or CBZ has been estimated to be between 1.0-4.5 per 
10,000 prescriptions (Tennis and Stern 1997). The overall incidence of long term 
sequelae was 11.5% in a Taiwanese cohort at least 1 year after resolution of 
symptoms. The most common complications were autoimmune disease (e.g. 
Graves’s disease, type 1 diabetes) amongst younger patients and end organ failure 
(e.g. renal failure) in older patients (Chen et al. 2013). The mortality associated with 
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HSS has been estimated to range between 1.7% and 5.0%, although death rates of 
up to 10% have been reported when anticonvulsants are the culprit drugs (Dodiuk-
Gad et al. 2014). 
 
1.2.3.3 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis 
SJS and TEN are considered to be the same condition differentiated by the degree 
of skin detachment. Skin detachment of 1-10% is diagnosed as SJS whilst 
detachment greater than 30% is classified as TEN. Skin detachment between 10-
30% is classified as overlap syndrome. Other clinical signs and symptoms include 
severe, often haemorrhagic, erosions of mucous membranes, severe pain and 
tenderness in the skin, target lesions to trunk and face and systemic manifestations 
(fever, deranged liver function tests, and lymphopaenia) (Bastuji-Garin et al. 1993). 
SJS and TEN are rare ADRs with an annual incidence of 1.2-6.0 and 0.4-1.2 per 
million individuals, respectively (Forman et al. 2002; Paquet and Pierard 2010). Drug 
exposure is the most common cause of SJS/TEN with antimicrobial sulphonamides, 
anticonvulsants, allopurinol and non-steroidal anti-inflammatory drugs (NSAIDs) 
most often implicated (Dodiuk-Gad et al. 2014). Most, but not all, cases of SJS/TEN 
present within 8 weeks of starting treatment with the culprit drug (Revuz and 
Roujeau 1996). The mortality rate of SJS/TEN is significant and has been reported to 
be 23% at 6 weeks and 34% at 1 year for TEN (Sekula et al. 2013; Lalosevic et al. 
2015) and 5% for SJS (Hsu et al. 2016). Up to 80% of patients that survive acute TEN 
will suffer with long term complications which include scarring, visual loss, chronic 
kidney disease, intestinal strictures and bronchiectasis (Schwartz et al. 2013; Quirke 
et al. 2015). 
 
1.2.3.4 Acute Generalised Exanthematous Pustulosis 
The incidence of AGEP is estimated to be 1-5 cases/million/year (Sidoroff et al. 
2001). Typical features include an acute widespread oedematous erythema 
followed by a sterile pustular eruption. The pustules occur initially in the neck, groin 
and axillae and become more widespread as the reaction progresses. Other 
features include fever and neutrophilia with mild eosinophilia (Pirmohamed et al. 
2011). Clinically AGEP resembles pustular psoriasis and there have been reported 
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links between the two conditions (Roujeau et al. 1991). Greater than 90% of cases 
of AGEP are triggered by drugs and the most commonly associated drugs are 
antibiotics, NSAIDs and anticonvulsants (Sidoroff et al. 2001). Onset of AGEP after 
drug administration is faster than HSS and SJS/TEN; typically occurring within a few 
days (Pirmohamed et al. 2011). Outcome in these patients is good with resolution 
after 15 days and mortality less than 5% after drug withdrawal (Hotz et al. 2013).  
 
1.2.4 Diagnosis of Delayed Drug Hypersensitivity Reactions 
In cases of suspected DHR, the clinician needs to make an assessment of causality 
based upon the type and timing of onset of the reaction and its relationship with 
the suspected culprit drug. The aim is to identify the causative agent so that it can 
be avoided in future (Schrijvers et al. 2015). However, clinical history can be 
unreliable as patients usually take multiple medications simultaneously and there is 
significant heterogeneity in clinical presentation with many non-specific features 
(Demoly et al. 2014). This can lead to inappropriate exclusion of multiple drug 
classes and switch towards suboptimal therapies. Although several in vivo and in 
vitro diagnostic tests are available for the diagnosis of delayed DHRs, none are ideal 
in the clinical environment.  
 
1.2.4.1 Skin Testing 
Skin testing involves application of the suspected antigen onto the skin by a patch 
or intradermal injection and is particularly effective for detection of IgE-mediated 
hypersensitivity reactions (Demoly et al. 2014). Patch and intradermal testing have 
been used for the diagnosis of delayed hypersensitivity reactions but for most 
drugs, except beta-lactam antibiotics, standardised and validated test 
concentrations for use in testing protocols are not available and its use is limited 
(Brockow et al. 2013). 
 
1.2.4.2 Drug Provocation Testing 
Drug provocation testing (DPT) involves re-administration of the suspected drug 
antigen to the patient in a controlled environment at graded doses. It is usually 
recommended after full evaluation of hypersensitivity in order to demonstrate 
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tolerance to a particular drug rather than for confirmation of a DHR (Joint Task 
Force on Practice Parameters; American Academy of Allergy 2010). DPT is limited 
because it is contraindicated in patients who have experienced severe cutaneous or 
systemic reactions (e.g. HSS, SJS/TEN, AGEP and vasculitis) and requires expertly 
trained staff and resuscitation equipment (Demoly et al. 2014).  
 
1.2.4.3 Lymphocyte Transformation Test 
The lymphocyte transformation test (LTT) is an in vitro lymphocyte proliferation 
assay that is used for the detection of T cells that are sensitised to specific drugs or 
metabolites (Nyfeler and Pichler 1997). It is one of the most widely used tests for 
the diagnosis of T cell mediated drug hypersensitivity (Porebski et al. 2011). The test 
has also been used for diagnosis of immediate DHRs (Luque et al. 2001), drug-
induced pancreatitis (Straumann et al. 1998) and hepatitis (Maria and Victorino 
1997). In the LTT, peripheral blood mononuclear cells (PBMCs) are obtained from a 
drug sensitised patient and cultured in the presence of multiple concentrations of 
the suspected drug, stable metabolite or drug-protein conjugate (if available). 
Proliferation is quantified by measuring the uptake of tritium-labelled thymidine 
(3H-thymidine) into the DNA of activated lymphocytes and calculation of the 
stimulation index (SI).  The SI is the ratio of cell proliferation [counts per minute 
(cpm)] with antigen divided by the background proliferation (cpm) in absence of 
antigen. A SI ≥ 2 indicates a drug-specific T cell response (Naisbitt et al. 2014). In a 
retrospective analysis of 923 cases of patients with probable/definite drug 
hypersensitivity, the LTT demonstrated a sensitivity of 78% and specificity of 85% 
(Nyfeler and Pichler 1997).  However, the LTT does have some limitations. 
Technically it is difficult to perform because it requires radioactivity and sterile 
culture for 6 days. The LTT is negative in many patients with SJS/TEN as these 
reactions are CD8+ T cell mediated and CD8+ T cells do not proliferate readily in the 
conditions of the LTT (Porebski et al. 2013). Most importantly, a negative LTT result 
cannot exclude drug hypersensitivity as it is impossible to include all possible 
antigens in the test (e.g. unstable reactive metabolites), and the assay is typically 
performed using the parent drug alone (Naisbitt et al. 2014). 
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1.2.4.4 Enzyme-Linked Immunosorbent Spot Assay 
Enzyme-linked immunosorbent spot (ELISpot) is an antibody based assay used for 
the detection of cytokine secreting cells (e.g. TNF-α, IL-5 and IL-13) or release of 
cytotoxic proteases (e.g. granulysin, perforin and Fas ligand) from T cells that have 
been isolated from patients with drug hypersensitivity (Naisbitt et al. 2014). Briefly, 
PBMCs are isolated from patients and cultured in the presence of the suspected 
drug. Cells that secrete the cytokine of interest are displayed as spots with the 
number of spots corresponding to the number of cytokine secreting T cells. Data 
from cells incubated with drug are then compared with control T cells that have not 
been incubated with the drug (Earnshaw et al. 2014). Elispot assays have several 
advantages over the LTT including the lack of requirement for radioactive 
substances and shorter incubation period. The incubation period for ELISpot assays 
is shorter than the LTT, between 48-72 h, as production of cytokines by T cells 
occurs as soon as they are activated (Porebski et al. 2011). Measurement of 
cytokine activity provides basic insight into pathophysiological mechanisms of 
delayed DHRs and there is data to suggest that measuring the level of four cytokines 
(IL-2, IL-5, IL-13 and IFN-γ) may improve sensitivity and specificity for in vitro 
diagnosis of delayed DHRs (Lochmatter et al. 2009).    
 
1.2.4.5 Flow Cytometry 
After stimulation, T cells express a number of surface molecules including CD25, 
CD69 and CD71 (Wieland and Shipkova 2015). Flow cytometry has been utilised in 
DHRs to characterise T cell subsets by surface receptors and to measure specific 
cytokine production (e.g. IL-5, IL-10 and IFN-γ) (Martin et al. 2010).  Furthermore, 
specific proliferation of drug specific T cells can be investigated using flow 
cytometry and fluorescent dyes such as carboxyfluorescin siccinimidyl ester (CFSE) 
to stain cell samples that contain drug specific T cells. The intensity of the CFSE is 
reduced by half following each cell division identifying the dividing population of 
antigen-specific T cells for further evaluation (Beeler et al. 2006).  
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1.2.4.6 T cell Cloning 
T cell cloning experiments provide a valuable alternative for the detection of drug-
specific T cells when other assays yield negative results. T cell clones (TCCs) are 
generated by serial dilution followed by repetitive mitogen stimulation. Several 
hundred single cell populations are generated and antigen-specificity is measured 
by culture with EBV-transformed B cells and antigen for 48 h. T cell proliferation is 
determined by incorporation of 3H-thymidine. Clones that are antigen-specific (SI ≥ 
2) are expanded and can be characterised with respect to phenotype, specificity 
and functionality by the techniques described earlier (Naisbitt et al. 2014). T cell 
cloning is a time-consuming process, taking weeks to months, so is unsuitable for 
acute diagnosis of delayed DHRs. 
 
1.3 Carbamazepine 
 
1.3.1 Indication 
CBZ is a tricyclic anticonvulsant that is primarily used for the treatment of partial 
and secondary generalised seizures in epilepsy (Marson et al. 2007). It was originally 
licensed for epilepsy in the UK in 1965 and remains one of the most frequently 
prescribed anticonvulsants (Moran et al. 2004). The indications for CBZ have 
widened and it is now also prescribed for the treatment of neuropathic pain and 
psychiatric disorders (Bialer 2012). 
 
1.3.2 Mechanism of Action 
The mechanism of action of CBZ is incompletely understood but its main target is 
believed to be voltage-dependent sodium channels in the neuronal membrane 
(Ambrosio et al. 2002).  CBZ is able to block high frequency repetitive spike firing, 
which occurs during the spread of seizure activity, leading to stabilisation of the 
neuronal membrane. The effect of CBZ on sodium channels is both voltage- and 
use- dependent so that only hyperactive neurons are affected. At hyperpolarized 
membrane potentials CBZ blocks sodium channels only weakly but when the neuron 
is depolarized, there is marked increase in inhibition. The inhibitory potency also 
accumulates with repetitive or prolonged activation. The effect on action potentials 
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translates into reduced neurotransmitter output at synapses, with glutamate 
release more strongly inhibited than that of other neurotransmitters such as GABA 
(Rogawski and Loscher 2004).   
 
1.3.3 Pharmacokinetics 
CBZ is typically used as an oral formulation and is absorbed slowly from the GI tract 
with a bioavailability of approximately 75% (Tolbert et al. 2015). Peak plasma 
concentrations of CBZ are typically reached between 4 and 8 h after oral 
administration and plateau for 10-30 h before declining (Rawlins et al. 1975). 
Plasma protein binding of CBZ reaches 70% to 80%. Carbamazepine 10,11-epoxide 
(CBZE) is the major metabolite of CBZ metabolism. It retains anticonvulsant activity 
and has plasma protein binding between 50% and 60%. CBZ and CBZE are both 
distributed rapidly and readily penetrate the blood brain barrier. Cerebrospinal fluid 
concentrations of CBZ have been reported to be between 17% to 31% of total 
plasma concentrations and CBZE levels are approximately 45% to 55% of 
corresponding plasma levels (Spina 2002). 
 
CBZ is extensively metabolised in the body, with less than 2% of the oral dose 
eliminated unchanged in the urine (Faigle 1975). Metabolism occurs mainly in the 
liver and involves oxidation, hydroxylation and conjugation, catalysed by a number 
of enzymes including cytochrome P450 enzymes (CYP), microsomal epoxide 
hydrolase (mEH) and glucuronyltransferases. More than 30 different metabolites of 
CBZ have been reported (Lertratanangkoon and Horning 1982). Three major 
pathways account for 80% to 90% of total metabolism: the epoxide-diol pathway, 
aromatic hydroxylation and conjugation reactions (Figure 1.3) (Spina 2002). The 
epoxide-diol pathway is quantitatively the most important biotransformation 
pathway where CBZ is oxidised, primarily by CYP3A4 and CYP2B6, to the chemically 
stable CBZE (Kerr et al. 1994).  CBZE is then extensively hydrolysed to the inactive 
metabolite trans-10,11-dihydroxy-10,11-dihydrocarbamazepine (DiOH-CBZ) by mEH 
(Kitteringham et al. 1996).  
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The second CBZ metabolism pathway involves hydroxylation at different positions 
of the six-membered aromatic rings leading to the formation of several phenolic 
products: 1-, 2-, 3- and 4-hydroxycarbazmepine. These reactions are catalysed by 
various CYP enzymes including CYP3A4, CYP2E1, CYP2B6 and CYP1A2 (Pearce et al. 
2002). There is evidence that reactive arene oxides are formed as intermediates 
during hydroxylation of the aromatic ring (Madden et al. 1996; Bu et al. 2007). 
These phenolic compounds are then conjugated with glucuronic acid by uridine 
diphosphate glucuronosyltransferase (UGT) 2B7 before excretion in urine (Staines 
et al. 2004). Direct conjugation of CBZ with glucuronic acid represents the third 
most important pathway in CBZ biotransformation. Glucuronidation can also occur 
as a secondary metabolic process in almost all CBZ metabolites that contain a free 
hydroxyl group to form their O-glucuronides (Spina 2002). Other reactive 
metabolites formed by CBZ metabolism have been reported and include CBZ-
iminoquinone (Pearce et al. 2005) and 9-acridine carboxaldehyde (Furst et al. 1995) 
(Figure 1.3). 
 
During long term therapy CBZ is able to induce its own metabolism (autoinduction) 
(Kudriakova et al. 1992) and concomitant therapy with other enzyme inducing 
anticonvulsants (e.g. phenytoin and phenobarbital) is able to further induce 
metabolism (heteroinduction) (Eichelbaum et al. 1979). Autoinduction occurs within 
24 h of starting therapy or change in dose and the process is usually complete after 
one week (Kudriakova et al. 1992; Bernus et al. 1994). The autoinduction process 
primarily involves the epoxide-diol pathway with both the epoxidation and 
subsequent epoxide hydrolysis affected although the latter to a lesser extent 
(Bernus et al. 1996). The exact cellular mechanism of autoinduction is not well 
understood but may involve nuclear hormone receptors such as the pregnane X 
receptor (PXR) and hepatocyte nuclear factor 4α (Saruwatari et al. 2014).  CBZ has 
been shown to be able to induce a broad spectrum of genes in the human liver that 
are involved with drug metabolism and drug transport (Oscarson et al. 2006). 
Reversal of autoinduction is rapid taking between 3-4 days if CBZ therapy is 
withdrawn meaning patients may need a reduced dose when restarting therapy 
after discontinuation (e.g. pre-operative EEG) (Schaffler et al. 1994). 
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Figure 1.3 Proposed major pathways of bioactivation of CBZ in humans and the 
enzymes catalysing the major metabolic reactions. (CYP: cytochrome P450, UGT: 
uridine diphosphate glucuronosyltransferase) 
 
Approximately 28% of an oral 14C-labeled CBZ dose is excreted in the faeces (Faigle 
1975) and 1% eliminated in the bile within 72 h (Terhaag et al. 1978). The major 
elimination pathway for CBZ is in the urine mainly as metabolites. 20% to 60% of 
the daily dose is excreted as DiOH-CBZ, 5% to 11% as 9-hydroxymethyl-10-
carbamoyl acridan, 5% to 10% as the phenolic metabolites, 1 to 2% as CBZE and 
0.5% as unchanged CBZ (Spina 2002).  
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1.3.4 Carbamazepine Hypersensitivity Reactions 
 
1.3.4.1 Overview 
CBZ is generally well tolerated but up to 10% of patients starting treatment 
experience a hypersensitivity reaction (Marson et al. 2007). The majority of these 
patients present with a skin rash which typically presents after a few days and can 
resolve spontaneously without further intervention. However, some patients 
present with more severe reactions that include HSS, SJS and TEN (Yip et al. 2012). 
The current clinical guidance is that patients should stop CBZ therapy if a rash 
appears as it is not possible to predict which patients will progress to more severe 
hypersensitivity and early discontinuation of the culprit drug leads to improved 
clinical outcomes (Garcia-Doval et al. 2000). The incidence of CBZ-induced HSS has 
an estimated frequency of 1.0-4.1 per 10,000 exposures (Tennis and Stern 1997). 
The estimated incidence of CBZ-induced SJS/TEN is greater in Asian populations 
(Chen et al. 2011) than European populations (McCormack et al. 2011), 25 cases per 
10,000 compared with 1 to 6 cases per 10,000, respectively.   
 
1.3.4.2 Pharmacogenetic Associations 
Predisposition to CBZ hypersensitivity reactions is thought to have a genetic 
component because of cases reported in families and monozygotic twins (Edwards 
et al. 1999). Chemically reactive metabolites generated by metabolism of CBZ, such 
as epoxides and arene oxides, can cause direct cellular toxicity or lead to generation 
of neo-antigens that could activate the immune system leading to hypersensitivity 
reactions (Knowles et al. 2000). Metabolism of CBZ involves multiple CYPs and 
detoxification pathways (Figure 1.3). Genetic variation in these enzymes leads to 
altered metabolism of CBZ and could possibly increase the formation of chemically 
reactive metabolites (Jaramillo et al. 2014). Microsomal epoxide hydrolase is 
responsible for biotransformation of active CBZE to inactive DiOH-CBZ. A recent 
study has shown that a single nucleotide polymorphism (SNP) (c.337T>C) in EPHX1, 
the gene that encodes mEH, was significantly associated with development of CBZ-
induced SJS/TEN in a Han Chinese population (He et al. 2014). However, a similar 
study in patients with heterogeneous clinical manifestations of CBZ hypersensitivity, 
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including SJS/TEN, hepatitis and pneumonitis, did not detect an association 
between genetic variation in EPHX1 and susceptibility to CBZ hypersensitivity 
(Green et al. 1995). Polymorphisms in ABCB1, CYP3A4, FAS, SCN1A, MICA and BAG6 
were not associated with susceptibility to CBZ-induced SJS/TEN in a Han Chinese 
cohort from Taiwan (He et al. 2014). CBZ is also able to covalently modify CYP3A4 
leading to a reduction in its catalytic activity (Kang et al. 2008). A summary of 
studies that have investigated the role of SNPs in metabolism enzymes and drug 
transporters involved in the metabolism of CBZ is outlined in Table 1.4. 
 
A study in Han Chinese patients from Taiwan reported a very strong association (OR 
> 2,000) between patients with CBZ-induced SJS/TEN and the HLA-B*15:02 allele 
(Chung et al. 2004). The association has subsequently been replicated in Han 
Chinese patients from other countries, including Hong Kong and China, as well as 
Thai, Malaysian and Indian patients (Yip et al. 2012). The association was not 
replicated in Caucasian, Japanese or Korean populations (Alfirevic et al. 2006; 
Kaniwa et al. 2008; Kim et al. 2011). The association between CBZ hypersensitivity 
and HLA-B*15:02 is both ethnicity and phenotype specific. Ethnic specificity may be 
explained by the differing background frequency of HLA-B*15:02 in different 
populations. The prevalence of HLA-B*15:02 is highest amongst Asian populations 
(0.057-0.145 in Han Chinese, 0.085-0.275 in Thais and 0.12-0.157 in Malaysians) and 
lowest in Europeans (0.01-0.02), Japanese (0.002), and Koreans (0.004) (Lim et al. 
2008). Subsequently, the drug label has been amended and physicians are warned 
and advised to undertake genotyping before initiation of CBZ treatment in patients 
of Asian descent (Ferrell and McLeod 2008). The utility of genotype testing has been 
confirmed in a prospective study in a Taiwanese population where pre-prescription 
genotyping reduced the incidence of CBZ-induced SJS/TEN from ten expected cases 
to zero (Chen et al. 2011). Despite these advances it is important that physicians 
receive education regarding pharmacogenetic tests. In Hong Kong introduction of 
HLA-B*15:02 testing led to reduction in CBZ prescribing from 16.2% to 2.6% of all 
new AEDs and an increase in use of alternative AEDs such as phenytoin. The net 
effect was no reduction in overall incidence of AED-induced SJS as the alternative 
AEDs are also associated with risk of SJS/TEN (Chen et al. 2014). 
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More recently, a significant association between HLA-A*31:01 and all phenotypes of 
CBZ hypersensitivity was reported in both Caucasian and Japanese patients 
(McCormack et al. 2011; Ozeki et al. 2011). Although the association was replicated 
in a Korean population (Kim et al. 2011), it was not significantly associated in 
Norwegian patients with non-bullous CBZ hypersensitivity (Shirzadi et al. 2015).  
Screening for HLA-A*31:01 is not currently part of clinical practice although studies 
suggest that the number needed to test in order to avoid a hypersensitivity reaction 
ranges between 47 and 91 and an economic evaluation from the perspective of the 
NHS suggests that screening would be cost-effective (Plumpton et al. 2015). It is 
unclear at present why HLA-B*15:02 predisposes only to SJS/TEN while HLA-
A*31:01 is a susceptibility factor for all forms of CBZ hypersensitivity and further 
functional studies are required to define the causal pathways. 
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Table 1.4 Studies that have investigated single nucleotide polymorphisms associated with pharmacokinetics of carbamazepine 
Study Population No. of 
Subjects 
SNP ID Gene Nucleotide 
change/allele 
Effect of Polymorphism 
(Ma et al. 2015) Chinese  166 rs2242480 CYP3A4 *1G NS 
rs776746 CYP3A5 *3 NS 
rs1051740 EPHX1 c.337T>C Higher CBZ maintenance dose, lower lnCDR for 
CBZ and higher CBZE concentration 
rs7439366 UGT2B7 c.802T>C Higher CBZ maintenance dose if also a carrier of 
ABCC2 c.1249G>A 
rs3740066 
 
rs2273697 
ABCC2 c.3972C>T 
 
c.1249G>A 
Higher CBZ maintenance dose and higher CBZE 
concentration 
Higher CBZ maintenance dose if also a carrier of 
UGT2B7 c.802T>C 
(Wang et al. 
2015) 
Chinese 88 rs4646440 
rs2242480 
CYP3A4 c.1023+608C>T 
*1G 
NS 
NS 
   rs15524 
 
rs776746 
CYP3A5 *1D 
 
*3 
Higher dose adjusted CBZ and CBZE concentration 
in subjects on concomitant PHT/PB 
Higher dose adjusted CBZ and CBZE concentration 
 48 
 
in subjects on concomitant PHT/PB 
   rs1045642 
rs2032582 
rs10234411 
rs1128503 
ABCB1 c.3435C>T 
c.2667G>T 
2481+882A>T 
c.1236T>C 
NS 
CBZ/CBZE ratio in subjects on concomitant 
PHT/PB 
CBZ/CBZE ratio in subjects on concomitant 
PHT/PB 
NS 
(Caruso et al. 
2014) 
Italian 50 rs1051740 
rs2234922 
EPHX1 c.337T>C 
c.416A>G 
NS 
NS 
rs35599367 CYP3A4 *22 NS 
(Zhu et al. 2014) Chinese 210 rs35599367 
rs2242480 
CYP3A4 
 
*22 
*1G 
NS 
Lower adjusted levels of CBZ and CBZE 
rs776746 CYP3A5 *3 Higher dose adjusted levels of CBZ 
rs1057868 POR *28 NS 
rs2234922 
 
rs3738046 
EPHX1 c.416A>G 
 
c.128G>C 
Lower dose adjusted levels of DiOH-CBZ and 
DiOH-CBZ:CBZE ratio 
Higher DiOH-CBZ:CBZE ratio 
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rs1051740 c.337T>C NS 
(Panomvana et 
al. 2013) 
Thai 70 rs776746 CYP3A5 *3 Trend towards reduced clearance (not significant) 
(Puranik et al. 
2013) 
African-
American 
Caucasian 
88 rs2740574 CYP3A4 *1B Reduced clearance 
rs776746 CYP3A5 *3 Longer half life for CBZ (African-Americans) 
rs1051740 
rs2234922 
EPHX1 c.337T>C 
c.416A>G 
Lower DiOH-CBZ:CBZE ratio (African-Americans) 
NS 
rs7439366 
rs11302069 
rs28365062 
rs28365063 
rs4292394 
UGT2B7 c.802T>C 
c.1090+155delA 
c.735A>G 
c.372A>G 
c.1059C>G 
NS 
NS 
NS 
Increased clearance (African-American) 
NS 
rs1045642 
rs1128503 
rs2032582 
rs4148734 
ABCB1 c.3435C>T 
c.1236T>C 
c.2677G>T 
c.702+1789C>T 
NS 
Higher clearance (African-Americans) 
NS 
NS 
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rs4148739 
rs4148740 
c.2482-236A>G 
c.2686-
1911T>C 
Higher DiOH-CBZ:CBZE ratio (African-American) 
Higher DiOH-CBZ:CBZE ratio (African-American) 
rs2273697 
rs3740066 
rs4148386 
 
rs8187710 
ABCC2 c.1249G>A 
c.3972C>A 
208-3523G>A 
 
c.4544G>A 
Higher clearance (Caucasians) 
Higher CBZE:CBZ ratio (Caucasian male) 
Reduced clearance and reduced CBZE:CBZ ratio 
(African-American) 
NS 
   rs1523127 
rs1523130 
rs2461817 
 
rs3814055 
rs4688040 
rs7643645 
NR1I2 c.-131C>A 
c.-1663T>C 
c.-22-1425A>C 
 
c.-1135C>T 
c.-22-1985G>T 
c.-22-579A>G 
NS 
NS 
Increased CBZE:CBZ ratio and reduced clearance 
(African-American) 
Reduced clearance 
Increased clearance (African-American) 
Increased CBZE:CBZ ratio 
(Yun et al. 2013) 
 
Chinese 
 
83 
 
rs1051740 
rs2234922 
EPHX1 c.337T>C 
c.416A>G 
NS 
Higher adjusted plasma CBZ levels 
rs2242480 CYP3A4 *1G NS 
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(Hung et al. 
2012) 
Taiwan 234 rs1051740 
rs2234922 
EPHX1 c.337T>C 
c.416A>G 
Higher maintenance dosage 
NS 
rs7668258 
rs7438135 
rs28365062 
rs7439366 
UGT2B7 
 
c.-161T>C 
c.-900G>A 
c.735A>G 
c.802T>C 
NS 
NS 
NS 
NS 
rs1128503 
rs2032582 
rs1045642 
ABCB1 
 
c.1236T>C 
c.2677G>T 
c.3435C>T 
NS 
NS 
NS 
rs717620 
rs2273697 
ABCC2 c.-24C>T 
c.3972C>T 
NS 
NS 
(Sterjev et al. 
2012) 
Macedonian 162 rs1045642 
 
ABCB1 c.3435C>T Higher CBZ plasma levels 
(Meng et al. 
2011a) 
Chinese 84 rs1045642 
rs1128503 
rs2032582 
ABCB1 c.3435C>T 
c.1236T>C 
c.2677G>T 
Lower plasma CBZ levels 
NS 
NS 
(Park et al. 2009) Korean 35 rs776746 CYP3A5 *3 Reduced clearance 
(lnCDR- natural log dose adjusted concentration, NS- not significant,  PB- phenobarbital, PHT- phenytoin  
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1.3.4.3 Functional Studies 
The clinical features of CBZ hypersensitivity reactions suggest an immune-mediated 
aetiology, and the discovery of drug-specific T cells in hypersensitive individuals is 
consistent with this hypothesis (Naisbitt et al. 2003; Wu et al. 2006; Wu et al. 2007). 
Drug-specific T cells have been generated against CBZ and several CBZ metabolites 
including CBZE (Wu et al. 2006). Stimulation of these T cells occurred in the absence 
of metabolism and antigen processing suggesting that CBZ is able to activate T cells 
by direct interaction in accordance with the PI hypothesis (Wu et al. 2006; Wu et al. 
2007). Because of the heterogeneity of clinical presentation of CBZ hypersensitivity 
reactions it is possible that several T cell activation pathways are involved. The 
metabolism of CBZ is postulated to generate chemically reactive metabolites 
including epoxides, arene oxides and iminoquinones (Figure 1.3) (Furst et al. 1995; 
Pearce et al. 2002; Pearce et al. 2005). These reactive metabolites could act as 
haptens and modify endogenous proteins leading to the generation of chemically 
modified peptides as outlined by the hapten hypothesis. Two glutathione (GSH) 
adducts were observed when GSH was incubated directly with CBZE (Bu et al. 2005). 
A third GSH adduct was identified in incubations containing CBZ and human liver 
microsomes (HLM) and postulated to be formed by an arene oxide intermediate of 
CBZ metabolism (Bu et al. 2007). CBZ is also able to form adducts with CYP3A4 
which led to reduced catalytic activity of the enzyme (Kang et al. 2008). Anti-CYP3A 
antibodies have been detected in patients with aromatic anticonvulsant-induced 
hypersensitivity reactions, including CBZ, although the immunogenicity and their 
role in hypersensitivity reactions is not understood (Leeder et al. 1996). The minor 
metabolite, 9-acridine carboxaldehyde, has been shown to be able to covalently 
modify neutrophils and inhibit neutrophil function at high concentrations (Furst et 
al. 1995; Furst and Uetrecht 1995).  
 
There has been evidence to suggest that CBZ-specific T cells may be activated by an 
altered peptide repertoire hypothesis. CBZ has been shown to be able to bind 
directly to the peptide binding groove of HLA-B*15:02 and activate T cells but only 
in the presence of endogenous peptides (Wei et al. 2012). A separate study 
reported that CBZ binding to HLA-B*15:02 leads to an alteration in the repertoire of 
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presented self peptides (Illing et al. 2012). A more recent structural model suggests 
that CBZ is located at the interface between the HLA-B*15:02/peptide and TCR, 
directly contacts the antigen peptide, and is bound within the TCR pocket (Zhou et 
al. 2015). Further evidence to support interaction between CBZ and TCR is the 
observation that CBZ-induced SJS/TEN patients have restricted TCR use (Ko et al. 
2011). CBZ cytotoxicity could only be primed from PBMCs of individuals who were 
carriers of both HLA-B*15:02 and TCR clonotype Vβ-11-ISGSY. This may explain why 
a significant number of patients who are HLA-B*15:02 carriers do not experience 
SJS/TEN when prescribed CBZ as a specific TCR clonotype is also required to initiate 
hypersensitivity. 
 
1.4 Liquid Chromatography Tandem Mass Spectrometry 
 
1.4.1 Overview 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) is an analytical 
chemistry technique that combines the separation capabilities of liquid 
chromatography with the mass analysis capabilities of mass spectrometry enabling 
high specificity analysis of complex mixtures (Pitt 2009). Over the last 10-15 years 
the technology has grown in popularity in both scientific and clinical laboratories 
and has many applications including therapeutic drug monitoring (TDM), toxicology, 
metabolomics and proteomics (Seidler et al. 2010; Adaway et al. 2015).  
 
1.4.2 High Performance Liquid Chromatography 
Chromatography is an analytical technique based on the separation of molecules 
due to differences in their structure and/or composition. Separation of components 
in a sample involves the movement of the sample through a HPLC column 
(stationary phase) in conjunction with mobile phase. Distinct molecules in the 
sample will interact differently with the stationary phase leading to separation of 
the components. Components that interact more strongly with the stationary phase 
will move more slowly through the column. Eventually each component of the 
analyte mixture elutes from the column and is detected as a peak on the data 
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display. High performance liquid chromatrography (HPLC) is a type of 
chromatography that is used to separate compounds that have been dissolved in 
solution (Kupiec 2004).  
 
A typical system for HPLC will include a pump, injector, column, detection system 
and data acquisition system (Figure 1.4). The injector is responsible for injecting the 
sample of interest into the HPLC system with high reproducibility and under high 
pressure (up to 4000 psi). The sample is then pumped along with mobile phase 
through the HPLC column which is tightly packed. A steady pump pressure is 
needed to ensure reproducibility and accuracy (1000 - 2000 psi). Highest purity 
solvents and inorganic salts should be used to make the mobile phase to ensure 
reproducibility and accuracy. Wide selections of HPLC columns are available 
commercially with varying lengths, pore size and different stationary phases. Choice 
of column is dependent on the analyte of interest. A detector is used to sense the 
presence of a compound passing through the column. Typical detectors in HPLC 
include ultraviolet, refractive index and fluorescence (Kupiec 2004). In HPLC-MS/MS 
the chromatographically separated compounds are further characterised using MS. 
 
 
Figure 1.4 Schematic representation of high performance liquid chromatography. 
The sample is injected and pumped through the HPLC column at high pressure with 
mobile phase. Analytes are separated according to their interactions with the 
stationary phase in the HPLC column. As each analyte elutes from the column it is 
detected as a peak on the data display or ionised for analysis by mass spectrometry. 
(HPLC- high performance liquid chromatography). 
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1.4.3 Mass Spectrometry 
Mass spectrometers function by applying a charge (ionisation) to analyte molecules, 
with subsequent analysis of the ions and any fragment ions generated, on the basis 
of their mass to charge ratio (m/z) (Pitt 2009). In HPLC-MS/MS, HPLC is used to 
separate the mixture before delivery to the MS instrument. The eluent from the 
HPLC is ionised, typically using electrospray ionization (ESI) (Whitehouse et al. 
1985). The ionised analytes then pass into the mass analyser. Tandem MS involves 
two or more stages of independent mass analysis and can be achieved using a triple 
quadrupole mass analyser. Each quadrupole consists of four parallel metal rods that 
are able to modify their voltages so that only a narrow band of m/z values are able 
to travel along the axis of the rods at a particular time. The quadrupole can scan a 
range of m/z values or be programmed to monitor for specific m/z (Pitt 2009). In a 
triple quadrupole mass spectrometer the first quadrupole (Q1) is used to select a 
known parent ion based on m/z. The selected ion then passes into a collision cell 
(Q2), which contains a low pressure inert gas such as nitrogen or argon, where 
collision between the analyte and inert gas molecules result in fragmentation. The 
third quadrupole (Q3) can then also be programmed to isolate a specific product ion 
based on m/z and is termed a transition (Adaway et al. 2015).  
 
For example, 25-hydroxy vitamin D3 produces a major M+H+ ion of 401 m/z during 
ESI that loses water in the collision cell to produce a major 383 m/z product ion 
(Chen et al. 2008). Highly sensitive detection of 25-hydroxy vitamin D3 can be 
achieved by setting Q1 and Q3 to transmit ions of only 401 and 383 m/z, 
respectively. Monitoring of a single transition as described above (401  383) is 
called selected reaction monitoring (Adaway et al. 2015). The first and third 
quadrupoles can also be set up to simultaneously monitor several m/z transitions in 
order to detect multiple targeted analyte transitions in a mixture and is termed 
multiple reaction monitoring (MRM) (Adaway et al. 2015). Product ion scanning 
involves fixing the m/z in the first quadrupole and application of scanning mode for 
product ions in the third quadrupole which generates structural information or 
unique “finger print” of the analyte that can be used to confirm its identity with 
great certainty (Pitt 2009). 
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Figure 1.5 A simplified representation of high performance liquid chromatography 
tandem mass spectrometry. The sample is separated by HPLC before being charged 
in the ionisation source. At the first quadrupole (Q1) the analyte of interest is 
selected according to m/z before transition to the collision cell (Q2). In the collision 
cell collision between the selected analyte and Ar gas induces fragmentation. The 
fragments are subjected to selection by the third quadrupole (Q3) with only the 
selected m/z fragment reaching the detector. Product ion scanning can also be 
applied in Q3 to obtain structural information about the analyte. (Ar – argon). 
 
1.4.4 Applications of High Performance Liquid Chromatography-Mass 
Spectrometry 
Clinical applications of HPLC-MS/MS include TDM, toxicology, endocrinology, 
paediatrics and microbiology (Adaway et al. 2015). In TDM HPLC-MS/MS 
demonstrates several advantages over traditional immunoassays including reduced 
inter-laboratory variability and lower sample volume requirement (Adaway et al. 
2015). A further advantage is the ability to multiplex several analytes into one run 
as illustrated by combined assays of multiple immunosuppressants (cyclosporin and 
tacrolimus, sirolumus and everolimus) (Ansermot et al. 2008) as well as parent drug 
and metabolite analyses (Breton et al. 2005).  
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HPLC-MS/MS is also increasingly used in proteomics for peptide sequencing, protein 
identification and detection of covalent modifications of proteins (Medzihradszky 
2005). In HPLC-MS/MS peptides are fragmented by collision induced dissociation, 
occurring in Q2 of Figure 1.5, generating multiple fragment (product) ions. 
Correlation of the mass spectrometric data with sequence databases [e.g. TANDEM 
(Craig and Beavis 2004)] allows the rapid identification of proteins (Seidler et al. 
2010). However, database recognition of peptides precludes the identification of 
peptides not present in the database or peptides with unknown modifications such 
as drug-modifications (Medzihradszky 2005). De novo peptide sequencing with 
HPLC-MS/MS can be used to identify these unknown or modified peptides (Seidler 
et al. 2010). Fragment ions provide information about the amino acid composition 
of the peptide as each of the 20 amino acids has a known and specific molecular 
mass (Table 1.5). Fragment ions are formed by peptide backbone cleavages and 
may occur between the alpha carbon and carbonyl group; at the peptide bond; 
between the amino group and the alpha carbon. When the charge is retained at the 
N-terminus a, b and c fragments are formed whereas x, y and z ions are produced 
when the charge is retained at the C-terminus (Figure 1.6) (Biemann 1990). The 
amino acid sequence of the peptide can then be determined by mass differences or 
additions. Drug-modification of peptides can be detected by combining peptide 
sequence information with knowledge of potential modification sites (e.g. cysteine), 
mass of drug or potential reactive metabolites and m/z of drug-modified peptides 
(Meng et al. 2014a). 
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Table 1.5 The 20 amino acids and their monoisotopic masses [adapted from 
(Medzihradszky and Chalkley 2015)] 
Name 3 Letter Code 1 Letter Code Elemental 
Composition 
Monoistopic 
Residue Mass 
Alanine Ala A C3H7NO2 71.03 
Arginine Arg R C6H14N4O2 156.10 
Asparagine Asn N C4H8N2O3 114.04 
Aspartic Acid Asp D C4H8NO4 115.02 
Cysteine Cys C C3H7NO2S 103.01 
Glutamic Acid Glu E C5H9NO4 129.04 
Glutamine Gln Q C5H10N2O3 128.06 
Glycine Gly G C2H5NO2 57.02 
Histidine His H C6H9N3O2 137.06 
Isoleucine Ile I C6H13NO2 113.08 
Leucine Leu L C6H13NO2 113.08 
Lysine Lys K C6H14N2O2 128.09 
Methionine Met M C5H11NO2 131.04 
Phenylalanine Phe F C9H11NO2 147.07 
Proline Pro P C5H9NO2 97.05 
Serine Ser S C3H7NO3 87.03 
Threonine Thr T C4H9NO3 101.05 
Tryptophan Trp W C11H12N2O2 186.08 
Tyrosine Tyr Y C9H11NO3 163.06 
Valine Val V C5H11NO2 99.07 
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Figure 1.6 Nomenclature of sequence-specific peptide fragments; a-, b- and c-type 
ions contain the N terminus; x-, y-, and z-ions contain the C-terminus. Rn represent 
the side chains of the amino acid residues (Dass 2001).  
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1.5 Pharmacokinetics 
 
1.5.1 Overview 
The relationship between drug dosage and the response to the drug is described by 
pharmacokinetics (PK) and pharmacodynamics. PK describes what the body does to 
the drug whilst pharmacodynamics explains what the drug does to the body. In 
order for a drug to produce its effect it has to be present at an appropriate 
concentration at the site of action (Rang et al. 2016). PK processes include 
absorption, distribution, metabolism and elimination. Quantification of these 
processes allows pharmacokineticists to understand, interpret and predict blood 
concentration-time profiles (Aarons 2005). However, intra- and inter-individual 
variability exists in these PK processes which contribute to the variability observed 
in the dose-concentration relationship.  
 
1.5.2 Pharmacokinetic Models 
PK models are mathematical schemes that attempt to describe the fate of a drug in 
a biological system after administration (Dhillon and Gill 2006). PK models can be 
classified by complexity. The simplest model is the one compartment model where 
the body is depicted as a kinetically homogenous unit. This model assumes that any 
drug administered is instantaneously distributed throughout the body and 
equilibration between tissues is also instant (Figure 1.7A). The relationship between 
log drug concentration and time will show a linear relationship (Figure 1.7B) (Dhillon 
and Gill 2006).  
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Figure 1.7 Theoretical Pharmacokinetic Models (A) One-compartment model ka = 
absorption rate constant, k = elimination rate constant (B) Time profile of a one-
compartment model depicting log plasma concentration (Cp) against time 
 
A two compartment model depicts the body as a central and peripheral 
compartment (Figure 1.8A). These compartments have no physiological meaning or 
anatomical meaning but should be viewed as semi-mechanistic models as it is 
possible to relate parameters to physiological processes (e.g. effect of renal 
function on clearance) (Aarons 2005). The model assumes that after administration 
of the drug into a central compartment, the drug distributes between that 
compartment and the peripheral compartment but does not achieve instantaneous 
distribution (equilibration) between the compartments. The log drug concentration-
time plot will show a biphasic response (Figure 1.8B) (Dhillon and Gill 2006).  
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Figure 1.8 Theoretical Pharmacokinetic Models (A) Two-compartment model. k12, 
k21, and k are first order rate constants; k12 = rate of transfer from central to 
peripheral compartment; k21 = rate of transfer from peripheral to central 
compartment; k = rate of elimination from central compartment (B) Time profile of 
a two-compartment model depicting log plasma concentration (Cp) against time 
 
The most complex PK models are multi-compartmental and can be based on 
physiological considerations. Physiologically based pharmacokinetic (PBPK) models 
are compartmental models where each compartment represents an actual tissue or 
organ space (Figure 1.9) (Aarons 2005). While conventional PK models are defined 
by drug-related data, PBPK models integrate information from drug-related data, 
physiological, and biological parameters as they vary between subjects or with age 
and disease state (Espié et al. 2009). The major limitation of PBPK models is the lack 
of human data meaning they rely heavily on animal studies and intensive sampling 
of tissues which is not possible for all tissue types (Aarons 2005).  
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Figure 1.9 An example of a physiologically based pharmacokinetic model for an 
orally administered drug. The compartments represent tissues and organs; 
connecting arrows represent blood supplies. 
 
In reality, because of the complexity of PBPK modelling and lack of sufficient data, 
partial PBPK or semi-mechanistic models often present more useful information 
(Aarons 2005). An elegant four-compartment semi-mechanistic model comprising 
the stomach, intestine, central and peripheral compartments was able to accurately 
describe that gastric emptying half-life was improved by a factor of 20 in patients 
intolerant to enteral nutrition after treatment with prokinetic agents (Figure 1.10) 
(Ogungbenro et al. 2011).  
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Figure 1.10 A four-compartment semi-mechanistic model with first order 
absorption. kg = gastric emptying rate constant, ka = absorption rate constant, CL = 
clearance, CLD = intercompartmental clearance, V1 = volume of central 
compartment, V2 = volume of peripheral compartment. 
 
1.5.3 Population Pharmacokinetics 
Population PK is the study of the sources and correlates of variability in drug 
concentrations among individuals who are the target patient population receiving 
clinically relevant doses of the drug of interest (Aarons 1991). The aims of a 
population PK approach are (Ette and Williams 2004a): 
 Identify and quantify sources of variability, such as inter-subject, intra-
subject, and inter-occasion. 
 Explain variability by identifying factors of demographic, pathophysiologic, 
environmental or drug-related origin that may influence the PK behaviour of 
the drug. 
 Quantitatively estimate the magnitude of the unexplained part of the 
variability in the patient population.  
Several methodological approaches for characterisation of population PK 
parameters have been proposed and include: naive pooled data analysis, two stage 
approaches (e.g. standard, Bayesian) and nonlinear mixed effects models (Ette and 
Williams 2004b). However the term population PK almost always means the use of 
nonlinear mixed effects modelling as it accounts for greater than 90% of published 
population PK methodology (Dartois et al. 2007).  
 
“Nonlinear” refers to the nonlinear relationship between the dependent variable 
(e.g. concentration) and model parameters and independent variable(s). “Mixed 
Ds CI C1 (V1) C2 (V2) 
Depot (Stomach) Intestine (small) Central (Body 1) Peripheral (Body 2) 
kg ka 
CLD 
CL 
CLD 
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effects” refers to the parameters and are defined as “fixed effects” if they do not 
vary between individuals and “random effects” if the parameters demonstrate 
variation across individuals (Mould and Upton 2013). Random effects include inter-
individual (e.g. inter-occasion) and residual variability (e.g. errors in dosing, 
sampling or recording time, assay errors, etc.) (Kiang et al. 2012). The population 
modelling approach considers the study population rather than each individual as 
the unit of analysis for estimating the distribution of PK parameters and their 
relationship with covariates within the population (Kiang et al. 2012). Covariates are 
factors such as weight, concomitant medications and genotype, that are predictive 
of PK variability in the target population (Mould and Upton 2012). 
 
In traditional PK studies, the emphasis was to minimise sources of inter-individual 
variability by complex study designs and application of strict inclusion and exclusion 
criteria. A small number of subjects would be given the drug of interest and then 
intensively sampled over a fixed post-dose period generating “dense” PK data for 
each participant. However, these traditional studies are limited as they are 
performed in subjects that are not representative of the patient population (e.g. 
healthy volunteers), require multiple blood samples for each subject (greater than 
6) and so are unsuitable for vulnerable patient groups (e.g. children) and unable to 
quantify effects of covariates (e.g. weight) on PK parameters (Ette and Williams 
2004a). Population PK studies differ from traditional PK studies because participants 
are representative of the intended target population of the drug and although the 
numbers of subjects in these population studies tend to be greater each participant 
contributes relatively few PK samples generating “sparse” data (Kiang et al. 2012). 
Nonlinear mixed effects modelling is able to integrate dense and sparse PK data 
along with different dosages, multiple subject types and a heterogeneity of other 
factors (e.g. concomitant medications, pathophysiology) (Ette and Williams 2004a).  
 
Population PK modelling requires skilled pharmacokineticists and 
pharmacometricians as well as specialised software (Ette and Williams 2004a). 
Several software programs are available for nonlinear mixed effects modelling and 
include: NONMEM, MONOLIX, Pmetrics, Phoenix NLME, Kinetica and S-ADAPT 
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(Kiang et al. 2012). NONMEM is the most widely used program in both academia 
and industry with approximately 70% of all population PK studies employing 
NONMEM for population modelling (Kiang et al. 2012). Population PK approaches 
have an important role in both drug development and routine drug therapy (Samara 
and Granneman 1997). In drug development population PK is useful for the 
integration of data from phase I, II and III of clinical studies which are likely to 
contain heterogeneous patients and both dense and sparse PK samples as well as 
longer term surveillance information (Food and Drug Administration 1999). In 
patient care population, PK can be used to individualise or optimise dosage 
regimens; for example, guidance for dose selection of metformin in patients with 
various stages of renal impairment where limited information was previously 
available as the drug was contraindicated in renal impairment (Duong et al. 2013).  
 
1.5.4 Population Pharmacokinetics in Carbamazepine Metabolism 
Because of the high intra- and inter-individual variability in relationship between 
dose and blood levels of CBZ, narrow therapeutic range, drug interaction profile and 
diverse treatment population (paediatric to elderly) several population PK models 
have attempted to describe the relationship between covariates and plasma levels 
of CBZ (Table 1.6). Patient factors that influence the PK of CBZ include gender, age 
and total body weight (Gray et al. 1998; Jiao et al. 2003; Milovanovic and Jankovic 
2011). Concomitant therapy with valproic acid, phenytoin, felbamate and 
phenobarbital has also been associated with significant modification of CBZ 
metabolism (Graves et al. 1998; Jankovic et al. 2008). Phenytoin and phenobarbital 
are known to induce many CYP isoforms and glucuronyl transferases whilst valproic 
acid is an inhibitor of drug metabolism enzymes (Perucca 2006). Only one 
population PK model has investigated the role of genetic variation in metabolising 
enzymes on PK of CBZ and reported that homozygotes of CYP1A2 -163A/A achieved 
lower concentrations of CBZ compared with other genotype groups (Djordjevic et 
al. 2016). Nearly all of the reported population PK models consider only the PK of 
the parent drug CBZ with a single study also analysing the metabolism of the 
metabolite CBZE (Jiao et al. 2004).  
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Table 1.6 Population pharmacokinetic studies using NONMEM in patients receiving carbamazepine therapy 
Study Number of 
Subjects 
Number of 
Observations 
Timing of 
Samples 
Ethnicity of 
Population 
Mean Age Analytes Statistically Significant 
Covariates 
(Djordjevic 
et al. 2016) 
40 40 Trough Serbian 11 (median) CBZ Gender 
Total daily dose 
CYP1A2 -163C>A 
(El Desoky et 
al. 2012) 
302 302 Trough Egyptian Paediatric: 
10.6 
Adults: 29.4 
CBZ Nil 
(Punyawudh
o et al. 2012) 
121 555 Sparse American Indian, 
Black, Hispanic, 
White 
70.5 CBZ Concomitant phenytoin 
(Milovanovic 
and Jankovic 
2011) 
151 167 Sparse Serbian Paediatric: 8 
Adults: 32 
CBZ Age 
Total daily dose 
(Jankovic et 
al. 2008) 
97 97 Trough 76% 
Cmax 24% 
Serbian 14.7 CBZ Age 
Total body weight 
Concomitant valproic acid 
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(Vucicevic et 
al. 2007) 
311 423 Sparse Serbian 37 CBZ Total body weight 
Total daily dose 
Concomitant phenobarbital 
Concomitant valproic acid 
(Perumandla 
et al. 2005) 
84 307 Sparse and 
rich 
Indian 15.2 CBZ Total body weight 
(Jiao et al. 
2004) 
585 687 Trough Chinese 23.3 CBZE Total body weight 
Total daily dose 
Concomitant valproic acid 
(Jiao et al. 
2003) 
585 687 Trough Chinese 23.3 CBZ Total body weight 
Total daily dose 
Age > 65 years 
Concomitant phenytoin 
Concomitant phenobarbital 
Concomitant valproic acid 
(Chan et al. 
2001) 
193 302 Trough Singaporean 12.5 CBZ Age 
Total body weight 
Concomitant phenobarbital 
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(Deleu et al. 
2001) 
48 149 Sparse Omani 27.8 CBZ Nil 
(Reith et al. 
2001) 
91 946 Sparse Australian 18.1 CBZ Surface area 
Total daily dose 
(Gray et al. 
1998) 
72 118 Sparse African and 
Indian 
8.7 CBZ Total body weight 
Concomitant valproate 
Concomitant phenytoin 
Concomitant phenobarbital 
(Graves et al. 
1998) 
829 1834 Sparse United States 35 CBZ Age > 70 years 
Concomitant phenytoin 
Concomitant phenobarbital 
Concomitant felbamate 
(Delgado 
Iribarnegaray 
et al. 1997) 
201 387 Trough Spain 9.5 CBZ Total body weight 
Age 
Total daily dose 
Concomitant phenobarbital 
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1.6 Transcriptomics 
 
1.6.1 Overview 
The genes in DNA encode protein molecules which are responsible for carrying out 
all functions of an organism. Each gene encodes for a particular protein and the 
process of manufacturing each particular protein consists of two steps: 
transcription and translation. Transcription is transfer of the information in DNA to 
messenger RNA (mRNA). During the second stage, translation, the mRNA is “read” 
according to the genetic code, which relates the DNA sequence to the amino acid 
sequence in the protein (Clancy 2008). The transcriptome is the entire repertoire of 
transcripts in a species and represents the genes that are actively expressed at any 
given moment (Malone and Oliver 2011). There about 8.423 RNA bases in the full 
human transcriptome (Velculescu et al. 1999). In addition to mRNA other RNA 
molecules exist. A microRNA (miRNA) is a small non-coding RNA molecule that 
functions in RNA silencing and post-transcriptional regulation of gene expression 
and so can also influence the transcriptome (Bartel 2004). Knowledge of the 
transcriptome can provide valuable insights into the pathophysiological processes 
involved in DHRs (Coulter et al. 2010; Bellon et al. 2010). 
 
1.6.2 Gene Expression Microarrays 
Gene expression microarrays have enabled rapid and high-throughput 
quantification of the transcriptome. A typical microarray experiment involves two 
components: the probe and target. Probes are cDNA or oligonucleotides that 
represent genomic DNA and are amplified and immobilised on a solid substrate (e.g. 
silicon wafer or glass slide). Target preparation involves extraction of transcripts 
from the experimental samples (e.g. cells or tissues) to be investigated. The target 
RNA is converted to cDNA by reverse transcription and labelled with fluorescent 
dyes. The labelled target cDNA is then hybridised to the array and scanned with a 
laser. Probes that correspond to the transcribed RNA hybridise to their 
complementary target and because transcripts are fluorescently-labelled light 
intensity can be used as a measure of gene expression (Figure 1.11) (Malone and 
Oliver 2011). Analysis of the large quantities of gene expression data generated by 
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microarrays is complex and typically consists of assessment of array quality, 
normalisation, summary of data, significance testing and biological interpretation 
(Reimers 2010). Commercial software (e.g. Genespring, GeneSifter) is available to 
help guide researchers through this process. Confirmation of gene expression 
changes on microarray should be validated using real-time polymerase chain 
reaction (PCR) (Reimers 2010). Construction of biological pathways from rich 
transcriptome data can help to explain how cellular decision making and responses 
are orchestrated in the whole cell/organism in response to specific stimuli (e.g. 
exposure to drug) leading to novel insights and hypotheses (Viswanathan et al. 
2008). Ingenuity pathway analysis (IPA) is a web-based software application that 
enables researchers to analyse gene lists derived from expression microarrays. 
Using the IPA knowledge database biological models can be generated that 
incorporate upstream and downstream effects of the identified differentially 
expressed targets (Kramer et al. 2014).  
 
1.6.3 Gene Expression Studies in Drug Hypersensitivity Reactions 
Several studies have analysed gene expression in delayed DHRs (Table 1.7). 
However, most of these studies have investigated specific candidate genes (e.g. 
cytokines and cytotoxic proteins) rather than utilising a more global approach that 
does not rely on prior knowledge and is hypothesis generating. Two studies have 
used gene expression microarrays to investigate the transcriptome profile in 
delayed DHRs (Bellon et al. 2010; Coulter et al. 2010). Bellon et al. isolated PBMCs 
from patients during the acute phase of the hypersensitivity reaction and compared 
gene expression in 12,000 genes with PBMCs isolated from the same patients when 
the DHR had resolved. Elevated gene expression was reported in genes related to 
inflammation, cell cycle and lymphocytes and differences noted between bullous 
and non-bullous hypersensitivity reactions. A second study by Coulter et al. 
examined the gene expression profile of PBMCs isolated from patients with allergic 
contact dermatitis to p-phenylenediamine (PPD).  PBMCs were then exposed to PPD 
in vitro and the expression profile of > 50,000 transcripts assessed. A network based 
analysis using IPA showed up-regulation of T helper 2 gene pathways in allergic 
individuals but a regulatory gene profile in tolerant individuals.   
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Figure 1.11 Overview of the process flow for gene expression microarray analysis 
(RT-PCR: real-time polymerase chain reaction) 
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Table 1.7 Summary of gene expression studies in drug hypersensitivity reactions  
Study No. of 
Patients 
Reaction(s)  Suspected 
Drugs/Chemicals 
Samples Analysed Gene Expression 
Analysis 
Technique 
Significant Genes 
(Bhardwaj and 
Ishmael 2013) 
1 DRESS Cefepime, Vancomycin, 
Cefdinir, Cephalexin, 
Ampicillin 
Isolated PBMCs from 
patient and stimulated 
in vitro  
Real-time 
quantitative PCR 
 Increases in GM-CSF, IL-5, IL-13, IL-
2 and IFN-γ in hypersensitive 
subject 
(Morel et al. 
2011) 
30 MPE, EM, 
SJS/TEN 
Unknown Isolated PBMCs from 
patients during acute 
phase and at least 1 
month after resolution 
of DHR 
Real-time 
quantitative PCR 
 Overexpression of α-defensins 1-3 
in patients with SJS/TEN  
(Coulter et al. 
2010) 
5 Allergic 
contact 
dermatitis 
p-Phenylenediamine PBMCs from allergic 
and tolerant patients 
stimulated with PPD in 
vitro 
Microarray  Allergic patients’ expressed genes 
related to positive regulation of 
cell proliferation, apoptosis, 
inflammatory response, humoral 
immune response and lymphocyte 
activation  
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(Bellon et al. 
2010) 
23 MPE, FDE, 
DRESS, EM, 
SJS, TEN 
Diazepam, 
Erythromycin, 
Metamizole, Imatinib, 
Tamoxifen, Valproic 
acid, Clindamycin, 
Pseudoephedrine, 
Carbamazepine, 
Phenytoin, Ibuprofen, 
Amoxicillin, Spiramycin, 
Metronidazole, 
Allopurinol, Fluvastatin, 
Paracetamol, 
Furosemide  
Isolated PBMCs from 
patients during acute 
phase and at least 1 
month after resolution 
of DHR 
Microarray  During acute phase of DHR 92 
genes differentially expressed 
 Genes expressed in lymphocytes 
are under-represented in PBMC of 
severe bullous reactions 
 Cell cycle genes are upregulated in 
severe reactions (SJS/TEN, EM and 
DRESS) 
 Expression of inflammation 
associated genes are strongly 
upregulated in bullous reactions 
(Fernandez et 
al. 2008) 
27 MPE Amoxicillin, Cefuroxime, 
Co-amoxiclav, 
Metamizol, 
Paracetamol, Cefaclor, 
Ibuprofen, Spiramicin, 
Tetrazepam, Ebastine 
Isolated PBMCs from 
patients during acute 
phase of reaction 
Semi-quantitative 
real-time PCR 
 Increased expression of IFN-γ, TNF-
α, CXCR3, CCR6 and CCR10 in 
patients with MPE 
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(Cornejo-
Garcia et al. 
2007) 
25 Urticaria, 
MPE, 
SJS/TEN 
Amoxicillin, Cephalexin, 
Spiramicin, Metamizol, 
Phenobarbital, 
Carbamazepine 
Paracetamol, 
Diphenylidantoine, 
Allopurinol 
Isolated PBMCs from 
patients during acute 
phase of reaction and 
45 days after 
resolution 
Semi-quantitative 
real-time PCR 
 Increased expression of IFN-γ, TNF-
α and T-bet in hypersensitivity 
reactions 
(Posadas et al. 
2002) 
15 MPE, 
SJS/TEN 
Ceftriaxone, Phenytoin, 
Amiodarone, 
Amoxicillin, 
Carbamazepine, 
Phenytoin, Ampicillin, 
Allopurinol, 
Sulphamethoxazole  
Isolated PBMCs from 
patient during acute 
phase of reaction and 
30 days later 
Competitive PCR  Increased expression of TNF-α, 
perforin, granzyme B in 
hypersensitivity reactions 
 Fas ligand expressed only in 
SJS/TEN reactions 
(Leyva et al. 
2000) 
3 TEN Phenytoin, 
Carbamazepine 
Isolated PBMCs from 
patients during day 1, 
3, 5, 15 and 24 
Semi-quantitative 
reverse 
transcription-PCR 
 Increased expression of IL-2, IL-4, 
TNF-α and IFN-γ 
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(Posadas et al. 
2000) 
9 MPE, 
SJS/TEN 
Carbamazepine, 
Hidantoin, Amoxicillin, 
Ampicillin Amiodarone, 
Ceftriaxone, 
Isolated PBMCs from 
patients during acute 
phase, 7, 15 and 30 
days after reaction 
Competitive PCR  Increased expression of IL-2, IFN-γ 
and TNF-α in hypersensitivity 
reactions 
CCR: chemokine receptor, CXCR: chemokine receptor, DRESS: drug reaction with eosinophilia and systemic symptoms, EM: erythema 
multiforme, GM-CSF: granulocyte macrophage colony stimulating factor, IFN-γ: interferon-gamma, IL: interleukin, MPE: maculopapular 
exanthema, PCR: polymerase chain reaction, SJS: Stevens-Johnson syndrome, T-bet: T helper type 1 cell transcription factor, TEN: toxic 
epidermal necrolysis, TNF-α: tumour necrosis factor alpha 
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1.7 Aims and Objectives of Thesis 
The aim of this thesis was to investigate the chemical, metabolic, immunological 
and genetic factors that may cause or contribute to CBZ-induced hypersensitivity 
reactions. Healthy volunteers and patients prescribed CBZ therapy were recruited 
to several clinical studies to obtain blood samples for a series of immunochemical, 
mass spectrometric, PK and transcriptomic experiments in order to investigate the 
links between metabolism and the immune response in CBZ hypersensitivity 
reactions. 
 
The specific aims of the thesis included: 
 Investigation of the bioactivation and chemical reactivity of CBZ and its 
metabolites by assessment of covalent modification of proteins both in vitro 
and in vivo 
 Development of a HPLC-MS/MS assay to accurately quantify CBZ and its 
major metabolites in human plasma 
 Determine the demographic, clinical and genetic factors that influence the 
metabolism of CBZ using a population PK modelling approach 
 Characterise T cell activation and response in patients with a history of CBZ 
hypersensitivity and to determine cross reactivity of these T cells to CBZ and 
CBZE 
 Transcriptomic analysis of PBMCs (obtained from patients with a history of 
CBZ hypersensitivity) exposed to CBZ in vitro and construction of biological 
pathways to elucidate possible novel pathways in CBZ hypersensitivity 
reactions 
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Chapter 2  
Assessment of the Reactivity of Carbamazepine 
Metabolites with Proteins In vitro and In vivo  
 79 
 
2.1 Introduction 
CBZ is an aromatic anticonvulsant that has been implicated in diverse 
hypersensitivity phenotypes that involve multiple organ systems including the skin 
and liver (Avancini et al. 2015; Chalasani et al. 2015). Chemically reactive 
metabolites of CBZ have been implicated as agents for hepatotoxicity in rat livers 
(Leone et al. 2014) and mortality from drug-induced liver injury (DILI) is significantly 
higher in individuals with concomitant skin reactions (Chalasani et al. 2015). Up to 
10% of patients prescribed CBZ experience a cutaneous hypersensitivity reaction 
(Marson et al. 2007) including MPE, HSS, SJS and TEN (Roujeau et al. 1995). While 
the majority of affected patients experience only mild symptoms that resolve on 
cessation of the medication, others suffer significant morbidity or mortality. TEN is 
associated with an acute mortality rate of greater than 20% (Sekula et al. 2013; 
Lalosevic et al. 2015) and survivors can suffer long-term dermatologic (e.g. 
pigmentation) and ophthalmic (e.g. myopia, corneal scarring) sequelae (Schwartz et 
al. 2013; Quirke et al. 2015). At present the molecular mechanism(s) of these 
reactions is not fully understood. This chapter is focused primarily on cutaneous 
hypersensitivity reactions because of their frequency and strong associations with 
HLA alleles (Yip et al. 2012), although it should be noted that many manifestations 
of CBZ hypersensitivity involve multiple organ systems including liver, skin and 
kidneys (Mehta et al. 2014).   
 
DHRs, such as those described above for CBZ, are a consequence of inappropriate 
activation of the immune system (Pavlos et al. 2015). These immune-mediated 
reactions are classified as type B ADRs as they are idiosyncratic and unpredictable 
with respect to the pharmacology of the drug (Rawlins 1981). According to the Gell-
Coombs classification CBZ hypersensitivity is a Type IV reaction because of the 
delayed clinical presentation and presence of drug-reactive T lymphocytes (Gell 
1963; Wu et al. 2007). Currently, there are three mechanistic hypotheses that 
attempt to explain how drugs activate T cells: the hapten hypothesis, the PI concept 
and the drug-dependent altered HLA peptide repertoire concept (Figure 2.1). The 
hapten hypothesis was originally outlined in the 1930’s (Landsteiner and Jacobs 
1935) and in its current form proposes that chemically reactive small molecules 
 80 
 
(including drugs) or reactive metabolites irreversibly bind to an endogenous protein 
such as albumin. The small molecule is known as the hapten. The modified protein 
is then processed by APCs, generating a pool of chemically modified peptides. These 
peptides are presented on the MHC and act as antigens to trigger an immune 
response via TCR (Park et al. 2001). Under the PI model of drug hypersensitivity, the 
drug or metabolite binds non-covalently to either the TCR or MHC in a peptide 
independent manner and directly activates T cells (Pichler 2002). According to the 
altered peptide repertoire model, the offending drug attaches to the peptide-
binding cleft of the MHC thereby altering the shape and chemistry of the binding 
cleft. As a result, altered self-peptide repertoires are presented by the MHC and 
recognised as “foreign” by the immune system with a subsequent T cell response 
(Illing et al. 2012). 
 
 
Figure 2.1 Models of T cell activation by small molecules. A. The hapten hypothesis 
postulates that the drug or its metabolite (yellow star) produces an antigen (yellow 
triangle) by binding covalently to protein (blue rectangle) which is then processed 
by APC, generating drug-modified peptides (blue triangle) that are presented on the 
MHC. The TCR recognises the haptenated peptides as neoantigens, activating the 
immune response. B. In the PI model the drug or metabolite binds noncovalently to 
either the TCR or MHC leading to activation of the immune system. C. The ‘altered 
peptide repertoire’ model proposes that the drug or metabolite (yellow star) binds 
noncovalently to the MHC binding cleft and alters the specificity of binding of 
natural peptides. This leads to the presentation of novel peptides (green triangle) 
that can elicit an immune response. 
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In vitro experiments have shown that CBZ and certain oxygenated derivatives, 
namely CBZE, a major metabolite of CBZ (Breton et al. 2005), and DiOH-CBZ, the 
major metabolite of oxcarbazepine (Flesch 2004), are able to activate T-cells 
obtained from patients with previous CBZ hypersensitivity reactions via a direct 
interaction with MHC consistent with the PI concept (Wu et al. 2007).  The exact 
molecular interactions between CBZ, MHC and TCR are unclear but a recent 
structural modelling study proposes that CBZ can bind to the TCR, shifting TCR 
specificity and thereby altering the identification of self- and non-self peptides 
presented on the MHC; leading to aberrant activation of the immune system (Zhou 
et al. 2015). 
 
The oxidative metabolism of CBZ in humans is complex, involving multiple P450 
isoforms, leading to the generation of greater than 30 metabolites 
(Lertratanangkoon and Horning 1982) (Figure 2.2). Bioactivation of CBZ by P450 in 
HLM has been demonstrated by the formation of both cytotoxic and protein-
reactive metabolites (Pirmohamed et al. 1992; Leone et al. 2007). Indeed chemically 
reactive metabolites of CBZ have been invoked as being responsible for 
hepatotoxicity (Leone et al. 2014; Iida et al. 2015). The reactive species were not 
identified but from their deactivation by conjugation with GSH were evidently soft 
electrophiles (Pirmohamed et al. 1992). Several reactive intermediates of CBZ have 
been proposed to be responsible for protein adduct formation, including an arene 
oxide (Pirmohamed et al. 1992; Madden et al. 1996; Elliott et al. 2012), 9-acridine 
carboxaldehyde (Furst et al. 1995), an iminostilbene (Ju and Uetrecht 1999; Pearce 
et al. 2005) and an o-quinone (Lillibridge et al. 1996) and CBZE (Bu et al. 2005) 
(Figure 2.2). Interestingly, CBZE, an abundant (Breton et al. 2005) and 
pharmacologically active (Potter and Donnelly 1998) plasma metabolite formerly 
believed to be chemically stable (Pirmohamed et al. 1992), has been demonstrated 
to be chemically reactive through the spontaneous formation of two isomeric CBZE-
GSH adducts (CBZE-SG1 and CBZE-SG2) in vitro (Bu et al. 2005). The microsomal 
proteins CYP1A2 and CYP3A4 have also been demonstrated to form covalent 
adducts with reactive intermediates of CBZ (Wolkenstein et al. 1998; Kang et al. 
2008). Molecular modelling has suggested that Cys239 of CYP3A4 could be a 
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haptenation site, creating a thioether antigen to which the immune response may 
be directed (Leeder et al. 1996; Kang et al. 2008).  That deduction, the reaction of 
CBZE with GSH (Bu et al. 2005), and the trapping of CBZ’s reactive metabolites by 
GSH in microsomal incubations predict modification of proteins at cysteine residues 
(Bu et al. 2007). The inferred structures of the multiple GSH adducts produced from 
CBZ by HLM included thioether derivatives of one or more arene oxides, namely 
products of nucleophilic conjugate addition, as well as the two adducts of CBZE (Bu 
et al. 2007). Nonetheless CBZE-SG1 and CBZE-SG2 were the most abundant adducts 
formed from CBZ. Consequently it has been suggested that CBZE is the principal 
protein-adducting, and thereby antigen-generating, metabolite of CBZ. This is 
supported by the significant association between polymorphisms in mEH (encoded 
by EPHX1), the enzyme responsible for deactivating CBZE (Pirmohamed et al. 1992), 
and severe cutaneous ADR in CBZ patients of Han Chinese ethnicity (He et al. 2014). 
However, this is an association rather than proof of causality as the polymorphisms 
are not invariably associated with higher plasma concentrations of CBZE (Caruso et 
al. 2014; He et al. 2014). The selective covalent modification of proteins at cysteine 
residues by alkane oxides is in fact a well-characterised reaction (Kim et al. 1997; 
Arafet et al. 2014; He et al. 2015).  
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Figure 2.2 Proposed pathways of the oxidative bioactivation of CBZ in humans. 
The P450 isoforms shown are those reported to be the most active catalysts of the 
biotransformations (Pearce et al. 2008; Pearce et al. 2005; Pearce et al. 2002; Kerr 
et al. 1994). Based upon the relative expression of P450 isoforms in livers of 
Caucasians (Achour et al. 2014), CYP3A4 will usually be the predominant catalyst of 
both CBZ 3-hydroxylation and 10,11-epoxidation; while CYP2E1 will usually be the 
predominant catalyst of CBZ C-2 hydroxylation. However it was found in our study 
that CYP2B6 and CYP2E1, as well as CYP3A4 (Kerr et al. 1994), catalyze the 10,11-
epoxidation of CBZ in vitro. The depiction of the 2,3-arene oxide as the sole product 
of aromatic epoxidation is purely representational; the number of arene oxides 
formed is unknown. The metabolic hydrolysis of CBZE, and therefore the epoxide’s 
chemical (Pirmohamed et al. 1992; Bu et al. 2005) and pharmacological (Bourgeois 
and Wad 1984) deactivation in vivo, is catalysed by mEH (Kitteringham et al. 1996). 
 
Although existing experimental evidence supports direct interaction between CBZ 
and MHC/TCR as the mechanism for hypersensitivity reactions (Wu et al. 2006; Wei 
et al. 2012; Zhou et al. 2015) it is possible that parallel or alternative processes such 
as the hapten mechanism, as a result of reactive metabolite formation, could also 
activate the immune system. None of the highly reactive CBZ metabolites described 
earlier has been tested in vitro because they are probably too unstable for chemical 
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synthesis, so their ability to activate T cells is unknown. Also, the phenotype of CBZ 
hypersensitivity is clinically diverse; raising the possibility that multiple 
pathophysiological mechanisms may be involved. The aims of this study were to 
characterize the structures of the protein conjugates, i.e. the potential antigens in 
vivo, formed by the reactive metabolites of CBZ and hence derive the metabolic 
pathways of their formation, using human serum albumin (HSA) and glutathione S-
transferase pi (GSTP) as model proteins in vitro. GSTP is a proven biochemical 
reagent for trapping highly reactive small-molecule electrophiles (Jenkins et al. 
2008; Callan et al. 2009; Boerma et al. 2011), its three nucleophilic cysteines 
exhibiting markedly disparate adduction capabilities (Boerma et al. 2011). HSA has a 
much more varied set of adductable nucleophilic side-chains (Meng et al. 2011b; 
Jenkins et al. 2013; Meng et al. 2013; Meng et al. 2014a). Previous experiments 
have isolated and identified conjugates of circulating HSA and intrinsically reactive 
drugs (Jenkins et al. 2009; Meng et al. 2011b; Meng et al. 2014b), circulating 
reactive drug metabolites (Meng et al. 2013; Hammond et al. 2014) and metabolic 
intermediates that might be confined to intracellular locations (Meng et al. 2013; 
Meng et al. 2014a). CBZE is a major plasma metabolite in patients (Breton et al. 
2005), whereas the arene oxides are likely to be fleeting entities in blood (Lau et al. 
1984).  HSA isolated from patients prescribed CBZ therapy were also analysed to 
determine if conjugates are present in vivo. These conjugates and similar structures 
on other proteins have the potential to trigger the immunological signals 
responsible for hypersensitivity to CBZ.   
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2.2 Methods 
 
2.2.1 Chemicals 
HSA (97-99% pure) was purchased from Sigma-Aldrich (Poole, Dorset, United 
Kingdom), sequencing-grade modified trypsin was from Promega (Southampton, 
United Kingdom), while liquid chromatography mass spectrometry (LC-MS) grade 
solvents were from Fisher Scientific UK Ltd. (Loughborough, United Kingdom). All 
other reagents were from Sigma-Aldrich (UK). CBZ and CBZE were both purchased 
from Sigma-Aldrich.  
 
2.2.2 Microsomes and Supersomes 
HLM preparations (UltraPool HLM 150; a mixed gender pool from 150 donors) were 
obtained from BD Gentest Corp (Oxford, United Kingdom). Microsomes from 
baculovirus-infected insect cells (Supersomes) expressing human P450 isoforms 
(CYP3A4, 2B6, or 2E1) were also purchased from BD Gentest Corp. All recombinant 
enzymes were co-expressed with human NADPH-CYP reductase and human 
cytochrome b5 (Sigma Aldrich). 
 
2.2.3 Bradford Assay 
Calibration dilutions of a standard protein (0.2, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2 and 1.4 
mg/mL) were prepared in phosphate buffer (0.1 M, pH 7.4), using bovine serum 
albumin (Sigma-Aldrich Co). Each dilution (5 µL) was plated into 3 wells of a 96-well 
plate. The protein samples were plated in triplicate on the same 96-well plate. 
Bradford reagent (250 µL) was added to each well. The contents were mixed and 
any air bubbles removed using a sterile needle. Absorbance at 570 nm was 
measured using a plate reader. The means of the calibration values were calculated, 
and plotted on a standard calibration curve on Microsoft Excel. The protein 
concentrations of the samples were determined using the standard curve. The 
calculated concentration was the mean value of the three wells. 
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2.2.4 Conjugation of GSH with CBZE and Microsomally Generated Metabolites of 
CBZ  
Incubations of synthetic CBZE with GSH were undertaken to confirm the 
spontaneous conjugation reaction of CBZE with thiols, using GSH as a biopeptide 
model as reported by Bu et al. (2005). Additionally, microsomal incubations were 
also undertaken with the parent drug, CBZ, and GSH to trap any distinctive 
dihydrohydroxydibenzoazepinyl thioether conjugates that may be formed by 
electrophilic [O]CBZ metabolites.  
 
CBZE (80 µM; final methanol concentration, 1% v/v) was directly incubated with 
GSH (5 mM) in 0.1 M phosphate buffer (pH 7.4, final volume 0.25 mL) at 37oC for 2 
h. The reaction mixtures were analysed by LC-MS and LC-MS/MS without 
treatment. HLM and Supersome incubations were also set up by incubating CBZ 
(100 µM) with HLM (2 mg/mL) or Supersomes (20 nM), NADPH (2 mM), MgCl2 (5 
mM) and GSH (2 mM) for 2 h at 37oC in 0.1 M phosphate buffer (pH 7.4; final 
volume, 0.2 mL). To terminate the enzymatic reaction, two volumes of ACN were 
added to the reaction mixtures. The samples were vortexed, and centrifuged at 
12,000 g for 5 min at 4oC. The supernatants were collected and evaporated to 
dryness under nitrogen. The dry residue was stored at -20oC until analysed. On the 
day of analysis the samples were reconstituted in 0.1% aqueous formic acid (0.5 
mL).  
 
Aliquots (5-20 L) were injected onto a Zorbax Eclipse XDB-C8 column (150  4.6 
mm, 5 µm; Agilent Technologies, Santa Clara, CA) fitted with a Zorbax C18 Reliance 
pre-column and connected to a PerkinElmer series 200 HPLC system (PerkinElmer, 
Norwalk, CT). Analytes were eluted at room temperature with a gradient program 
of acetonitrile (5% to 30% over 20 min; 30% to 60% over 0.5 min; 60% for 4.5 min; 
60% to 5% over 0.1 min; 5% for 3.9 min) in 0.05% aqueous formic acid at 1.0 
mL/min. This gradient resolved GSH adducts of [O]CBZ ([O]CBZ represents 
generically the reactive monoxygenated metabolites of CBZ, i.e. CBZE and any 
isomeric arene oxide), the CBZ phenols and CBZE. The split-flow to the mass 
spectrometer was approximately 150 L/min. Analytes were detected in positive-
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ion mode with a 4000 Qtrap instrument (Sciex, Warrington, United Kingdom) that 
was operated under the following conditions: source temperature, 450 oC; ionspray 
voltage, 4,500 V;  desolvation potential, 100 V; entrance potential, 10 V; CAD gas 
setting, 5; collision energy, 25 eV; collision exit potential, 3 V; channel dwell time, 
150 ms; curtain gas setting, 15; Gas-1 and Gas-2 settings, 50; scanning, m/z 100-
1,000 over 5 s. The complete set of MRM monitoring transitions are listed in Table 
2.1. Transitions for the GSH conjugates were taken from the data of Bu et al. (2005). 
Instrument management and data processing were accomplished through Analyst 
1.5.1 software (Sciex). 
 
Table 2.1. MRM transitions for CBZ, CBZ metabolites and GSH adducts 
Analyte Transition 
DihydrohydroxyCBZ-S-glutathione conjugates 
m/z 560  542 
m/z 560  431 
m/z 560  413 
2-hydroxycarbamazepine m/z 253  210 
CBZ 10,11-epoxide m/z 253  210; m/z 253  180 
3-hydroxycarbamazepine m/z 253  210 
Carbamazepine m/z 237  194  
 
 
2.2.5 Covalent Modification of His-Tagged GSTP by Microsomally Generated 
Monoxygenated Metabolites of CBZ  
Hexahistidine-tagged human glutathione S-transferase π (His-GSTP) was expressed 
in E.coli as described previously (Chang et al. 1999) and kindly provided for these 
experiments by Dr Holly Bryan, University of Liverpool. Reactive metabolites were 
generated from CBZ (1 mM; final methanol concentration, 2% v/v) in co-incubations 
of nickel bead-captured GSTP (40 µM), prepared as described by Jenkins et al. 
(Proteomics, 2008), with either HLM (protein concentration, 2 mg/mL) or 
Supersomes (P450 concentration, 40 mM), MgCl2 (5 mM), and phosphate buffer (pH 
7.4), for 6 h at 37oC. The reactions were started by addition of NADPH (final 
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concentration, 1 mM). The final volume was 0.4 mL. Protein concentrations in this 
and all the other experiments were determined by the Bradford assay (section 
2.2.3). After the 6 h incubation period, a 0.2 mL aliquot was removed from the 
reaction mixture, taking care not to remove any nickel beads, and stored at 4oC for 
analysis of CBZ metabolite formation according to section 2.2.9. The nickel beads 
were recovered from the reaction mixture using magnetic separation and were 
washed 5 times with 1 mL phosphate buffer. Ammonium bicarbonate solution (50 
µL of 50 mM, pH 8.0) was added to the beads and the protein subjected to on-bead 
tryptic digestion (1 µg of trypsin per 200 µg of protein) at 37oC for 16 h. The 
digestion reaction was terminated by acidification of the incubation with 
trifluoroacetic acid (TFA 1%, final concentration 0.1%). Identification of covalently-
modified GSTP was undertaken using LC-MS according to section 2.2.12. 
 
2.2.6 Covalent Modification of HSA by Microsomally Generated Metabolites of 
CBZ 
CBZ (50 mM) was freshly dissolved in methanol and then diluted 1:5 with phosphate 
buffer (0.1 M, pH 7.4). The CBZ (final concentration, 1 mM) was co-incubated with 
either HLM (2 mg/mL) or Supersomes (20 nM), NADPH (1 mM) and MgCl2 (5 mM) 
and HSA (0.6 mM) in phosphate buffer, pH 7.4, for 2 h at 37oC (final methanol 
concentration, 2% v/v). The final volume was 0.2 mL. Each microsome/Supersome 
incubation was completed in duplicate and the second mixture was used to confirm 
metabolism of CBZ to monoxygenated metabolites according to section 2.2.9. The 
incubations for analysis of adduct formation were ultra-centrifuged at 100,000 rpm 
for 30 min at 4oC to remove microsomes and Supersomes from the mixture. HSA 
was isolated from the sample by using an anti-HSA affinity column (Agilent 
Technologies) attached to a PerSeptive Biosystems Vision Workstation (Applied 
Biosystems, Foster City, CA). The HSA was eluted with 12mM HCl and precipitated 
from the eluate with nine volumes of ice-cold methanol. The protein was re-
suspended in 50 µL of phosphate buffer, then reduced with 10 mM dithiothreitol 
(15 min) followed by alkylation with 50 mM iodoacetamide (15 min) at room 
temperature. The protein was precipitated once more with methanol and the 
concentration of HSA was determined using the Bradford assay (section 2.2.3). 
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Trypsin (1 µg per 200 µg protein) was added to the isolated HSA and incubated 
overnight for 16 h at 37oC before mass spectrometric characterisation of covalently-
modified protein according to section 2.2.12.  
 
2.2.7 Concentration-Dependent Modification of HSA by CBZE in vitro  
CBZE (50 mM) was freshly dissolved in methanol and diluted in phosphate buffer 
(0.1M, pH 7.4) and incubated with HSA (1 mM, 40 µL) in phosphate buffer (0.1 M, 
pH 7.4) at 37oC for 16 h. The molar ratios of CBZE to protein were 0.1:1, 1:1 and 5:1. 
The final concentration of methanol ranged between 0.1% (0.1:1 concentration) to 
5% (5:1 concentration). Protein was precipitated twice with nine volumes of ice-
cold methanol to remove non-covalently bound CBZ, re-suspended in 50 µL of 
phosphate buffer, and then reduced with 10 mM dithiothreitol (15 min) and 
alkylated with 50 mM iodoacetamide (15 min) at room temperature. The protein 
was precipitated once more with methanol and finally dissolved in 50 µL of 50 mM 
ammonium bicarbonate, pH 8.0. The protein concentration in each sample was 
determined using the Bradford assay (section 2.2.3). The protein (400 µg) was 
incubated with trypsin (2 µg) overnight for 16 h at 37oC. Samples of the digest (50 
µL) were processed for LC-MS/MS analysis according to section 2.2.12. 
 
2.2.8 Time-Dependent Modification of HSA by CBZE in vitro 
CBZE (50 mM) was freshly dissolved in methanol and diluted in phosphate buffer 
(0.1 M, pH 7.4) (1:5, v/v) before incubation with HSA (1 mM, 40 µL) in phosphate 
buffer (0.1 M, pH 7.4) at 37oC (final CBZE concentration, 5 mM). The final 
concentration of methanol was 10% (v/v). Aliquots of 80 µL were removed after 0.2, 
0.5, 1, 3, and 6 h and processed for LC-MS/MS analysis of tryptic digests as 
described in sections 2.2.7 and 2.2.12. 
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2.2.9 Analysis of CBZ Metabolites Produced by Microsomes and Recombinant 
P450 Isoforms  
To confirm metabolism of CBZ, reaction mixtures obtained from incubations with 
microsomes and GSTP (section 2.2.5) or HSA (section 2.2.6) were processed by the 
addition of equal volumes of ACN and were then centrifuged at 400g for 10 min at 
4oC. The supernatants were filtered using 0.22 µM filter units (Millipore, Cork, 
Ireland) and evaporated to dryness using nitrogen. Dry residues were reconstituted 
in 200 µL methanol/water (1:1 v/v) and transferred to glass autosampler vials (VWR 
International, Lutterworth, Leicestershire, United Kingdom) for analysis of 
metabolites by LC-MS and LC-MS/MS. Aliquots (5-20 L) were injected onto a 
Zorbax Eclipse XDB-C8 column (150  4.6 mm, 5µm; Agilent Technologies, Santa 
Clara, CA) fitted with a Zorbax C18 Reliance pre-column and connected to a 
PerkinElmer series 200 HPLC system (PerkinElmer, Norwalk, CT). Analytes were 
eluted at room temperature with a gradient programme of acetonitrile (15% to 33% 
over 12 min; 33% to 50% over 0.5 min; 50% for 5.5 min; 50% to 15% over 0.1 min; 
15% for 4 min) in ammonium formate (2 mM, pH 3.0) at 1.0 mL/min. The split-flow 
to the mass  spectrometer was approximately 150 L/min. Metabolites were 
detected in positive-ion mode with a 4000 Qtrap instrument (Sciex, Warrington, 
United Kingdom) that was operated under the following conditions: source 
temperature, 450 oC; ionspray voltage, 4,500 V; desolvation potential, 100 V; 
entrance potential, 10 V; CAD gas setting, 5; collision energy, 41 eV; collision exit 
potential, 3 V; dwell time, 150 ms; curtain gas setting, 15; Gas-1 and Gas-2 settings, 
50; scanning, m/z 100-1,000 over 5 s. The analyte transitions were m/z 253  m/z 
210 ([O]CBZ), 253  m/z 180 (CBZE). Instrument management and data processing 
were accomplished through Analyst 1.5.1 software (Sciex). Analytes were identified 
by chromatographic and mass spectrometric comparisons with authentic standards.    
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2.2.10 Patients’ Plasma Samples 
Twenty plasma samples from patients receiving maintenance CBZ therapy for 
epilepsy were analysed for the presence of [O]CBZ-HSA adducts. None of the 
patients had experienced an adverse reaction to CBZ. The samples were obtained 
from the Walton Centre NHS Foundation Trust as part of the PICME II clinical trial (a 
PK investigation into the metabolism of CBZ in epilepsy patients). The study had 
received ethics committee approval from the National Research Ethics Service 
Committee North West – Haydock (ethics reference: 13/NW/0503). All the patients 
were prescribed a stable dose of CBZ for at least 4 weeks. Clinical history and 
patient demographics were recorded. Blood (5 mL) was collected into lithium 
heparin-containing tubes and centrifuged immediately at 1500 g for 10 min at 4oC. 
The plasma was separated into 100 µL aliquots and frozen at -80oC until required 
for analysis. Further details regarding the recruitment of the patients to the PICME 
II clinical study can be found in chapter 3. 
 
2.2.11 Isolation of HSA from Patients’ Plasma Samples by Depletive Resin Binding 
and Normalisation of the Albumin Concentration 
Patient plasma samples (100 L) were thawed at room temperature on the morning 
of analysis, and HSA was isolated from 50 µl of the aliquot using a Pierce albumin 
depletion kit (Thermo Fisher Scientific, Paisley, UK) according to manufacturer 
instructions. Briefly, HSA-binding resin (400 µL) was transferred to the spin column 
and centrifuged at 12,000 g for 1 min. The flow-through was discarded and 200 µL 
of binding buffer centrifuged through the spin column for 1 min at 12,000 g. The 
flow-through was discarded and 50 µL of plasma incubated with the resin for 2 min 
at room temperature. The plasma incubation was centrifuged at 12,000 g for 1 min. 
The flow-through was collected and centrifuged again through the resin. Unbound 
proteins were washed off the resin by adding wash buffer and centrifuging at 
12,000 g for 1 min. The process was repeated three times. Albumin was eluted from 
the resin by centrifuging with 200 µL 1 M NaCl five times and retaining all of the 
flow-through. The albumin was reduced with 10 mM dithiothreitol for 15 min 
before alkylation with 50 mM iodoacetamide for 15 min, both steps at room 
temperature. An Amicon Ultra-0.5 mL centrifugal filter unit with Ultracel-50 
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membrane spin columns (Millipore, Watford, UK) was used to concentrate the 
albumin samples. The albumin samples were added to the spin column and 
centrifuged at 9200 g for 20 min. The spin columns were washed with 400 µL of 
LCMS-grade water at 9200 g for 20 min. LCMS-grade water (50 µL) was added to the 
albumin sample in the spin column and pipette into a new eppendorf tube. The 
albumin content was determined using the Bradford assay (section 2.2.3). All the 
albumin solutions were normalised to 100 pmol/µL and 2 µg of trypsin was added 
to each solution before overnight incubation. After trypsin digestion, incubations 
were diluted to 5 pmol/µL in 2% ACN/0.1% FA and K541 peptide (ATKEQLK) 
(internal standard) added such that its final concentration was 2.5 pmol/µL. 
Aliquots were analysed by mass spectrometry according to section 2.2.12. 
 
2.2.12 Mass Spectrometric Characterisation of Covalently Modified Proteins 
Chromatographic loading and mass spectrometric analysis of the tryptic digest 
samples was kindly undertaken by Dr Xiaoli Meng, University of Liverpool, according 
to the following standard method.  
 
Tryptic digests of the recovered GSTP and the recovered or isolated HSA (50 µL) 
were desalted using C18 ZipTips (Millipore, Watford, United Kingdom). Briefly, the 
bed of the C18 ZipTip was humidified with acetonitrile and equilibrated with an 
aqueous solution of TFA (0.1%). The digests were then loaded onto the pipette tip, 
washed with TFA (0.1%) and finally eluted with a mixture of acetonitrile (50%) and 
TFA (0.1%). The eluate was evaporated to dry residue and reconstituted in 2% 
ACN/0.1% formic acid (v/v). Aliquots (2.4−5.0 pmol) of these solutions were 
delivered into a QTRAP 5500 hybrid triple quadrupole/linear ion trap mass 
spectrometer (Sciex, Framingham, MA, USA), ﬁtted with a NanoSpray II source, by 
automated in-line liquid chromatography (U3000 HPLC System, 5 mm C18 
nanoprecolumn and 75 μm × 15 cm C18 PepMap column [Dionex, California, USA]) 
via a 10 μm inner diameter PicoTip (New Objective, Massachusetts, USA). A 
gradient from 2% ACN/0.1% FA (v/v) to 50% ACN/0.1% FA (v/v) in 60 min was 
applied at a ﬂow rate of 300 nL/min. The ion spray potential was set to 2,200−3,500 
V, the nebulizer gas to 19, and the interface heater to 150 °C. Spectra were acquired 
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automatically in positive-ion mode using information-dependent acquisition 
powered by Analyst 1.5 software, across mass ranges of 400−1000 amu in MS and 
100−1000 amu in MS/MS. The 5 most intense ions were selected for MS/MS, using 
a threshold of 5000 counts per second, with dynamic exclusion for 30 s and rolling 
collision energy. Modiﬁed peptides were identiﬁed by ﬁltering the product-ion 
signals for speciﬁc fragment ions in PeakView 1.2.0.3 (Sciex) and manual inspection 
of the spectra. 
 
For MRM detection of modiﬁed tryptic peptides from both GSTP and HSA 
incubations, MRM transitions specific for [O]CBZ-modified peptides were selected 
as follows: the mass/charge ratio (m/z) values were calculated for all possible 
peptides containing a histidine, lysine or cysteine residue; to these was added the 
mass of the prospective hapten (for CBZE and an arene oxide that has not 
rearomatized after its reaction with the protein , 252 amu; for an arene oxide that 
has rearomatized after its reaction with the protein, 234 amu); and finally the 
precursor ion masses were paired with the mass of a fragment ion that was 
expected to be a generic fragment of the predicted adducts, namely the 
hydroxydibenzoazepinyl species of m/z 210 shown in Figure 2.6. Analysis of 
histidine, lysine and cysteine residues was undertaken as these residues have been 
found to be the most commonly modified when drug-protein adducts are 
characterised by LC-MS/MS analysis of tryptic peptides (Osaki et al. 2014). MRM 
transitions were acquired at unit resolution in both the Q1 and Q3 quadrupoles to 
maximize specificity. They were optimized for collision energy and collision cell exit 
potential, and the dwell time was 50 ms. MRM survey scans were used to trigger 
enhanced product ion scans of [O]CBZ-modified peptides, with Q1 set to unit 
resolution, dynamic fill selected, and dynamic exclusion for 20 s. Total ion counts 
were determined from a second aliquot of each sample analysed by conventional 
LC-MS and were used to normalize sample loading on the column. Relative 
quantification of modified peptides was performed by comparing the relative 
normalized intensity of MRM peaks for each of the modified residues against total 
ion counts across samples. Data were analysed using Analyst software (Sciex).  
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2.3 Results 
 
2.3.1 Formation of GSH Conjugates by Microsomally Generated CBZ Metabolites  
As reported (Bu et al. 2007), two isomeric dihydrohydroxy-S-glutathione conjugates 
of CBZE (CBZE-SG1 and CBZE-SG2) were produced by direct incubation of CBZE with 
GSH. The conjugates, which were detected using the MRM transition m/z 560 431 
(the elimination of pyroglutamate from the glutamyl residue), which is effectively 
the generic fragmentation of S-glutathione conjugates in positive-ion analysis 
(Baillie and Davis 1993), eluted at 12.9 and 13.4 min, respectively (Figure 2.3). These 
two conjugates were also produced in the incubations of CBZ with HLM and all 
three CYP isoforms. The microsomal incubations also produced a singleton 
dihydrohydroxy-S-glutathione conjugate of CBZ at 11 min that was more polar, and 
consistently less abundant, than the isomeric metabolites derived from CBZE (Figure 
2.4). By a process of elimination, the polar product was deduced to be a conjugate 
of an arene oxide. Bu et al. (2007) came to the same conclusion (see Figure 2B in 
that paper). By way of confirmation, the reaction mixture was also analysed for a 
rearomatized, i.e. a dehydrated, S-glutathione conjugate, which is generally 
considered to be the signature GSH conjugate of arene oxides (Maggs et al. 2000; 
Henderson et al. 2005); using by analogy the MRM transition m/z 542 413. 
Indeed there is tentative evidence that a dihydrohydroxyCBZ-S-glutathione 
conjugates of CBZ produced by isolated rat hepatocytes underwent this dehydration 
(Mahajan and Evans 2008). However, no MRM signal was detected in our 
experiments. Because certain dihydrohydroxyaryl thioether conjugates are in fact 
somewhat stable, and require acidic conditions to undergo appreciable 
rearomatization (Jerina et al. 1970; Jeffery and Jerina 1975), aliquots of the reaction 
mixture were incubated with 5% TFA at room temperature for 2-28 h. Although 
extensive rearrangements of the conjugates were evident, the rearomatization 
product was not seen. The proportions of the three GSH conjugates generated by 
CYP3A4 and CYP2E1 were similar but a relatively higher proportion of the more 
polar singleton conjugate was produced by CYP2B6 (Table 2.2). All three CYP 
isoforms generated CBZE, 2OH-CBZ and 3OH-CBZ metabolites (Figure 2.5). 
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Figure 2.3 Isomeric GSH adducts of CBZE.  Formed on the incubation of GSH (5 mM) 
with synthetic CBZE (80 µM) in phosphate buffer, 0.1M, pH 7.4, at 37 oC for 2 h. The 
adducts were resolved on a C8 column, and detected in positive-ion mode by MRM 
(m/z 560  431, the neutral loss of pyroglutamate from the protonated molecule). 
 
 
Figure 2.4 Isomeric GSH adducts of monoxygenated CBZ metabolites that were 
formed from CBZ incubated with HLM and Supersomes. The thioether metabolites 
produced by CYP2B6 Supersomes are shown. CYP2B6 is the most active CBZ C-2 
hydroxylase (Pearce et al. 2002) and the most active CBZ hydroxylase overall (Table 
2.2). CBZE-SG1 and CBZE-SG2 were assigned by comparison with standards 
prepared from synthetic CBZE. The assignment of the third product to an adduct of 
CBZ arene oxide was based on inference. 
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Table 2.2 Relative proportions of the three isomeric dihydrohydroxyCBZ-S-
glutathione conjugates formed from CBZ by HLM and Supersomes 
Enzymic 
Preparation 
Ratio of GSH Adducts 
([O]CBZ-SG: CBZE-SG1: CBZE-SG2)* 
Aromatic Hydroxylase Activity 
(pmol/nmol P450/min)** 
HLM 7.0 : 45.2 : 47.8 NA 
CYP3A4 10.3 : 42.5 : 47.2 72.5 
CYP2B6 25.5 : 34.5 : 40.0 186 
CYP2E1 13.1 : 40.6 : 46.3 38 
*Relative areas of peaks in m/z 560  431 MRM chromatograms acquired by LC-
MS/MS (neutral loss of pyroglutamate from the protonated molecule) 
**Combined C-2 and C-3 CBZ hydroxylase activities of human P450 isoforms taken 
from Pearce et al (2002) 
 
 
 
Figure 2.5 Representative MRM chromatogram of [O]CBZ metabolites formed 
from the incubation of CBZ (100 µM), HLM (2 mg/mL), NADPH (2 mM), MgCl2 (5 
mM) and GSH (5 mM) in phosphate buffer (0.1 M, pH 7.4) for 2 h at 37 oC. The 
metabolites were resolved on a C8 column, and detected in positive-ion mode by 
MRM (m/z 253  210 CBZE and [O]CBZ). 
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2.3.2 Characterisation of GSTP Modified by Microsomally Generated Metabolites 
of CBZ  
A [O]CBZ adduct was identified at Cys47 of GSTP that was isobarically consistent 
with the adduct identified previously when GSTP was reacted with synthetic CBZE 
(Yip et al. 2014). LC-MS/MS analysis of the tryptic digests demonstrated the 
unmodified Cys47-containing 45ASCLYGQLPK54 peptide (+2 ion at m/z 540.3). 
Modification of Cys47 by one or more [O]CBZ species (CBZE and/or one or more  
arene oxides; the adduct’s product ion spectrum does not enable a more precise 
chemical assignment) resulted in a doubly charged peptide ion at m/z 666.3 that 
eluted at 34 min, corresponding to a mass increase of 252 amu compared with the 
mass of the unmodified peptide. The sequence of the proposed [O]CBZ-modified 
peptide, 45ASC*LYGQLPK54, was confirmed by the peptide’s product ion spectrum 
(Figure 2.7). An abundant ion at m/z 210.18 corresponded to a fragment ion derived 
from synthetic CBZE (the proposed structure is shown in Figure 2.6), providing the 
first-line evidence of the adduct’s structure. The b3* ion (m/z 514.21), with an 
adduction of 252 amu, confirmed the addition of [O]CBZ species to Cys47. Although 
human GSTP contains four cysteine residues, three of which are nucleophilic 
(Antonini et al., 1997; Chang et al., 2001), only Cys47 was found to be modified by 
metabolites of CBZ. Metabolism of CBZ to CBZE and [O]CBZ metabolites was 
confirmed in all experiments (Figure 2.8). 
 
 
 
 
 
 
 
 
Figure 2.6 Proposed structure and mass spectrometric fragmentation of the 
conjugate formed by the reaction of enzymatically generated [O]CBZ with Cys47. 
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Figure 2.7 Adduct of microsomally generated [O]CBZ and human GSTP. CBZ was incubated with CYP2B6 Supersomes and recombinant human 
GSTP at pH 7.4 and 37oC for 6 h. Representative product ion spectrum of the modified tryptic peptide adducted with one or more [O]CBZ 
species at Cys47. The red circle highlights the fragment ion m/z 210 consistent with fragmentation of [O]CBZ. 
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Figure 2.8 Representative MRM chromatogram of [O]CBZ metabolites formed 
from the incubation of CBZ (1 mM), Supersomes (CYP2B6 20nM), NADPH (2 mM) 
and HSA (0.6 mM) in phosphate buffer (0.1 M, pH 7.4) for 2 h at 37oC. The 
metabolites were resolved on a C8 column, and detected in positive-ion mode by 
MRM (m/z 253  210 CBZE and [O]CBZ).  
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2.3.3 Characterisation of Concentration-Dependent and Time-Course Modification 
of HSA by CBZE in vitro 
Figure 2.9 outlines the proposed general structure and fragmentation of conjugate 
formed by the reaction of CBZE with His146 on HSA with abundant ions at m/z 180, 
210, 236 and 253. A triply charged ion of m/z 717.8 was detected by LC-MS/MS at 
70 min, corresponding to an adduct derived from the tryptic peptide 
145RHPYFYAPELLFFAK159 with an additional mass of 252 amu (Figure 2.10). The b2* 
ion (m/z 546) confirms the addition of CBZE to His146. The His146 adduct was 
detected at all concentrations and relative abundance was positively correlated 
with increasing CBZE concentration (Figure 2.11). The reaction between CBZE and 
HSA was first detected at 30 min and showed a positive trend towards greater 
relative abundance of adduct over time up to 6 h (Figure 2.12).  
 
 
 
 
 
 
 
 
 
 
Figure 2.9 Proposed general structure and mass spectrometric fragmentation of 
conjugate formed by the reaction of CBZE with His 146 on HSA. 
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Modified HSA tryptic peptide 145RH([O]CBZ)PYFYAPELLFFAK159 (adducted at His 146) 
 
Figure 2.10 Representative product ion spectrum for adduct of CBZE and HSA (His 146). HSA (0.6 mM) was incubated with CBZ (1 mM), 
CYP3A4 Supersomes (20 nM), NADPH (1 mM) and MgCl2 (5 mM) at 37
oC for 2 h. The red circles highlight the fragments of the CBZE-derived 
moiety of the adduct. 
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Figure 2.11 Abundance of the CBZE-HSA His146 adduct relative to CBZE:HSA molar 
ratios. CBZE was incubated with HSA at pH 7.4 and 37oC for 16 h. 
 
 
Figure 2.12 Abundance of CBZE-HSA His146 adduct relative to incubation time. 
CBZE was incubated with HSA at pH 7.4 and 37oC, at a molar ratio of 10:1 
(CBZE:HSA). Adduct was first detected at 0.5 h; no adduct was detectable at 0.2 h. 
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2.3.4 Characterisation of HSA Modified by Microsomally Generated Metabolites 
of CBZ 
LC-MS/MS analysis of tryptic digests of HSA recovered from incubations with CBZ 
and HLM revealed the same [O]CBZ adduct at His146 as described above (Figure 
2.10). There was also tentative evidence for formation of a CBZ adduct at His146, 
that is, a stable adduct produced by dehydration of a primary, dihydrohydroxyaryl, 
structure derived from an arene oxide. Figure 2.13 outlines the proposed 
mechanism for formation of the arene oxide adduct. A triply charged ion of m/z 
711.7 detected at 63 min corresponded to an adduct of 145RHPYFYAPELLFFAK159 
with an additional mass of 234 amu (Figure 2.14) and the highlighted b and y 
fragments confirm the peptide sequence. 
 
 
 
 
 
 
Figure 2.13 Proposed reaction of arene oxide metabolite with his-146 residue of 
HSA
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Modified HSA tryptic peptide 145RH([O]CBZ)PYFYAPELLFFAK159 (adducted at His146) 
  
Figure 2.14 Representative product ion spectrum for possible adduct of monoxygenated CBZ (arene oxide) and HSA formed in microsomal 
incubations. HSA (0.6 mM) was incubated with CBZ (1 mM), CYP3A4 Supersomes (20 nM), NADPH (1 mM) and MgCl2 (5 mM) at 37
oC for 2 h.  
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2.3.5 Detection of CBZ-Derived Covalent Modification of HSA in Epilepsy Patients 
The clinical details for the patients who kindly donated the plasma samples are 
outlined in Table 2.3. The same [O]CBZ-modified His146 peptide, 
145RH*PYFYAPELLFFAK159, was identified in all twenty plasma samples (Figure 2.10). 
There was a 16-fold variability between the lowest level of [O]CBZ-HSA adduct 
(subject C009) and the highest (subject C036). Some subjects donated two plasma 
samples from separate visits and these are denoted as (b) in Figure 2.15 and Table 
2.3. The greatest intra-subject variability for amount of adduct observed was 3.6-
fold for subject C037 despite remaining on the same 1000mg total daily dose of CBZ 
during the 91 day interval between blood sampling. There was a moderate positive 
correlation between total daily CBZ dosage and the relative amount of the adduct 
(r2 = 0.3932, p = 0.0031) (Figure 2.16A). Plasma levels of CBZ, CBZE, 2OH-CBZ and 
3OH-CBZ were measured using HPLC-MS/MS for these subjects (Table 2.3) and 
further details regarding this method can be found in chapter 3. The strongest 
positive correlation was observed between CBZ plasma levels and relative amount 
of adduct observed (r2 = 0.4387, p = 0.0015) (Figure 2.16B). Moderate positive 
correlations were also reported between the relative amount of adduct observed 
and plasma CBZE levels (r2 = 0.3545, p = 0.0056, Figure 2.16C) and total plasma 
[O]CBZ levels (r2 = 0.3568, p = 0.0054, Figure 2.16E). The weakest positive 
correlation was observed between plasma levels of 2OH- and 3OH-CBZ with relative 
amount of adduct (r2 = 0.2619, p = 0.0211, Figure 2.16D).  
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Figure 2.15 Relative quantitation of [O]CBZ-HSA adduct in patients’ plasma 
samples [(b) denotes second plasma sample from same patient at separate visit; 
data represents mean (n=3) and standard deviation.] 
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Table 2.3 Patients’ clinical details and the relative levels of [O]CBZ-HSA adduct in their plasma [(b) represents second plasma sample from 
same patient at separate visit]. 
Patient 
ID 
Gender Age 
(years) 
Days 
between 
visits 
Total daily 
CBZ dosage 
(mg) 
Relative quantity of 
[O]CBZ-HSA adduct 
(mean, n=3)* 
Standard 
Deviation 
CBZ level 
(µg/mL) 
CBZE level 
(µg/mL) 
2OH-CBZ 
level 
(ng/mL) 
3OH-CBZ 
level 
(ng/mL) 
C009 M 34 X 200 1.00 0.00 1.56 0.16 1.76 2.96 
C011 M 53 X 800 1.99 0.34 1.31 0.231 1.04 1.82 
C011 (b) M 53 245 800 5.85 0.51 3.8 1.46 6.41 23.70 
C015 M 46 X 600 4.56 2.25 6.97 1.2 5.85 15.9 
C015 (b) M 46 202 600 2.22 1.16 6.76 0.918 6.77 15.2 
C018 F 46 X 1200 13.89 0.63 8.06 2.57 6.51 16.1 
C024 M 50 X 200 1.17 0.25 2.04 0.181 2.56 5.51 
C025 M 75 X 200 2.19 0.50 4.46 0.851 4.06 10.5 
C025 (b) M 75 210 200 6.44 0.99 5.05 1.18 10.5 21.6 
C034 M 60 X 800 5.02 1.08 8.86 1.32 10.3 17.1 
C035 F 62 X 1000 9.62 0.65 11.0 2.93 14.9 31.6 
C036 M 51 X 800 16.67 0.91 8.56 1.5 15.3 33.3 
C036 (b) M 51 53 800 6.79 1.15 11.7 1.68 16.4 38.5 
C037 F 27 X 1000 12.50 1.88 11.7 2.13 9.84 23.9 
C037 (b) F 27 91 1000 3.52 0.57 11.6 2.88 14.1 31.2 
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Patient 
ID 
Gender Age 
(years) 
Days 
between 
visits 
Total daily 
CBZ dosage 
(mg) 
Relative quantity of 
[O]CBZ-HSA adduct 
(mean, n=3)* 
Standard 
Deviation 
CBZ level 
(µg/mL) 
CBZE level 
(µg/mL) 
2OH-CBZ 
level 
(ng/mL) 
3OH-CBZ 
level 
(ng/mL) 
C044 F 48 X 1200 10.48 2.36 9.22 5.2 10.7 22.6 
C052 F 53 X 600 6.86 2.23 7.86 1.85 11.4 23.9 
C056 M 46 X 300 4.55 2.57 5.56 0.57 10 17.1 
C061 F 61 X 1000 12.75 3.85 8.09 2.68 11.5 26.9 
C067 F 58 X 1600 9.23 0.74 14.3 3.77 33.3 59.2 
* [O]CBZ-HSA adduct: an adduct derived from one or more reactive [O]CBZ species, namely CBZE and/or one or more  arene oxides. 
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Figure 2.16 Correlation between relative amounts of [O]CBZ-HSA adduct in 
patients’ plasma samples when compared with (A) total daily dosage, (B) CBZ 
plasma levels, (C) CBZE plasma levels, (D) 2OH- and 3OH-CBZ plasma levels and (E) 
total [O]CBZ plasma levels (CBZE + 2OH-CBZ + 3OH-CBZ).   
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2.4 Discussion 
This study demonstrates that microsomally generated electrophilic monoxygenated 
metabolites of CBZ are able to form covalent adducts with co-incubated human 
GSTP and HSA as well as with GSH (Bu et al., 2005) (Figure 2.17). Reactive 
metabolite trapping by exogenous protein incubated with hepatic microsomes has 
been employed previously to identify the metabolites and characterize the protein 
adducts. Yukinaga et al. (2012) captured reactive intermediates of paracetamol and 
raloxifene on Cys47 of human GSTP. Damsten et al. (2007) produced an adduct of 
N-acetyl-p-benzoquinone imine (NAPQI), the reactive metabolite of paracetamol, 
on Cys34 of HSA by incubating whole plasma with the drug and rat liver 
microsomes. The [O]CBZE-GSTP adduct at Cys47 was indistinguishable by LC-MS/MS 
from that formed in earlier incubations of synthetic CBZE and GSTP (Yip et al. 2014). 
That is, the adducts were isobaric and yielded the same diagnostic fragment ions. 
The Cys47 residue of human GSTP is a proven biochemical reagent for trapping 
highly reactive small molecule electrophiles; for example, the residue has been 
shown to trap the reactive quinoneimine metabolite of paracetamol in vitro (Jenkins 
et al. 2008). Direct incubation between CBZE and GSH yielded two isomeric 
dihydrohydroxyCBZ-S-glutathione conjugates of CBZE (CBZE-SG1 and CBZE-SG2). 
These two conjugates had been identified previously (Bu et al. 2005). Incubation of 
GSH with CBZ and HLM or Supersomes yielded an additional singleton 
dihydrohydroxyCBZ-S-glutathione conjugate ([O]CBZ-SG) (Figure 2.4). The singleton 
adduct was consistently less abundant than the other two conjugates and 
hypothesised to be formed via an arene oxide (Bu et al. 2007). Comparison of the 
relative aromatic hydroxylase activity of the three CYP isoforms demonstrated 
positive correlation with the relative abundance of [O]CBZ-SG (Table 2.2). It has 
been proposed that a reactive arene oxide intermediate is formed during 
hydroxylation of CBZ to 2OH-CBZ and 3OH-CBZ (Pirmohamed et al. 1992; Bu et al. 
2007).  The greater formation of [O]CBZ-SG by CYP2B6, the isoform with greatest 
aromatic hydroxylase activity, as presented in the results, is therefore consistent 
with this hypothesis. 
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Figure 2.17 Proposed conjugation of CBZE and CBZ 2,3-arene oxide with cysteine 
and histidine residues. Synthetic CBZE forms two isomeric thioether adducts when 
it reacts spontaneously with GSH at pH 7.4. Under identical conditions it reacted 
with human GSTP at Cys47, but with HSA at His146 and His338, by nucleophilic 
conjugate addition. HSA recovered from an incubation with human liver 
microsomes, CBZ and NADPH was modified at His146 by addition of 
monoxygenated CBZ ([O]CBZ; CBZE and/or one or more arene oxides, which are 
anticipated to yield dihydrohydroxyCBZ adducts indistinguishable by LC-MS/MS). 
HSA isolated from patients receiving CBZ therapy was modified only at His146 by 
[O]CBZ. The depiction of the 2,3-arene oxide as the sole product of aromatic 
epoxidation is purely representational; the number of arene oxides formed is 
unknown. The HSA incubated with CBZ and microsomes was also adducted at 
His146 by a residue of mass 234 amu, which was assigned tentatively to the 
dehydration product of the conjugate of an arene oxide (Figure 2.14).  
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Intracellular GSTP can be modified by chemically reactive drug metabolites in vivo: 
it is one of the adduction targets of NAPQI in mouse liver (Qiu et al. 1998). 
However, although the GSTP1 subunit is expressed in many human tissues it is not 
normally expressed in human liver (Sherratt et al. 1997). The protein is normally 
present in human plasma (Steinkellner et al. 2005) but at concentrations (approx. 
20-50 ng/mL) that are presently far too low for it to be used as a molecular 
dosimeter. Whereas HSA (66.5 kDa, t½ = 19 days), and specifically its Cys34 thiol 
(the anticipated reaction site of CBZE), has been recognised as a possible high-
abundance target for reactive drug metabolites (Damsten et al. 2007) and 
electrophilic species generally (Rappaport et al. 2012). Firstly because it is 
synthesized extensively in the liver (Ballmer et al. 1990), and thereby in close 
proximity to a major site of drug bioactivation, and secondly because is the most 
abundant plasma protein, normally constituting about 60% of the total protein in 
plasma (Quinlan et al. 2005; Goto et al. 2013) (Figure 2.18). Consequently, HSA 
might be an intracellular target of short-range reactive metabolites and an 
extracellular target of persistent circulating electrophiles such as CBZE. It has been 
widely used as a model protein to detect drug-mediated protein modifications 
(Meng et al. 2011b; Whitaker et al. 2011; Jinno et al. 2011; Ariza et al. 2012; 
Hammond et al. 2014). A CBZE-HSA adduct, at His146, was identified on direct 
incubation of CBZE and HSA, and was detectable at low concentrations (0.1:1, 
CBZE:HSA) after an incubation period of 30 min. An analogous (isobaric) His146 
[O]CBZ-HSA adduct was formed in microsomal incubations that also generated 
CBZE, 2OH-CBZ  and 3OH-CBZ in the presence of HSA (Figure 2.10). A second adduct 
at His146, having the form of CBZ-HSA, was also found in the microsomal 
incubations of CBZ with HSA (Figure 2.14), and was assigned preliminarily to a 
rearomatized derivative of an arene oxide adduct. If confirmed, this would 
represent the first chemical evidence of a CBZ arene oxide that has the ability to 
escape the microsomal microenvironment and modify soluble proteins. The His146 
residue of HSA has been shown to react with diverse electrophilic species including 
nevirapine metabolites (Meng et al. 2013), abacavir (Meng et al. 2014a) and delta 
12-prostaglandin J2 which functions as a regulator of inflammation (Yamaguchi et 
al. 2010). Although the Cys34 residue is conventionally regarded as the 
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predominant site of HSA’s reactions with organic electrophiles (Rappaport et al. 
2012), no adducts were detected with CBZE or [O]CBZ metabolites. However, a 
number of other thiophilic compounds have also failed to react with Cys34 on HSA 
(Yamaguchi et al. 2010; Yang et al. 2016). Docking studies have shown that the 
cavity lined by Cys34 is narrow which can therefore restrict access by thiophilic 
compounds (Aldini et al. 2008).   
 
Figure 2.18 Ribbon diagram of HSA showing the locations of the two residues 
adducted by synthetic CBZE in vitro: His146 and His338 (blue residues). Only His146 
was modified detectably, by monoxygenated CBZ (CBZE and/or CBZ arene oxide), in 
hepatic microsomal incubations and patients. The single free cysteine residue, 
Cys34, is shown as a red residue. It was not modified detectably, either in vitro or in 
vivo. The diagram was drawn with PyMol software (Schrödinger, Munich, Germany). 
 
If the adverse skin reactions associated with CBZ (Roujeau et al. 1995; Avancini et al. 
2015) are initiated by local protein haptenation, the haptenating species might be 
CBZE formed in the liver and delivered via the blood (Breton et al. 2005). However, 
protein-reactive metabolites of CBZ might also be produced locally.  
Cys34 
His146 
His338 
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Sulfamethoxazole and dapsone are two effective antimicrobials for the treatment of 
Pneumocystis carinii pneumonia but their use is limited by cutaneous ADRs which 
includes MPE, HSS and SJS/TEN (Svensson et al. 2001). Bioactivation of 
sulfamethoxazole and dapsone to reactive metabolites has been proposed to be a 
critical step for initiation of cutaneous ADR (Svensson 2003). Intracellular 
drug/reactive metabolite protein adducts were detected from incubations of 
sulfamethoxazole or dapsone with either normal human epidermal keratinocytes or 
HaCaT (an immortalised human keratinocyte cell line) (Roychowdhury et al. 2005; 
Vyas et al. 2006a; Vyas et al. 2006b). These studies provide evidence that 
keratinocytes are able to bioactivate drugs and form drug-protein adducts which 
may represent the antigenic determinants for T cells in hypersensitivity reactions. 
Interestingly, bioactivation in keratinocyte cell lines was mediated by flavin-
containing monoxygenases and peroxidases with limited involvement of CYP450 or 
COXs (Vyas et al. 2006a; Vyas et al. 2006b). Human skin has been shown to express 
multiple CYP450 isoforms including CYP3A4 and CYP2B6 (Yengi et al. 2003). Levels 
of CYP2B6 mRNA demonstrated the largest inter-individual variation with CYP2B6 
mRNA undetectable in some skin samples. Taken together, these findings suggest 
that metabolism of CBZ to reactive [O]CBZ metabolites could occur in keratinocytes 
and there would be variation between patients in the levels of [O]CBZ generated. 
Patients susceptible to hypersensitivity to CBZ may generate higher levels of [O]CBZ, 
overwhelming detoxification pathways and leading to keratinocyte death and 
manifestation of hypersensitivity.    
 
For the first time [O]CBZ-modified HSA was also detected in vivo, in patients 
prescribed standard CBZ therapy for epilepsy and without any indications of drug 
toxicity; including any indications of the neurotoxicity that has been associated with 
unusually high plasma concentrations of CBZE (Russell et al. 2015). The His146 
[O]CBZ-HSA protein adduct was identified in plasma samples from all of the 20 
patients. There was 16-fold inter-patient variation and 3.5-fold intra-patient 
variation in relative abundance of the CBZE-HSA adduct (Table 2.3). The presence of 
significant intra-patient variation in relative adduct abundance implies that even 
within a single patient the levels of [O]CBZ -HSA adduct are likely to be variable and 
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dependent on factors other than the size and time of dose. It is possible that all 
patients who receive CBZ therapy have [O]CBZ-HSA adducts in their circulation, 
irrespective of the imminence or presence of hypersensitivity, implying that other 
factors need also to be present to trigger a hypersensitivity reaction. Similar 
analyses conducted in patients receiving flucloxacillin therapy also identified parent 
drug- and metabolite-modified HSA in all (n=8) tolerant patients (Jenkins et al. 
2009). These data combined suggest that circulating drug-modified HSA alone is 
insufficient to trigger hypersensitivity. 
 
CBZE-HSA adducts appeared detectably in vitro from 30 min and increased over 
time (Figure 2.12). The half-life of human albumin is 19 days, so it is expected that 
as patients commence CBZ therapy and titrate their dosages the levels of CBZE-HSA 
adduct will also increase. It is possible that hypersensitivity reactions to CBZ may 
develop only when a critical threshold of adducts is exceeded. The amount of time 
taken to reach this threshold could partially explain the two to six week delay 
between starting CBZ therapy and manifestation of hypersensitivity (Knowles et al. 
1999). Cystic fibrosis patients receive multiple intravenous courses of antibiotics 
because of recurrent infections and are known to have a high incidence of 
piperacillin hypersensitivity (30-50%) (Parmar and Nasser 2005). Studies in these 
patients demonstrated that as the plasma concentration of piperacillin is increased 
then the number of modified residues on albumin increases, generating a larger 
number of epitopes that could be recognised by the immune system (Whitaker et 
al. 2011). Similarly, the current study has identified a moderate but significant 
positive correlation between the dosage of CBZ and relative abundance of [O]CBZ-
HSA adduct (r2 = 0.3932, p= 0.0031). The strongest positive correlation was 
observed between plasma CBZ levels and relative abundance of [O]CBZ-HSA adduct 
(r2= 0.4387, p = 0.0015). However, comparison of relative amount of [O]CBZ-HSA 
adduct with plasma CBZE concentrations (r2 = 0.3545, p = 0.0056) and all plasma 
[O]CBZ metabolites (CBZE, 2OH-CBZ and 3OH-CBZ) concentrations (r2 = 3568, p = 
0.0054) resulted in weaker positive correlations. The assay for measuring the 
amount of plasma CBZE-HSA adduct is only semi-quantitative, because it was not 
possible to synthesis CBZE-modified HSA peptides during the study, leading to 
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inaccurate measurement of adducts present. CBZE has also been previously shown 
to form covalent adducts with other (unidentified) plasma proteins and HLM, which 
were not measured as part of this study and may have led to underestimation of 
total amount of CBZE adducts formed (Bu et al. 2005).   
 
High concentrations of CBZ (1mM) were chosen for the in vitro experiments in 
comparison with the typical therapeutic plasma levels of CBZ observed in patients 
(0.05mM) in order to maximise generation of minor reactive metabolites thereby 
increasing the potential for detection of metabolite-modified protein adducts by 
HPLC-MS/MS. Incubation of synthetic CBZE and HSA generated a second CBZE-HSA 
adduct at His338 (Yip et al. 2014). However, no adduct other than the [O]CBZ-HSA 
at His146 was observed in microsomal or patient samples because microsomally 
generated and plasma levels of CBZE are unlikely to reach the molar ratios tested in 
vitro. The greatest concentration of CBZE observed in patients was 5.2 µg/mL (0.02 
mM) and when compared with a typical plasma albumin concentration of 0.6 mM 
results in a molar ratio of 0.03:1 (CBZE:HSA) in comparison with molar ratios of 
0.1:1 to 5:1 (CBZE:HSA) tested in vitro. Although unlikely it is possible that a small 
fraction of patients form a second hapten with CBZ therapy. Russell et al. found a 
plasma CBZE concentration of 54 µg/mL (214 µM) or 450% of the parent drug after 
multiple medication overdose, including 17.8 g of CBZ, which would translate to 
molar ratios in the range of the in vitro incubations (Russell et al. 2015). The 
relationship between plasma levels of drug/metabolite-protein adduct and 
susceptibility to hypersensitivity is poorly understood and warrants further 
investigation. 
 
It has been suggested that CBZ hypersensitivity is mediated through a direct PI 
mechanism (Wei et al. 2012). However, most of this evidence is derived from in 
vitro experiments which cannot replicate the complexity of in vivo situations where 
drug concentrations can vary in different tissues and genetic variation in drug 
metabolism enzymes might lead to differences between the levels of reactive 
metabolites (Yip et al. 2015b). HLA-B*15:02 and HLA-A*31:01 have both been 
associated with specific phenotypes of CBZ hypersensitivity reaction but both 
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associations have very low positive predictive values (Yip et al. 2012), implying that 
factors other than HLA genotype are involved in pathogenesis of hypersensitivity. 
The PI mechanism alone is unable to account for these findings. It is possible that 
CBZ may modify the MHC or TCR directly but CBZ or metabolite-modified peptide 
fragments are also required to be presented with MHC to activate T-cells. If the 
threshold of drug/metabolite-peptide is not reached or reactive metabolites 
detoxified then the peptide fragments may not be presented and activation of T 
cells avoided. There is significant heterogeneity of immune response in CBZ 
hypersensitivity which could imply that multiple complementary molecular 
mechanisms are involved in different patients or organ systems. There is also 
evidence from CBZ hypersensitivity consistent with the altered peptide repertoire 
model, where 15% of eluted peptides from CBZ-treated APCs expressing HLA-
B*15:02 were distinct from those bound to HLA-B*15:02 in the absence of CBZ 
exposure (Illing et al. 2012); highlighting the possibility of multiple aetiological 
mechanisms. Similar heterogeneity in mechanism of hypersensitivity has also been 
postulated for abacavir. Abacavir, a nucleoside reverse transcriptase inhibitor used 
for treatment of HIV, is associated with hypersensitivity reactions in patients 
positive for HLA-B*57:01, and crystal structure and modelling studies have provided 
evidence for the altered peptide repertoire model of immune system activation 
(Illing et al. 2012; Ostrov et al. 2012). Despite these findings analysis of HSA from 
patients prescribed abacavir revealed that the metabolic intermediate abacavir 
aldehyde was also able to modify multiple amino acid residues on HSA, including 
His146, leading to the possible generation of multiple antigens (Meng et al. 2014a). 
Current in vitro assays for diagnosis and investigation of DHRs (e.g. LTT) are limited 
because only stable compounds, such as parent drug and stable metabolites, are 
routinely investigated (Schrijvers et al. 2015). Future studies need to focus on assay 
systems that enable the generation of reactive metabolites and incorporate drug-
modified peptides to determine their ability to elicit T-cell responses (Whitaker et 
al. 2011).  
 
In conclusion, this study has provided the first chemical evidence for the 
microsomal production of [O]CBZ species that are able to escape the microsomal 
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domain to react covalently with exogenous soluble proteins. If those species are 
equally able to escape from the endoplasmic reticulum of living cells they might 
haptenate numerous intracellular proteins (in fact the ER membrane is significantly 
more permeable to small organic molecules than other cellular membranes (Le Gall 
et al. 2004). Most importantly, this study has demonstrated the presence of 
circulating [O]CBZ-modified HSA in patients without ADR who were receiving 
standard CBZ therapy and did not have exceptionally high concentrations of CBZE in 
their plasma. 
  
 119 
 
 
Chapter 3  
The development of a high-performance liquid 
chromatography-tandem mass spectrometry 
technique for measurement of carbamazepine 
and four metabolites in human plasma 
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3.1 Introduction 
The metabolism of CBZ in humans is complex, with multiple pathways leading to the 
generation of over 30 metabolites (Lertratanangkoon and Horning 1982). CBZ is 
almost completely metabolised in the liver, with only approximately 5% excreted 
unchanged in the urine (Thorn et al. 2011). CBZ is oxidised by several CYP450 
isoforms and is known to induce its own metabolism through transcriptional up-
regulation of multiple CYPs in the liver (Oscarson et al. 2006). Autoinduction is 
usually complete within the first two weeks of starting therapy but contributes to 
drug-drug interactions when CBZ is prescribed as part of polytherapy (Kudriakova et 
al. 1992; Dresser et al. 2000). 
 
It has been persistently hypothesised that reactive drug metabolites could be 
responsible for hypersensitivity to some drugs in certain patients (Park et al. 2001; 
Faulkner et al. 2014). The exact identities of those reactive metabolites remain 
unknown but arene oxide, o-quinone, iminoquinone and acridine species have been 
hypothesised in the case of CBZ (Madden et al. 1996; Pearce et al. 2002; Pearce et 
al. 2005; Pearce et al. 2008). The major oxidative route of metabolism for CBZ is 
conversion to the pharmacologically active CBZE, which is primarily catalysed by 
CYP3A4 and accounts for approximately 70% of total metabolism (Thorn et al. 
2011). CBZE is further metabolised in humans by mEH to DiOH-CBZ (Kroetz et al. 
1993; Kerr et al. 1994). The second most important pathway in metabolism of CBZ is 
the formation of 2OH-CBZ and 3OH-CBZ, which are postulated to proceed through 
the highly reactive arene oxide intermediate, CBZ 2,3-epoxide (Madden et al. 1996; 
Bu et al. 2007) (Figure 3.1).  
 
CYP2E1 is the most active catalyst for the formation of 2OH-CBZ in HLMs, whilst 
CYP2B6 is the most active catalyst for 3-hydroxylation (Pearce et al. 2002). 
However, CYP3A4, which is generally the most abundant P450 isoform in adult 
human liver (Achour et al. 2014), also possesses substantial C-3 hydroxylase activity 
(Pearce et al. 2002), and additionally has minor C-2 hydroxylase activity (Section 
2.3). From a combination of specific activities and the isoform abundance in livers of 
adult Caucasians, it is probable that CYP2E1 and CYP3A4 are usually the 
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predominant hepatic catalysts of CBZ C-2 hydroxylation and C-3 hydroxylation, 
respectively. Breton et al. (2005) found that 3OH-CBZ was the principal phenolic 
metabolite of CBZ in plasma from a set of chronically treated patients: 2OH-CBZ, 
0.023–0.057 µg/mL (9/30 patients); 3OH-CBZ, 0.023–0.72 µg/mL (25/30 patients). 
This finding conformed with the documented enzymology of CBZ’s hydroxylation: 
the specific C-3 hydroxylase activity of CYP3A4 is approximately five-fold greater 
than the specific C-2 hydroxylase activity of CYP2E1 (Pearce et al. 2002).  
 
 
Figure 3.1 Simplified representation of the oxidative and hydrolytic pathways of 
the metabolism of CBZ in humans. Showing all of the plasma metabolites assayed 
in the present investigations (CBZ 2,3-epoxide is shown in brackets as this 
intermediate species is a hypothetical structure, based on the known chemical 
structures of the stable phenolic metabolites). The complete oxidative pathways of 
the metabolism of CBZ in humans, as currently known, are shown in Figure 1.3. 
 
CBZE is a reactive metabolite that forms covalent adducts with HSA in vitro, and 
probably contributes to the production of circulating CBZ[O]-HSA adducts in 
patients established on CBZ therapy (Figure 2.10). The formation of 2OH- and 3OH-
CBZ implies the bioactivation of CBZ to a reactive arene oxide intermediate (Pearce 
et al. 2002). Indeed, arene oxide metabolites have been shown to contribute to the 
covalent binding of CBZ to hepatic microsomal protein (Pirmohamed et al. 1992), 
and GSH adducts of epoxides have been identified in the bile of rats given CBZ 
(Madden et al. 1996). The liver contains multiple detoxification pathways as it is 
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exposed to potentially harmful exogenous chemical substances each day from the 
environment (Grant 1991).  
 
Chemical deactivation (bioinactivation) of CBZ, and of pre-reactive and reactive CBZ 
metabolites, is proposed to be through glucuronidation by UGT2B7 (Staines et al. 
2004), reduction by DT-diaphorase, methylation by catechol-O-methyltransferase 
(Lillibridge et al. 1996), hydrolysis by mEH (Kitteringham et al. 1996; Nakajima et al. 
2005) and conjugation with GSH (Madden et al. 1996; Bu et al. 2005; Bu et al. 2007). 
These pathways could play an important role in limiting the hypersensitivity 
reactions to CBZ. Intrinsic or acquired insufficiency of those detoxification pathways 
or generation of excessive reactive metabolites could lead to the initiation of 
cellular damage and CBZ-induced hypersensitivity (Green et al. 1995; Zhu et al. 
2014). 
 
To investigate the roles of bioactivation and bioinactivation pathways in the 
development of CBZ hypersensitivity reactions, it is necessary to measure human 
plasma levels of CBZ and its metabolites. In clinical practice TDM of CBZ can help to 
guide dosing especially as CBZ interacts with many drugs, including other 
antiepileptics (Neels et al. 2004).  Correlation between CBZ dosage and plasma 
levels is poor so TDM is important in detecting elevated CBZ levels in patients with 
signs of toxicity or low levels in those with no therapeutic effect (Bondareva et al. 
2006). Therapeutic levels of CBZ are between 4-12 mg/L and fatalities have been 
reported at levels >20 mg/L  (Schulz et al. 2012). Because CBZE contributes to the 
clinical response - the therapeutic range is considered to be 0.4-4 mg/L - its plasma 
concentration should not be greater than 9 mg/L to prevent toxicity (Burianova and 
Borecka 2015). Other metabolites of CBZ are not routinely measured in clinical 
practice. It was therefore necessary to develop an assay capable of measuring 
plasma levels of CBZ, CBZE, DiOH-CBZ, 2OH-CBZ and 3OH-CBZ in patients. These 
analytes were selected because of their hypothesised role as reactive metabolites in 
vivo (CBZE) or as downstream products of reactive metabolites (DiOH-CBZ, and 
2OH- and 3OH-CBZ; Figure 3.1) 
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Several HPLC-MS/MS techniques to assay CBZ and one or more of its metabolites in 
human plasma or serum have been published (Eto et al. 1995; Wad et al. 1997; Van 
Rooyen et al. 2002; Breton et al. 2005; Lionetto et al. 2012; Shibata et al. 2012). 
Two of the methods quantify only CBZ and CBZE (Van Rooyen et al. 2002; Lionetto 
et al. 2012) whilst two other methods quantify only individual minor metabolites 
(Eto et al. 1995; Wad et al. 1997). The most comprehensive HPLC-MS/MS assay 
quantified CBZ and nine metabolites with 2-methyl-carbamazepine (2Me-CBZ) as 
internal standard (IS) (Breton et al. 2005). This method included all of the analytes 
of current interest: CBZ, CBZE, DiOH-CBZ, 2-hydroxycarbamazepine (2OH-CBZ) and 
3-hydroxycarbamazepine (3OH-CBZ), and acted as a basis for the development of 
the HPLC-MS/MS assays described below. Assay development was undertaken 
according to the guidelines for bioanalytical method validation outlined by the FDA 
(Food and Drug Administration 2001). 
 
 
3.2 Methods 
 
3.2.1 Chemicals and Reagents 
CBZ (Sigma-Aldrich Co, Poole, UK), CBZE (Sigma-Aldrich Co), DiOH-CBZ (NewChem 
Technologies, Durham, UK), 2OH-CBZ (NewChem Technologies) and 3OH-CBZ 
(NewChem Technologies) were measured using the HPLC-MS/MS assay. The 
purities for each compound were reported by the manufacturers and are as follows: 
CBZ ≥98%, CBZE ≥98%, DiOH-CBZ 98.5%, 2OH-CBZ 99.4% and 3OH-CBZ 97.6%. 2Me-
CBZ (NewChem Technologies) was used as the internal standard for all the assays of 
plasma analytes and its purity was reported as 99.7%. The ammonium formate 
buffer solution (pH 3) consisted of the formic acid salt (126 mg/L) dissolved in 
purified water (HPLC eluent A). Purified water was generated by a PURELAB Ultra 
water system (Veolia Water Technologies UK, High Wycombe, Buckinghamshire). 
Acetonitrile (Fisher Scientific, Loughbrough, UK) used in eluent B was LCMS grade. 
All reagents were LCMS grade unless otherwise specified. 
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For validation of the method, blood samples from healthy volunteers were collected 
in lithium heparin tubes and centrifuged at 1500g for 10 min at 4oC to obtain 
plasma. 1 mL aliquots of plasma were separated, and frozen at -80oC. Plasma 
aliquots were thawed at room temperature when required during the study for the 
preparation of calibration and quality control (QC) standards. The study protocol 
was approved by the University of Liverpool research ethics committee. 
 
Stock solutions of the analytes and internal standard were prepared by dissolving 
each compound in acetonitrile (Table 3.1). Stock solutions were stored at 4oC and 
protected from light during the analyses. Working solutions were prepared fresh 
daily by diluting stock solutions with acetonitrile-water (50:50, v/v) (Breton et al. 
2005). 
 
Table 3.1 Concentrations of stock solutions (all analytes were dissolved in 
acetonitrile) 
Analyte Concentration (mM) 
Carbamazepine 45 
Carbamazepine-10,11-epoxide 12.5 
10,11-dihydro- 10,11-trans- dihydroxy-
carbamazepine 
4 
2-hydroxycarbamazepine 2.5 
3-hydroxycarbamazepine 10 
2-methylcarbamazepine 4 
 
 
3.2.2 Preparation of Calibration and Quality Control (QC) Standards 
The calibration set consisted of eight concentrations and they were prepared by 
adding 3 µL of each analyte (CBZ, CBZE, DiOH-CBZ, 2OH-CBZ and 3OH-CBZ) and 3 µL 
of internal standard (2Me-CBZ, 0.2mM) into 482 µL of drug-free human plasma. 
After addition of the analytes and internal standard the samples were vortexed for 
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30 s to ensure thorough mixing. The calibration concentrations for each analyte are 
recorded in Table 3.2. The plasma was pooled from six volunteer donors to 
minimise volunteer-specific matrix effects. QC standards used for assay validation, 
and thereby the acceptance of the assays of each batch of analytical samples, were 
prepared in the same way as the calibration standards. Three QC standards, 
corresponding to low (Q1), middle (Q2) and high (Q3) concentration points of the 
calibration curve, were prepared by mixing volunteer plasma and 3 µL of working 
solution for each analyte and 3 µL of internal standard (0.2 mM) (Table 3.3). To 
ensure that the physico-chemical integrity of the matrix was maintained, the total 
volume of working solution added to the matrix (human pooled plasma) was always 
less than 4% of the final volume of the spiked plasma. Acetone (500 µL) was added 
to each calibration and QC standard and then vortexed for 30 s. The mixtures were 
centrifuged at 1400g for 10 min at room temperature. The supernatant was 
collected carefully, leaving behind the precipitate. The supernatants were 
evaporated to dry residue using a SpeedVac vacuum concentrator (Eppendorf, 
Germany). The dried residues were then reconstituted in 500 µL of acetone and 
water (50:50 v/v). The samples were vortexed to ensure complete homogenisation. 
An aliquot of the vortexed solution (100 µL) for analysis of CBZ, CBZE and DiOH-CBZ 
was transferred into a glass HPLC autosampler vial (VWR, Leicestershire, UK) ready 
for immediate analysis.  
 
For analysis of the plasma QC and calibration standards for 2OH- and 3OH-CBZ, 100 
µL of each standard was aliquoted from the deproteinized and reconstituted 
supernatants, and centrifugally filtered at 450 g for 15 min at 4oC through a 0.45 µm 
hydrophilic PTFE filter plate (Merck Millipore, Watford, UK). The filter plates were 
prepared by adding 100 µL of water and centrifuging at 450 g for 15 min at 4oC prior 
to sample processing. The filtrates were subsequently transferred into glass HPLC 
autosampler vials (VWR) ready for immediate analysis. The PTFE filter plates were 
used to further remove any proteins that may have still been present. 
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Table 3.2 Calibration ranges for each analyte 
Calibration 
Points 
CBZ 
(µg/mL) 
CBZE 
(µg/mL) 
DiOH-CBZ 
(µg/mL) 
2OH-CBZ 
(ng/mL) 
3OH-CBZ 
(ng/mL) 
1 0.33 0.10 0.10 0.92 4.73 
2 0.66 0.20 0.20 1.85 9.46 
3 1.33 0.39 0.41 3.69 18.91 
4 2.66 0.79 0.81 7.39 37.83 
5 5.32 1.58 1.62 14.77 75.66 
6 7.97 3.15 3.24 29.54 151.32 
7 10.63 4.73 4.86 59.09 302.64 
8 15.95 6.30 6.49 118.18 605.28 
 
 
Table 3.3 Quality control sample concentrations 
Quality 
Control 
CBZ 
(µg/mL) 
CBZE 
(µg/mL) 
DiOH-CBZ 
(µg/mL) 
2OH-CBZ 
(ng/mL) 
3OH-CBZ 
(ng/mL) 
QC1 (low) 0.475 0.150 0.150 2.000 10.000 
QC2 (middle) 4.750 1.500 1.500 10.000 50.000 
QC3 (high) 9.500 6.000 6.000 100.000 500.000 
 
 
3.2.3 Liquid Chromatography-Tandem Mass Spectrometric Analysis of Calibration 
and QC Standards 
Aliquots (20 µL) of the calibration and QC standards for CBZ, CBZE and DiOH-CBZ 
were injected onto an Agilent 5-µM Zorbax Eclipse XDB-C8 column (150 mm x 4.6 
mm; Agilent Technologies, Santa Clara, CA, USA) also attached to a 5 µM Eclipse 
XDB-C18 guard column (Agilent Technologies) without further treatment for 
determination of CBZ, CBZE and DiOH-CBZ levels. The samples were separated by 
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gradient elution at room temperature with acetonitrile in ammonium formate 
buffer (2 mM, pH 3). The eluent was delivered by a PerkinElmer series 200 HPLC 
system (pump and autosampler; PerkinElmer, Norwalk, CT, USA). The MS analysis 
was performed using a 4000 QTrap hybrid quadrupole mass spectrometer (Sciex, 
Warrington, UK) with a Turbo V electrospray source that was connected to the 
column using a Valco flow-splitting T-piece. The split flow of the eluate was 
approximately 150 µL/min. CBZ, CBZE and DiOH-CBZ were eluted with the following 
optimized gradient of acetonitrile: 15% to 33% over 12 min; 33% to 50% over 0.5 
min; 50% for 2 min; 50% to 15% over 0.5 min; 15% for 4 min. The eluent flow rate 
was 1.0 mL/min. The operating parameters of the mass spectrometer (source and 
Q1) were as follows: source temperature, 450oC; ionspray (electrospray capillary) 
voltage, 4,500 V; entrance potential, 10 V; curtain gas setting, 15; spray gas (Gas-1) 
setting, 50; heater gas (Gas-2) setting, 50. Table 3.4 outlines the analyte specific 
mass spectrometric parameters for CBZ, CBZE, DiOH-CBZ and 2Me-CBZ. The 
instrument was set up for MRM acquisitions. Instrument management and data 
processing were accomplished through Analyst 1.5.2 software (Sciex, Framingham, 
MA, USA). 
 
Table 3.4 Mass spectrometer parameters for CBZ, CBZE,DiOH-CBZ and 2Me-CBZ 
MS Parameter CBZ CBZE DiOH-CBZ 2Me-CBZ 
Dwell time (msec) 150 150 150 150 
Desolvation potential 
(V) 
121 76 46 121 
Exit potential (V) 10 10 10 10 
Collision energy (V) 27 33 41 27 
Collision exit potential 
(V) 
12 48 10 12 
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To measure levels of 2OH-CBZ and 3OH-CBZ, 5 µL of the calibration and QC 
standards were injected onto a Waters 2.5 µM Xbridge BEH C18 column (2.1 mm x 
150 mm; Waters Limited, Herts, UK) which was also attached to a 2.5 µM Xbridge 
BEH C18 VanGuard pre-column (Waters Limited, UK). The samples were separated 
by optimized gradient elution at 40oC with acetonitrile containing 0.1% formic acid 
in ammonium formate buffer (2 mM, pH 3). The eluent was delivered by an 
UltiMate 3000 HPLC system (Dionex, Sunnyvale, CA, USA). The MS analysis was 
performed using a 4000 QTrap hybrid quadrupole mass spectrometer (Sciex, UK) 
with a Turbo V electrospray source that was connected directly to the column. 2OH-
CBZ and 3OH-CBZ were eluted with the following gradient of acetonitrile: 15% to 
20% over 2 min; 20% to 25% over 2 min; 25% to 30% over 2 min; 30% to 60% over 2 
min; 60% for 4 min; 60% to 15% over 0.1 min; and 15% for 6.9 min. The eluent flow 
rate was 200 µL/min. The operating parameters of the mass spectrometer (source 
and Q1) were as follows: source temperature, 450oC; ion spray (electrospray 
capillary) voltage, 5,500 V; entrance potential, 10 V; curtain gas setting, 30; spray 
gas (Gas-1) setting, 40; heater gas (Gas-2) setting, 40. Table 3.5 outlines the analyte 
specific mass spectrometer parameters for 2OH-CBZ, 3OH-CBZ and 2Me-CBZ. The 
instrument was set up for MRM acquisitions. Management of the HPLC pump was 
achieved using the Chromeleon 6.80 software (Dionex Corporation, CA, USA) linked 
using Dionex chromatography MS link version 2.7.0.2551 (Dionex Corp, USA) to 
Analyst 1.5.1 software (Sciex, UK), which was used to the control the MS. Data 
processing was accomplished through Analyst 1.5.1 software (Sciex, UK). 
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Table 3.5 Mass spectrometer parameters for 2OH-CBZ, 3OH-CBZ and 2Me-CBZ 
MS Parameter 2OH-CBZ 3OH-CBZ 2Me-CBZ 
Dwell time (msec) 100 100 100 
Desolvation potential 
(V) 
56 61 121 
Exit potential (V) 10 10 10 
Collision energy (V) 27 27 27 
Collision exit potential 
(V) 
14 16 12 
 
For each analyte and the internal standard, two ions were selected: the protonated 
molecule (M + H+), as the parent ion, and a daughter ion (Table 3.6). The most 
abundant ions following full scanning acquisitions were chosen as the daughter 
ions. Secondary, less abundant, confirmation-of-identity transitions were also 
selected for each analyte from the full scanning acquisition data (Table 3.6). 
 
Table 3.6 Selected parent and daughter ions for each compound 
Drugs Parent Ions (M + 
H+), (m/z) 
Daughter Ions (m/z) Confirmation-of-
Identity Ions (m/z) 
CBZ 237 192 194 
CBZE 253 180 208 
DiOH-CBZ 271 180 210 
2OH-CBZ 253 210 167 
3OH-CBZ 253 210 180 
2Me-CBZ 251 208 206 
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3.2.4 Data Analysis 
Mass spectrometric data analysis was undertaken using the quantitation facility of 
the relevant Analyst 1.5-generation software (Sciex, UK). From the automatically 
computed and visually inspected peak areas, the ratio of each analyte to the 
internal standard was calculated and plotted against analyte concentrations to 
confirm the linearity of each standard curve. The analyte concentrations were 
calculated from the equation y = mx + b, as determined by the weighted (1/x) linear 
regression of the standard line. The regression was not forced through zero. The 
correlation coefficient (r2) was determined for each calibration curve and only 
accepted if >0.99. 
  
3.2.5 Accuracy and Precision 
Intra- and inter-day accuracy and precision (collectively, repeatability) for each 
analyte in the assays were determined. Intra-day repeatability was assessed by 
analysing low, middle and high QC standards for each analyte in pooled plasma five 
times in a single day against a set of freshly prepared calibration standards. Inter-
day repeatability was assessed by repeating the above procedure on five separate 
days using freshly prepared low, middle and high QC standards against freshly 
prepared sets of calibration standards. The accuracy of the method was expressed 
by [(mean observed concentration)/ (spiked concentration)] x 100. Precision was 
determined by calculating the coefficient of variation (CV) (%).  
 
3.2.6 Analyte Specificity Studies 
To investigate the specificity of the assays, drug-free plasma was obtained from five 
healthy volunteers and processed separately as described in 3.2.2 to determine if 
signal-conflicting endogenous constituents coeluted with the different analytes. 
Elution times and relative intensities of endogenous MRM signals were then 
compared with those of the analytes of interest. 
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3.2.7 Determination of the Lower Limit of Quantitation 
The lower limit of quantitation (LLOQ) for each analyte was defined as the lowest 
concentration which could be determined with an accuracy of 100 +/- 20% and a 
precision of ≤20%, in line with FDA recommendations.  
 
3.2.8 Recovery and Matrix Effects 
Recovery and matrix effects for the assays were measured according to a strategy 
outlined by Matuszewski et al. (2003). Matrix effect is the effect on an analytical 
method caused by all other components of the sample except the analyte to be 
quantified and may result in ion suppression or enhancement of the target analyte 
in the presence of co-eluting compounds (Matuszewski et al. 2003). The presence of 
matrix effects needs to be investigated to ensure that the assay is valid and 
accurate for assessment of patient plasma samples (Food and Drug Administration 
2001). Three sets of calibration samples were prepared using pooled plasma from 
six healthy volunteers. Set 1 consisted of 3 µL of each analyte added to 485 µL 
acetone:water (50:50, v/v) without further processing prior to injection onto the 
HPLC-MS/MS. Set 2 was prepared by evaporating to dry residue 500 µL of volunteer 
plasma in a SpeedVac (Eppendorf, Germany) before reconstitution in 485 µL 
acetone:water (50:50, v/v) and addition of 3 µL of each analyte. The final set 
consisted of 485 µL volunteer plasma spiked with 3 µL of each analyte that was 
evaporated to dry residue in a SpeedVac vacuum concentrator (Eppendorf) and 
finally reconstituted in 500 µL acetone:water (50:50, v/v). An aliquot (20 µL) of each 
sample was injected onto the HPLC-MS/MS in accordance with section 3.2.3.  
 
Recovery (%) was calculated as the ratio of the mean peak area (n=3) of an analyte 
spiked before extraction (set 3) to the mean of the peak area of an analyte spiked 
post extraction (set 2) multiplied by 100. Matrix effect was expressed as the ratio of 
the mean peak area of an analyte spiked post extraction (set 2) to the mean peak 
area of the same analyte standards in solvent (set 1) multiplied by 100. 
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3.2.9 Storage of Plasma Samples and Stability of the Analytes 
QC standards containing all five analytes and internal standard were prepared 
according to section 3.2.2 and analysed in triplicate on the day of preparation 
according to section 3.2.3; thereby establishing the starting concentrations for the 
storage stability assessments (day 1). Aliquots of the QC standards were frozen at -
80oC for storage stability analyses. Storage stability for 2OH-CBZ, 3OH-CBZ and 
DiOH-CBZ were analysed on day 90 and 246.  
 
New QC standards containing CBZ, CBZE and internal standard had to be prepared 
approximately 96 days into the original storage stability analyses because CBZ and 
CBZE had precipitated out of solution in the original working solutions. Precipitation 
had occurred secondary to evaporation of acetonitrile because of the small volumes 
that were originally used to dissolve the analytes (CBZ: 1167µL and CBZE: 824.5µL). 
New stock solutions for CBZ and CBZE were made according to the concentrations 
in Table 3.1 using significantly larger volumes of acetonitrile. New QC standards 
containing CBZ, CBZE and internal standard were prepared and analysed in triplicate 
on the day of preparation according to section 3.2.3, thereby establishing the 
starting concentration for storage stability assessment (day 1). Aliquots of the new 
QC standards for CBZ and CBZE were frozen at -80oC and analysed on day 151. The 
new CBZ and CBZE working solutions were used in calibration and QC standards for 
all patient analyses. 
 
All of the QC aliquots for storage stability analyses were thawed and re-analysed in 
triplicate on the same day using a freshly prepared set of calibration standards. The 
average concentration values for the storage samples were compared against the 
average concentration values from the day 1 analyses, and expressed as a 
percentage to represent analyte stability in plasma. 
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3.2.10 Linear Dilution of Samples  
It was possible that plasma samples obtained during the study might have 
demonstrated analyte concentrations above the upper limit of the standard curve. 
In those instances the samples would have been diluted 1:1 using pooled plasma 
from six healthy volunteers prior to extraction and processing of samples. An 
assessment to confirm linear dilution of CBZ was undertaken by 1:1 serial dilution of 
the top calibration point using pooled human plasma until a dilution factor of 1:32 
was obtained and checked for linearity. 
 
3.2.11 Recruitment Sites for Patients   
Participants were recruited from two study sites: The Royal Liverpool and 
Broadgreen University Hospitals NHS Trust and the Walton Centre NHS Foundation 
Trust. The Clinical Research Unit at the Royal Liverpool Hospital is a phase I 
accredited unit with facilities for conducting clinical trials and access to the Consent 
4 Consent (C4C) database. The C4C database contains contact details for 
prospective trial participants who have already provided consent to be contacted 
when suitable clinical trials arise. The PICME I (a PK Investigation into the formation 
of CBZ Metabolites and CBZ-protein conjugates in healthy volunteers) clinical trial 
was conducted at the Royal Liverpool Hospital. 
 
The Walton Centre is a tertiary referral centre for neurology and neurosurgery and 
the Neuroscience Research Centre is attached to the outpatients department with 
clinic rooms and equipment for sample collection and processing as part of the 
study. Daily outpatient epilepsy clinics are undertaken by neurologists and epilepsy 
nurse specialists. The PICME II (a PK Investigation into the formation of CBZ 
Metabolites and CBZ-protein conjugates in Epilepsy patients) clinical trial was 
conducted at the Walton Centre. 
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3.2.12 Study Populations 
PICME I Clinical Trial: 
Healthy adult male volunteers were recruited using the C4C database. 
 
The inclusion criteria were: 
 Subject willing and able to give written and informed consent 
 Healthy male subjects between 18 and 55 years of age inclusive 
 Subject’s body weight between 50 and 100 kg 
 Subject’s body mass index between 18 and 32 kg/m2 
The exclusion criteria were: 
 Subject not willing to take part or unable to give written informed consent 
 Subject with clinically significant abnormal medical history or physical exam 
 Subject with history of febrile illness within 4 weeks prior to admission 
 Subject with a clinically significant abnormal laboratory test at screening 
including HBV/HCV/HIV 
 Subject taking any interacting prescription or non-prescription drug, or 
dietary supplements within 2 weeks prior to study admission. Herbal 
supplements had to be discontinued at least 4 weeks prior to admission to 
the clinical research facility 
 Subject positive for either the HLA-B*15:02 or HLA-A*31:01 genotype 
 Subject with a clinically significant ECG abnormality – prolonged corrected 
QT>450ms, 2nd or 3rd degree atrioventricular conduction block 
 Subject with known hypersensitivity to CBZ or structurally related drugs (e.g. 
tricyclic antidepressants) or any other component of the formulation 
 Subject with history of bone marrow depression 
 Subject with history of hepatic porphyrias (e.g. intermittent porphyria, 
variegate porphyria, porphyria cutanea tarda) 
 Subject who had taken part in another research study within 90 days of 
commencement 
 Subject with any condition which in the opinion of the investigator will 
interfere with the study 
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PICME II Clinical Trial: 
Two groups of patients were recruited for the PICME II clinical trial: an 
autoinduction group and a maintenance group. The autoinduction group comprised 
patients with epilepsy for whom a neurologist had decided to newly initiate CBZ 
modified release therapy. The maintenance group consisted of patients with 
epilepsy who had been established on a stable dose of CBZ modified release for at 
least 4 weeks. Patients were recruited according to the following inclusion and 
exclusion criteria. 
 
Autoinduction group: 
Inclusion criteria: 
 Subject willing and able to give written informed consent 
 Subject aged 18 or over 
 Subject newly prescribed CBZ by their attending physician 
Exclusion criteria: 
 Subject not willing to take part or unable to give written informed consent 
 Subject who in the past 4 weeks received another medication that was a 
CYP3A4 inducer or inhibitor 
 Subject with any condition which in the opinion of the investigator will 
interfere with the study 
Maintenance Group: 
Inclusion criteria: 
 Subject willing and able to give written informed consent 
 Subject aged 18 or over 
 Subject had received CBZ therapy at the same dosage for at least 4 weeks 
Exclusion criteria: 
 Subject not willing to take part or unable to give written informed consent 
 Subject with any condition which in the opinion of the investigator was likely 
to interfere with the study 
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3.2.13 Population Sample Size 
An accurate calculation of the population sample size required for these 
investigations could not be performed because the variables that affect the 
metabolism of CBZ and the extent of any effects remained under investigation. For 
the PICME I trial, 8 healthy male volunteers were recruited. In the PICME II trial the 
aim was to recruit 8 patients for the autoinduction group and to collect 150 blood 
samples from the maintenance group. Due to difficulty with recruitment to the 
PICME II trial, only 3 patients were recruited to the autoinduction group and 77 
blood samples were collected from the maintenance group. Despite the reduction 
in number of subjects recruited the number of samples would still be sufficient to 
provide rich and sparse PK data and is consistent with other studies of a similar 
nature (Yun et al. 2013; Panomvana et al. 2013).  
 
3.2.14 Ethical Approval 
Ethical approval for the PICME I study was granted by the North West Research 
Ethics Committee – Greater Manchester (12/NW/0780). Approval covered 
collection of blood for measurement of routine clinical parameters (full blood 
count, urea and electrolytes, and liver function tests), viral safety (hepatitis B/C, 
HIV), storage and analysis of DNA, and the identification and analysis of CBZ 
metabolites and CBZ-HSA adducts.  
 
Ethical approval for the PICME II study was granted by the North West Research 
Ethics Committee – Haydock (13/NW/0503). Approval covered collection of blood 
for measurement of routine clinical parameters (full blood count, urea and 
electrolytes, and liver function tests), storage and analysis of DNA, and the 
identification and analysis of CBZ metabolites and CBZ-HSA adducts.  
 
  
 137 
 
3.2.15 Recruitment 
PICME I 
Prospective healthy volunteer participants were identified from the consent 4 
consent database held by the Clinical Research Unit at the Royal Liverpool 
University Hospital. They were contacted by e-mail and those expressing an interest 
in participation were e-mailed the participant information leaflet (PIL) and consent 
form and invited for a screening visit. During the screening visit, the research 
physician [Vincent Yip (VY)] confirmed that the PIL and consent form had been read 
and understood. If the person consented and satisfied the inclusion and exclusion 
criteria, they were recruited to the study.  
 
PICME II 
Prospective participating patients were identified from outpatient epilepsy clinics at 
the Walton Centre. In the autoinduction group, neurologists referred patients who 
were newly prescribed CBZ. If the patient was interested in participating in a trial, a 
copy of the PIL and consent form were given to them and a consultation with the 
research physician (VY) was organised. If the patient satisfied the inclusion and 
exclusion criteria, consent was obtained. The patient was advised to refrain from 
taking CBZ until their first study visit, which could be up to 72 h after their 
outpatient appointment. 
 
For the maintenance group, patients attending epilepsy outpatient clinics who were 
prescribed CBZ therapy were identified by the neurologist or nurse. On arrival for 
the clinic appointment, the PIL and consent form was given to the patient. If the 
patient was interested in taking part they were invited for a separate consultation 
with the research physician (VY). During the study consultation, the research 
physician confirmed the patient understood the PIL and consent form, and the 
patient was recruited to the study if all inclusion and exclusion criteria were 
satisfied. All the required personal information and the blood samples were 
collected immediately. 
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3.2.16 Data Collection 
The following data were collected from the medical case notes and in consultation 
with the patient: 
 Demographic details including age, sex, ethnicity, smoking status, alcohol 
intake 
 Physical characteristics including height, weight, BMI, blood pressure, 
temperature 
 Past medical history including allergies 
 Concomitant medications (type, dose and formulation) 
 Co-morbid illnesses 
 Physical examination (cardiovascular, respiratory, abdominal and 
neurological) (PICME I only) 
 Electrocardiogram (PICME I only) 
 
3.2.17 Venepuncture and Sample Processing Procedures 
Venepuncture was undertaken by qualified health professionals at both recruitment 
sites. In the PICME I trial, samples for full blood count, urea and electrolytes, and 
liver function tests were undertaken by the Blood Sciences Laboratory at the Royal 
Liverpool University Hospital. Samples for hepatitis B and hepatitis C testing, HIV 
screening and HLA genotyping were undertaken in the Immunology Department at 
the Royal Liverpool University Hospital. The above blood samples were taken at 
baseline as part of the screening visit. Blood samples for storage and analysis of 
DNA were frozen immediately at -80oC. Blood samples for analysis of CBZ and its 
metabolites were centrifuged at 1500g for 10 min at 4oC. Aliquots of plasma were 
pipetted into cryovials and stored at -80oC. 
 
In the PICME II trial, blood samples for full blood count, urea and electrolytes, and 
liver function tests were undertaken by the Blood Sciences Laboratory at Aintree 
University Hospital NHS Foundation Trust. Blood samples for storage and analysis of 
DNA were frozen immediately at -80oC. Blood samples for analysis of CBZ and its 
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metabolites were centrifuged at 1500g for 10 min at 4oC. Aliquots of plasma were 
pipetted into cryovials and stored at -80oC until further analysis. 
 
3.2.18 PK Sample Collection Time Points 
In the PICME I clinical trial, PK blood samples were collected immediately prior to 
dosing and at the following time points after ingestion of a 400-mg CBZ tablet: 15 
min and 30 min, and 1, 2, 4, 6, 8, 12, 24, 48 and 72 h. The choice of CBZ dosage was 
based on the recommended starting dose according to the summary of product 
characteristics (Electronic Medicines Compendium 2015).  
 
At visit 1 of the autoinduction group of PICME II, a pre-dose PK sample was 
collected immediately before administration of 200 mg CBZ. Subsequent PK 
samples were collected at 1, 2, 4, 6, 8 and 24 h post-dose. Participants were then 
discharged, and they self-administered CBZ (200 mg) once daily. On day 14, 
participants returned to the clinical trials unit for visit 2; when PK samples were 
collected pre-dose and then 1, 2, 4, 6 and 8 h post dose. After this visit the dosage 
of CBZ was increased to 200 mg twice daily. The participant was asked to return to 
the clinical trials unit on day 28 and undergo PK sampling at the times listed above. 
At the end of this visit the participant was asked to increase the dosage of CBZ to 
200 mg in the morning and 400 mg at night. The participant returned on day 42 and 
underwent PK sampling at the time points described above. The dose titration 
regimen is standard practice for initiation of CBZ therapy at the Walton Centre NHS 
Foundation Trust. 
 
Participants in the maintenance group of the PICME II clinical trial underwent PK 
sampling either before or after their scheduled clinical appointment with the 
neurologist. Timing of the PK sample was calculated by asking the subject the timing 
and dosage of the previous dose of self-administered CBZ.  
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3.2.19 Patient Sample Processing for HPLC-MS/MS 
Aliquots of patients’ plasma (300 µL) were thawed at room temperature on the day 
of analysis and 10 µL of IS (0.2 mM) was added to each plasma sample and mixed 
thoroughly. Acetone (300 µL) was added to the plasma aliquot and vortexed for 30 
s. The mixtures were then centrifuged at 1400g for 10 min at room temperature. 
Supernatant was collected carefully, discarding the precipitate. The supernatant 
was evaporated to dryness using a SpeedVac (Eppendorf, Germany). The dried 
residues were reconstituted in 300 µL of acetone and water (50:50 v/v), and 
vortexed briefly to ensure complete homogenisation. An aliquot of 100 µL of the 
vortexed solution was transferred to an autosampler vial (VWR, UK) ready for 
injection onto the column for analysis of CBZ, CBZE and DiOH-CBZ as described in 
section 3.2.3. For analysis of 2OH-CBZ and 3OH-CBZ, 100 µL of the vortexed sample 
was centrifugally filtered at 450 g for 15 min at 4oC through a 0.45-µm hydrophilic 
PTFE filter plate (Merck Millipore, Watford, UK) to further remove any protein. The 
filter plates were prepared by adding 100 µL of water and centrifuging at 1500 rpm 
for 15 min at 4oC prior to sample processing. The filtrates were transferred into 
glass autosampler vials (VWR, UK) ready for immediate analysis. Analysis was 
undertaken according to section 3.2.3. The PK variables, Cmax, Tmax, t½ and AUC, 
were computed for CBZ using the PKSolver program and compared with existing 
data for CBZ. PKSolver is a freely available program for solving basic problems in PK 
and pharmacodynamic data analysis (Zhang et al. 2010). 
 
3.2.20 Assessment for the Possibility of Analytical Conflicts with Concomitant 
Medications 
The theoretical possibility of analytical conflicts, i.e. LC-MS/MS signal conflicts, 
between the concomitant medications and the analytes was assessed by comparing 
the molecular mass of drug and its known metabolites to determine whether or not 
the protonated molecules had m/z of any of the analytes.  
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3.3 Results 
3.3.1 Chromatographic Resolution and Analyte Specificity 
Representative LC-MS/MS chromatograms obtained with the Zorbax Eclipse XDB-C8 
column are shown in Figure 3.2 for (A) drug-free volunteer plasma and (B) pooled 
volunteer plasma spiked with the analytes and the internal standard. The retention 
times (Rt) during assay validation are outlined in Table 3.7.  Figure 3.2a contains a 
broad peak in the MRM channel for CBZ extending from 13.5 to 14.5 min, which 
coincides with the Rt for CBZ and 2Me-CBZ. The peak was present amongst all five 
samples of drug-free plasma from healthy volunteers. The source of this peak was 
unclear as it persisted despite changing to a new HPLC column and alternative HPLC 
pump. However, the intensity of the interfering peak was low relative to the 
anticipated and actual intensities of CBZ and 2Me-CBZ peaks from calibration and 
QC standards, and ultimately did not affect the accuracy and precision of the assay. 
 
Table 3.7. Retention times for each analyte using the Zorbax Eclipse XDB-C8 
column 
Analyte Retention Time (min) 
DiOH-CBZ 6.8 (± 0.0) 
2OH-CBZ 9.0 (± 0.1) 
CBZE 9.7 (± 0.2) 
3OH-CBZ 10.4 (± 0.1) 
CBZ 13.6 (± 0.1) 
2Me-CBZ 14.2 (± 0.0) 
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Typical chromatograms obtained using the Xbridge BEH C18 column, representing 
(A) drug-free plasma and (B) volunteer plasma spiked with analytes and the internal 
standard, are shown in Figure 3.3. Rt for each analyte are outlined in Table 3.8. 
Figure 3.3a is representative of all five healthy volunteer samples and does not 
demonstrate any chromatographic interference or coincidence in time with any 
analytes in the MRM channel for 2OH- and 3OH-CBZ.  
 
Table 3.8 Retention times for each analyte using the Xbridge BEH C18 column 
Analyte Retention Time (min) 
DiOH-CBZ 8.2 (± 0.1) 
2OH-CBZ 9.9 (± 0.2) 
CBZE 11.0 (± 0.2) 
3OH-CBZ 11.3 (± 0.2) 
CBZ 13.2 (± 0.2) 
2Me-CBZ 13.9 (± 0.1) 
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(A) 
 
 
(B) 
Figure 3.2 Typical LC-MS/MS (MRM) chromatograms of (a) drug-free human 
plasma, and (b) drug-free human plasma spiked with CBZ, CBZE, DiOH-CBZ, 2OH-
CBZ, 3OH-CBZ and 2Me-CBZ, on a Zorbax Eclipse XDB-C8 column. Secondary, less 
abundant peaks represent the confirmation of identity transitions. The samples 
were chromatographed as described in 3.2.3. 1: DiOH-CBZ, 2: 2OH-CBZ, 3: CBZE, 4: 
3OH-CBX, 5: CBZ, 6: 2Me-CBZ. 
XIC of +MRM (9 pairs): 237.100/194.100 Da  from Sample 1 (blank2) of DataSET8.wiff (Turbo Spray) Max. 5986.7 cps.
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(A) 
 
 
(B) 
Figure 3.3. Typical LC-MS/MS (MRM) chromatograms of (A) drug-free human 
plasma, and (B) drug-free human plasma spiked with CBZ, CBZE, DiOH-CBZ, 2OH-
CBZ, 3OH-CBZ and 2Me-CBZ, on a XBridge BEH C18 column. Secondary, less 
abundant peaks represent the confirmation of identity transitions. The samples 
were chromatographed as described in 3.2.3. 1: DiOH-CBZ, 2: 2OH-CBZ, 3: CBZE, 4: 
3OH-CBX, 5: CBZ, 6: 2Me-CBZ. 
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3.3.2 Calibration Curves 
Linearity of calibration was observed amongst all five analytes throughout the 
investigated calibration ranges and the coefficient (r2) of all the calibration curves 
was greater than 0.99. Figure 3.4 demonstrates representative calibration curves 
for each analyte. 
 
 
 (A) 
 
 
(B)  
C002-C047 recheck CBZ 08.03.15.rdb (237.100 / 192.100): "Linear" Regression ("1 / x" weighting): y = 0.0538 x + -0.0103 (r = 0.9995)
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(C) 
 
 
(D) 
A001 DHD (16.01.15).rdb (CBZ DHD): "Linear" Regression ("1 / x" weighting): y = 0.409 x + -0.00104 (r = 0.9996)
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(E) 
Figure 3.4 Representative calibration curves for all the analytes: (A) CBZ, (B) CBZE, 
(C) DiOH-CBZ (D) 2OH-CBZ and (E) 3OH-CBZ.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3OH A002 15.07.15.rdb (3-OH-CBZ): "Linear" Regression ("1 / x" weighting): y = 1.54 x + 0.00835 (r = 0.9993)
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3.3.3 Accuracy and Precision 
All of the assays achieved the required accuracy and precision parameters (CV of 
±15%) as outlined by the FDA for both intra- and inter-day analysis (n=5) (Table 3.9 
and Table 3.10). 
 
Table 3.9 Intra-day accuracy and precision 
Analyte Nominal 
Conc. 
Set 1 Set 2 Set 3 Set 4 Set 5 Mean Accuracy 
(%) 
Precision 
(% CV) 
 
CBZ 
(µg/mL) 
0.33 0.36 0.38 0.39 0.38 0.38 0.38 114.2 2.7 
2.66 2.35 2.34 2.41 2.54 2.45 2.42 91.0 3.4 
10.6 11.6 10.2 11.2 10.8 11.4 11.0 103.9 5.0 
 
CBZE 
(µg/mL) 
0.10 0.10 0.09 0.09 0.09 0.10 0.09 92.9 4.9 
1.57 1.69 1.71 1.62 1.73 1.65 1.68 106.6 2.7 
6.31 5.87 6.03 5.85 5.85 5.92 5.90 93.6 1.3 
 
DiOH-
CBZ 
(µg/mL) 
 
0.10 0.10 0.09 0.07 0.08 0.09 0.09 85.0 11.8 
1.62 1.69 1.71 1.64 1.69 1.63 1.67 103.2 2.1 
6.49 6.26 6.30 6.01 6.22 6.19 6.20 95.5 1.8 
 
2OH-
CBZ 
(ng/ml) 
2.00 2.16 2.03 2.33 2.29 2.13 2.2 109.4 5.6 
10.0 11.1 11.2 11.4 11.5 11.7 11.4 113.8 2.1 
100 94.9 92.6 109 100 101 99.5 99.5 6.4 
 
3OH-
CBZ 
(ng/ml) 
10.0 10.8 11.1 11.1 11.3 10.5 11.0 109.6 2.9 
50.0 57.6 55.1 57.5 57.4 57.1 56.9 113.9 1.8 
500 480 464 538 490 495 493 98.8 5.6 
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Table 3.10 Inter-day accuracy and precision 
Analyte Nominal 
Conc. 
Set 1 Set 2 Set 3 Set 4 Set 5 Mean Accuracy 
(%) 
Precision 
(% CV) 
 
CBZ 
(µg/mL) 
0.33 0.31 0.35 0.41 0.39 0.39 0.37 111.4 11.8 
2.66 2.41 2.64 2.50 2.43 2.46 2.49 93.6 3.7 
10.6 10.8 11.1 11.3 10.3 11.4 11.0 103.3 4.0 
 
CBZE 
(µg/mL) 
0.15 0.14 0.14 0.17 0.15 0.14 0.15 96.8 8.2 
1.50 1.65 1.43 1.62 1.65 1.57 1.58 105.6 5.8 
6.00 6.15 5.40 6.08 6.20 6.08 5.98 99.7 5.5 
 
DiOH-
CBZ 
(µg/mL) 
 
0.10 0.10 0.09 0.09 0.11 0.10 0.10 94.3 7.1 
1.62 1.69 1.81 1.59 1.66 1.55 1.66 102.4 6.1 
6.49 6.26 6.47 5.84 6.29 5.92 6.16 94.9 4.3 
 
2OH-
CBZ 
(ng/mL) 
2.00 2.16 2.03 2.13 1.84 2.01 2.03 101.7 6.2 
10.0 11.1 11.2 10.6 8.58 11.1 10.5 105.2 5.6 
100 94.9 92.6 94.6 91.7 103 95.3 95.4 4.7 
 
3OH-
CBZ 
(ng/mL) 
10.0 10.8 11.1 9.83 10.9 9.95 10.5 105.2 5.6 
50.0 57.6 55.1 55.4 55.2 57.2 56.1 112.2 2.1 
500 480 464 433 435 457 454 90.8 4.4 
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3.3.4 Recovery and Matrix Effects 
Recovery and matrix effects were assessed for all analytes throughout the 
calibration range (Table 3.11). A negative matrix effect was most pronounced with 
CBZ, with peak areas reduced by an average of 35.8% across the calibration range. 
CBZE, 2OH-CBZ, 3OH-CBZ and DiOH-CBZ had mean matrix effects of 100.1%, 97.4%, 
96.1% and 94.0%, respectively.  The CV of matrix effects for all the analytes were 
between 3.5% and 9.2%. Mean recovery of all the analytes ranged between 76.9% 
for 3OH-CBZ to 80.7% for CBZE, and CV values for recovery were between 4.4% and 
7.5% (Table 3.11). 
Table 3.11 Table of recovery (RE) and matrix effects (ME) (set 1: solvent; set 2: 
plasma spiked after processing; set 3: plasma spiked before processing) 
  Mean Peak Area  
[cps (x106)] 
    
Analyte Conc 
point 
Set 1 Set 2 Set 3 ME (%) CV ME 
(%) 
RE (%) CV RE 
(%) 
 
 
 
CBZ 
(µg/ml) 
0.33 0.68 0.40 0.34 58.7  84.6  
0.66 1.41 0.87 0.71 61.6  81.2  
1.33 2.92 1.87 1.38 64.1  73.8  
2.66 5.47 3.82 2.81 69.8  73.6  
5.32 11.7 7.78 6.03 66.7  77.5  
10.6 21.3 14.7 11.4 68.9  77.6  
21.3 36.1 21.6 17.9 59.9  82.7  
    Mean 
ME (%) 
64.2 6.8 78.7 5.4 
 
 
 
CBZE 
(µg/ml) 
0.10 0.51 0.48 0.38 94.5  79.2  
0.20 0.98 0.94 0.78 95.9  82.9  
0.39 1.93 1.94 1.47 100.3  75.8  
0.79 3.43 3.51 2.77 102.4  79.0  
1.58 6.33 6.41 5.13 101.3  80.1  
3.15 10.9 11.6 9.42 107.1  81.0  
6.31 18.2 18.0 15.7 98.9  87.1  
    Mean 
ME (%) 
100.1 4.2 80.7 4.4 
 151 
 
  Mean Peak Area  
[cps (x106)] 
    
Analyte Conc 
point 
Set 1 Set 2 Set 3 ME (%) CV ME 
(%) 
Analyte Conc 
point 
 
 
 
DiOH-
CBZ 
(µg/ml) 
 
0.10 0.84 0.73 0.58 86.9  79.3  
0.20 1.65 1.50 1.14 90.7  76.2  
0.41 3.53 3.23 2.33 91.6  72.2  
0.81 6.39 6.26 4.74 97.9  75.7  
1.62 12.8 12.4 9.41 96.6  75.9  
3.24 24.4 24.0 18.2 98.1  76.0  
6.49 39.6 38.1 33.4 96.1  87.7  
    Mean 
ME (%) 
94.0 4.6 77.6 6.3 
 
 
 
2OH-CBZ 
(ng/ml) 
7.40 0.06 0.05 0.04 87.9  78.1  
14.8 0.12 0.10 0.09 88.5  84.6  
29.6 0.24 0.24 0.18 102.2  74.9  
59.1 0.45 0.48 0.36 107.2  75.5  
118 0.93 0.93 0.72 101.0  76.9  
236 1.80 1.90 1.40 105.4  73.7  
473 3.41 3.22 2.78 94.3  86.3  
    Mean 
ME (%) 
97.4 9.2 78.6 6.3 
 
 
 
3OH-CBZ 
(ng/ml) 
18.9 0.08 0.08 0.06 98.8  70.0  
37.8 0.15 0.16 0.13 102.2  79.8  
75.7 0.33 0.34 0.25 103.7  72.1  
151 0.60 0.65 0.51 108.1  78.4  
302 1.25 1.34 1.01 106.9  75.7  
605 2.52 2.67 2.00 105.9  74.9  
1210 4.38 4.36 3.82 99.5  87.6  
    Mean 
ME (%) 
103.6 3.5 76.9 7.5 
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3.3.5 Analyte Storage Stability in Plasma 
All of the QC standards for the assessments of the analytes’ storage stability were 
prepared on day 1 and frozen at -80OC until further analysis. Samples containing 
2OH-CBZ, 3OH-CBZ and DiOH-CBZ were analysed on days 1, 90 and 246 against 
freshly prepared calibration standards. Due to precipitation of the CBZ and CBZE 
working solutions, new QC standards for CBZ and CBZE had to be prepared for 
storage stability analysis on days 1 and 151. All of the QC standards for each analyte 
were within ±15% for accuracy and precision, confirming that the analytes were 
stable in human plasma at -80oC (Table 3.12). 
 
3.3.6 Linear Dilution 
CBZ demonstrated a linear dilution pattern (r2 = 0.9951) throughout the serial 
dilution range (Figure 3.5). 
 
 
Figure 3.5 Serial dilution of CBZ in pooled volunteer plasma up to 1:32  
R² = 0.9951 
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Table 3.12 Storage stability analyses (*day 90 applicable to 2OH-CBZ, 3OH-CBZ 
and DiOH-CBZ, day 151 applicable to CBZ and CBZE) 
Analyte Theoretical 
Conc. 
Day 1 
(mean) 
Day 90 or 
151* 
(mean) 
Day 
246 
(mean) 
Overall 
Mean 
Accuracy 
(%) 
Precision 
(CV) (%) 
CBZ 
(µg/mL) 
0.475 0.516 0.508 NA 0.512 107.8 1.2 
4.75 4.85 4.96 NA 4.91 103.3 1.7 
9.50 10.80 10.70 NA 10.8 113.3 0.9 
CBZE 
(µg/mL) 
0.15 0.14 0.14 NA 0.14 93.1 0.7 
1.50 1.68 1.62 NA 1.64 109.2 1.6 
6.00 6.00 6.41 NA 6.20 103.4 4.7 
DiOH-
CBZ 
(µg/mL) 
 
0.15 0.17 0.138 0.14 0.15 99.6 12.0 
1.50 1.61 1.52 1.48 1.54 102.5 4.4 
6.00 5.89 5.96 6.03 5.96 99.3 1.1 
2OH-
CBZ 
(ng/mL) 
10.0 11.3 9.90 11.3 10.8 108.2 7.6 
100 110 95.1 110 105 105.0 8.2 
400 434 389 434 419 104.7 6.2 
3OH-
CBZ 
(ng/mL) 
33.0 37.5 35.0 34.4 35.7 108.0 4.6 
330 366 329 351 349 105.6 5.4 
1000 1053 1030 1053 1045 104.5 1.3 
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3.3.7 Failure of Sensitivity and Specificity in 2OH-CBZ and 3OH-CBZ Analysis Using 
Agilent 5-µM Zorbax Eclipse XDB-C8 column 
It was the initial intention for all five analytes to be quantified using the Agilent 5-
µM Zorbax Eclipse XDB-C8 column. However, data from patient samples 
demonstrated significant interference in the MRM channel for 2OH- and 3OH-CBZ, 
which meant that sensitivity and specificity for quantitation of both 2OH-CBZ and 
3OH-CBZ were insufficient (Figure 3.6). The interference was present in all patient 
samples. The lack of sensitivity and specificity was isolated to patient samples only 
and not present in either the calibration or QC standards from pooled plasma 
(Figure 3.7). Therefore, quantitation of 2OH-CBZ and 3OH-CBZ was undertaken 
using a Waters 2.5-µM Xbridge BEH C18 column as outlined above (section 3.2.3). 
 
 
Figure 3.6 Representative LC-MS/MS (MRM) chromatogram demonstrating 
insufficient specificity for 2OH-CBZ and 3OH-CBZ peaks (Table 3.4) in patient 
samples when analysed on a Zorbax Eclipse XDB-C8 column. 
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Figure 3.7 Representative LC-MS/MS (MRM) chromatogram of calibration 
standards for CBZE, 2OH-CBZ and 3OH-CBZ when analysed on a Zorbax Eclipse 
XDB-C8 column. (1: 2OH-CBZ, 2: CBZE, 3: 3OH-CBZ, 4: 2Me-CBZ)  
 
3.3.8 Patient Demographics and Plasma Assays  
In total, 8 healthy male volunteers were recruited to the PICME I clinical trial. Their 
demographics are outlined in Table 3.13. Three participants, two female and one 
male, were recruited to the autoinduction group of the PICME II clinical trial and 
their clinical details are represented in Table 3.14. In the maintenance group of 
PICME II, 77 plasma samples were obtained from 69 participants (Table 3.15). Eight 
of those subjects were sampled on two separate visits. Thirty seven of the 
participants in the maintenance group were male and 32 female. Median age in the 
group was 48 with a range between 25 and 75. CBZ dosages ranged from 100 mg 
per day to 1600 mg per day (Table 3.15). All of the patients in the PICME II clinical 
trial had been diagnosed with epilepsy. 
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Table 3.13 Demographics of subjects recruited to the PICME I clinical trial 
ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
status 
Medical 
History 
Medication* Allergies 
P001 M 29 1.76 90.0 128/77 70 36.3 European Ex-smoker Depression Nil Nil 
P002 M 21 1.78 99.4 115/64 65 36.5 European Non smoker Nil Nil Penicillin 
P003 M 26 1.81 69.8 130/80 55 36.8 European Non smoker Eczema Eumovate Nil 
P004 M 26 1.78 87.0 122/73 73 37.1 European Non smoker Osteoarthritis Ibuprofen Nil 
P005 M 24 1.72 70.6 114/58 70 37.5 European Non smoker Nil Nil Nil 
P006 M 32 1.72 84.8 137/80 80 36.7 European Ex-smoker Nil Nil Penicillin 
P007 M 29 1.81 97.1 132/74 59 36.8 European Non smoker Nil Nil Nil 
P008 M 28 1.84 77.8 116/69 75 36.7 Egyptian 
and UK 
Non-
smoker 
Eczema Nil Shellfish 
* No analytical conflicts were detected between concomitant medications and the analytes.
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Table 3.14 Demographics of subjects recruited to the auto-induction group of PICME II clinical trial 
ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
A001 M 42 1.78 88.0 150/98 80 37.0 European Ex-smoker Epilepsy Mirtazapine, 
olanzapine, 
methadone 
A002 F 43 1.63 124.5 149/86 88 35.9 European Non Smoker Epilepsy,  type 2 
diabetes, 
congenital small 
kidney 
Atorvastatin 
A003 F 44 1.67 73.1 144/95 82 35.7 European Ex-smoker Epilepsy, 
hypertension, 
Raynaud’s, 
previous 
intraventricular 
haemorrhage 
Venlafaxine,   co-
codamol 
*No analytical conflicts were detected between concomitant medications and analytes. 
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Table 3.15 Demographics of subjects recruited to the maintenance group of PICME II clinical trial 
ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C001 M 32 1.64 112.5 145/85 77 36.5 European Non-
smoker 
Fatty liver, anxiety Citalopram 
C002 F 48 1.62 86.6 107/71 68 37.3 European Current 
smoker 
- - 
C003 F 27 1.70 50.0 132/76 85 37.6 European Non-
smoker 
Asthma Venlafaxine 
C004 F 32 1.54 59.5 123/80 68 37.8 European Non-
smoker 
Asthma, irritable 
bowel syndrome 
Clobazam 
C005 F 71 1.55 39.0 224/102 78 35.6 European Current 
smoker 
Osteopaenia Multivitamins,Vitamin 
D 
C006 F 67 1.63 62.5 142/77 77 36.7 European Current 
smoker 
Chronic obstructive 
pulmonary disease 
Lamotrigine, 
symbicort, 
salbutamol, spiriva, 
pyroxidine, 
*No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C007 M 53 1.72 93.5 170/100 66 36.3 European Non-
smoker 
Knee replacement Levetiracetam, 
cetirizine, 
lansoprazole, 
pravastatin 
C008 M 46 1.73 140.5 149/73 57 36.8 European Ex-
smoker 
Asthma, chronic 
obstructive 
pulmonary disease, 
atrial fibrillation, 
osteoarthritis, sleep 
apnoea 
Bisoprolol, calichew 
D3 forte, fostair, 
clobazam, phenytoin, 
salbutamol 
C009 M 34 1.75 83.0 139/81 48 36.2 European Ex-
smoker 
- - 
C010 F 37 1.60 60.0 124/74 82 37.0 European Non-
smoker 
Panic attacks Senna 
  *No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C011 M 53 
 
1.84 107.5 140/87 68 36.2 European Non-
smoker 
Inflammatory bowel 
disease, urolithiasis 
Levetiracetam, 
Sodium valproate, 
clobazam, Asacol, 
phenytoin, Vitamin D 
C012 M 60 1.88 91.0 185/104 52 37.0 European Non-
smoker 
- Folic acid, zonisamide, 
clobazam, 
C013 F 34 1.61 75.5 110/84 80 36.8 European Current 
smoker 
- Quetiapine, 
levetiracetam, folic 
acid 
C014 F 28 1.63 90.5 128/84 70 36.9 European Non-
smoker 
Irritable bowel 
syndrome, migraines 
Paracetamol, 
Ibuprofen 
C015 M 46 1.80 75.0 154/94 65 36.7 European Current 
smoker 
- Levetiracetam 
C016 M 47 1.82 86.5 136/90 71 36.8 European Ex-
smoker 
Seborrheic 
dermatitis 
Topiramate 
*No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C017 F 58 1.59 50.0 111/61 73 37.5 European Non-
smoker 
Irritable bowel 
syndrome, 
osteoporosis 
Adcal D3, alendronic 
acid, levetiracetam, 
movicol, lactulose 
C018 F 46 1.55 84.5 143/77 74 37.4 European Current 
smoker 
- Levetiracetam 
C019 M 43 1.70 67.0 133/94 81 36.6 European Current 
smoker 
- Levetiracetam, 
citalopram, ranitidine 
C020 F 57 1.63 57.5 142/87 89 36.9 European Current 
smoker 
Hypertension, 
indigestion, 
recurrent urinary 
tract infection 
Lansoprazole, 
citalopram, ramipril, 
trimethoprim, 
nitrofurantoin 
C021 F 60 1.80 124.5 126/65 85 36.6 European Non-
smoker 
Osteoarthritis, 
hayfever 
Adcal D3, clonidine, 
folic acid, 
levocetirizine, 
zonisamide 
*No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C022 F 48 1.64 55.0 150/91 74 37.7 European Current 
smoker 
Asthma, chronic 
obstructive 
pulmonary disease 
Salbutamol 
C023 M 61 1.77 93.5 149/88 82 36.0 European Ex-
smoker 
Hip replacement, 
brain tumour 
Levetiracetam 
C024 M 50 1.76 86.5 156/90 45 35.8 European Non-
smoker 
- Sodium valproate 
C025 M 75 1.81 99.0 148/97 67 37.1 European Non-
smoker 
- Levetiracetam, 
clobazam, duloxetine 
C026 M 36 1.73 76.5 150/92 71 38.8 European Non-
smoker 
- Lamotrigine, 
levetiracetam 
C027 F 30 1.75 71.0 111/79 76 37.3 European Non-
smoker 
- Levetiracetam, 
clobazam, citalopram 
C028 M 50 1.78 68.0 135/86 55 36.6 European Ex-
smoker 
Overactive bladder - 
  *No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C029 F 59 1.60 98.0 207/109 70 37.0 European Non-
smoker 
Angina, 
hypertension, prev 
stroke, aortic and 
mitral valve 
regurgitation, 
diverticular disease, 
cervical spondylosis 
clopidogrel, 
bisoprolol, clonidine, 
ramipril, telmisartan, 
bendroflumethiazide, 
atorvastatin, 
isosorbide 
mononitrate 
C030 M 25 1.81 87.0 105/63 71 36.6 European Ex-
smoker 
- - 
C031 M 45 1.90 106 153/101 77 35.3 European Non-
smoker 
Encephalitis, 
hermiparesis 
Calcichew, folic acid 
C032 M 33 1.71 69.5 141/95 76 36.7 European Non-
smoker 
- - 
C033 M 69 1.77 97.5 156/81 69 37.1 European Non-
smoker 
Hypertension, stroke 
constipation, 
bladder cancer 
Aspirin, atorvastatin, 
amlodipine, ramipril, 
senna, docusate 
*No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C034 M 60 1.77 84.5 123/76 67 36.5 European Current 
smoker 
Spinal stenosis, 
sciatica 
Zonisamide, 
dihydrocodeine, 
pregabalin 
C035 F 62 1.60 77.7 155/85 72 37.1 European Non-
smoker 
Pacemaker, stroke Amolodipine, 
atorvastatin, 
clobazam, clopidogrel, 
lansoprazole, 
levetiracetam, 
paroxetine, ramipril 
C036 M 51 1.62 69.0 185/93 66 36.7 European Non-
smoker 
Hypertension, 
diabetes 
Amlodipine, aspirin, 
atenolol, atorvastatin, 
irbesartan, 
perampanel 
levetiracetam, 
novomix 30 
  *No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C037 F 
 
27 
 
1.63 78.5 140/83 87 36.0 European Non-
smoker 
Constipation, 
cerebral palsy 
Levetiracetam, 
lacosamide, 
clobazam, midazolam 
C038 F 38 1.68 69.0 157/91 67 36.1 European Current 
smoker 
Irritable bowel 
syndrome, 
hydrocephalus, 
temporal 
mandibular joint 
dysfunction 
Levetriacetam, 
alverine citrate, 
premarin, tramadol, 
morphine sulphate 
continus, vitamin D, 
domperidone, 
ibuprofen, 
paracetamol 
C039 F 43 1.69 77.5 141/89 98 37.3 European Non-
smoker 
- - 
C040 M 37 1.70 68.0 127/60 82 36.1 European Current 
smoker 
- - 
*No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C041 F 47 1.55 83.5 140/84 70 35.9 European Ex-
smoker 
hypertension Perindopril, folic acid 
C042 M 49 1.77 68.5 118/71 57 36.4 European Non-
smoker 
Brain tumour, visual 
impairment 
Clobazam 
C043 F 43 1.68 66.5 139/100 85 36.9 European Current 
smoker 
Constipation Levtiracetam, 
clobazam, 
mirtazepine, 
omeprazole, codeine, 
Oxycontin (morphine 
sulphate), 
paracetamol, HRT 
patch 
C044 F 48 1.66 68.0 122/65 82 36.9 European Ex-
smoker 
Urinary 
incontinence, 
osteoarthritis, 
thyroidectomy 
Levetiracetam, 
clobazam, 
levothyroxine, 
calcichew 
*No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C045 F 40 1.60 61.0 115/86 84 37.5 European Ex-
smoker 
Behcet’s disease Clobazam, 
topiramate, 
mirtazapine, 
pregabalin 
C046 M 28 1.75 87.5 127/63 84 36.8 European Non-
smoker 
Psychosis, 
depression 
Citalopram, 
fexofenadine, 
levetiracetam 
C047 M 54 1.70 62.5 151/95 53 37.0 European Non-
smoker 
Osteoporosis, 
fibroma 
Phenobarbital 
C048 F 58 1.56 52.0 109/66 75 37.1 European Current 
smoker 
Chronic obstructive 
pulmonary disease, 
constipation, 
osteoporosis, 
psoriasis 
Zonisamide, 
clobazam, 
venlafaxine, 
salbutamol, 
symbicort, alendronic 
acid, beconase nasal 
spray, duloxetine, 
fexofenadine 
*No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C049 M 40 1.73 88.0 143/95 67 36.3 European Current 
smoker 
- Levetiracetam, 
clobazam 
C050 F 33 1.71 104.0 142/72 66 37.0 European Current 
smoker 
Asthma  Phenytoin, symbicort, 
Salbutamol, 
clobazam, midazolam 
C051 M 44 1.67 66.0 116/81 69 36.6 European Non-
smoker 
- Clobazam, 
atorvastatin, 
levetiracetam, 
topiramate 
C052 F 53 1.59 75.0 165/99 68 36.1 European Ex-
smoker 
Hypertension, high 
cholesterol 
Levetiracetam, 
ramipril, 
lercanidipine, 
atorvastatin, adcal D3, 
salbutamol 
  *No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C053 M 45 1.75 98.0 135/98 115 37.1 European Non-
smoker 
Hypertension Felodipine, lisinopril, 
pregabalin, 
omeprazole 
C054 F 60 1.58 86.5 154/77 65 36.4 European Non-
smoker 
Irritable bowel 
syndrome, 
osteoarthritis, 
osteoporosis, 
calcium deficiency, 
hypothyroid, 
schizophrenia, 
dementia 
Procyclidine, 
simvastatin, 
aripiprazole, 
calcichew D3 forte, 
calcitriol, donepezil, 
haloperidol, 
lamotrigine, 
levothyroxine, 
mebeverine, 
naproxen, 
omeprazole, 
paroxetine 
  *No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C055 M 59 1.70 76.5 174/94 64 36.2 European Non-
smoker 
Asthma, eczema Salbutamol, Qvar, 
phenytoin, calcichew 
D3 forte, midazolam 
C056 M 46 1.88 95.0 159/100 93 36.8 European Non-
smoker 
- sodium valproate 
C057 M 59 1.77 78.6 125/74 55 35.6 European 
and South 
African 
Non-
smoker 
Hypertension Lamotrigine, 
omeprazole, 
indapamide 
atorvstatin, atenolol, 
amlodipine, ramipril 
C058 M 45 1.75 106.6 132/90 91 36.7 European Non-
smoker 
Indigestion Diazepam, 
levetiracetam, 
omeprazole, setraline, 
sulpiride, thiamine, 
vitamin B co strong, 
zopiclone 
*No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C059 F 68 1.51 48.5 162/82 75 36.3 European Non-
smoker 
Osteoporosis Pregabalin, 
zonisamide 
C060 M 50 1.65 69.0 143/81 72 36.8 European Current 
smoker 
- Levetiracetam, 
atorvastatin 
C061 F 61 1.64 50.5 128/74 67 36.2 European Current 
smoker 
Osteoporosis, 
osteoarthritis 
Adcal D3, alendronic 
acid, clobazam, co-
codamol, 
levetiracetam, 
lansoprazole, senna 
C062 M 40 1.81 69.5 143/85 68 37.0 European Ex-
smoker 
- lacosamide, 
levetiracetam 
C063 M 43 1.86 80.0 134/78 59 36.2 European Non-
smoker 
- Topiramate, 
levetiracetam, 
lacosamide 
  *No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C064 M 54 1.74 95.0 153/102 65 37.0 European Non-
smoker 
Angina, 
osteoarthritis 
Bisoprolol, isosorbide 
mononitrate xl, 
lansoprazole, co-
dydramol, 
atorvastatin, aspirin, 
thiamine 
C065 M 55 1.72 103.0 167/101 79 36.8 European Non-
smoker 
- - 
C066 M 59 1.58 69.0 135/82 55 36.9 European Current 
smoker 
Osteoarthritis, 
migraine 
Levetiracetam 
C067 F 58 1.60 78.5 189/113 62 36.7 European Current 
smoker 
Hypertension, 
headaches 
Calcichew D3, 
bisoprolol, lisinopril 
C068 F 44 1.75 89.0 112/75 72 36.8 European Non-
smoker 
Asthma salbutamol, Qvar 
  *No analytical conflicts were detected between concomitant medications and analytes. 
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ID Gender Age 
(y) 
Height 
(m) 
Weight 
(kg) 
Blood 
Pressure 
(mmHg) 
Pulse 
(bpm) 
Temp 
(oC) 
Ethnicity Smoking 
Status 
Medical History Concomitant 
Medications* 
C069 F 58 1.58 95.5 169/93 78 37.5 European Ex-
smoker 
Chronic back pain, 
multiple strokes 
Gabapentin, 
omeprazole, senna, 
atorvastatin, 
amitriptyline, 
clobazam, 
paracetamol, 
lactulose, citalopram, 
naproxen 
* No analytical conflicts were detected between concomitant medications and analytes.
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Plasma PK profiles of CBZ and its metabolites for the single-dose healthy volunteers 
are presented in Table 3.16 and Figure 3.8. Cmax for CBZ ranged between 2.33 µg/mL 
and 3.03 µg/mL with corresponding Tmax between 6 and 12 h. The mean half-life 
(t½) for CBZ was 46.5 h (±12.2 h) amongst the 8 participants (Table 3.17).  Tmax for 
CBZE was reached at 24 h except in one volunteer when it was 48 h. Cmax ranged 
from 0.08 µg/mL to 0.22 µg/mL. Cmax for DiOH-CBZ ranged between 0.20 µg/mL and 
0.30 µg/mL with Tmax at 48 h. Cmax for 2OH-CBZ ranged between 1.84 ng/mL and 
5.69 ng/mL, and time taken to reach Tmax was typically between 12 and 24 h. Finally, 
Cmax for 3OH-CBZ ranged between 1.82 ng/mL and 6.83 ng/mL with Tmax typically 
between 24 and 48 h. It should be noted that due to the low levels of 3OH-CBZ only 
two out of eight patients had Cmax values above the LLOQ (P004 and P005).   
 175 
 
Table 3.16 Plasma levels of CBZ, CBZE, DiOH-CBZ, 2OH-CBZ and 3OH-CBZ in the PICME I clinical trial 
Analyte Participant Time post dose (h) 
 
 
 
 
 
CBZ 
(µg/ml) 
 0 0.25 0.5 1 2 4 6 8 12 24 48 72 
P001 0.00 0.20 0.26 0.68 1.19 2.13 2.49 2.43 2.18 2.09 1.25 0.850 
P002 0.00 0.52 1.21 1.65 1.91 2.33 2.32 2.33 2.16 2.03 1.59 1.11 
P003 0.00 0.20 0.23 0.37 0.88 1.79 2.72 2.78 2.54 2.51 1.57 1.14 
P004 0.00 0.00 0.36 1.04 1.46 1.89 1.93 2.05 2.63 2.01 1.61 1.21 
P005 0.00 0.27 0.50 1.62 2.48 2.90 2.96 2.89 2.58 2.74 1.77 1.16 
P006 0.00 0.35 1.07 1.61 2.24 2.63 2.74 2.70 2.96 2.79 1.94 1.35 
P007 0.00 0.00 0.29 0.749 1.39 1.87 1.87 1.96 2.89 1.97 1.37 0.97 
P008 0.00 0.19 0.42 0.83 1.76 2.34 2.45 3.03 2.89 2.60 1.65 0.92 
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Analyte Participant 0h 0.25h 0.5h 1h 2h 4h 6h 8h 12h 24h 48h 72h 
 
 
 
 
CBZE 
(µg/ml) 
P001 0.00 0.00 0.00 0.00 0.01 0.03 0.07 0.09 0.10 0.13 0.08 0.06 
P002 0.00 0.00 0.00 0.01 0.03 0.05 0.05 0.06 0.06 0.07 0.09 0.06 
P003 0.00 0.00 0.00 0.00 0.00 0.01 0.05 0.08 0.10 0.15 0.08 0.06 
P004 0.00 0.00 0.00 0.00 0.00 0.02 0.03 0.04 0.05 0.08 0.08 0.05 
P005 0.00 0.00 0.00 0.01 0.03 0.05 0.07 0.07 0.09 0.13 0.13 0.07 
P006 0.00 0.00 0.00 0.01 0.02 0.03 0.05 0.07 0.08 0.15 0.15 0.08 
P007 0.00 0.00 0.00 0.02 0.04 0.06 0.07 0.09 0.09 0.12 0.11 0.09 
P008 0.00 0.00 0.01 0.02 0.04 0.06 0.08 0.11 0.13 0.22 0.20 0.11 
 
 
 
 
DiOH-CBZ 
(µg/ml) 
 
P001 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.03 0.08 0.17 0.20 0.15 
P002 0.00 0.00 0.00 0.00 0.01 0.00 0.03 0.05 0.07 0.12 0.20 0.15 
P003 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.04 0.08 0.18 0.29 0.24 
P004 0.00 0.00 0.00 0.00 0.01 0.02 0.03 0.04 0.07 0.14 0.22 0.18 
P005 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.05 0.14 0.27 0.22 
P006 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.05 0.16 0.27 0.22 
P007 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.05 0.13 0.20 0.18 
P008 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.06 0.24 0.30 0.23 
 177 
 
Analyte Participant 0h 0.25h 0.5h 1h 2h 4h 6h 8h 12h 24h 48h 72h 
 
 
 
 
2OH-CBZ 
(ng/ml) 
P001 0.00 0.00 0.00 0.57 0.67 1.85 2.16 2.69 2.70 2.63 1.88 1.65 
P002 0.00 0.29 1.00 1.49 1.93 2.23 2.36 2.32 2.31 2.36 1.91 1.65 
P003 0.00 0.00 0.00 0.00 0.17 0.52 0.79 0.87 0.87 1.02 1.84 1.63 
P004 0.00 0.00 0.38 2.13 2.40 3.08 3.88 4.36 5.56 5.69 4.64 2.66 
P005 0.00 0.16 0.72 2.62 3.15 3.68 4.05 4.67 4.42 4.91 4.19 3.02 
P006 0.00 0.20 0.87 1.55 1.61 1.93 2.07 2.55 2.84 2.96 2.87 1.73 
P007 0.00 0.04 0.23 0.70 1.16 1.60 1.66 1.76 1.80 2.17 1.81 1.41 
P008 0.00 0.04 0.45 0.83 1.37 1.99 2.33 2.41 2.72 3.45 2.82 1.64 
 
 
 
3OH-CBZ 
(ng/ml) 
P001 0.00 0.00 0.00 0.06 1.75 1.52 1.79 2.59 2.93 2.54 1.75 1.46 
P002 0.00 0.00 0.48 1.49 2.19 2.74 3.18 3.11 3.00 3.12 2.56 1.83 
P003 0.00 0.00 0.00 0.00 0.00 0.55 1.36 1.44 1.56 2.06 2.55 1.97 
P004 0.00 0.00 0.00 0.00 0.73 1.92 3.62 4.42 5.67 6.83 4.88 1.49 
P005 0.00 0.00 0.00 0.11 1.71 3.36 4.60 5.62 5.04 6.35 4.69 2.44 
P006 0.00 0.00 0.00 0.00 0.00 0.10 0.41 1.08 1.38 1.73 1.82 0.00 
P007 0.00 0.00 0.00 0.00 1.04 1.92 2.09 2.44 2.39 2.84 2.68 1.61 
P008 0.00 0.00 0.00 0.00 0.60 1.26 1.58 1.94 2.31 3.25 2.98 1.00 
 178 
 
 
(A) 
(B) 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
0 20 40 60 80 
C
o
n
ce
n
tr
at
io
n
 (
u
g/
m
l)
 
Time (h) 
PICME I - CBZ 
P001 
P002 
P003 
P004 
P005 
P006 
P007 
P008 
0.00 
0.05 
0.10 
0.15 
0.20 
0.25 
0 20 40 60 80 
C
o
n
ce
n
tr
at
io
n
 (
u
g/
m
l)
 
Time (h) 
PICME I - CBZE 
P001 
P002 
P003 
P004 
P005 
P006 
P007 
P008 
 179 
 
 
(C) 
(D) 
0.00 
0.05 
0.10 
0.15 
0.20 
0.25 
0.30 
0.35 
0 20 40 60 80 
C
o
n
ce
n
tr
at
io
n
 (
u
g/
m
l)
 
Time (h) 
PICME I - DiOH-CBZ 
P001 
P002 
P003 
P004 
P005 
P006 
P007 
P008 
0.0 
1.0 
2.0 
3.0 
4.0 
5.0 
6.0 
7.0 
0 20 40 60 80 
C
o
n
ce
n
tr
at
io
n
 (
n
g/
m
l)
 
Time (h) 
PICME I - 2OH-CBZ 
P001 
P002 
P003 
P004 
P005 
P006 
P007 
P008 
 180 
 
 
(E) 
Figure 3.8 Plasma PK profiles for healthy volunteers following a single 400 mg 
dose of CBZ: (A) CBZ, (B) CBZE, (C) DiOH-CBZ (D) 2OH-CBZ and (E) 3OH-CBZ.  
 
Table 3.17 PK parameters for CBZ following a single 400 mg dose 
 Cmax (µg/mL) Tmax (h) t½ (h) AUC 
(µg/mL*h) 
P001 2.49 6 37.0 114.2 
P002 2.33 4 63.7 126.2 
P003 2.78 8 42.2 136.0 
P004 2.63 12 65.6 127.3 
P005 2.96 6 38.7 151.9 
P006 2.96 12 45.8 160.6 
P007 2.89 12 47.0 119.3 
P008 3.03 8 31.9 142.7 
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Plasma PK profiles for CBZ, CBZE, DiOH-CBZ, 2OH-CBZ and 3OH-CBZ in the 
autoinduction patients in the PICME II clinical trial are presented in Table 3.18. For 
all three subjects, as the dosage of CBZ increased during the study, plasma levels of 
CBZ, CBZE, DiOH-CBZ, 2OH-CBZ and 3OH-CBZ also increased. There was variability in 
levels of all the analytes despite subjects being prescribed the same dosages of CBZ. 
Subject A003 demonstrated the highest plasma levels of CBZ, CBZE, DiOH-CBZ and 
3OH-CBZ; while subject A002 consistently had the lowest plasma levels of the same 
analytes. Plasma levels of 2OH-CBZ were highest throughout the course of therapy 
in subject A001 and lowest in A003. Figure 3.9 represents the mean concentrations 
of plasma CBZ at each visit as dosage was increased. 
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Table 3.18 Plasma concentrations of CBZ and its metabolites in the autoinduction group of the PICME II clinical trial 
  Time Post Dose (h) 
CBZ (µg/mL) Participant 0 1 2 4 6 8 24 
 
Visit 1 
A001 0.00 1.48 1.77 2.06 1.57 1.60 1.54 
A002 0.00 0.20 0.29 0.77 0.72 0.90 0.89 
A003 0.00 0.18 0.37 1.00 1.42 1.22 1.34 
 
Visit 2 
A001 2.18 2.93 3.27 3.46 3.58 3.65 X 
A002 2.21 2.30 2.59 3.10 2.65 2.26 X 
A003 3.77 4.38 4.05 4.21 4.39 4.96 X 
 
Visit 3 
A001 3.79 4.35 4.97 4.98 4.54 4.68 X 
A002 2.79 2.97 3.06 2.69 2.94 2.69 X 
A003 6.39 6.14 6.52 7.27 6.57 6.55 X 
 
Visit 4 
A001 4.72 5.03 5.52 6.01 5.03 4.93 X 
A002 3.69 3.36 3.63 3.82 3.62 3.42 X 
A003 7.33 7.67 7.02 6.79 7.42 6.58 X 
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  Time Post Dose (h) 
CBZE 
(µg/mL) 
Participant 0 1 2 4 6 8 24 
 
Visit 1 
A001 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
A002 0.00 0.05 0.01 0.03 0.00 0.07 0.04 
A003 0.00 0.00 0.00 0.00 0.02 0.03 0.08 
 
Visit 2 
A001 0.30 0.30 0.30 0.23 0.24 0.26 X 
A002 0.23 0.15 0.17 0.25 0.17 0.13 X 
A003 0.53 0.40 0.45 0.48 0.48 0.46 X 
 
Visit 3 
A001 0.87 0.72 0.66 0.62 0.67 0.87 X 
A002 0.33 0.27 0.33 0.29 0.40 0.29 X 
A003 1.34 1.18 1.21 1.23 1.26 1.26 X 
 
Visit 4 
A001 1.46 0.89 1.18 1.22 1.10 0.86 X 
A002 0.48 0.34 0.44 0.47 0.44 0.43 X 
A003 1.34 1.27 1.34 1.21 1.42 1.22 X 
 
  
 184 
 
DiOH-CBZ 
(µg/mL) 
 Time Post Dose (h) 
Participant 0 1 2 4 6 8 24 
 
Visit 1 
A001 0.00 0.01 0.01 0.01 0.02 0.02 0.08 
A002 0.00 0.00 0.00 0.00 0.00 0.00 0.02 
A003 0.00 0.00 0.00 0.00 0.01 0.02 0.09 
 
Visit 2 
A001 0.62 0.60 0.60 0.52 0.58 0.54 X 
A002 0.40 0.37 0.36 0.39 0.38 0.40 X 
A003 1.06 0.80 0.85 0.85 0.90 0.89 X 
 
Visit 3 
A001 1.47 1.34 1.33 1.28 1.32 1.69 X 
A002 0.74 0.70 0.70 0.68 0.75 0.74 X 
A003 2.48 2.71 2.68 2.50 2.47 2.44 X 
 
Visit 4 
A001 3.23 2.22 1.98 2.49 2.46 2.02 X 
A002 1.30 1.26 1.27 1.30 1.40 1.35 X 
A003 4.23 4.34 4.24 4.08 4.27 3.98 X 
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2OH-CBZ 
(ng/mL) 
 Time Post Dose (h) 
Participant 0 1 2 4 6 8 24 
 
Visit 1 
A001 0.00 0.42 0.60 0.89 0.62 0.74 0.75 
A002 0.00 0.00 0.00 0.52 0.72 0.73 0.97 
A003 0.00 0.00 0.00 0.13 0.28 0.36 0.58 
 
Visit 2 
A001 1.90 2.91 1.86 3.16 3.15 2.95 X 
A002 4.61 4.60 4.04 4.96 4.69 4.19 X 
A003 1.97 1.94 2.59 2.69 3.93 2.76 X 
 
Visit 3 
A001 6.67 7.49 6.28 6.12 5.59 6.96 X 
A002 5.89 6.29 6.50 7.76 7.0 6.28 X 
A003 3.32 3.90 4.13 3.48 3.93 4.03 X 
 
Visit 4 
A001 10.8 8.26 9.59 8.80 7.99 7.00 X 
A002 6.40 6.11 7.47 7.59 8.42 8.20 X 
A003 6.62 6.18 7.01 7.02 6.76 6.71 X 
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3OH-CBZ 
(ng/mL) 
 Time Post Dose (h) 
Participant 0 1 2 4 6 8 24 
 
Visit 1 
A001 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
A002 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
A003 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
 
Visit 2 
A001 1.49 1.52 1.53 1.77 1.93 1.56 X 
A002 2.00 2.27 1.90 2.71 2.57 1.84 X 
A003 5.64 4.55 5.82 5.62 6.56 6.16 X 
 
Visit 3 
A001 7.68 8.74 6.85 6.66 6.04 7.11 X 
A002 6.18 6.65 6.73 7.45 7.12 6.02 X 
A003 9.89 12.10 12.40 10.40 11.30 11.40 X 
 
Visit 4 
A001 12.6 9.82 12.50 11.10 10.00 7.79 X 
A002 6.28 5.98 8.48 8.73 9.96 6.01 X 
A003 19.50 16.40 17.80 20.70 19.00 17.50 X 
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Figure 3.9 Mean CBZ plasma levels on PK sampling days as dosage increased in the 
autoinduction group of the PICME II clinical trial (day 1: 200 mg once daily, day 14: 
200 mg twice daily, day 28: 200 mg in the morning and 400 mg at night, day 42: 
200 mg in the morning and 400 mg at night)  
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Plasma levels of CBZ, CBZE, DiOH-CBZ, 2OH-CBZ and 3OH-CBZ for the maintenance 
group subjects in the PICME II clinical trial are presented in Table 3.19. There was no 
correlation between levels of CBZ and PK sampling time post dose (r2= 0.0443, 
p=0.0662) (Figure 3.10). There was a weak correlation between total daily CBZ 
dosage and plasma levels of CBZ (r2= 0.1903, p<0.0001) (Figure 3.11). One subject 
(C020) in the maintenance dosage group did not have any detectable peaks for CBZ 
or any of the metabolites. It is most likely that this subject had not taken the 
prescribed CBZ. CBZ, CBZE, DiOH-CBZ and 2OH-CBZ were detectable in all other 
plasma samples at concentrations greater than the LLOQ of the assay. Plasma 
concentrations of CBZ ranged from 0 – 18.9 µg/mL; CBZE, 0-5.20 µg/mL; DiOH-CBZ, 
0-6.9 µg/mL; and 2OH-CBZ, 0-33.3 ng/mL.  3OH-CBZ was detected in all the other 
patients but was below the LLOQ in three patients (C009, C011 and C046). 3OH-CBZ 
plasma concentrations ranged from 0 – 60.8 ng/mL. 
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Table 3.19 Plasma concentrations of CBZ, CBZE, 2OH-CBZ, 3OH-CBZ and DiOH-CBZ at sparse pharmacokinetic time points (BD: twice daily, 
TDS: three times a day, OM: morning, PM: afternoon, ON: night time) 
ID Gender Age 
(years) 
CBZ Dose 
(mg) 
Frequency PK time 
post-dose 
(mins) 
CBZ  
(µg/mL) 
CBZE 
(µg/mL) 
DiOH-CBZ 
(µg/mL) 
2OH-CBZ 
(ng/mL) 
3OH-CBZ 
(ng/mL) 
C001 M 32 200 BD 220 7.96 0.53 1.23 3.22 6.95 
C002 F 48 400 ON 800 8.93 1.47 2.67 17.4 30.80 
C003 F 27 700 BD 500 6.81 1.79 4.25 14.6 43.90 
C004 F 32 600 BD 385 7.55 1.54 5.08 9.92 25.30 
C005 F 71 200 BD 560 5.11 0.659 2.79 7.62 14.60 
C006 F 67 400 BD 405 8.52 1.73 3.78 11.1 17.40 
C007 M 53 200 BD 222 5.29 0.455 0.62 4.78 14.80 
C008 M 46 600 BD 145 9.37 1.83 4.91 5.39 18.80 
C009 M 34 200 ON 580 1.56 0.16 0.20 1.76 2.96 
C010 F 37 400/600 OM/ON 410 7.83 1.75 3.09 11 35.50 
C010 (2) “ “ 400/600 OM/ON 140 3.42 0.598 1.33 7.99 14.30 
C011 M 53 400 BD 325 1.31 0.231 0.75 1.04 1.82 
C011 (2) “ “ 400 BD 245 3.8 1.46 2.07 6.41 23.70 
C012 M 60 400/600 OM/ON 1030 5.4 1.07 3.40 6.54 16.10 
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ID Gender Age 
(years) 
CBZ Dose 
(mg) 
Frequency PK time 
post-dose 
(mins) 
CBZ  
(µg/mL) 
CBZE 
(µg/mL) 
DiOH-CBZ 
(µg/mL) 
2OH-CBZ 
(ng/mL) 
3OH-CBZ 
(ng/mL) 
C013 F 34 600 BD 390 8.44 2.86 4.48 6.3 29.80 
C014 F 28 200 BD 900 4.82 0.468 1.00 3.76 13.70 
C015 M 46 200 TDS 220 6.97 1.2 1.36 5.85 15.9 
C015 (2) “ “ 200 TDS 225 6.76 0.918 1.00 6.77 15.2 
C016 M 47 400/600 OM/ON 90 8.23 1.34 3.16 5.83 12.9 
C017 F 58 400/600 OM/ON 580 5.46 2.35 4.99 11.8 38.0 
C018 F 46 400/200/600 OM/PM/ON 155 8.06 2.57 4.60 6.51 16.1 
C019 M 43 800 BD 120 13.6 1.02 0.99 10.5 19.3 
C020 F 57 800 BD 240 0.00 0.00 0.00 0.00 0.00 
C021 F 60 400/200/800 OM/PM/ON 430 8.51 1.81 4.82 4.66 12.7 
C022 F 48 200/400 OM/ON 230 5.89 1.16 2.78 12.9 45.6 
C023 M 61 400/500 OM/ON 425 6.98 1.32 3.34 6.75 20.4 
C024 M 50 200 OM 130 2.04 0.181 0.39 2.56 5.51 
C025 M 75 100 BD 240 4.46 0.851 0.78 4.06 10.5 
C025 (2) “ “ 200/100 OM/ON 195 5.05 1.18 1.34 10.5 21.6 
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ID Gender Age 
(years) 
CBZ Dose 
(mg) 
Frequency PK time 
post-dose 
(mins) 
CBZ  
(µg/mL) 
CBZE 
(µg/mL) 
DiOH-CBZ 
(µg/mL) 
2OH-CBZ 
(ng/mL) 
3OH-CBZ 
(ng/mL) 
C026 M 36 400/800 OM/ON 200 9.09 2.01 3.54 7.78 26.4 
C027 F 30 200/400 OM/ON 380 6.95 1.44 2.20 12.9 22.6 
C027(2) “ “ 200/400 OM/ON 155 5.06 0.941 1.98 9.62 18.9 
C028 M 50 400 BD 265 8.79 1.21 3.00 14 21.7 
C029 F 59 200/400 OM/ON 265 10.4 1.13 2.75 7.88 24.4 
C030 M 25 800 ON 785 10.2 1.72 3.95 15.2 42.1 
C031 M 45 600 BD 280 10.7 1.92 3.98 11.9 36.9 
C032 M 33 400/300 OM/ON 525 6.46 0.854 2.07 7.95 11.3 
C033 M 69 200/400 OM/ON 435 6.01 1.21 3.00 6.87 24.0 
C034 M 60 400 BD 415 8.86 1.32 3.18 10.3 17.1 
C034 (2) “ “ 400 BD 123 7.22 1.11 2.28 7.58 13.1 
C035 F 62 400/600 OM/ON 135 11.0 2.93 5.66 14.9 31.6 
C036 M 51 400 BD 100 8.56 1.5 3.22 15.3 33.3 
C036 (2) “ “ 400 BD 387 11.7 1.68 2.90 16.4 38.5 
C037 F 27 400/600 OM/ON 70 11.7 2.13 3.88 9.84 23.9 
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ID Gender Age 
(years) 
CBZ Dose 
(mg) 
Frequency PK time 
post-dose 
(mins) 
CBZ  
(µg/mL) 
CBZE 
(µg/mL) 
DiOH-CBZ 
(µg/mL) 
2OH-CBZ 
(ng/mL) 
3OH-CBZ 
(ng/mL) 
C037 (2) “ “ 400/600 OM/ON 221 11.6 2.88 4.73 14.1 31.2 
C038 F 38 400/800 OM/ON 225 9.86 1.88 3.20 8.32 20.1 
C039 F 43 200 BD 110 6.19 1.12 1.97 6.95 11.8 
C040 M 37 500/600 OM/ON 360 9.54 1.48 4.16 8.33 21.3 
C041 F 47 400/600 OM/ON 140 5.99 1.45 4.36 9.32 23.2 
C042 M 49 600 BD 70 9.90 2.51 5.74 8.8 26.1 
C043 F 43 600 ON 805 4.45 0.83 1.74 7.41 18.8 
C044 F 48 600 BD 395 9.22 5.2 6.90 10.7 22.6 
C045 F 40 400 BD 362 5.32 0.80 1.58 5.82 16.9 
C046 M 28 200 ON 1028 2.6 0.26 0.35 2.29 3.37 
C047 M 54 200 TDS 253 5.42 1.49 3.59 7.12 16.1 
C048 F 58 300 BD 263 7.88 1.81 3.81 6.48 15.7 
C049 M 40 600/400 OM/ON 995 6.51 1.79 2.52 11 26.1 
C050 F 33 600/800 OM/ON 170 3.88 1.15 2.90 6.09 21.2 
C051 M 44 400/200/400 OM/PM/ON 343 8.57 2.51 3.89 9.38 20.8 
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ID Gender Age 
(years) 
CBZ Dose 
(mg) 
Frequency PK time 
post-dose 
(mins) 
CBZ  
(µg/mL) 
CBZE 
(µg/mL) 
DiOH-CBZ 
(µg/mL) 
2OH-CBZ 
(ng/mL) 
3OH-CBZ 
(ng/mL) 
C052 F 53 200/400 OM/ON 314 7.86 1.85 2.77 11.4 23.9 
C053 M 45 200 BD 115 6.28 0.87 1.13 5.08 15.5 
C054 F 60 200/400 OM/ON 185 5.7 1.77 4.90 10.4 27.1 
C055 M 59 200 BD 410 3.01 0.44 0.74 3.89 8.5 
C056 M 46 100/200 OM/ON 185 5.56 0.57 0.73 10 17.1 
C057 M 59 400 BD 275 10 1.46 3.93 19.4 44.0 
C058 M 45 400 BD 889 8.09 1.23 1.85 6.02 15.8 
C059 F 68 300/400 OM/ON 330 10.4 2.21 5.52 13.4 38.3 
C060 M 50 200/400 OM/ON 220 7.14 1.18 2.03 11.5 23.4 
C061 F 61 400/600 OM/ON 225 8.09 2.68 5.63 11.5 26.9 
C062 M 40 400/600 OM/ON 275 8.89 2.75 4.38 11.8 33.2 
C063 M 43 400 BD 440 4.67 1.43 2.55 8.05 12.8 
C064 M 54 600/800 OM/ON 245 18.9 2.59 4.29 25.7 60.8 
C065 M 55 200 BD 195 7.47 0.98 1.34 7.70 8.8 
C066 M 59 200/400 OM/ON 165 9.90 2.78 3.75 11.7 36.4 
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ID Gender Age 
(years) 
CBZ Dose 
(mg) 
Frequency PK time 
post-dose 
(mins) 
CBZ  
(µg/mL) 
CBZE 
(µg/mL) 
DiOH-CBZ 
(µg/mL) 
2OH-CBZ 
(ng/mL) 
3OH-CBZ 
(ng/mL) 
C067 F 58 600/400/600 OM/PM/ON 210 14.3 3.77 6.26 33.3 59.2 
C068 F 44 200 BD 200 9.34 1.41 3.40 15.1 31.5 
C069 F 58 200/400 OM/ON 310 8.95 1.76 4.21 8.88 14.1 
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Figure 3.10 Correlation between PK sampling time post dose and plasma levels of 
CBZ 
 
  
Figure 3.11 Correlation between total daily CBZ dosage and plasma levels of CBZ  
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3.4 Discussion  
Two HPLC-MS/MS assays for quantification of CBZ, CBZE, DiOH-CBZ, 2OH-CBZ and 
3OH-CBZ in human plasma have been developed and validated according to FDA 
guidance (Food and Drug Administration 2001). It was initially the intention to 
utilise a single assay to quantify all five analytes. Unfortunately due to insufficient 
specificity for 2OH-CBZ and 3OH-CBZ in patient samples (Figure 3.6) a second assay 
had to be utilised. The interference on the MRM chromatogram preventing 
quantitation of 2OH-CBZ and 3OH-CBZ was absent from the pooled healthy 
volunteer plasma calibration and QC samples and not present in pre-dose patient 
samples. The samples were stored and treated identically. Therefore it is possible 
that the interference was caused by drug excipients, or their metabolites, although 
it was not possible to ascertain their identities. A Waters XBridge C18 BEH column 
was used for assaying the phenols and the reconstituted deproteinized plasma 
samples were filtered through a hydrophilic PTFE filter plate for further removal of 
proteins prior to injection onto the HPLC column. These adjustments for the new 
assay delivered the required specificity for 2OH-CBZ and 3OH-CBZ, and the assay 
was validated for use in patient plasma samples.  
 
Matrix effect is a physico-chemical phenomenon that is essentially intrinsic to the 
ESI process used in LC-MS/MS assays. It refers to the matrix-induced suppression 
and/or enhancement of analyte ionisation when other ions or substances co-elute 
with the analyte, and can lead to sample-to-sample inconsistencies in analyte 
response versus concentration (Matuszewski et al. 2003). Although the matrix 
(plasma) was qualitatively consistent throughout the study, inter-individual 
variations of plasma composition, and especially of phospholipids (Ismaiel et al. 
2013), might lead to differential effects. To assess ME, the peak areas of analytes 
dissolved in acetonitrile were compared with those of the analytes spiked into 
deproteinized and reconstituted pooled plasma (from 6 volunteers). Minor ME were 
observed in respect of four of the analytes: CBZE, 2OH-CBZ, 3OH-CBZ and DiOH-CBZ 
(Table 3.11). However, a ME on CBZ of 64.2% was observed. Although a substantial 
ME on CBZ was present it was similar across the whole calibration range and 
demonstrated a low CV of 5.4%, minimising any adverse effects on quantitation of 
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CBZ. The recovery of all 5 analytes ranged between 76.9% and 80.7% and was 
consistent throughout the concentration range, with low CVs ranging from 4.4% to 
7.5% thereby minimising adverse effect on quantitation of analytes. 
 
Acetone was chosen as the plasma protein precipitant because it has previously 
been demonstrated to provide the highest analyte recovery efficiencies compared 
with methanol or acetonitrile (Breton et al. 2005), and the same method was 
utilised for the current assays. 2Me-CBZ was utilised as the internal standard in both 
assays to account for the loss of any sample during the extraction process and for 
any variation in ionisation at the mass spectrometer source (Annesley 2003). 
Although stable isotopically labelled analogues are considered the best type of 
internal standard because of its nearly identical chemical and physical properties to 
target analytes, it was not possible to use them for the current assay as they were 
not easily commercially available (Hewavitharana et al. 2014). In addition, 
structurally similar compounds can perform as well as stable isotope IS and both 
new assays reported here satisfied bioanalytical assay validation criteria using 2Me-
CBZ as the IS (Wieling 2002). Assessment of the freeze-thaw cycle stability of 
analytes was not undertaken during assay validation because as intended all the 
plasma samples, having been separated into multiple aliquots, were frozen at -80oC 
and thawed only for analysis and not returned to the freezer.  
 
Although the assays were based upon existing HPLC-MS/MS methods, these new 
assays improved sensitivity and specificity whilst reducing the time required to 
analyse each sample. The only method in the literature to quantify all of the 
analytes of interest had a total cycle time of 50 min (Breton et al. 2005) whereas the 
total cycle time for each of the new assays is 20 min. Although other assay cycle 
times are shorter, ranging from four to ten minutes, they do not quantify as many 
analytes (Van Rooyen et al. 2002; Lionetto et al. 2012; Shibata et al. 2012). The new 
assays improve sensitivity for all the analytes compared with the original assay 
devised by Breton et al. (2005). Two other assays demonstrated lower LLOQ for CBZ 
and CBZE but they were complicated by difficult extraction procedures or the 
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requirement for much larger volumes of serum (Van Rooyen et al. 2002; Lionetto et 
al. 2012).   
 
In total 248 individual plasma samples were analysed using the newly developed 
HPLC-MS/MS assays of CBZ, CBZE, DiOH-CBZ, 2OH-CBZ and 3OH-CBZ. The PK 
variables for CBZ reported in the PICME I clinical trial, namely a Tmaz of 6-12 h and an 
average t½ of 46.5 h (Table 3.17), were consistent with previously reported data for 
single doses in healthy volunteers (Bertilsson 1978). In the PICME II autoinduction 
group subjects A001 and A003 had reached therapeutic levels of CBZ (4-12 µg/mL) 
(Schulz et al. 2012), 4.93 µg/mL and 6.58 µg/mL, respectively, after the dose 
titration regimen. CBZ levels in subject A002 remained below the therapeutic 
window, with a concentration of 3.59 µg/mL (Figure 3.9). On review of the clinical 
history, subject A002 was noted to have a very large BMI (46.8) compared with the 
other two subjects and the increased weight is most likely to account for the 
reduced plasma levels of CBZ. In addition subject A002 had been commenced on 
atorvastatin therapy by her general practitioner during the dose titration process. 
Data from pre-clinical mouse models have demonstrated that chronic treatment 
with atorvastatin reduces the anticonvulsant potency of CBZ (Stepien et al. 2012). 
The exact mechanism by which this occurs is unclear but atorvastatin, like CBZ, is 
metabolised by CYP3A4 and it is possible that reduction of anticonvulsant activity is 
mediated by an unidentified PK effect (Shitara et al. 2006).  
 
The plasma level range of CBZ in the maintenance group of the PICME II clinical trial 
(0-18.9 µg/mL) was found to be similar to that reported in the literature (Breton et 
al. 2005; Lionetto et al. 2012). Plasma levels of CBZ were below the therapeutic 
range in nine participants and above the therapeutic range in three cases. In all 
three cases of elevated levels, the total daily dosage of CBZ was greater than 1400 
mg. The recommended daily dosage for CBZ according to the summary of product 
characteristics is between 800-1200mg daily (Electronic Medicines Compendium 
2015). Plasma concentrations of CBZE (0-5.2 µg/mL) and DiOH-CBZ (0-6.9 µg/mL) 
measured in the current study were comparable to the results of previous studies 
(Breton et al. 2005; Lionetto et al. 2012). It is interesting to note that 2OH-CBZ was 
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above the LLOQ in all 77 plasma samples in this study whereas a previous study only 
identified the metabolite in 9 out of 30 subjects (Breton et al. 2005). However, the 
previous assay was not as sensitive as the updated assay. The LLOQ in the older 
assay was 23 ng/mL, compared with the new assay’s LLOQ of 0.9 ng/mL. If the 
calibration range from the older assay had been applied to the plasma samples in 
the current clinical trial, only two samples would have been above the LLOQ. 
Additionally, the previous study obtained PK samples only at the trough of the 
dosing interval whereas the current study sampled across a much wider post-dose 
time frame (70 to 1030 min). Also, 3OH-CBZ was assayable in only 25 out of 30 
subjects in the previous study, with concentrations between 23.0 to 720 ng/mL. 
Whereas 3OH-CBZ was above the LLOQ in 73 out of 77 plasma samples assayed 
during the present study, with concentrations ranging from 0 to 60.8 ng/mL. The 
increased detection rate is attributable to the lower LLOQ in the new assay: 4.73 
ng/mL against 23.0 ng/mL (Breton et al. 2005). There was only a weak correlation 
between CBZ dosage and plasma CBZ levels (r2=0.1903, p<0.0001) (Figure 3.11). This 
highlights the significant variability associated with CBZ metabolism. Polymorphisms 
of drug metabolising enzymes and transporters as well as external factors such as 
concomitant medications are likely to play an important role in explaining variability 
in plasma levels (Yun et al. 2013; Caruso et al. 2014; Wang et al. 2015). Detailed 
population PK modelling of CBZ and its metabolites has been undertaken, 
incorporating multiple covariates, gene polymorphisms and patient variables. It is 
described and analysed in the next chapter. 
 
In conclusion, two HPLC-MS/MS assays were developed and validated according to 
FDA guidance, and utilised for the measurement of the concentrations of CBZ, CBZE, 
DiOH-CBZ, 2OH-CBZ, and 3OH-CBZ in 248 patient and volunteer plasma samples. 
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Chapter 4  
A Population PK Model to Investigate the Role of 
Patient Demographics and Genetic Variation on 
the Metabolism of Carbamazepine 
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4.1 Introduction 
CBZ is a tricyclic anticonvulsant that is used for the treatment of epilepsy (Marson 
et al. 2007). CBZ is almost completely metabolised in the liver and the major route 
of metabolism is conversion to CBZE (Pearce et al. 2008). CBZE is a 
pharmacologically reactive metabolite that can also form protein conjugates in vivo 
(Figure 2.10). CBZE is converted to DiOH-CBZ by mEH (Tomson et al. 1983). Other 
metabolites include 2OH-CBZ and 3OH-CBZ, presumed to be formed via a reactive 
arene oxide intermediate (Pearce et al. 2002). Multiple CYP isoforms are involved in 
formation of these metabolites including CYP3A4, CYP3A5, CYP2B6 and CYP2C9 
(Thorn et al. 2011). UGT2B7 is responsible for glucuronidation of CBZ (Staines et al. 
2004) and metabolism of 2OH-CBZ and 3OH-CBZ by myeloperoxidase (MPO) may 
lead to formation of free radicals (Lu and Uetrecht 2008). Formation of multiple 
reactive metabolites may be implicated in hypersensitivity reactions observed with 
CBZ therapy (Knowles et al. 2000).   
 
CBZ undergoes autoinduction through upregulation of multiple CYP isoforms and 
drug transporters meaning patients typically need to undergo dose titration 
regimens at the beginning of therapy (Oscarson et al. 2006). The role of drug 
transporters, such as P-glycoprotein (P-gp), in CBZ response is unclear at present 
but there is some evidence to suggest that variable transport across the blood brain 
barrier could influence clinical outcomes with CBZ treatment (Sisodiya and 
Goldstein 2007). Clinically, CBZ has a narrow therapeutic index and therapeutic 
levels are estimated to range between 4 and 12 µg/mL (Schulz et al. 2012). There is 
large inter-individual variability in plasma levels of CBZ with little apparent 
relationship to dose as demonstrated in Figure 3.12. This has led researchers to 
postulate that factors other than dose are responsible for variation in CBZ plasma 
levels. These factors include: concomitant medications (Spina et al. 1996) and 
genetic polymorphisms in metabolising enzymes and transporter proteins (Puranik 
et al. 2013).   
 
In subjects receiving CBZ treatment concomitantly with phenytoin or phenobarbital, 
dose-adjusted plasma concentrations of CBZ and CBZ plus CBZE concentrations 
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were significantly associated with SNPs in CYP3A5 (rs776746 and rs15524) and the 
haplotype (rs15524-rs776746 GT, AC) (Wang et al. 2015). A second study in Korean 
patients reported that oral clearance of CBZ was significantly higher in CYP3A5 non-
expressors (rs776746) compared with wild type and heterozygotes (Park et al. 
2009). However, two studies did not find a significant association between CBZ 
levels and CYP3A5 polymorphisms (Panomvana et al. 2013; Zhu et al. 2014). The 
CYP3A4*1B SNP was significantly associated with reduced clearance for CBZ 
(Puranik et al. 2013). Several other studies have investigated the association 
between polymorphisms in CYP3A4 and CBZ metabolism but no significant effects 
have been reported (Yun et al. 2013; Caruso et al. 2014; Zhu et al. 2014; Wang et al. 
2015). 
 
P-gp is a drug efflux transporter that is encoded for by ATP-binding cassette sub-
family B member 1 (ABCB1) and plays a significant role in drug absorption and 
disposition (Lin and Yamazaki 2003). SNPs in ABCB1 (rs2032582 and rs10234411) 
were associated with altered CBZE/CBZ ratio in subjects receiving CBZ therapy with 
phenytoin or phenobarbital (Wang et al. 2015). Patients who were wild-type for 
ABCB1 c.3435C>T were found to have significantly higher dose adjusted 
concentrations of CBZ, CBZE and DiOH-CBZ (Meng et al. 2011a; Zhu et al. 2014).  A 
third study reported that subjects with the CC genotype had a higher likelihood of 
response to CBZ compared with patients with CT or TT genotypes (Sterjev et al. 
2012).  
 
CBZE is metabolised to DiOH-CBZ by mEH, which is encoded by EPHX1 gene. The 
EPHX1 SNPs, c.416A>G and c.128G>C, were significantly associated with higher and 
lower DiOH-CBZ:CBZE ratios, respectively (Zhu et al. 2014). Higher adjusted CBZ 
plasma concentrations were reported in Chinese epilepsy patients with the variant 
EPHX1 c.416A>G compared to those with the wild-type genotype. Another study in 
Japanese patients reported that specific haplotype structures of EPHX1 were 
significantly associated with increased or decreased ratios of DiOH-CBZ/CBZE ratios 
(Nakajima et al. 2005). Carriers of EPHX1 c.337T>C required higher doses of CBZ 
(Hung et al. 2012; Ma et al. 2015) and potentially showed increased susceptibility to 
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CBZ-induced SJS/TEN (He et al. 2014). However, one study did not find any 
significant association between carriers of EPHX1 c.337T>C and c.416A>G with 
plasma CBZE levels (Caruso et al. 2014). These data suggest that combinations of 
SNPs in multiple genes involved in the metabolism of CBZ are likely to contribute to 
the inter-individual variability in plasma levels of CBZ. 
 
Population PK modelling aims to evaluate sources and correlates of PK variability in 
target populations receiving a specific pharmacological agent (Kiang et al. 2012). 
Traditional PK studies employed “intensive” PK sampling from relatively small 
numbers of subjects that were not representative of the target population meaning 
physicians did not have enough information to use the drug properly in the patient 
group (Aarons 1991). Population PK studies employ a “sparse” sampling approach 
whereby only a small number of PK samples are collected from each patient but the 
patients are representative of the target population (Ette and Williams 2004a). The 
“sparse” sampling approach for characterising population PK enables better 
estimation of inter-subject variability. PK variability is affected by several factors 
including demographics (e.g. age, weight, gender, etc), environmental factors (e.g. 
smoking, alcohol), genetic variation in metabolising enzymes (e.g. CYP), drug-drug 
interactions and disease states (e.g. hepatic or renal impairment) (Ette and Williams 
2004a). Population PK modelling is often carried out with nonlinear mixed effects 
approach, where fixed effects and random effects parameters are estimated to 
describe a dataset and its variability. Fixed effects are generally the population 
average PK parameters while the random effects are used to account for variability 
in the data from the trends described by the fixed effects; such as inter-individual, 
inter-occasion and residual variability (the latter including errors in dosing, sampling 
or recording time or assay noise) (Kiang et al. 2012). In drug development, 
population PK modelling can be used to guide the first dose in humans from 
preclinical data (Kiang et al. 2012). In direct patient care, population PK modelling 
can allow for dosage individualisation once variables such as weight, concomitant 
medications and medical history for the intended patient is obtained through 
history and physical examination (Ette and Williams 2004a). NONMEM (non-linear 
mixed effects modelling) is the most widely used software program for population 
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PK modelling and has gained wide acceptance in both industry and academia 
(Dartois et al. 2007). 
 
Therapy with CBZ is complicated because of its complex PK profile. The drug has 
high inter-individual variability in response, is metabolised to an active metabolite 
(CBZE), it has the ability to autoinduce its own metabolism and is subject to a high 
number of drug interactions due to metabolism by several CYP isoforms (Thorn et 
al. 2011). Due to the unpredictable response to CBZ therapy, several population PK 
models have been developed to investigate factors responsible for this variation 
and to enable personalised dosing (Milovanovic and Jankovic 2013). Previous 
population PK models have investigated clinical covariates such as gender, dose, 
age, weight and concomitant medications with only a single study using population 
PK modelling to investigate the role of genetic variants in metabolising enzymes on 
variability in the metabolism of CBZ (Djordjevic et al. 2016). However, this recent 
study only examined the effect of two SNPs in a single gene (CYP1A2) against 
plasma levels of CBZ. The aim of this chapter was to generate a comprehensive 
population PK model with NONMEM using the plasma concentrations of CBZ, CBZE, 
DiOH-CBZ, 2OH-CBZ and 3OH-CBZ obtained from patients described in chapter 3. 
Twenty SNPs in multiple CBZ metabolism enzymes as well as traditional covariates 
(e.g. age, gender, weight, etc.) have been incorporated to improve our 
understanding of the metabolism of CBZ in patients. 
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4.2 Methods 
4.2.1 Study Population 
Blood samples were obtained for the study from the PICME I and PICME II clinical 
trials. Further details regarding these two studies can be found in chapter 3. There 
were three groups of patients: 
 Healthy volunteers receiving a single 400mg dose of CBZ with rich PK 
sampling over 72 h (n= 8). 
 Subjects with a diagnosis of epilepsy that were newly started on CBZ with 
rich PK samples at two weekly intervals during dose titration for the first six 
weeks of therapy (n= 3). 
 Sparse PK samples from epilepsy patients who had been on the same 
dosage of CBZ for at least four weeks (n= 69). 
 
4.2.2 Measurement of Plasma CBZ and Metabolite Levels in Patient Plasma 
Blood samples for measurement of CBZ and its metabolites were collected from 
study participants in tubes containing lithium heparin and centrifuged at 1500 g for 
10 min at 4oC. Aliquots of plasma were pipette into cryovials and frozen at -80oC 
until analysis. Plasma was thawed at room temperature on day of analysis. Plasma 
levels of CBZ, CBZE, DiOH-CBZ, 2OH-CBZ and 3OH-CBZ were determined using HPLC-
MS/MS according to Section 3.2.19. 
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4.2.3 DNA Extraction Procedure 
Whole blood was collected in tubes containing ethylenediaminetetraacetic acid 
(EDTA) and frozen immediately at -80oC until further analysis. Blood samples were 
thawed at room temperature on the same day as DNA extraction. DNA was 
extracted from 4-5 mls of whole blood using a Chemagic magnetic separation 
module (Chemagen Biopolymer-Technologie AG, Baeweiler, Germany) according to 
the manufacturer’s protocol. The concentration of DNA was measured using 
NanoDrop (Thermo Scientific, Wilmington, USA). The extracted DNA was stored in 
aliquots at 4oC until ready for further analysis. 
 
4.2.4 Selection of Genetic Polymorphisms 
The role of genetic variation on the metabolism of CBZ was investigated by analysis 
of SNPs. The selection of these SNPs was based upon known pathways of CBZ 
metabolism, expected minor allele frequencies (MAF) in the study population and 
review of previous polymorphism association studies (Table 1.4). A total of 20 SNPs 
were chosen in 11 genes (Table 4.1).  
 
4.2.5 Analysis of Single Nucleotide Polymorphisms 
SNPs were typed using either the Sequenom MassArray iPLEX platform (Sequenom 
Inc, Sand Diego CA) or TaqMan real-time PCR SNP genotyping assays (Life 
Technologies, Paisley, UK) according to the manufacturer’s protocols (Table 4.1). 
Genotype frequencies for each SNP were examined for deviation from Hardy-
Weinberg equilibrium (HWE) using the chi-squared test. 
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Table 4.1 Selection of genes and single nucleotide polymorphisms for genotyping studies 
SNP ID Gene Nucelotide 
Change/Allele 
Potential Change in Function References SNP Typing Platform 
rs1045642 ABCB1 3435C>T Reduced expression (Hodges et al. 2011) Taqman 
rs1128503 ABCB1 1236T>C Inconclusive (Hodges et al. 2011) Sequenom 
rs2032582 ABCB1 2677G>T Inconclusive (Hodges et al. 2011) Sequenom 
rs2273697 ABCC2 1249G>A Increased activity (Bruhn and Cascorbi 2014) Sequenom 
rs3740066 ABCC2 3972C>T Inconclusive (Bruhn and Cascorbi 2014) Sequenom 
rs717620 ABCC2 -24C>T Reduced activity (Bruhn and Cascorbi 2014) Taqman 
rs28365062 UGT2B7 735A>G Increased activity (Kwara et al. 2009) Sequenom 
rs28365063 UGT2B7 372A>G Increased activity (Puranik et al. 2013) Sequenom 
rs7438135 UGT2B7 -900G>A Increase activity (Matic et al. 2014) Sequenom 
rs1051740 EPHX1 337T>C Increased activity (Nakajima et al. 2005) Sequenom 
rs2234922 EPHX1 416A>G Reduced activity (Nakajima et al. 2005) Sequenom 
rs11572080 CYP2C8 *3 Inconclusive (Aquilante et al. 2013) Sequenom 
rs1058930 CYP2C8 *4 Reduced activity (Aquilante et al. 2013) Sequenom 
rs4244285 CYP2C19 *2 Loss of function (Scott et al. 2012) Sequenom 
rs192154563 CYP2C19 *17 Gain of function (Scott et al. 2012) Sequenom 
rs3745274 CYP2B6 *6 Reduced activity (Thorn et al. 2010) Taqman 
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SNP ID Gene Nucelotide 
Change/Allele 
Potential Change in Function References SNP Typing Platform 
rs2242480 CYP3A4 *1G Increased activity (Zhu et al. 2014) Sequenom 
rs776746 CYP3A5 *3 Loss of function (Lamba et al. 2012) Sequenom 
rs2333227 MPO -463G>A Reduced activity (Hansson et al. 2006) Taqman 
rs1057868 POR *28 Increased activity (Lunde et al. 2014) Taqman 
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4.2.6 Development of Population PK Model 
Development of the population PK model was undertaken under the supervision of 
Dr. Henry Pertinez (Department of Molecular and Clinical Pharmacology, University 
of Liverpool). NONMEM (Sheiner et al. 1972) (version 7.2) was used with the first-
order conditional estimation (FOCE) method for modelling the plasma dataset. 
Model selection was based on goodness of fit and the likelihood ratio test, using the 
difference in the NONMEM minimum objective function value (OFV) to discriminate 
between nested models with increasing degrees of freedom provided by extra 
model parameters. Covariate model building was carried out using the method of 
forward addition: with the NONMEM OFV (-2 x log likelihood) being approximately 
χ2 distributed, a significant improvement in OFV from one model to the next was 
judged to have been achieved at the p < 0.05 significance level if the OFV was 
reduced by 3.84 by the addition of 1 additional structural model parameter (i.e. one 
degree of freedom) to the model, 3.84 being the critical χ2 value for a p value of 
0.05 for 1 degree of freedom. Goodness of modelled fits was assessed with the 
standard errors and correlation matrix of parameter estimates and graphically with 
diagnostic plots (observed vs. population predicted data, observed vs. individual 
predicted data, residual plots) and visual predictive checks (VPCs). Prediction 
corrected VPCs (Bergstrand et al. 2011) were produced in R (version 0.98.1091), 
with 1000 simulations (of the fitted dataset) carried out using the PK model 
parameters and residual error estimates given by the final NONMEM model fitting. 
 
 
4.2.7 Correlation of Plasma CBZ Metabolite Concentrations with Single 
Nucelotide Polymorphisms in CBZ Metabolising Enzymes 
Analysis of variance (ANOVA) was undertaken using GraphPad Prism 6 software 
(GraphPad Software, San Diego, CA). Dose-adjusted plasma concentrations of CBZE, 
DiOH-CBZ, 2OH-CBZ and 3OH-CBZ were compared against SNPs involved in the 
pharmacokinetics of CBZ to determine if there were any significant associations 
between genotype and plasma levels.  
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4.3 Results 
4.3.1 Subject Demographics and Genetic Polymorphisms 
In total, 80 subjects were recruited into the study: 8 healthy volunteers, 3 patients 
with diagnosis of epilepsy and newly started on CBZ treatment and 69 subjects on a 
stable dose of CBZ for at least 4 weeks. A summary of patient demographics and 
medication data is outlined in Table 4.2. Rich PK samples were obtained from the 8 
healthy volunteers and 3 patients newly commenced on CBZ therapy. Sparse PK 
samples were collected from the 69 patients identified in clinic who had been on a 
stable dose of CBZ for at least 4 weeks. More detailed clinical information for each 
patient was previously reported in chapter 3 (Tables 3.13, 3.14, and 3.15). 
 
The distribution of the 20 SNPs amongst subjects is outlined in Table 4.3. For a 
single SNP, CYP2C19*17 (rs192154563), all subjects were homozygous for the wild-
type allele. Each genotype frequency was consistent with HWE and minor allele 
frequencies ranged from 4% to 55%.  
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Table 4.2 Demographic and Medication Data for Subjects included in Population 
Analysis. Data are expressed as mean values ± standard deviation (ranges) 
Parameter Index 
Number of subjects 80 
Number of observations 248 
Gender (%):                                                      Male 
Female 
46 (57.5%) 
34 (42.5%) 
Age (years) 45.8 ± 12.7 (21.0 – 75.0) 
Total body weight (kg) 80.8 ± 18.4 (39.0 – 140.5) 
Smokers (%)                                                        Yes 
No 
20 (25%) 
60 (75%) 
Sparse PK sampling time points* (mins) 337.5 ± 230.9 (70 – 1030) 
CBZ dose (mg/day) 765 ± 359 (200 – 1600) 
CBZ therapy without concomitant AEDs or CYP3A4 
inducer/inhibitor (%) 
29 (36.2%) 
Concomitant with 1 AED (%) 26 (32.5%) 
Concomitant with 2 AEDs (%) 16 (20.0%) 
Concomitant with 3 AEDs (%) 5 (6.3%) 
Concomitant with 1 CYP3A4 inducer/inhibitor (%) 13 (16.3%) 
Concomitant with 2 CYP3A4 inducer/inhibitors (%) 3 (3.8%) 
Number of subjects for each AED: 
 
Valproate 
Phenytoin 
Phenobarbital 
Clobazam 
Lamotrigine 
Levetiracetam 
3 
4 
1 
18 
5 
26 
Zonisamide 
Topiramate 
Lacosamide 
Pregabalin 
Perampanel 
5 
4 
3 
4 
1 
Number of subjects for each CYP3A4 
inducer/inhibitor: 
Omeprazole 
Statin 
6 
13 
*time points applicable only to sparse PK sampling group; AED: antiepileptic drug; 
CBZ: carbamazepine, PK: pharmacokinetic  
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Table 4.3 The Distribution of SNPs Amongst Study Subjects (n= 80) 
SNP ID Gene Allele Genotype Frequency (%) Minor Allele 
Frequency 
Hardy Weinberg 
Equilibrium Wild type Heterozygote Homozygote 
rs1045642 ABCB1 3435C>T 14 (17.5%) 44 (55%) 22 (27.5%) 0.55 0.32 
rs1128503 ABCB1 1236T>C 14 (17.5%) 42 (52.5%) 24 (30%) 0.56 0.55 
rs2032582 ABCB1 2677G>T 24 (30.0%) 39 (48.8%) 17** (21.2%) 0.46 0.88 
rs2273697 ABCC2 1249G>A 49 (61.3%) 29 (36.3%) 2 (2.4%) 0.21 0.34 
rs3740066 ABCC2 3972C>T 25 (31.3%) 42 (52.5%) 13 (16.2%) 0.43 0.51 
rs717620 ABCC2 -24C>T 50 (62.5%) 26 (32.5%) 4 (5.0%) 0.21 0.80 
rs28365062 UGT2B7 735A>G 62 (77.5%) 18 (22.5%) 0 (0.0%) 0.11 0.26 
rs28365063 UGT2B7 372A>G 56 (70.0%) 24 (30.0%) 0 (0.0%) 0.15 0.11 
rs7438135 UGT2B7 -900G>A 27 (33.8%) 39 (48.7%) 14 (7.5%) 0.42 0.99 
rs1051740 EPHX1 337T>C 36 (45.0%) 37 (46.3%) 7 (8.7%) 0.32 0.56 
rs2234922 EPHX1 416A>G 53 (66.3%) 24 (30.0%) 3 (3.7%) 0.19 0.89 
rs11572080 CYP2C8 *3 62 (77.5%) 16 (20.0%) 2 (2.5%) 0.13 0.44 
rs1058930 CYP2C8 *4 70 (87.5%) 10 (12.5%) 0 (0.0%) 0.06 0.55 
rs4244285 CYP2C19 *2 57 (71.3%) 19 (23.7%) 4 (5.0%) 0.17 0.17 
rs192154563 CYP2C19 *17 80 (100%) 0 (0.0%) 0 (0.0%) 0.00 NA 
rs3745274 CYP2B6 *6 52 (65.0%) 26 (32.5%) 2 (2.5%) 0.19 0.55 
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SNP ID Gene Allele Genotype Frequency (%) Minor Allele 
Frequency 
Hardy Weinberg 
Equilibrium Wild type Heterozygote Homozygote 
rs2242480 CYP3A4 *1G 71 (88.8%) 9 (11.2%) 0 (0.0%) 0.06 0.59 
rs776746 CYP3A5 *3 73 (91.3%) 7 (8.7%) 0 (0.0%) 0.04 0.68 
rs2333227 MPO -643G>A 12 (15%) 41 (51.3%) 27 (33.7%) 0.59 0.58 
rs1057868 POR *28 40 (50.0%) 27 (33.8%) 13 (16.2%) 0.33 0.53 
**included 3 TA subjects, NA: not applicable 
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4.3.2 Base Model Fitting 
The plasma exposure data for CBZ only was adequately described with a one-
compartment, first order absorption model.  Residual error was modelled with a 
proportional error model. Parameter estimates from the base model fitting 
(without incorporating any covariates into the model) are given in Table 4.4. Log 
normal distributions were assumed for the description of inter-individual variability 
in PK parameters, as shown in the following equation: 
 
θxi = θx * exp (Ƞxi)      (1) 
 
where θxi is the PK parameter ‘x’ of the  
th individual; θx is the fixed effect 
population parameter estimate; and Ƞxi is the log inter-individual variability for 
parameter ‘x’ in individual ‘i’ drawn from a normal distribution with a mean of zero 
and a variance of ω2. 
 
Table 4.4 Parameter estimates and standard errors for the base model fitting 
 CL/F 
(L h-1) 
V/F 
(L) 
ka 
(h-1) 
IIV 
CL/F 
(%) 
IIV V/F 
(%) 
IIV ka 
(%) 
Proportional 
residual error 
variance 
OFV 
Estimates 2.47 132 0.579 52.1% 10.4% 82.0 0.0354 
255.685 
%RSE 7% 5% 22% 18% 73% 29% 23% 
CL/F: apparent clearance, IIV: interindividual variability, ka: absorption constant, 
OFV: objective function value, RSE: residual standard error, V/F: apparent volume of 
distribution.    
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4.3.3 Covariate Model Fitting 
Patient demographic variables, concomitant medications and 19 SNPs were 
explored as covariates on the CL/F structural parameter of the model and effect on 
OFV are outlined in Table 4.5. The SNP rs192154563 (CYP2C19*17) was not 
explored as a covariate as all subjects in the study were wild-type. 
 
Dichotomous and trichotomous covariates were introduced as a power model and 
continuous variables were modelled using a power model with the covariate value 
normalised to the dataset population mean value, i.e.: 
 
θx = θx x θCOV 
zi x θCOV 
z2i     (2) 
 
θxi = [θx x (COVi/COVmean)
θCOV]*exp (Ƞxi)    (3) 
 
where θxi is PK parameter ‘x’ in the i
th individual and θx is the population parameter 
estimate as previously; in equation 2 (dichotomous and/or trichotomous covariates) 
θCOV is the ratio value for the typical value of parameter ‘x’ in individuals according 
to their dichotomous classification Zi or Z2i which can both be equal to 0 or 1. In 
equation 3 (for continuous covariates), COVi is the value of the covariate for the i
th 
individual, COVmean is the mean value in the population dataset, and θCOV is the 
exponent describing the covariate effect. For weight as a covariate, an allometric 
model (Anderson and Holford 2008) was applied to standardise the CL and V PK 
parameters using a standard weight (WTstd) of 70 kg in equation 3 above instead of 
the mean for the dataset, and fixing the exponent to 0.75 for CL and 1 for V.  
 
Age, weight and gender were patient variables that were explored as covariates on 
the CL/F structural parameter of the model. Plots of the post hoc individual subject 
estimates of CL (from the base model fitting) vs weight and CL (from the base model 
model fitting) vs subject age are given in Figure 4.1. A box and whisker plot of the 
individual subject estimates of CL categorised according to gender is given in Figure 
4.2. The lack of an obvious trend in the plot of individual CL estimates against 
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weight, age or gender was confirmed by non-significant drops in OFV when these 
covariates were incorporated into the population PK model (Table 4.5). 
 
 
Figure 4.1 Individual subject estimates of CL vs. individual patient weights and 
individual subject estimates of CL vs.individual patient ages   
 
 
Figure 4.2 Box and whisker plot of individual subject estimates of CL from the base 
model fitting, categorised by gender 
 
 
Table 4.5 Effect of covariates on objective function value in univariate analysis 
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Covariate ∆OFV 
Total CBZ daily dose (mg) -53.974 
Study group  
(PICME I, PICME II: autoinduction, or PICME II: maintenance) 
-6.953 
Occasion -84.933 
Age 0.01 
Gender 26.901 
Weight (kg) -6.42 
Smoker -1.281 
Concomitant therapy with:  
Sodium valproate -0.143 
Phenytoin -10.399 
Phenobarbital -1.671 
Clobazam -3.126 
Lamotrigine -0.022 
Levetiracetam -2.967 
Zonisamide -0.231 
Topiramate -1.99 
Lacosamide -0.105 
Pregabalin -0.945 
Perampanel -0.219 
Omeprazole -0.08 
Statin -1.323 
Single Nucleotide Polymorphisms  
SNP ID Gene Allele  
rs1045642 ABCB1 3435C>T -1.301 
rs1128503 ABCB1 1236T>C -1.65 
rs2032582 ABCB1 2677G>T -1.856 
rs2273697 ABCC2 1249G>A -0.499 
rs3740066 ABCC2 3972C>T -2.906 
rs717620 ABCC2 -24C>T -2.011 
rs28365062 UGT2B7 735A>G -0.085 
SNP ID Gene Allele ∆OFV 
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rs28365063 UGT2B7 372A>G -0.843 
rs7438135 UGT2B7 -900G>A -5.086 
rs1051740 EPHX1 337T>C -2.949 
rs2234922 EPHX1 416A>G -3.272 
rs11572080 CYP2C8 *3 -6.756 
rs1058930 CYP2C8 *4 -4.842 
rs4244285 CYP2C19 *2 -1.977 
rs3745274 CYP2B6 *6 -0.729 
rs2242480 CYP3A4 *1G -0.108 
rs776746 CYP3A5 *3 -1.962 
rs2333227 MPO -643G>A -0.486 
rs1057868 POR *28 -3.512 
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Concomitant medications, both AEDs and other medications, were also explored as 
covariates in the model. Representative box and whisker plots of individual subject 
estimates of CL categorised according to statin therapy and phenytoin are 
presented in Figure 4.3. Apart from phenytoin, no other concomitant medications 
were significant covariates. Multiple SNPs in CBZ metabolism enzymes were also 
explored in the PK model. None of the SNPs were found to significantly reduce the 
OFV of the population PK model. Figure 4.4 is a depiction of representative box and 
whisker plots comparing individual subject estimates of CL to SNPs in 4 genes (wild 
type, heterozygotes and homozygotes): ABCC2 (3972C>T), UGT2B7 (-900G>A), 
EPHX1 (337T>C) and CYP2C8*3. The effect of mutants (combining heterozygotes 
and homozygotes) and wild-types on individual subject estimates of CL was also 
investigated for the SNPs, but none were found to significantly reduce OFV (Figure 
4.5). 
 
 
Figure 4.3 Box and whisker plots of individual subject estimates of CL from base 
model fitting, categorised by statin or phenytoin therapy 
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Figure 4.4 Box and whisker plots of individual subject estimates of CL from the 
base model fitting, characterised by genotype for ABCC2 (3972C>T), UGT2B7 (-
900G>A), EPHX1 (337T>C) and CYP2C8*3. (Het: heterozygote, HOM: homozygote, 
WT: wild type) 
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Figure 4.5 Box and whisker plots of individual subject estimates of CL from the 
base model fitting, characterised by genotype for ABCC2 (3972C>T), UGT2B7 (-
900G>A), EPHX1 (337T>C) and CYP2C8*3. [MUT: mutant (homozygote and 
heterozygote), WT: wild type]  
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The largest significant drop in OFV was seen with the occasion covariate (-84.9). 
Occasion was used to describe completion of autoinduction in the final visit for the 
three subjects in the PICME II: autoinduction group. Visual inspection of the 
observed vs. predicted concentration demonstrated that the base model over-
predicted the final visit. At the final visit for these subjects, autoinduction was 
completed as the dose of CBZ had been stable for two weeks. Addition of the 
occasion variable significantly improved the prediction of the model and this was 
confirmed by significant reduction in OFV. A box and whisker plot comparing the 
individual subject estimates of CL to occasion is given in Figure 4.6. Concomitant 
therapy with phenytoin and total daily dose of CBZ were the other covariates that 
resulted in a significant drop in OFV (Table 4.5). A box and whisker plot comparing 
the individual subject estimates of clearance to the total daily dose of CBZ is given in 
Figure 4.7. 
 
 
Figure 4.6 Individual subject estimates of CL vs. final dose occasion in subjects 
newly started on CBZ therapy (indicative of completion of autoinduction) 
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Figure 4.7 Box and whisker plots for individual subject estimates of CL vs. total 
daily dose of CBZ 
 
A summary of the final model selection is illustrated in Table 4.6. Parameter 
estimates from the final model fitting with the covariate effect are given in Table 
4.7. Prediction corrected VPCs demonstrating the goodness of fit for each of the 
study groups are given in Figure 4.8, Figure 4.9 and Figure 4.10. Figure 4.11 
represents the VPC for the final PK model fitting for all patient groups combined. 
Plot of observed vs. population predicted concentrations in Figure 4.12 and with 
observed vs. individual predicted concentrations in Figure 4.13. The population PK 
model provides a satisfactory description of the PK profile data and its variability. 
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The final model equation: 
 
CLi = (θCL x θocc x θPHT x Dose
θTDD) x exp (Ƞxi)   (4) 
 
where θCL is the fixed effect coefficient for population mean clearance, θocc is the 
fractional effect of full autoinduction at the end of dose titration for subjects newly 
started on CBZ therapy, θPHT is the fractional effect if the subject is taking phenytoin 
and θTDD is the exponent effect of the total daily dose.  
 
Table 4.6 Summary of final model selection 
Model ∆OFV CL/F  
(L h-1) 
V/F  
(L) 
ka 
(h-1) 
ε 
Base model 0 2.47 132 0.579 0.0354 
Occasion (completion 
of autoinduction) 
-84.933 2.60 127 1.75 0.0195 
Concomitant 
phenytoin 
-93.068 2.52 127 1.76 0.0194 
Total CBZ daily dose -99.695 0.969 126 0.899 0.0162 
∆OFV: change in objective function value, ε = proportional residual error variance, 
CL/F: apparent clearance, IIV: interindividual variability, ka: absorption constant, 
OFV: objective function value, RSE: residual standard error, V/F: apparent volume of 
distribution.   
 
 
Table 4.7 Parameter estimates and standard errors for the final model fitting 
incorporating occasion, concomitant phenytoin therapy and total CBZ daily dose 
covariates 
 θCL V/F 
(L) 
ka 
(h-1) 
θOCC θPHT θTDD IIV 
CL/F 
(%) 
IIV 
V/F 
(%) 
IIV ka 
(%) 
ε OFV 
Est 0.969 126 0.899 1.57 2 0.15 50.5 11.5 123 18 
155.99 
%RSE 86% 5% 29% 18% 23% 91% 17% 54% 56% 23% 
ε = proportional residual error variance, CL: clearance, Est: estimates, IIV: 
interindividual variability, ka: absorption constant, OFV: objective function value, 
RSE: residual standard error, V/F: apparent volume of distribution.   
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Figure 4.8 Visual predictive check (VPC) for the final pharmacokinetic model fitting 
in the healthy volunteer subjects (PICME I). The red lines represent a 90% 
prediction interval (5th, 50th and 95th percentiles) for the fitted dataset based on 
1000 simulations of the dataset using the final model parameter estimates and the 
dataset covariates. 
 
Figure 4.9 Visual predictive check (VPC) for the final pharmacokinetic model fitting 
in the newly diagnosed epilepsy patients (PICME II). The red lines represent a 90% 
prediction interval (5th, 50th and 95th percentiles) for the fitted dataset based on 
1000 simulations of the dataset using the final model parameter estimates and the 
dataset covariates. 
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Figure 4.10 Visual predictive check (VPC) for the final pharmacokinetic model 
fitting in epilepsy patients prescribed a stable dose of CBZ (PICME III). The red 
lines represent a 90% prediction interval (5th, 50th and 95th percentiles) for the fitted 
dataset based on 1000 simulations of the dataset using the final model parameter 
estimates and the dataset covariates. 
 
Figure 4.11 Visual predictive check (VPC) for the final pharmacokinetic model 
fitting for all patient groups. The red lines represent a 90% prediction interval (5th, 
50th and 95th percentiles) for the fitted dataset based on 1000 simulations of the 
dataset using the final model parameter estimates and the dataset covariates. Note 
both the time and plasma concentration are in logarithmic scale. 
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Figure 4.12 Observed vs population predicted CBZ plasma concentrations for final 
covariate model fitting to plasma exposure data. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 Observed vs individual predicted CBZ plasma concentrations for final 
covariate model fitting to plasma exposure data.  
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4.3.4 Incorporation of Multiple CBZ Metabolites into Population PK Model 
It was originally intended for the population PK model to include the major 
metabolites of CBZ: CBZE, DiOH-CBZ, 2OH-CBZ and 3OH-CBZ (Figure 4.14). This 
model was identifiable, parameterised successfully and able to generate initial 
estimates. Details of the model differential equations are included in the appendix 
(Figure 9.1), but briefly, to constrain the model to make the parameters identifiable 
in a fitting exercise, the model was parameterised with a total clearance for CBZ 
with the rates of formation of the 3 primary metabolites being fractions of this total 
value (FM1, FM2, FM3 for CBZE, CBZ-2OH and CBZ-3OH respectively). In addition, 
only 3 volumes of distribution (Vd) were estimated: one for parent CBZ, one for 
CBZ-DiOH and a third which was used for each of CBZE, CBZ-2OH and CBZ-3OH - i.e. 
the Vd of these 3 metabolites was fixed to the same value; this was required to 
make the parameterisation identifiable and was also plausible given the 
physicochemical properties of each of the analytes. However, when the metabolites 
were incorporated with parent in a single analytical run, the description for oral 
absorption of CBZ was lost.  
 
 
Figure 4.14 Proposed semi-mechanistic CBZ metabolite model 
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Various efforts were made to improve the model and address the issue of 
description of the absorption phase of parent CBZ. Principally these included 
implementations of various structural model alternatives to a first order absorption 
model for the description of oral absorption including:  
 a zero order absorption model (where the oral absorption is modelled as if it 
were an infusion but where the duration of infusion is estimated during the 
fitting process). 
 a transit compartment model (Savic et al. 2007) where the number of transit 
compartments was both estimated and fixed to n = 2, 3, and 4. 
 a simultaneous zero order and first order absorption model, which had been 
used for CBZ PK modelling in the past (Riad et al. 1986). 
 a sequential zero order and first order absorption model (where the lag-time 
for the 1st order absorption (i.e. when the 1st order phase begins) was set 
to equal the duration of the zero order phase (i.e. when the infusion ends), 
the value of which was estimated as a parameter in the fitting. 
 
Attempts were also made where the model was simplified by one analyte at a time 
to potentially narrow down if the loss of description of the absorption of CBZ was 
due to the data of any one metabolite component in particular. Unfortunately, all 
versions of the model including ones with only one metabolite being directly 
produced were still unable to describe the profile of parent CBZ as successfully as a 
1-compartment 1st order model was able to describe CBZ modelled alone.  
 
Also attempted was a full re-parameterisation of the model with the CBZ-DiOH 
metabolite removed according to the method set out by Bazzoli et al where the 
ratios of elimination rate constant parameters to volumes of distribution are 
estimated instead of the parameters directly themselves (Bazzoli et al. 2011).  
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4.3.5 Dose-adjusted CBZE plasma concentrations are associated with SNPs in 
ABCB1 and EPHX 
Dose-adjusted plasma levels of CBZE were found to be significantly associated with 
two SNPs in the gene ABCB1 (c.1236T>C and c.2677G>T) and a single SNP in the 
gene EPHX1 (c.416A>G) (p = 0.0019). Plasma concentrations of CBZE were lower in 
subjects that were heterozygotes or homozygotes for ABCB1 c.1236T>C (p = 
0.0055). Homozygous mutants for ABCB1 c.2677G>T were found to have higher 
plasma concentrations of dose-adjusted CBZE. Finally, homozygous mutants for 
EPHX1 c.416A>G were found to have significantly higher dose-adjusted plasma 
concentrations of CBZE compared with wild-type and homozygotes (p = 0.003) 
(Figure 4.15). No other SNPs or dose-adjusted metabolites for CBZ demonstrated 
significant associations. 
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Figure 4.15 Significant associations between SNPs in ABCB1 and EPHX1 with dose-
adjusted plasma levels of CBZE by ANOVA (data plotted are mean and standard 
deviation)  
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4.4 Discussion 
A population PK model was developed in order to investigate the role SNPs in genes 
involved in the metabolism of CBZ have on the plasma exposure and clearance of 
CBZ in healthy volunteers and epilepsy patients. In addition, the influence of 
different demographic and clinical characteristics of the patients on CBZ clearance 
was also investigated. The model revealed that completion of autoinduction, 
concomitant therapy with phenytoin and the total daily dose of CBZ were significant 
factors that affect the clearance of CBZ. Despite investigating 19 SNPs from genes 
suspected to be involved in metabolism of CBZ, there was no demonstrable effect 
of these on CBZ PK. 
 
CBZ is known to induce its own metabolism (autoinduction) through activation of 
nuclear hormone receptors (Saruwatari et al. 2014) and induction of a broad 
spectrum of genes involved with drug metabolism and drug transport (Oscarson et 
al. 2006). Autoinduction starts within 24 h after starting therapy or increasing the 
dose and the process is typically complete in one week (Kudriakova et al. 1992). The 
CBZ population PK model that has been developed is consistent with these findings. 
The clearance of CBZ in all three subjects that had been newly started on treatment 
stabilised once the total daily dose of CBZ was fixed at 600mg for 2 weeks.  
 
Concomitant medication with phenytoin significantly increased clearance of CBZ in 
the population PK model. The influence of phenytoin therapy on CBZ metabolism 
has been recognised in several other population PK models previously (Graves et al. 
1998; Gray et al. 1998; Jiao et al. 2003; Punyawudho et al. 2012). Phenytoin 
increases metabolism of many drugs including immunosuppressants (D'Souza et al. 
1988), chemotherapeutic agents (Pursche et al. 2008) and antiretroviral drugs (Lim 
et al. 2004) through induction of multiple CYP isoforms and upregulation of P-gp 
(Brodie et al. 2013). Patients who are co-prescribed CBZ with phenytoin are likely to 
require a larger dose of CBZ to maintain plasma levels and caution should be taken 
if discontinuing phenytoin therapy as this may lead to toxicity with CBZ as the 
inductive effect of phenytoin is removed.  
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Total daily dose of CBZ was the final covariate that was found to be significant in the 
CBZ population PK model. All subjects in this study were prescribed controlled 
release formulations of CBZ. There was a positive correlation between total daily 
dose of CBZ and clearance of CBZ. The effect of dose on clearance of CBZ may be 
explained by a reduction in the bioavailability of CBZ and increase of its clearance 
through greater autoinduction at higher doses (Kudriakova et al. 1992). Several 
other population PK models of CBZ have reported that the total daily dose is a 
significant covariate in the PK of CBZ (Delgado Iribarnegaray et al. 1997; Reith et al. 
2001; Vucicevic et al. 2007; Milovanovic and Jankovic 2011; Djordjevic et al. 2016).  
 
Concomitant therapy with sodium valproate (Gray et al. 1998; Jiao et al. 2003; 
Vucicevic et al. 2007; Jankovic et al. 2008), phenobarbital (Delgado Iribarnegaray et 
al. 1997; Graves et al. 1998; Gray et al. 1998; Chan et al. 2001; Jiao et al. 2003; 
Vucicevic et al. 2007) and felbamate (Graves et al. 1998) had previously been 
reported to be significant covariates in population PK models of CBZ. None of these 
AEDs were significant in the current model and this is most likely secondary to the 
small numbers of subjects in the study receiving these particular AEDs. Other AEDs 
that were investigated using the current population PK model included clobazam, 
lamotrigine, levetiracetam, zonisamide, topiramate, lacosamide, pregabalin and 
perampanel but none were found to significantly affect the PK of CBZ. Apart from 
levetiracetam (n=26) and clobazam (n=18) the other AEDs were prescribed to fewer 
than 5 patients in the study population making any significant effects on CBZ PK 
very difficult to detect.  
 
Two other concomitant medications that were not AEDs were also investigated as 
covariates in the population PK model: omeprazole (n=6) and statin therapy (n=13). 
Omeprazole is a proton pump inhibitor that is subject to drug-drug interactions 
secondary to inhibition of CYP2C19 and CYP3A4 (Shirasaka et al. 2013). Statins are 
plasma lipid lowering drugs that act by inhibiting the enzyme 3-hydroxy-3-
methylglutaryl-coenzyme A reductase (Brown and Goldstein 1986). They have been 
reported to inhibit CYP enzymes (Transon et al. 1996) and act as substrates of the 
organic anion transporters OATP1B1 and OATP1B3 and P-gp (Lennernas and Fager 
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1997). These characteristics mean that omeprazole and statins could interact with 
the metabolism of CBZ but this was not identified in the current population PK 
model.  
 
Age and total body weight have previously been reported to be significant 
covariates (Delgado Iribarnegaray et al. 1997; Graves et al. 1998; Chan et al. 2001; 
Jiao et al. 2003; Perumandla et al. 2005; Jankovic et al. 2008; Milovanovic and 
Jankovic 2011; Djordjevic et al. 2016) but neither of these patient factors was 
identified as significant in the current model. Clearance of CBZ can be affected by 
extremes of age, with increased clearance in the paediatric population (Delgado 
Iribarnegaray et al. 1997) and reduced clearance in the elderly (Jiao et al. 2003) 
when compared with adults. The effect of total body weight on clearance of CBZ is 
significant in studies where a significant proportion of the study subjects include 
paediatric patients and it has been postulated that in children, total body weight 
more accurately represents physiologic conditions and metabolic capacity 
compared with age (Jiao et al. 2003). The current study population did not include 
any paediatric subjects and only 6 patients were over the age of 65 meaning it is 
unlikely to have the power to detect any significant effects on the clearance of CBZ 
exerted by age and total body weight. 
 
Two SNPs in the drug transporter gene ABCB1, c.1236T>C and c.2677G>T, were 
significantly associated with dose-adjusted plasma concentrations of CBZE by 
ANOVA. Up to one third of patients with epilepsy do not respond to AED therapy 
and the transporter hypothesis proposes that over-expression of efflux transporters 
such as ABCB1, in the blood-brain barrier limits the access of AEDs to the epileptic 
focus (Aronica et al. 2012). In this study, subjects with the genotype 1236TT (wild-
type) and 2677TT (homozygous mutants) were found to have higher dose-adjusted 
plasma concentrations of CBZE. Elevated concentrations of CBZE may lead to 
greater formation of the CBZE-modified HSA adduct identified in chapter 2, which 
could lead to increased susceptibility to CBZ hypersensitivity reactions. There 
remains significant controversy regarding the influence of genetic variation on 
metabolism of CBZ with conflicting results from many studies (see Table 1.4). For 
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example, CYP3A4 is the major CYP isoform responsible for metabolism of CBZ and 
the allele CYP3A4*1G has been associated with lower serum levels of CBZ and CBZE 
in Chinese patients with epilepsy implying that the SNP was associated with 
increased function (Zhu et al. 2014). However, three other studies were not able to 
replicate this association (Yun et al. 2013; Ma et al. 2015; Wang et al. 2015). 
Similarly, the SNP c.337T>C  in the gene EPHX1, which encodes for mEH responsible 
for metabolism of CBZE to DiOH-CBZ (Thorn et al. 2011), has been associated with 
increased levels of CBZE in one study (Ma et al. 2015) but no differences were 
detected in the current study or studies by others (Yun et al. 2013; Caruso et al. 
2014; Zhu et al. 2014). Subjects that were homozygous for the SNP c.416A>G in 
EPHX1 were found to have higher dose-adjusted CBZE levels. This result is 
consistent with the observation that EPHX1 c.416A>G has reduced metabolic 
activity (Nakajima et al. 2005). Elevated levels of plasma CBZE may predispose 
subjects to greater formation of the CBZE-modified HSA adduct identified 
previously.  
 
Limitations of the current study include the relatively small number of subjects, 
absence of paediatric patients and limited number of elderly patients compared 
with other population PK studies meaning that it may not have had sufficient power 
to detect significant covariates with small effects or covariates affecting extremes of 
age only. CYP1A2 (c.-163C>A) genotype has been shown to affect CBZ PK in children 
(Djordjevic et al. 2016) but was not investigated as part of the current study as 
CYP1A2 had not previously been associated with metabolism of CBZ. In future, it 
would be worthwhile using stored DNA samples to genotype subjects in the study 
for polymorphisms in CYP1A2. It was originally intended for the population PK 
model to explore the metabolism of CBZ including its metabolites CBZE, DiOH-CBZ, 
2OH-CBZ and 3OH-CBZ. The metabolite model was not able to describe the entire 
dataset accurately (performance was adequate for the metabolites themselves, but 
the description of the parent CBZ was poor) and due to its complexity (a 6-state 
system of ordinary differential equations whose numerical solution for fitting is not 
a parallelisable computer task) led to impractical extended runtimes (>48h) during 
parameter estimation, particularly when the full dataset was used and random 
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effects parameters to account for inter-individual variability  were being included. 
For these reasons, work on the metabolite data remains incomplete for the 
purposes of this thesis; however it is the intention of the authors to continue 
exploring this model in the future.  
 
In conclusion, a population PK model has been developed for CBZ with the 
completion of autoinduction, concomitant therapy with phenytoin and total daily 
dose of CBZ as significant covariates which influence PK of CBZ in an adult epilepsy 
population from the UK. 
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Chapter 5  
Characterisation and Activation of T Cell Clones 
from Patients with Carbamazepine 
Hypersensitivity 
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5.1 Introduction 
DHRs are defined as adverse events that resemble clinical allergy with evidence of 
either drug-specific antibodies or T cells to an otherwise safe and effective 
therapeutic agent. They account for approximately 15% of all ADRs and can affect 
up to 7% of the general population (Demoly et al. 2014). Accurate diagnosis of DHR 
is important to ensure optimum treatment and prevention of future episodes but is 
very difficult in the clinical setting. Currently, assessment of causality in DHRs is 
based upon clinical history and examination of the relationship between drug 
intake, type of drug, time of onset of reaction and clinical presentation of DHR 
(Schrijvers et al. 2015). This approach usually leads to exclusion of multiple drug 
classes and switch towards suboptimal therapies. After recovery from the initial 
reaction definitive workup to identify the culprit drug, potential cross-reactive 
compounds and safe alternatives requires the use of in vivo tests such as skin 
testing and drug provocation tests (Demoly et al. 2014). However, in vivo tests are 
contraindicated in very severe reactions because of the risk for re-eliciting 
symptoms and it is not possible to test all chemical entities (e.g. drug metabolites) 
using these methods (Aberer et al. 2003). Therefore, there is a clinical need for an in 
vitro validated assay for diagnosis of DHRs. 
 
The only common aspect for all delayed type DHRs is the activation of drug-specific 
T lymphocytes, which cannot be detected in drug-tolerant subjects (Naisbitt et al. 
2014). This observation has led to the development of test systems for detection of 
these drug-specific T cells. The LTT is an in vitro assay that measures lymphocyte 
proliferation and is used for the detection of sensitised T cells to a specific drug, 
metabolite and/or drug-protein conjugate (if available) in order to diagnose T cell 
mediated DHRs (Earnshaw et al. 2014). The assay is based on incubation of fresh 
PBMCs from hypersensitive patients with titrated concentrations of the suspected 
culprit drug(s) and vehicle control for 6 days (Nyfeler and Pichler 1997). Comparison 
of proliferation between drug and control, assessed by incorporation of [3H] 
thymidine, is determined by the stimulation index (SI) with SI ≥ 2 indicative of T cell 
sensitisation. The LTT has a reported specificity of at least 85% (Porebski et al. 2011) 
and sensitivity of 60-70% (Pichler and Tilch 2004). Limitations of the LTT include the 
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need for technical expertise, the prolonged duration of the assay, use of radioactive 
[3H] thymidine and the inability of a negative LTT to conclusively exclude DHR. 
Despite these shortcomings the LTT has been successfully used to confirm CBZ-
induced hypersensitivity reactions in patients (Naisbitt et al. 2003; Wu et al. 2006; 
Wu et al. 2007). 
 
To determine the profile of drug-specific T cells, alternative techniques such as T 
cell cloning (Naisbitt 2004), cell surface marker detection using flow cytometry 
(Beeler et al. 2006) and measurement of cytokines using enzyme-linked 
immunosorbent spot (ELISpot) assay (Naisbitt et al. 2003) have been utilised. 
Generation of TCCs provides a platform in which the pathophysiology of the 
hypersensitivity reaction can be investigated with respect to the phenotype, 
specificity and functionality of T cells that have been isolated from patients with 
hypersensitivity (Pichler et al. 2002). Cytokine release from T cells act as effectors 
for the immune system and quantification of their secretion using ELISpot assay can 
provide important insights into the mechanisms of DHRs; there is also the added 
benefit of shorter incubation time (48-72 h) and the ability to detect much lower 
numbers of drug-specific T cells (1:8000 to 1:30000) (Rozieres et al. 2009) in 
comparison with the LTT (1:250 to 1:10000) (Beeler et al. 2006). Measurement of 
panels of cytokines, including interferon gamma (IFN-γ), interleukin (IL) -4, IL-5, IL-
13, IL-17, IL-22, FasL, TNF-α, granzyme B and perforin have the potential to increase 
sensitivity of diagnostic assays and are currently being investigated (Naisbitt et al. 
2014). Previous work with TCCs isolated from patients with CBZ hypersensitivity has 
identified multiple cytokine secretion patterns from T cells including IFN-γ, IL-4, IL-5 
and IL-10 (Naisbitt et al. 2003). 
 
CBZ undergoes extensive metabolism and multiple reactive metabolites have been 
postulated as the species responsible for triggering hypersensitivity reactions 
(Pearce et al. 2002; Pearce et al. 2005; Pearce et al. 2008). Due to the unstable 
nature of these reactive metabolites none have been tested using in vitro assays so 
their ability to activate T cells is not known. T cell responses have been detected 
against some stable CBZ metabolites including CBZE and 10-hydroxycarbamazepine 
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but not others (2OH-CBZ, 3OH-CBZ, DiOH-CBZ) (Wu et al. 2006). Activation of these 
T cells was through direct interaction with the MHC via a pathway consistent with PI 
mechanism of hypersensitivity. However, earlier in chapter 2 of this thesis we 
demonstrated that CBZE, the most abundant stable metabolite, is able to form 
protein conjugates with albumin (Figure 2.10). CBZE-modified HSA was also 
detected in vivo from the circulation of patients prescribed long-term CBZ therapy 
for epilepsy raising the possibility that CBZE could act as a hapten by modification of 
endogenous proteins that could then be detected by the immune system (Faulkner 
et al. 2014). Based on the multiple phenotypes of CBZ hypersensitivity including 
MPE, HSS, SJS and TEN it is possible that a combination of pathophysiological 
mechanisms are responsible for hypersensitivity. 
 
In this chapter using the techniques described above, freshly isolated PBMCs were 
obtained from 12 patients with a known history of hypersensitivity to CBZ and 
incubated with different concentrations of CBZ and/or CBZE in the LTT to assess 
lymphocyte proliferation. TCCs were generated from two patients using CBZ and 
CBZE and cell surface markers characterised using flow cytometry. Cross-reactivity 
of TCCs to CBZ and CBZE, the role of antigen processing and MHC class in activation 
of TCCs and cytokine secretion profile were assessed using the ELISpot assay. 
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5.2 Methods 
 
5.2.1 Chemicals and Reagents 
CBZ (Sigma-Aldrich Co, UK) and CBZE (Sigma-Aldrich Co) were prepared as stock 
solutions (10 mg/mL) in T cell medium containing 10% dimethyl sulfoxide (DMSO; 
Sigma-Aldrich Co). The stock solutions were made up fresh and diluted to the 
appropriate concentrations directly before use. Tetanus toxoid (TT) was obtained 
from the Statens Serum Institut in Denmark. Nitroso-sulphamethoxazole (SMX-NO) 
was purchased from Dalton chemical laboratories Inc. (Toronto, Canada). Tritiated 
[3H]-methyl thymidine was purchased from Moravek (California, USA). ELISpot kits 
including antibodies (IFN-γ, IL-13, granzyme B and perforin) and substrate solution 
were purchased from Mabtech (Stockholm, Sweden). ELISpot plates were bought 
from Millipore Corporation (Millipore, Watford, UK).  
 
5.2.2 Cell Culture Medium 
T cell culture medium consisted of RPMI 1640 medium supplemented with 10% 
human pooled AB serum (Innovative Research, USA), 25 mM HEPES buffer, 2 mM L-
glutamine, 100 µg/mL streptomycin, 100 U/mL penicillin and 25 µg/mL transferrin. 
To maintain T cells in long term culture, the medium was supplemented with 200 
U/mL IL-2 (Preprotech, UK). B-cell medium comprised of RPMI 1640 medium 
supplemented with 10% foetal bovine serum (FBS; Invitrogen, UK), 25 mM HEPES 
buffer, 100 µg/mL streptomycin and 100 U/mL penicllin.  
 
5.2.3 Isolation of Peripheral Blood Mononuclear Cells 
PBMCs were isolated from the whole blood of patients with CBZ hypersensitivity by 
density gradient centrifugation. The blood was layered on top of an equal volume of 
Lymphoprep (Axis Shield, UK) and centrifuged at 400g for 25 min at room 
temperature. The layer of PBMCs was extracted carefully with a Pasteur pipette and 
washed twice in Hank’s balanced salt solution (HBSS) to remove any excess 
Lymphoprep. Isolated PBMCs were re-suspended in T cell culture medium. 
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5.2.4 Lymphocyte Transformation Test 
The LTT was performed on PBMCs using an established protocol (Nyfeler and 
Pichler 1997). Briefly, PBMCs (1.5 x 105; 100 µL) were cultured with either CBZ (12.5, 
25 and 50 µg/mL; 100 µL) or CBZE (12.5, 25, 50 µg/mL; 100 µL) in a 96-well U 
bottom plate in triplicate for six days. TT (1 µg/mL) was used as a positive control 
and cell culture medium acted as a negative control. [3H]-thymidine (Moravek, USA) 
was added for the final 16 h of incubation. Cells were harvested and proliferation 
determined by [3H]-thymidine incorporation as cpm using a MicroBeta TriLux β-
counter (Perkin Elmer, USA). Proliferative responses were calculated as SI = cpm in 
drug treated cultures/cpm in medium control. An SI ≥ 2 was considered a positive 
response.  
 
5.2.5 Generation of EBV-Transformed B-Cells 
Epstein-Barr virus (EBV) transformed B-lymphoblastoid cell lines were used as 
antigen-presenting cells (APC). B-lymphoblastoid cell lines were generated by 
transforming PBMCs using supernatant from the EBV-producing cell line B9.58 
(Neitzel 1986). PBMCs (5 x106) were resuspended with 5 mL of filtered (0.45 µM 
syringe filter) supernatant from the B95.8 cell line. Cyclosporin A (1 µg/mL) was 
added to inhibit T cell proliferation before the PBMCs were incubated overnight at 
37oC under an atmosphere of 95% air/5% CO2. After incubation the cells were 
centrifuged at 400g for 5 min and resuspended in 2 ml B-cell medium that had been 
supplemented with cyclosporin A (1 µg/mL). The cells were cultured in a 24-well 
plate and the cyclosporin A supplemented B-cell medium was changed twice per 
week. Cyclosporin A treatment was stopped after 2 weeks in order to enhance the 
proliferation of B-cells.  Cells were transferred to a tissue culture flask when 
confluent and maintained with fresh B-cell medium twice a week.  
 
5.2.6 Generation of Drug-Specific T Cell Clones 
PBMC (1 x 106, 1 mL) from CBZ hypersensitive patients were cultured in T cell 
medium containing either CBZ (25 µg/mL) or CBZE (25 µg/mL) for 14 days in a 48-
well plate at 37oC. Culture medium was supplemented with IL-2 (200 IU/mL) on 
days 5 and 9 to expand the number of antigen specific T cells. On day 14, T cell bulks 
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were separated into CD4+ and CD8+ T cells using magnetic sorting beads (Miltenyl 
Biotech, UK). T cells were incubated with CD8 beads and separated over a magnetic 
column in a syringe. The flow through contained CD4+ T cells and CD8+ T cells were 
collected by flushing the syringe using the plunger. CD4+ and CD8+ TCCs were 
cloned by serial dilution using an established method (Naisbitt et al. 2003). Briefly, 
cells were transferred into a 96-well U bottomed plates at concentrations of 0.3, 1.0 
and 3.0 cells per well. Allogeneic irradiated PBMCs (5 x 105/well), 
phytohaemoagglutinin (PHA, 5 µg/mL) and IL-2 (200 U/mL) were added to stimulate 
T cell growth. T cell growth was assessed every other day and indicators of good 
growth included change in colour of the culture medium and increasing size of the 
cell pellet. Well growing clones were expanded and split into new plates when 
necessary.  
 
Antigen specificity was assessed by culturing irradiated EBV-transformed B-cells (1 x 
104/ well) and CBZ (12.5 µg/mL) or CBZE (12.5 µg/mL) with clones (5 x 104/well; 200 
µL) for 48 h. Proliferation was measured by the addition of [3H]-thymidine followed 
by scintillation counting. Clones with a stimulation index greater than 2 were 
further expanded by repetitive stimulation with irradiated allogeneic PBMCs (5 x 
105/well), PHA (5 µg/mL) in IL-2 (5 µg/mL) containing medium.  
 
5.2.7 T Cell Phenotyping Using Flow Cytometry 
CD4 and CD8 cell surface expression of clones were determined by flow cytometry. 
Clones (50 µL) were stained with phycoerythrin (PE) labelled anti-CD4 antibodies (3 
µL) and allophycocyanin (APC) labelled anti-CD8 antibodies (3 µL) for 20 min at 4oC 
in the dark. After incubation the clones were washed and resuspended in HBSS 
containing 1% FBS and 0.02% sodium azide. Fluorescence was measured using a BD 
FACS Canto II flow cytometer (BD Biosciences) and data analysed using Cyflogic 
software (CyFlo Ltd, Finland).  
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5.2.8 Enzyme-Linked Immunospot Assay (ELISpot) for Measurement of Cytokine 
Secretion 
Cytokine secretion (IFNγ, IL-13, granzyme B and perforin) was determined by 
ELISpot assay according to the manufacturer’s protocol. Multiscreen HTS filter 
plates (Millipore, UK) were coated with the cytokine-specific capture antibody and 
incubated overnight at 4oC. Following incubation the wells were washed five times 
using sterile phosphate buffer saline (PBS) and then blocked with T cell culture 
medium (200 µL) for 30 min at room temperature. Drug-specific TCCs (5 x 104; 50 
µL), autologous EBV-transformed B-cells (1 x 104; 50 µL) and multiple 
concentrations of CBZ (5, 10, 20 µg/mL; 100 µL) or CBZE (5, 10, 20 µg/mL; 100 µL) 
were added to the wells and incubated for 48 h at 37oC. The cells were discarded 
and the wells were washed five times with 200 µL PBS. Biotin-labelled detection 
antibody (1 µg/mL) was added to the wells and incubated at room temperature for 
2 h. Wells were then washed again using PBS. Streptavidin-alkaline phosphatase 
(100 µL), diluted in PBS containing 0.5% FBS (1:1000), was added to each well and 
incubated for 1 h at room temperature. Wells were washed five further times using 
PBS (200 µL). Spots were developed by addition of BCIP/NBT substrate solution for 
approximately 10-15 min until distinct spots were visible. The development reaction 
was terminated by running the plate under tap water. Plates were left to air dry and 
the spots visualised and counted using an AID ELISpot reader (Cadama Medical, 
Stourbridge, UK). 
 
5.2.9 Confirmation of Antigen Specificity and Concentration Response of TCCs 
Antigen specificity and concentration response of TCCs were assessed by measuring 
IFN-γ secretion using the ELISpot assay. TCCs (5 x 104 cells/well; 50 µL) were 
cultured with irradiated EBV-transformed B-cells (1 x 104 cells; 50 µL) and one of 
CBZ (0, 5, 10, 20 µg/mL; 100 µL), CBZE (0, 5, 10, 20 µg/mL; µL) or SMX-NO (25 µM; 
100 µL; SMX-NO) according to section 5.2.8. PHA (10 µg/mL) acted as positive 
controls for each experiment. 
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5.2.10 Antigen Pulsing Assays 
The role of hapten formation and APC processing in the activation of TCCs was 
investigated by pulsing EBV-transformed B-cells (1 x 106 cells; 1mL) with CBZ (20 
µg/mL) or CBZE (20 µg/mL) for 16 h at 370C before extensive washing with HBSS to 
exclude free drug. The pulsed EBV-transformed B-cells (1 x 104 cells/well; 50 µL) 
were then incubated with drug-specific TCCs (5 x104 cells/well; 50 µL) and T cell 
culture medium (100 µL). Activation of TCCs was measured by IFN-γ secretion using 
the ELISpot assay (section 5.2.8). Comparison of IFN-γ secretion was made with TCC 
incubations with EBV-transformed B-cells and freshly added CBZ or CBZE. Negative 
control incubations consisted of TCCs, EBV-transformed B-cells and T cell culture 
medium. Each condition was repeated in duplicate and mean IFN-γ secretion 
reported.  
 
5.2.11 MHC Restriction Assay 
To determine if presentation of CBZ or CBZE to drug-specific TCCs is MHC class I or 
class II restricted anti-human HLA-A, -B, -C (MHC I) and anti-human HLA-DP, -DQ, -
DR (MHC II) antibodies (5 µg/mL) were pre-incubated with autologous EBV-
transformed B-cell lines (1 x 104, 50 µL) for 30 mins at 37oC. The APCs were then co-
cultured with either CBZ- or CBZE-specific TCCs with or without CBZ/CBZE for 48 h. 
IFN-γ secretion determined by ELISpot assay was used as a measure of TCC 
activation according to section 5.2.8. Isotype antibody (5 µg/mL) incubations were 
used as controls in this experiment. Each experiment was repeated in duplicate and 
mean IFN-γ secretion reported. 
 
5.2.12 Statistical Analysis 
Mean values and standard deviations or standard error of the mean were calculated 
and statistical analysis was performed using paired T-test on the GraphPad Prism 6 
software (GraphPad Software, San Diego, CA). 
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5.3 Results 
 
5.3.1 Patient Characteristics and Results of Lymphocyte Transformation Test 
Twelve patients with a history of CBZ hypersensitivity were recruited and their 
PBMCs tested in the LTT. Their clinical characteristics and responses to the LTT are 
outlined in Table 5.1. The interval between onset of hypersensitivity reaction and in 
vitro testing using LTT ranged from one year to greater than 25 years. The time to 
reaction following initiation of CBZ ranged from one day to seven months. The 
clinical presentation of hypersensitivity was variable and ranged from MPE to 
descriptions that could be compatible with SJS and TEN. Unfortunately, due to the 
extensive time that had passed since the hypersensitivity reactions, some subjects 
were unable to recall their symptoms and the clinical records were poorly 
documented. Six patients (50%) demonstrated positive stimulation index (SI ≥ 2) on 
LTT to CBZ. The SI ranged from 3.0 to 16.4. Three subjects (50%) were positive to 
CBZE on LTT with SI of 2.6, 3.7 and 5.9. Two subjects were positive to both CBZ and 
CBZE and a single patient was positive to CBZE only. The concentration response 
relationships for subjects with positive LTT to CBZ and CBZE are illustrated in Figure 
5.1 and Figure 5.2.  
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Table 5.1 Clinical Characteristics of Patients with CBZ Hypersensitivity (mth: 
months, NA: not applicable SI: stimulation index, unk: unknown) 
Subject Clinical Presentation Time to 
Reaction 
CBZ LTT 
(SI) 
CBZE 
LTT (SI) 
RLH001 1989 – unknown 21 d +ve  
(3.6) 
NA 
RLH002 1991 – generalised rash, flu 
symptoms, mucosal inflamed 
8 d -ve NA 
RLH005 2013 – red blisters to palms, soles 
and mouth. Rash on arms and legs 
4 d +ve  
(3.0) 
NA 
RLH007 1989 – generalised erythematous 
rash 
6 d +ve 
(16.4) 
+ve  
(3.7) 
RLH010 2002 – ulceration of oral cavity and 
lips 
Unk +ve  
(3.2) 
-ve 
WAL003 2006 – generalised, itchy 
erythematous macules 
1 mth +ve  
(6.0) 
+ve  
(2.6) 
WAL004 2004 -  generalised , itchy, scaly 
erythematous rash 
7 mth -ve +ve  
(5.9) 
WAL005 2012 – Generalised, itchy, flaking 
skin, lethargy, hair loss 
6 d -ve -ve 
WAL006 2008 – generalised papular erythema 
and fever 
1 d -ve -ve 
WAL007 1994 – generalised maculopapular 
exanthema 
Unk +ve  
(3.1) 
NA 
WAL008 2013 – generalised itchy 
maculopapular exanthema 
35 d -ve NA 
WAL009 2002 – Itchy erythema over arms and 
legs 
7 d -ve NA 
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Figure 5.1 Positive LTT to CBZ in six patients. PBMCs (1.5 x 104 cells, 100µL) were 
incubated with graded concentrations of CBZ (6.25 - 100 µg/mL) in 96-well U 
bottomed plates. Plates were incubated at 37oC for 5 days before addition of [3H]-
thymidine (0.5 µCi) and a further 16 h incubation. T cell proliferation was measured 
using scintillation counting. (Data represents mean proliferation and standard 
deviation of triplicate cultures). 
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Figure 5.2 Positive LTT to CBZE in 3 patients. PBMCs (1.5 x 104 cells, 100µL) were 
incubated with graded concentrations of CBZE (6.25 - 100 µg/mL) in 96-well U 
bottomed plates. Plates were incubated at 37oC for 5 days before addition of [3H]-
thymidine (0.5 µCi) and a further 16 h incubation. T cell proliferation was measured 
using scintillation counting. (Data represents mean proliferation and standard 
deviation of triplicate cultures).  
 
5.3.2 Characterisation of Drug-Specific T Cell Clones 
Based upon the results of the LTT, TCCs to CBZ and CBZE were generated from 
subjects RLH001 and RLH007 using serial dilution as described above (section 5.2.6). 
The reactivity of clones was tested using a 48 h proliferation assay. Seventeen CBZ-
specific TCCs were generated after testing 638 clones (Table 5.2). Eleven CBZE-
specific TCCs were generated after testing 579 clones (Table 5.3). The phenotype of 
all 28 drug-specific TCCs were CD4+ despite attempts to isolate CD8+ T cells using 
magnetic MultiSort beads (section 5.2.6) (Figure 5.3). An attempt was made to 
generate TCCs from WAL004 because this subject expressed positive lymphocyte 
proliferation to CBZE exclusively. Unfortunately the TCC generating procedure was 
not successful. 
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Table 5.2. Characteristics of CBZ-specific TCCs  
Subject Clones 
tested 
(n) 
Specific 
clones (n) 
Proliferation (cpm) CD phenotype (%) 
Control CBZ 
(25 µg/mL) 
CD4+ CD8+ CD4+ 
CD8+ 
TOTAL 638 17 1406.4 
(±395.1) 
13434.6 
(±10472.8) 
100 0 0 
RLH001 350 8 1456.2 
(±530.8) 
14910.9 
(±11048.1) 
100 0 0 
RLH007 288 9 1362.1 
(±223.5) 
12122.3 
(±10066.4) 
100 0 0 
  
Table 5.3. Characteristics of CBZE-specific TCCs 
Subject Clones 
tested 
(n) 
Specific 
clones (n) 
Proliferation (cpm) CD phenotype (%) 
Control CBZE 
(25 µg/mL) 
CD4+ CD8+ CD4+ 
CD8+ 
TOTAL 579 11 2180.7 
(±2007.7) 
17137.6 
(±12178.5) 
100 0 0 
RLH001 363 4 3610.9 
(±2894.4) 
23551.6 
(±16620.1) 
100 0 0 
RLH007 216 7 1363.5 
(±150.5) 
13472.4 
(±7146.2) 
100 0 0 
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Figure 5.3 Representative CD4 and CD8 phenotyping by FACs for a selection of 
CBZ- and CBZE-specific clones. TCC suspensions (50 µL) were stained with 
phycoerythrin (PE) labelled anti-CD4 antibodies (3 µL) and allophycocyanin (APC) 
labelled anti-CD8 antibodies (3 µL) for 20 min. Cells were washed and signals 
acquired by flow cytometry and analysed using cyflogic. 
 
5.3.3 Concentration Response and Cross Reactivity of Drug-specific T Cell Clones 
Concentration response and cross reactivity of drug-specific TCCs was determined 
by measurement of IFN-γ secretion using ELISpot. All drug-specific TCCs 
demonstrated concentration-dependent secretion of IFN-γ (Figure 5.4). For CBZ-
specific TCCs, 11/17 (64.7%) were cross reactive to CBZE (Figure 5.5A). For CBZE-
specific TCCs, 9/11 (81.8%) were cross reactive to CBZ (Figure 5.5B). Interestingly, a 
single TCC generated initially by stimulation of lymphocytes to CBZ secreted IFN-γ 
only in the presence of CBZE and not CBZ.   
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Figure 5.4 (A) Representative drug specificity and concentration response 
secretion of IFN-γ by drug-specific TCCs using ELISpot. (B) CBZ-dependent 
secretion of IFN-γ by CBZ-specific TCCs. (C) CBZE-dependent secretion of IFN-γ by 
CBZE-specific TCCs. TCCs were incubated with autologous EBV-transformed B-cells 
and CBZ or CBZE at indicated concentrations for 48 h. Data represent mean spot 
forming units (SFU) ± SEM of n clones. Statistical analysis was performed using 
paired T-test. (SMX-NO: nitroso-sulphamethoxazole, PHA: phytohaemagglutinin ). 
*p < 0.001. 
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Figure 5.5 (A) Cross reactivity of 11/17 (64.7%) CBZ-specific TCC to CBZE measured 
by IFN-γ secretion using ELISpot. (B) Cross reactivity of 9/11 (81.8%) CBZE-specific 
TCC to CBZ measured by IFN-γ secretion using ELISpot. TCCs were incubated with 
autologous EBV-transformed B-cells and CBZ or CBZE at indicated concentrations for 
48 h. Data represent mean spot forming units (SFU) ± SEM of n clones. Statistical 
analysis was performed using paired T-test. *p < 0.0001. 
 
5.3.4 Cytokine Secretion Profile of Drug-Specific T Cell Clones 
The secretion of IFN-γ, IL-13, granzyme B and perforin by drug-specific TCCs was 
measured using ELISpot. Concentration-dependent secretion of IFN-γ by CBZ- and 
CBZE-specific TCCs was previously demonstrated in Figure 5.4. All 28 drug-specific 
TCCs secreted IL-13 in response to CBZ or CBZE. Maximal secretion of IL-13 was 
typically reached with the lowest concentration of CBZ or CBZE tested (5 µg/mL) 
with only a limited concentration response (Figure 5.6A and B). Granzyme B 
secretion was measured by ELISpot in 7 drug-specific clones (3 CBZ-specific TCCs 
and 4 CBZE-specific TCCs). All 7 drug-specific TCCs secreted granzyme B in response 
to incubation with CBZ or CBZE (Figure 5.6C and D). Perforin secretion was 
measured in the remaining 21 drug-specific TCCs but due to technical failure, the 
experiment worked in only five CBZE-specific TCCs. However, perforin secretion was 
detected in all five clones at multiple concentrations of CBZE (Figure 5.6E). 
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Figure 5.6 (A) IL-13 secretion by CBZ-specific TCCs in response to ascending 
concentrations of CBZ (B) IL-13 secretion by CBZE-specific TCCs in response to 
ascending concentrations of CBZE (C) Granzyme B secretion by CBZ-specific TCCs in 
response to ascending concentrations of CBZ (D) Granzyme B secretion by CBZE-
specific TCCs in response to ascending concentrations of CBZE (E) Perforin 
secretion by CBZE-specific TCCs in response to ascending concentrations of CBZ. 
TCCs were incubated with autologous EBV-transformed B-cells and CBZ or CBZE at 
indicated concentrations for 48h. Data represent mean spot forming units (SFU) ± 
SEM of n clones. Phytohaemoagglutinin (PHA) acted as a positive control. Statistical 
analysis was performed using the paired T-test. *p < 0.05. 
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5.3.5 The Role of Antigen Pulsing in Activation of T cell Clones 
The role of antigen processing was investigated by comparing IFN-γ secretion in 
response to TCC incubations with EBV-transformed B-cells that had been pulsed 
with CBZ or CBZE against TCC incubations with EBV-transformed B-cells and freshly 
added CBZ or CBZE. Pulsed EBV-transformed B-cells were thoroughly washed prior 
to incubation with TCCs to ensure that any excess drug had been removed. All 17 
CBZ-specific TCCs and all 11 CBZE-specific TCCs responded to incubations with 
freshly added CBZ or CBZE supportive of a P-I mechanism of hypersensitivity (Figure 
5.7B). Interestingly, one CBZ-specific clone (CBZ TCC 109) was also activated by the 
pulsed EBV-transformed B-cells (Figure 5.7A). None of the 11 CBZE-specific TCCs 
were responsive to the pulsed EBV-transformed B-cells (Figure 5.7A).  
 
5.3.6 The Role of MHC Class I and Class II in Activation of T Cell Clones 
The role of MHC class I and class II in the activation of TCC was investigated by 
incubation of MHC class I or MHC class II blocking antibodies with autologous EBV-
transformed B-cells before addition of TCCs and drug or T cell culture medium. 
Activation of TCCs was measured as IFN-γ secretion by ELISpot. Activation was 
blocked by anti-MHC II antibodies in 5/17 (29.4%) CBZ-specific TCCs (Figure 5.8).  
For CBZE-specific TCCs, anti-MHC II antibodies blocked activation in 6/11 (54.5%) 
clones (Figure 5.8). MHC I blocking antibodies did not prevent activation of any 
drug-specific TCCs.  
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Figure 5.7 (A) Representative IFN-γ secretion measured by ELISpot for  drug-
specific TCCs in response to negative control, freshly added drug and EBV-
transformed B-cells pulsed with drug for 16 h. (B) Effect of fresh drug and pulsed 
drug on activation of TCCs in response to CBZ or CBZE as measured by IFN-γ 
secretion using ELISpot. EBV-transformed B-cells were pulsed with drug for 16 h. 
Excess drug was washed off after incubation period before incubation with TCCs for 
48 h. Comparison of IFN-γ secretion was made with TCC incubations containing EBV-
transformed B-cells with fresh drug or T cell culture medium only. Data represent 
mean spot forming units (SFU) ± SEM of n clones. Statistical analysis was performed 
using paired T-test. (*p < 0.0001, ** p = 0.0015) 
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Figure 5.8 (A) Representative secretion of IFN-γ by drug-specific TCCs using 
ELISpot in response to MHC I, MHC II and isotype blocking antibodies. (B) Effect of 
MHC I and II blocking antibodies on activation of TCCs in response to CBZ or CBZE 
as measured by IFN-γ secretion using ELISpot. EBV-transformed B-cells were 
incubated with anti-MHC I, anti-MHC II or isotype control antibody for 30 min. TCCs 
were then added with either T cell culture medium or CBZ/CBZE at indicated 
concentrations before culture for 48 h. Data represent mean spot forming units 
(SFU) ± SEM of n clones. Statistical analysis was performed using paired T-test. (*p = 
0.003, **p = 0.001, ***p= 0.03, NS = not significant) 
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5.4 Discussion 
During the study, 12 subjects with a clinical history of CBZ hypersensitivity were 
identified. The clinical presentations of CBZ hypersensitivity were highly variable 
with case descriptions possibly consistent with MPE, HSS and SJS/TEN which 
correlates with the varied clinical manifestations of hypersensitivity reported 
previously (Yip et al. 2012). Unfortunately, clinical and patient descriptions of the 
lesions were poor and documentation incomplete, which is a limitation. There were 
no photographs making definitive diagnosis more difficult. The interval between 
onset of reaction and commencement of therapy was between 1 day and 4 weeks 
for most patients although one subject reported hypersensitivity after 28 weeks. 
This is broadly consistent with previously reported time frames for CBZ-induced 
hypersensitivity reactions of 2-8 weeks after starting treatment (Knowles et al. 
1999). Only half of the patients demonstrated a positive response on the LTT which 
is lower than the reported specificity for detection of CBZ-induced hypersensitivity 
of greater than 80% in other studies (Naisbitt et al. 2003; Wu et al. 2006; Wu et al. 
2007). The reasons for this could be inability of the LTT to detect the T cell 
population responsible for a specific phenotype of hypersensitivity or misdiagnosis 
of CBZ hypersensitivity reaction. The LTT is often negative in patients who present 
with drug-induced SJS/TEN (Tang et al. 2012; Porebski et al. 2013). CD8+ T cells are 
the primary effector cells in SJS/TEN (Nassif et al. 2002) and it has been postulated 
that they do not proliferate readily in the LTT (Naisbitt et al. 2014). The inability to 
generate CBZ- or CBZE-specific CD8+ TCCs in this chapter would corroborate this 
hypothesis. Secondly, clinical diagnosis of drug-induced hypersensitivity reactions is 
difficult as patients are likely to be taking multiple concomitant medications and the 
signs and symptoms of hypersensitivity can be non-specific leading to incorrect 
diagnosis. New guidelines for the investigation and evaluation of suspected drug-
induced skin reactions should improve the situation in the future (Pirmohamed et 
al. 2011).  
 
The LTT was undertaken using CBZE in six of the participants. Two subjects tested 
negative to both CBZ and CBZE, two subjects demonstrated positive lymphocyte 
proliferation to both CBZ and CBZE, one participant demonstrated a positive 
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lymphocyte response to CBZ only and the final patient demonstrated lymphocyte 
proliferation to CBZE only. These results suggest that some drug-specific T-cells 
from patients with CBZ hypersensitivity may respond only to parent drug or CBZE 
whilst others demonstrate a pattern of cross-reactivity. Previous work by Wu et al 
investigated the proliferation of lymphocytes to CBZ and several stable metabolites 
in five patients with a history of CBZ hypersensitivity using the LTT (Wu et al. 2006). 
Lymphocyte proliferation was observed with CBZ, CBZE, 10-hydroxycarbamazepine 
and oxcarbazepine. No proliferation was seen with 2OH-CBZ, 3OH-CBZ or DiOH-CBZ. 
All lymphocytes that proliferated in the presence of the parent drug also 
proliferated with CBZE, 10-hydroxycarbamazepine and oxcarbazepine. There were 
no LTT responses only to the parent compound or a specific metabolite.  
 
Two subjects had experienced hypersensitivity reactions greater than 25 years ago 
yet still retained drug-specific T cells which proliferated when incubated with CBZ in 
the LTT in the case of subject RLH001 and both CBZ and CBZE for subject RLH007. 
This suggests that drug-specific T cells to CBZ could persist lifelong within a memory 
pool in the peripheral circulation despite avoidance of the culprit drug. Previously, 
drug-specific T cells had been observed for up to 12 years following a 
hypersensitivity reaction to sulfamethoxazole (Beeler et al. 2006). At present the 
antigens that maintain these long lived T cell responses are unknown but viral 
antigens have been proposed by the heterologous immunity model (White et al. 
2015) (Figure 5.9). According to this model, the subject acquires primary infection 
by a viral pathogen (e.g. HHV or varicella zoster virus [VZV]). Viral peptides are then 
presented in the context of a HLA risk allele (e.g. HLA-B*15:02) leading to the 
generation of a polyclonal CD8+ T cell response that contains the virus. The virus 
becomes latent and the memory T cells persist at the site of antigen interaction 
(e.g. skin).  The T cells are then intermittently stimulated by viral antigens during 
viral activation but effector memory T cells ensure the virus does not cause clinical 
symptoms leading to persistence of T cells over many years. The patient is then 
exposed to the drug that causes hypersensitivity (e.g. CBZ). The offending drug or 
metabolite then interacts with the HLA risk allele through mechanisms such as the 
hapten hypothesis, PI concept or altered peptide repertoire concept. The offending 
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drug peptide-MHC complex is subsequently recognised by the TCR that was 
originally primed against the viral pathogen leading to activation of the memory T 
cells and clinical ADR.  This possible mechanism needs further investigation to either 
confirm or refute the hypothesis. 
 
Generation of TCCs provides a platform to further investigate the pathophysiology 
of the hypersensitivity reaction with respect to phenotype, specificity and 
functionality of the T cells isolated from the hypersensitive patients (Naisbitt 2004). 
In total, 28 drug-specific TCCs were generated from two subjects. Seventeen clones 
were specific to CBZ and eleven clones specific to CBZE. All of the clones were CD4+ 
phenotype despite attempts to generate CD8+ clones using CD8 magnetic beads. 
Although one CD4+CD8+ TCC and two CD8+ TCCs were initially identified as CBZE-
specific in the cloning procedure, all became nonresponsive to CBZE in functional 
analyses and were therefore classed as non-specific. Antigen specific immune 
tolerance or anergy is a recognised feature of repeatedly stimulating cloned CD8+ T 
cells (Wu et al. 2007). The failure to generate drug-specific CD8+ TCCs emphasises 
the reduced proliferation capacity of CD8+ T cells compared to CD4 T cells (Naisbitt 
et al. 2014) although it should be noted that CBZ-specific CD8+ TCCs have been 
successfully generated previously (Wu et al. 2006; Wu et al. 2007).   
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Figure 5.9. Proposed mechanism for generation of heterologous immune 
responses in pathogenesis of T cell-mediated ADRs. Patient is known carrier of a 
risk HLA allele (e.g. HLA-B*15:02) and acquires viral infection (e.g. HHV). Viral 
peptides are presented with the autologous risk HLA allele by APCs leading to 
activation of T cell responses that contain viral infection. TEM persist in the 
circulation and other tissues (e.g. skin). Intermittent reactivation of viruses lead to 
persistence of TEM cells. Patient is then exposed to offending drug (e.g. CBZ). The 
offending drug interacts with the risk autologous HLA, possibly by hapten, PI or 
altered repetoire mechanisms. The drug-peptide-MHC complex is recognised by the 
T cell and TCR that was originally primed by the viral pathogen leading to activation 
of T cell response and hypersensitivity. (HHV – human herpes virus, HLA- human 
leukocyte antigen TEM – memory effector T cells). 
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Cytokines are an important component of the effector phase of the immune 
response and IFN-γ is considered as a dominant cytokine in multiple drug-induced 
exanthemas including with CBZ, lamotrigine and penicillins (Naisbitt et al. 2003; 
Halevy et al. 2005; Khalil et al. 2008). Consistent with previous findings, all 28 drug-
specific TCCs secreted IFN-γ, as measured by the ELISpot assay, in a concentration-
responsive manner when incubated with CBZ and/or CBZE. IL-13 secretion was 
detected in all 28 drug-specific TCCs when co-incubated with CBZ or CBZE. IL-13 is 
typically secreted by CD4+ T helper type 2 (Th2) cells in conjunction with IL-4 
leading to activation of type 2 inflammation commonly manifesting clinically as 
asthma or allergy (Bao and Reinhardt 2015). Both IFN-γ and IL-13 have been 
detected in cutaneous lesions of erythema multiforme and SJS/TEN (Caproni et al. 
2006). It has been proposed that measurement of a combination of cytokines 
including IFN-γ and IL-13 (as well as IL-2 and IL-5) from patients with suspected DHR 
could improve in vivo detection of T cell sensitisation to drugs (Lochmatter et al. 
2009). Perforin and granzyme B have also been detected from blood and blister 
fluid of subjects with MPE, SJS and TEN with levels of both cytokines demonstrating 
strong positive correlation with disease severity (Posadas et al. 2002). Activated T 
cells and natural killer cells secrete perforin, which leads to the formation of 
channels in the target cell membrane (e.g. keratinocyte), allowing granzyme B to 
enter the cell to activate the caspase cascade with resultant apoptosis (Lowin et al. 
1995). In line with the above findings, secretion of granzyme B and perforin was 
detected in all of the clones tested (7 for granzyme B and 5 for perforin).  
 
Cross-reactivity to CBZ or CBZE, measured by IFN-γ secretion using ELISpot, was 
observed in 20 out of 28 drug-specific TCCs. Six CBZ-specific TCCs were responsive 
to CBZ only whilst eleven were responsive to both CBZ and CBZE. Two CBZE-specific 
TCCs were responsive to CBZE exclusively whilst nine were responsive to both CBZE 
and CBZ. These results suggest that patients with CBZ hypersensitivity possess a 
range of T cells that are responsive to both CBZ and CBZE in vivo. These findings are 
in line with previous studies that have identified CBZ-specific T cells from 
hypersensitive patients which are responsive to CBZE, other stable metabolites such 
as 10-hydroxycarbamazepine and oxcarbazepine, an alternative anticonvulsant with 
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structural similarities to CBZ (Naisbitt et al. 2003; Wu et al. 2006). It is possible that 
CBZ- and CBZE-specific TCCs generated in this study may also respond to other CBZ 
metabolites. In chapter 2 of this thesis a CBZE-modified albumin conjugate was 
detected in patients receiving CBZ therapy for clinical indications. Similar albumin 
modifications have also been detected with piperacillin. Antigenicity of the 
piperacillin-modified albumin was confirmed by stimulation of T cell responses 
using characterised synthetic conjugate and TCCs from patients with known 
piperacillin hypersensitivity (Whitaker et al. 2011). In future, similar experiments 
using synthetic CBZE-protein conjugates and TCCs from CBZ hypersensitive patients 
could be undertaken to investigate the ability of CBZ- and CBZE-specific TCCS to 
respond to metabolite-modified proteins.  
 
The antigen pulsing assay provides indirect evidence for the hapten mechanism of 
drug hypersensitivity. In the current study, APCs, in this case EBV-transformed B 
cells, were incubated with CBZ or CBZE for 16 h before thorough washing to ensure 
removal of any drug that had not been taken up into the APC. These pulsed APCs 
were then incubated with the drug-specific TCCs and activation of TCCs measured 
by IFN-γ secretion. Comparisons of activation were made against incubations with 
TCCs, APCs and freshly added CBZ/CBZE or drug negative controls. All 28 drug-
specific TCCs secreted IFN-γ when fresh drug was added indicative of a direct PI 
mechanism for hypersensitivity. These findings are consistent with previous findings 
that CBZ is able to directly interact with T cells or HLA to initiate hypersensitivity 
(Wei et al. 2012; Zhou et al. 2015).  However, one CBZ specific clone also responded 
to pulsed EBVs suggestive of antigen-dependent presentation and hapten 
mechanism for hypersensitivity. Previously, two [O]CBZ-HSA conjugates were 
identified in vitro (Figure 2.10 and Figure 2.14). It is possible that these protein 
conjugates were formed during the incubation of CBZ with APC as the T-cell culture 
medium contains HSA and it is not possible to exclude metabolism of CBZ to [O]CBZ 
metabolites during the 16 h overnight incubation. The [O]CBZ-HSA conjugate could 
then have been processed and presented by the APC to the TCC. In future, to assess 
for the presence of protein conjugates and drug metabolism an aliquot of the 
supernatant could be removed from the incubation of CBZ and APC, prior to 
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addition of TCC, for analysis by HPLC-MS/MS as described in chapters 2 and 3. It is 
possible that multiple T cell activation pathways are triggered during a CBZ 
hypersensitivity reaction. 
 
Predisposition to multiple DHRs have been associated with multiple HLA alleles (Yip 
et al. 2015a). HLA-B*15:02 has been strongly associated with CBZ-induced SJS/TEN 
in Asian patients (Chung et al. 2004) whilst HLA-A*31:01 is strongly associated with 
all phenotypes of CBZ hypersensitivity in multiple ethnicities (McCormack et al. 
2011). Antibodies to MHC class I and MHC class II were used in the study to 
investigate the role HLA in activation of CBZ- and CBZE-specific TCCs. As expected, 
activation of drug-specific TCCs was not MHC class I restricted as all TCCs were CD4+ 
phenotype. Activation of drug-specific TCCs was MHC class II restricted in 11 out of 
28 drug-specific TCCs (5 for CBZ and 6 for CBZE). The remaining 17 drug-specific 
TCCs were responsive in the presence of both MHC class I and II antibodies. These 
TCCs may have been directly activated by CBZ without presentation on MHC or the 
experimental conditions for antibody blocking of MHC were not optimised. In future 
studies it will be important to test a range of concentrations for both CBZ/CBZE and 
MHC blocking antibodies to investigate the sensitivity of response of individual TCCs 
to antigen and MHC blocking antibodies. Recently, it has been shown that specific 
HLA class I and class II alleles are associated with particular phenotypes of 
nevirapine hypersensitivity; HLA-B*35:01 and HLA-Cw*04 were associated with 
cutaneous hypersensitivity, HLA-Cw*08 was associated with eosinophilia and HLA-
DRB*01:01 was associated with hepatitis. Cellular studies in these patients 
identified specific combinations of class I restricted CD8+ T cells and class II 
restricted CD4+ T cells that contributed to pathogenesis of specific phenotypes of 
nevirapine hypersensitivity (Keane et al. 2014). The exact relationship between HLA 
class I and class II alleles in CBZ hypersensitivity requires further investigation. The 
HLA class II allele, HLA-DRB1*04:04, has been reported to be functionally significant 
for the activation of T cells generated from a HLA-A*31:01 positive patient 
(Lichtenfels et al. 2014). The authors reported strong linkage disequlibrium between 
the two alleles and suggest that a common haplotype may contribute to the 
multiclonal response seen in Caucasian patients with CBZ hypersensitivity.  
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Carriage of the risk HLA alleles alone is insufficient to generate a hypersensitivity 
response when exposed to CBZ (Yip et al. 2012). CBZ responsive CD8+ T cells 
isolated from HLA-B*15:02 positive patients with a history of CBZ-induced SJS were 
all found to use a common restricted TCR repertoire and over express specific TCR 
Vβ profiles (Ko et al. 2011). These results suggest that specific TCRs could also act as 
a risk factor in development of specific phenotypes of CBZ hypersensitivity. In future 
studies it would be informative to investigate the range of TCR profiles expressed in 
CBZ- and CBZE-specific TCCs generated from subjects with multiple phenotypes of 
CBZ hypersensitivity. 
 
In conclusion, positive lymphocyte proliferation responses can be generated from 
patients with a history of CBZ hypersensitivity even if presentation of the original 
symptoms were longer than 25 years ago. It is possible that these drug-specific 
memory T cells persist in the circulation lifelong and are possibly maintained by the 
heterologous immunity model. In this study, twenty eight CD4+ drug-specific TCCs 
were generated to CBZ or CBZE. Specificity of TCCs was variable with some clones 
responsive only to original stimulating antigen whilst others were also responsive to 
both CBZ and CBZE. Activation of clones was through a direct PI mechanism 
although a single CBZ TCC did respond to pulsed APCs consistent with the hapten 
hypothesis. MHC class II is responsible for presentation of antigen to CD4+ TCCs. 
Secretion of IFN-γ, IL-13, granzyme B and perforin were detected in the TCCs 
providing evidence for the pathophysiological mechanism of hypersensitivity. These 
data demonstrate that CBZ hypersensitivity is characterised by plurality of T cell 
responses reacting with multiple antigens using different mechanistic pathways. 
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Chapter 6  
Gene Expression Analysis of Peripheral Blood 
Mononuclear Cells from Patients with 
Carbamazepine Hypersensitivity Exposed to 
Carbamazepine and Carbamazepine 10,11-
Epoxide  
  
 266 
 
6.1 Introduction 
The clinical presentation of CBZ hypersensitivity reactions is diverse, ranging from 
mild eruptions such as MPE to more severe systemic manifestations, which include 
HSS, SJS and TEN (Yip et al. 2012). Up to 10% of patients experience hypersensitivity 
when prescribed CBZ (Marson et al. 2007) and the presence of rash warrants 
withdrawal of the drug as it is currently not possible to predict who will progress to 
the more severe systemic conditions (Mehta et al. 2014). Early withdrawal of CBZ 
improves prognosis and survival, and if possible, other aromatic anticonvulsants 
should be avoided in the future (Garcia-Doval et al. 2000; Błaszczyk et al. 2015).  
 
Despite the importance of early recognition, diagnosis of hypersensitivity reactions 
remains difficult in everyday clinical practice. Diagnostic tests are not routinely 
available and acute diagnosis is typically based on limited clinical history and 
examination (Polak et al. 2013). Even after recovery, testing is required to 
determine the culprit drug/chemical in order for the patient to avoid it in the 
future. In vivo investigations, such as skin prick and patch testing, have been utilised 
for the diagnosis of CBZ hypersensitivity but there has been a high variability in 
response rates (Alanko 1993; Seitz et al. 2006). In addition, in vivo tests are only 
recommended in cases of mild exanthems because of the risk of inducing life-
threatening reactions, and are not suitable for acute diagnosis (Mirakian et al. 
2009). Therefore, there is a clinical need for accurate in vitro diagnostic tests.  
 
The LTT, also known as the lymphocyte proliferation assay, is the most widely 
reported in vitro diagnostic test for drug hypersensitivity (Pichler and Tilch 2004). It 
detects the presence of drug-specific T-cells and measures the proliferation of these 
T-cells when re-exposed to titrated concentrations of the suspected drug (Nyfeler 
and Pichler 1997). The LTT has been used for the diagnosis of CBZ hypersensitivity 
but the sensitivity and specificity for the test are influenced by the clinical 
manifestation of hypersensitivity and the timing of the test since the reaction 
(Elzagallaai et al. 2009). The LTT does have other limitations: it is technically 
demanding, requires thymidine (a radioactive isotope) and the typical duration for 
the assay is 5-7 days (Nyfeler and Pichler 1997). In chapter 5, twelve patients had 
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been clinically diagnosed with CBZ hypersensitivity but only six tested positive (50%) 
on LTT using CBZ. The reasons for this variation remain unknown and require 
further investigation. 
 
The identification of CBZ-specific T-cells (Wu et al. 2007) and strong associations 
with specific HLA-alleles (Chung et al. 2004; McCormack et al. 2011) provide 
evidence that CBZ hypersensitivity reactions are immune-mediated. The utility of 
screening for HLA-B*15:02 for prevention of CBZ-induced SJS/TEN in Asian 
populations has been demonstrated prospectively (Chen et al. 2011) and the drug 
label for CBZ has been changed by many drug regulatory agencies, including the 
European Medicines Agency and US Food and Drug Administration, to mandate 
screening. HLA-A*31:01 is associated with all phenotypes of CBZ hypersensitivity in 
European (McCormack et al. 2011) and Japanese populations (Ozeki et al. 2011) but 
screening is not mandatory at present. However, not all patients that carry the risk 
HLA alleles will experience hypersensitivity if exposed to CBZ, resulting in the denial 
of therapy to many patients who would have tolerated treatment (Yip et al. 2012). 
These data suggest that HLA are necessary for a CBZ hypersensitivity reaction but 
insufficient to trigger hypersensitivity on their own. There remains a need to 
understand the other factors that lead to a CBZ hypersensitivity reaction in order 
that better treatments and diagnostic tests can be developed. 
 
Transcriptomics is the study of the transcriptome - the complete set of RNA 
transcripts that are produced by the genome, under specific circumstances or in a 
specific cell - using high throughput technologies such as RNA sequencing and 
microarray analysis (Wang et al. 2009). Comparison of transcriptomes allows 
identification of genes that are differentially expressed in distinct cell populations 
(e.g. diseased and non-diseased) (Costello et al. 2005), recognition of subtypes of 
known pathology (Bradley et al. 2015), and detection of novel biomarkers for 
prognosis of a disease (Moreno and Sanz-Pamplona 2015). MicroRNAs are small 
noncoding RNAs that are approximately 22 nucleotides long and regulate the 
expression of mRNA (Bartel 2004). More than 1000 miRNAs have been identified in 
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humans and they have been implicated in the immune response, inflammation and 
autoimmune diseases (Friedman et al. 2009; Furer et al. 2010).    
 
The aims of this chapter were to obtain and compare transcriptome profiles from 
PBMCs of patients with known clinical CBZ hypersensitivity in order to unravel the 
underlying mechanisms related to these ADRs. PBMCs were isolated from patients 
with heterogeneous responses to the LTT and incubated with CBZ, CBZE, TT or cell 
culture medium alone to determine if differentially expressed genes could explain 
variability in response to LTT and offer novel insight for development of new 
treatments and diagnostic biomarkers. 
 
 
6.2 Methods 
 
6.2.1 Patient Characteristics  
Five subjects with a clinical history of hypersensitivity to CBZ were recruited 
retrospectively from the Royal Liverpool University Hospital and the Walton Centre 
for Neurology and Neurosurgery. The subjects were chosen based on their known 
responses to the LTT (Figure 6.1). Clinical details for the patients are summarised in 
Table 6.1. The study was approved by the local ethics committee and informed 
consent was obtained from each patient.  
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Subjects 
Drug 
Response to LTT 
Clinical Phenotype 
CBZ 
Hypersensitivity 
Positive 
CBZ 
RLH001 
RLH007 
CBZE 
RLH007 
WAL004 
Negative 
CBZ 
RLH002 
WAL004 
CBZE 
RLH010 
  
Figure 6.1 Selection of subjects for gene expression analysis based on response to 
lymphocyte transformation test (LTT) 
 
 
Table 6.1 Clinical Characteristics of Patients Selected for Transcriptome Analysis 
(SI: stimulation index, d: days, mth: months, NA: not applicable) 
Subject Clinical Presentation Time to 
reaction 
CBZ LTT 
(SI) 
CBZE LTT 
(SI) 
RLH001 1989 – unknown 21 d 3.6 NA 
RLH002 1991 – generalised rash, mucosal 
involvement and flu symptoms 
8 d negative NA 
RLH007 1989 – generalised erythematous rash 6 d 16.4 3.7 
RLH010 2002 – ulceration of oral cavity and lips Unknown 3.2 Negative 
WAL004 2004 – generalised, itchy and scaly 
erythematous rash 
7 mth negative 5.9 
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6.2.2 Chemicals and Reagents 
CBZ (Sigma-Aldrich Co, UK) and CBZE (Sigma-Aldrich Co) were prepared as stock 
solutions (10 mg/mL) in T-cell medium containing 10% DMSO (Sigma-Aldrich Co). 
The stock solutions were made up fresh and diluted to the appropriate 
concentrations directly before use. TT was obtained from the Statens Serum Institut 
in Denmark. RNA extraction was undertaken using the miRNeasy extraction kit 
(Qiagen, Manchester, UK). All other reagents were from Sigma-Aldrich Co unless 
otherwise stated. 
 
6.2.3 Cell Culture Medium 
T-cell culture medium consisted of RPMI 1640 medium supplemented with 10% 
human pooled AB serum (Innovative Research, USA), 25 mM HEPES buffer, 2 mM L-
glutamine, 100 µg/mL streptomycin, 100 U/mL penicillin and 25 µg/mL transferrin. 
 
6.2.4 Isolation of Peripheral Blood Mononuclear Cells 
PBMCs were isolated from whole blood of patients by density gradient 
centrifugation on the same day that blood samples were obtained. The blood was 
layered on top of an equal volume of Lymphoprep (Axis Shield, UK) and centrifuged 
at 400g for 25 min at room temperature. The layer of PBMCs was extracted 
carefully with a Pasteur pipette and washed twice in HBSS to remove any excess 
Lymphoprep. Isolated PBMCs were re-suspended in T-cell culture medium.  
 
6.2.5 Culture of Isolated PBMC with CBZ and CBZE 
Isolated PBMCs (3.0 x 106; 2 mL) were cultured with CBZ (25 µg/mL) or CBZE (25 
µg/mL) in triplicate in a 24-well plate and incubated at 37oC under an atmosphere 
of 95% Air/ 5% CO2 for 24 h. TT (1 µg/mL) and culture medium were used as positive 
and negative controls, respectively. After the incubation period, the cells were 
harvested into sterile collection tubes and centrifuged at 400 g for 10 min. Cell 
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culture medium was carefully removed and the PBMCs were re-suspended in RNA 
later (Qiagen, UK) and stored at -80oC until RNA extraction. 
 
6.2.6 RNA Extraction and Quantification 
RNA extraction was undertaken according to manufacturer instructions using the 
miRNeasy kit (QIAgen, UK). Briefly, PBMCs suspended in RNA later were thawed at 
room temperature before centrifugation at 2000g for 10 min. The supernatant was 
removed carefully from the pelleted cells and 700 µL of QIAzol lysis reagent was 
added to each sample. The cells were homogenized by vortexing for 1 min and then 
placed on the benchtop at room temperature for 5 min. Chloroform (140 µL) was 
added to each sample and thoroughly mixed for 15 sec, and then left at room 
temperature for 3 min. The homogenates were then centrifuged for 15 min at 
12000g at 4oC.  The upper aqueous phase was transferred into a new collection 
tube and 1.5 volumes of 100% ethanol added to each sample before mixing. The 
sample was then centrifuged in an RNeasy mini spin column at 8000g for 15 s at 
room temperature. Buffer RWT (700 µL) was added to wash the spin column and 
centrifuged for 15 s at 8000g. The spin columns were washed two further times by 
addition of 500 µL RPE buffer and centrifugation at 8000g for 15 s and 2 min, 
respectively. To eliminate any carryover of buffer or ethanol, the spin column was 
centrifuged at 12000g for 1 min. All flow-through from the above steps was 
discarded. The RNeasy mini spin columns were transferred to a new collection tube 
and RNA was eluted by addition of 50 µL RNAse-free water directly onto the spin 
column membrane and centrifuged for 1 min at 8000g. A second elution step with a 
further 50 µL RNAse-free water was undertaken to obtain a greater concentration 
of RNA. The concentration of RNA was measured using a NanoDrop 
spectrophotometer (Thermo Scientific, Wilmington, USA). RNA samples were frozen 
at -80oC until ready for microarray analysis. 
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6.2.7 Microarray Data Expression Analysis 
Expression profiles of mRNA and miRNA were undertaken by Dr Lucille Rainbow at 
the Centre for Genomics Research (University of Liverpool, UK) using the Affymetrix 
GeneChip Human Transcriptome Array 2.0 and the Affymetrix GeneChip 4.0 miRNA 
array (Santa Clara, CA, USA) according to manufacturer’s instructions. The Centre 
for Genomics Research is a core facility and all RNA underwent QC procedures. 
Quality and concentration of RNA was checked using nanodrop and Qubit 
(ThermoFisher Scientific, Wilmington, USA). The RNA integrity number (RIN) 
(Schroeder et al. 2006) for all samples was determined using an Agilent bioanalyzer 
(Santa Clara, CA, USA). The RIN values for the RNA samples ranged from 7.6 to 9.2. 
Data was normalised against internal controls using the Affymetrix expression 
console (build 1.4.1.46).  
 
Expression data from cells treated with CBZ, CBZE or TT were compared with 
untreated control samples in cell culture medium. Differential gene expression 
analysis was performed by Dr Kim Clarke (Institute for Integrative Biology, 
University of Liverpool, UK) using the LIMMA package (Smyth 2005) in the R 
statistical software (https://www.r-project.org/). Genes known to be specifically 
associated with gender were removed prior to analysis to minimise the effects of 
genetic heterogeneity between patient groups. The genes were ranked in a list 
according to their differential expression. The associated RNA expression levels 
were normalised against the control expression level of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). Similarly, the associated miRNA expression levels were 
normalised against the control expression of HSA-miR-92a-3p. Plots were then 
generated using the R statistical software package (version 3.2.1). Within the plots, 
the y-axis value is the normalised mRNA or miRNA expression level and the x-axis 
denotes the test group of either CBZ/CBZE, negative control or TT. The points from 
CBZ are coloured black and the points from CBZE are coloured red. The plots were 
kindly generated by Dr Ben Francis (Department of Biostatistics, University of 
Liverpool, UK).  
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Pathway analyses were performed using IPA software (Qiagen, Redwood City, Ca, 
USA). Dr. Eunice Zhang (Institute of Translational Medicine, University of Liverpool, 
UK) and Dr. Olga Vasieva (Institute of Integrative Biology, University of Liverpool, 
UK) provided supervision and guidance when using IPA. Significant genes derived 
from the LIMMA analysis were uploaded for core analysis within IPA. Significance 
was defined as p < 0.05 and Log2-fold change < -1 or > 1. Comparison analyses were 
undertaken using IPA in order to determine pathways and networks that were 
specific to CBZ or CBZE when compared with TT. 
 
Gene set enrichment analysis (GSEA) (Subramanian et al. 2005) was undertaken by 
Dr Kim Clarke (Institute of Integrative Biology, University of Liverpool, UK). GSEA 
aims to overcome problems associated with conventional single gene methods by 
evaluating microarray data at the level of gene sets. Gene sets are defined based on 
prior biological knowledge of particular processes (e.g. apoptosis). The goal of GSEA 
is to determine whether members of a gene set tend to occur toward the top (or 
bottom) of the ranked gene list, in which case the gene set is correlated with the 
phenotypic class distinction (e.g. responsive to drug) (Subramanian et al. 2005). The 
entire gene list was used for GSEA analysis irrespective of fold change and p-value. 
 
 
6.3 Results 
6.3.1 Gene Expression Profiles in Subjects with CBZ Hypersensitivity Reactions 
We performed whole genome mRNA and miRNA expression profiling using PBMCs 
isolated from a cohort of 5 patients with a clinical history of CBZ hypersensitivity. A 
mixture of patients who were positive and negative to CBZ/CBZE in the LTT (Figure 
6.1) were included to determine if specific mRNA or miRNA transcripts could be 
used to identify T cell activation to drug irrespective of response to LTT. For each 
incubation with CBZ or CBZE the PBMCs were also incubated with cell culture 
medium (negative control) and TT (positive control). Subject RLH007 and WAL004 
donated PBMCs twice for incubation with both CBZ and CBZE. In total 21 RNA 
samples were analysed by microarray for mRNA and miRNA. Differential gene 
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expression was determined by comparing PBMCs incubated with CBZ, CBZE or TT 
against PBMCs from the same subjects that had been incubated with cell culture 
medium alone. A significant change in expression for both mRNA and miRNA was 
classified as a Log2-fold change > 1 or < -1 in conjunction with an unadjusted p-value 
< 0.05. PBMCs incubated with TT demonstrated the greatest number of significant 
differentially expressed mRNA and miRNA, 159 and 104, respectively (Table 6.2 and 
Table 6.3). The expression values, precise p-values and identity of all the mRNA and 
miRNA differentially expressed are listed in the appendix (Tables 9.1 to 9.8 and 
Tables 9.18 to 9.25).  
 
Table 6.2 Number of significant differentially expressed genes according to 
incubation conditions 
Incubation Condition  
(all compared with cell 
culture medium) 
LTT Result (number of 
genes differentially 
expressed) 
Number of Significant 
Differentially Expressed Genes 
(mRNA) (duplicates removed) 
CBZ 
Positive (n=24) 
25 
Negative (n=1) 
CBZE 
Positive (n=14) 
32 
Negative (n=18) 
TT NA 159 
 
Table 6.3 Number of significant differentially expressed miRNA according to 
incubation conditions 
Incubation Condition  
(all compared with cell 
culture medium) 
LTT Result (number of 
miRNA differentially 
expressed) 
Number of Significant 
Differentially Expressed miRNA 
(duplicates removed)  
CBZ 
Positive (n=24) 
35 
Negative (n=14) 
CBZE 
Positive (n=13) 
41 
Negative (n=30) 
TT NA 104 
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No mRNA transcripts were differentially expressed across all three conditions or in 
incubations between CBZ and CBZE. Two mRNA were differentially expressed in 
both CBZ and TT incubations. Ten mRNA were differentially expressed between 
CBZE and TT (Figure 6.2). A single miRNA (miR-181a-5p) was differentially expressed 
across all three incubation conditions and one miRNA (MIR6124) was differentially 
expressed in both CBZ and CBZE incubations. Sixteen miRNA were differentially 
expressed in both CBZ and TT and thirteen miRNA were differentially expressed in 
both CBZE and TT incubations (Figure 6.2). 
 
Figure 6.2 Differential RNA expression in PBMC incubated with CBZ, CBZE or TT 
compared with negative controls (significance was defined as Log2-fold change <-
1 or >1 and p < 0.05). 
 
6.3.2 Ingenuity Pathway Analyses for mRNA 
To define the molecular mechanisms involved in the development of CBZ 
hypersensitivity reactions, we initially used the “canonical pathways” function in IPA 
on the gene expression lists generated in section 6.3.1. In subjects where the LTT 
was positive to CBZ, multiple pathways involving the immune system were enriched 
in comparison with PBMCs incubated with cell culture medium alone (Figure 6.3A). 
These included the following pathways: interferon signalling, death receptor 
signalling and antiviral responses. In PBMCs that were positive on LTT to CBZE, 
different canonical pathways were significant when compared with those that were 
positive to CBZ. The most significant pathways with CBZE were prostanoid 
biosynthesis and eicosanoid signalling (Figure 6.3B). Pathways involving the immune 
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system were also significant. Interestingly, pathways involving biosynthesis of 
dermatan sulfate, chondroitin sulfate and heparan sulphate were also significant. 
No significant canonical pathways were reported in PBMCs where the LTT was 
negative to CBZ when compared with negative control PBMCs. In PBMC incubations 
with TT, multiple pathways involving regulation of the immune system, cytokine 
signalling and antiviral response were significant (Figure 6.3C, D and E). No 
significant pathways were reported in PBMCs that were negative on LTT to CBZE. 
 
(A)       (B) 
(C)      (D) 
 
Figure 6.3 Top canonical pathways 
identified in IPA when compared with 
negative controls. (A) CBZ LTT positive 
(B) CBZE LTT positive (C) TT in CBZ LTT 
positive PBMC (D) TT in CBZE LTT 
positive PBMC (E) TT in CBZ negative 
LTT PBMC  
 
(E)  
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Comparison analyses were undertaken in IPA to identify canonical pathways that 
were only differentially regulated in drug treated PBMC when compared with TT 
treated cells (Table 6.4). Twelve genes were identified to be either significantly 
upregulated or downregulated in PBMCs that were positive on LTT to CBZ or CBZE. 
The list of CBZ/CBZE-specific genes was reduced to nine when duplicates were 
removed by comparing with the TT gene list generated by LIMMA analysis (Section 
6.3.1). No significant canonical pathways were identified when comparison analyses 
were undertaken between PBMCs that were negative on LTT to both CBZ and CBZE 
in comparison with TT. Using the 9 CBZ/CBZE-specific genes a network of 
interactions was generated in IPA (Figure 6.4). The top 5 diseases and functions 
involving at least 3 drug-specific molecules from the network were viral infection, 
psoriasis, antiviral response, infection cells and infection by RNA virus (Table 6.5). 
 
Figure 6.4 Network representation of interactions between the 9 CBZ/CBZE-
specific genes identified from comparison analyses of PBMCs treated with 
CBZ/CBZE against TT treated PBMCs. Viral infection has been added to illustrate 
the 5 molecules involved with the specific function. 
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Table 6.4 CBZ and CBZE-specific canonical pathways derived from comparison analyses with TT positive controls. The differential expression 
of genes responsible for each significant canonical pathway are expressed as exp log ratio with associated p value.  
Comparison Analyses Canonical Pathways Molecules Exp Log Ratio P-Value 
CBZ LTT positive VS TT 
positive control 
Interferon signalling IFI35 
IFIT3 
↑1.142 
↑2.419 
0.046 
0.045 
Retinoic acid mediated apoptosis signalling 
UVA-induced MAPK signalling 
PARP9 
PARP12 
↑1.424 
↑1.091 
0.035 
0.041 
Role of lipids/lipid rafts in the pathogenesis of influenza RSAD2 ↑2.825 0.030 
Protein ubiquitination pathway USP18 
USP41 
↑1.882 
↑1.259 
0.033 
0.050 
 
CBZE LTT positive VS TT 
positive control 
Prostanoid biosynthesis 
Eicosanoid signalling 
PTGES 
PTGS2 
↓-1.147 
↓-6.122 
0.029 
0.045 
NAD biosynthesis III NAMPT ↓-2.367 0.047 
Dermatan sulphate biosynthesis 
Chondroitin sulphate biosynthesis 
Heparan sulphate biosynthesis 
CHST15 ↓1.176 0.035 
Oxidative phosphorylation COX8A ↑1.133 0.016 
Fatty acid α-oxidation PTGS2 ↓-6.122 0.045 
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MIF-mediated glucocorticoid regulation 
MIF regulation of innate immunity 
Role of IL-17A in arthritis 
IL-17 signalling 
CD40 signalling 
Role of MAPK signalling in the pathogenesis of influenza 
PPAR signalling 
HGF signalling 
LXR/RXR activation 
PI3K/AKT signalling 
Endothelin-1 signalling 
ILK signalling 
 280 
 
Table 6.5 Top 5 diseases and functions associated with the CBZ/CBZE-specific gene 
network 
Diseases and Functions P-value Molecules 
Viral infection 1.02 x 10-3 IFI35, IFIT3, PARP12, PARP9, RSAD2 
Psoriasis 7.86 x 10-5 IFI35, IFIT3, PARP9, RSAD2 
Antiviral response 1.09 x 10-4 COX8A, IFIT3, RSAD2 
Infection of cells 4.51 x 10-3 IFI35, PARP9, RSAD2 
Infection by RNA virus 8.39 x 10-3 IFI35, PARP9, RSAD2 
 
6.3.3 CBZ/CBZE-Specific mRNA Expression 
Expression values for the 9 CBZ/CBZE-specific genes were normalised according to 
GAPDH (Appendix, Table 9.9) and expression of each gene according to exposure 
are outlined in Figure 6.5. Analysis of mean expression levels of CBZ/CBZE-specific 
genes reveals that expression tends to be increased in PBMCs incubated with either 
drug or TT. However, it is not possible to identify genes that were upregulated 
specifically in CBZ/CBZE-incubated samples only. 
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Figure 6.5 Relative expression levels of CBZ/CBZE-specific mRNA generated from 
comparison analyses in IPA. (mRNA expression normalised to GAPDH, black circles 
represent CBZ incubations, red circles represent CBZE incubations, horizontal line 
represents mean expression). 
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6.3.4 Gene Set Enrichment Analysis 
GSEA was undertaken using the ranked gene lists generated from LIMMA analysis 
(section 6.3.1). GSEA directly scores pre-defined gene sets for differential 
expression and is able to identify gene sets with subtle but coordinated expression 
changes that cannot be detected with traditional candidate gene analysis that are 
based upon arbitrarily chosen threshold levels (e.g. fold changes and p-values) 
(Nam and Kim 2008). Gene sets with a false discovery rate (FDR) < 0.05 were 
considered significant. Only the top 10 enriched gene sets are included in the 
results section but full lists for each incubation condition are included in the 
appendix (Tables 9.10 to 9.16). 
 
Gene sets involving the immune system (chemokines, cytokines and viral response) 
were the most significant (lowest FDR) and demonstrated the greatest enrichment 
when PBMCs positive to CBZ LTT were compared with PBMCs incubated in cell 
culture medium alone (Table 6.6). Interestingly, different gene sets were enriched 
in PBMCs that were positive to CBZE in LTT when compared with enriched gene sets 
of LTT CBZ positive PBMCs (Table 6.7). Gene sets involved in protein synthesis, RNA 
processing and mitochondria dominated. Only a single gene set, structural 
constituent of ribosome, was significantly enriched in PBMCs that were negative in 
the LTT to CBZ. No significantly enriched gene sets were identified from PBMCs that 
were negative to CBZE in the LTT. The top 10 most significantly enriched gene sets 
when PBMCs were incubated with TT are outlined in Table 6.8 and Table 6.9. There 
is significant overlap between the top 10 enriched gene sets in PBMCs incubated 
with TT and those incubated with CBZ or CBZE. 
 
In total there were 51 gene sets that were exclusively enriched in PBMCs that were 
incubated with CBZ or CBZE and not with TT. Table 6.10 outlines the top 10 most 
significantly enriched gene sets specific to CBZ and CBZE incubations. Drug specific 
gene sets included those that regulate T lymphocytes, bind collagen and are 
involved in control of the cell cycle. The full list of gene sets is available in the 
appendix (Table 9.17).   
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Table 6.6 Top 10 enriched gene sets when PBMCs positive to CBZ in LTT are 
compared with PBMCs incubated with cell culture medium (NES: normalised 
enrichment score, FDR: false discovery rate) 
Gene Set (Functional Category) Size NES FDR 
Chemokine receptor binding 41 2.89 0 
Chemokine activity 40 2.87 0 
G-protein coupled receptor binding 51 2.86 0 
Cytokine activity 108 2.76 0 
Structural constituent of ribosome 77 2.74 0 
Locomotory behavior 89 2.66 0 
Response to virus 42 2.56 0 
Behaviour 139 2.54 0 
Response to external stimulus 296 2.35 0 
Inflammatory response 124 2.34 0 
 
Table 6.7 Top 10 enriched gene sets when PBMCs positive to CBZE in LTT are 
compared with PBMCs incubated with cell culture medium (NES: normalised 
enrichment score, FDR: false discovery rate) 
Gene Set (Functional Category) Size NES FDR  
Structural constituent of ribosome 77 3.05 0 
RNA binding 240 2.95 0 
Ribonucleoprotein complex 135 2.77 0 
Ribonucleoprotein complex biogenesis and assembly 80 2.63 0 
Nucleolus 115 2.63 0 
RNA processing 164 2.62 0 
Mitochondrion 314 2.56 0 
Organelle membrane 280 2.56 0 
Mitochondrial inner membrane 58 2.54 0 
Intracellular organelle part 1110 2.51 0 
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Table 6.8 Top 10 enriched gene sets when PBMCs positive to CBZ in LTT are 
incubated with TT and compared with cell culture medium (NES: normalised 
enrichment score, FDR: false discovery rate) 
Gene Set (Functional Category) Size NES FDR  
Cytokine activity 108 2.93 0 
Extracellular space 230 2.84 0 
Extracellular region part 320 2.82 0 
G-protein coupled receptor binding 51 2.75 0 
Chemokine receptor binding 41 2.75 0 
Chemokine activity 40 2.69 0 
Response to external stimulus 296 2.68 0 
Inflammatory response 124 2.62 0 
Locomotory behavior 89 2.61 0 
Negative regulation of cell proliferation 148 2.60 0 
 
 
Table 6.9 Top 10 enriched gene sets when PBMCs positive to CBZE in LTT are 
incubated with TT and compared with cell culture medium (NES: normalised 
enrichment score, FDR: false discovery rate) 
Gene Set (Functional Category) Size NES FDR 
Structural constituent of ribosome 77 3.00 0 
RNA binding 240 2.87 0 
Ribonucleoprotein complex 135 2.78 0 
Organelle membrane 280 2.67 0 
RNA processing 164 2.66 0 
Organelle part 1115 2.61 0 
Intracellular organelle part 1110 2.60 0 
Ribonucleoprotein complex biogenesis and assembly 80 2.59 0 
Endoplasmic reticulum part 91 2.56 0 
Nucleolus 115 2.49 0 
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Table 6.10 Top 10 CBZ/CBZE-specific significantly enriched gene sets (NES: 
normalised enrichment score, FDR: false discovery rate)  
Gene Set (Functional Category) Size NES FDR Drug 
Nuclease activity 53 1.96 0.005 CBZE 
Negative regulation of DNA metabolic process 17 1.93 0.007 CBZE 
Collagen binding 14 1.89 0.036 CBZ 
Mitochondrial small ribosomal subunit 10 1.89 0.010 CBZE 
Centrosome 54 1.87 0.012 CBZE 
Cellular protein complex disassembly 12 1.87 0.011 CBZE 
Caspase activation 26 1.87 0.041 CBZ 
Regulation of cyclin dependent protein kinase 
activity 
42 1.83 0.049 CBZ 
Positive regulation of T cell activation 20 1.82 0.017 CBZE 
Positive regulation of lymphocyte activation 23 1.80 0.019 CBZE 
 
6.3.5 Ingenuity Pathway Analysis for miRNA 
Significant miRNA (Log2-fold change < -1 or > 1, unadjusted p < 0.05) identified from 
LIMMA analysis were uploaded into IPA and comparison analyses were undertaken 
with CBZ and CBZE incubated PBMCs against TT incubated PBMCs to identify the 
miRNA transcripts differentially expressed only in drug treated cells. There were 39 
miRNA molecules identified as being differentially expressed in CBZ or CBZE treated 
samples (Appendix, Table 9.26). The miRNA target function in IPA was used to 
identify mRNA targets for these 39 CBZ/CBZE-specific miRNA. In total 5794 mRNA 
targets were identified for 30 of the miRNA molecules. Five of the drug-specific 
miRNA molecules were found to target 4 CBZ/CBZE-specific mRNA (Table 6.11). The 
network of interactions is illustrated in Figure 6.6. The top 5 diseases and functions 
involving at least 3 drug specific molecules from the network were viral infection, 
psoriasis, inflammation of body region, inflammation of organ and antiviral 
response (Table 6.12). 
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Table 6.11 CBZ/CBZE specific miRNA with their CBZ/CBZE mRNA targets 
miRNA Exp Log 
Ratio 
P-value mRNA target Exp Log 
Ratio 
P-value 
miR-433-3p -1.087 0.020 COX8A 1.133 0.016 
miR-3194-5p -1.106 0.009 IFIT3 2.419 0.045 
miR-455-3p 1.779 0.046 
PARP9 1.424 0.035 
miR-4723-5p -1.786 0.047 
miR-345-5p -1.579 0.020 RSAD2 2.825 0.030 
 
 
 
Figure 6.6 Network representation of interactions between the 9 CBZ/CBZE-
specific genes and 5 overlapping CBZ/CBZE-specific miRNA identified from 
comparison analyses of PBMCs treated with CBZ/CBZE against TT treated PBMCs 
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Table 6.12 Top 5 diseases and functions associated with the CBZ/CBZE-specific 
mRNA and miRNA network 
Diseases and Functions P-value Molecules 
Viral infection 4.91 x 10-3 IFI35, IFIT3, PARP12, PARP9, RSAD2 
Psoriasis 2.88 x 10-4 IFI35, IFIT3, PARP9, RSAD2 
Inflammation of body region 9.40 x 10-3 miR-345-5p, miR433-3p, PTGES, USP18 
Inflammation of organ 1.71 x 10-2 miR-345-5p, miR433-3p, PTGES, USP18 
Antiviral response 2.78 x 10-4 IFIT3, RSAD2, COX8A 
 
 
6.3.6 CBZ/CBZE-Specific miRNA Expression 
Expression values for the CBZ/CBZE-specific miRNA involved in the CBZ/CBZE-
specific network analysis were normalised to HSA-miR-92a-3p and expression 
plotted in Figure 6.7 (Appendix, Table 9.27). The top 5 most upregulated CBZ/CBZE-
specific miRNA identified by IPA are outlined in Table 6.13 and their expression 
under different incubation conditions in Figure 6.8. 
 
Table 6.13 Top 5 up-regulated CBZ/CBZE-specific miRNA identified in IPA 
comparison analyses 
miRNA Exp Log Ratio Exp P-Val Drug 
hsa-miR-548f-3p 3.052 2.44E-04 CBZE 
hsa-miR-711 2.184 2.76E-02 CBZ 
hsa-miR-197-5p 2.174 1.08E-02 CBZE 
hsa-miR-532-3p 1.921 1.55E-02 CBZE 
hsa-miR-455-3p 1.779 4.58E-02 CBZ 
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Figure 6.7 Relative expression levels of CBZ/CBZE-specific miRNA identified from 
the CBZ/CBZE-specific network analysis. (Expression normalised to HSA-miR-92a-
3p, black circles represent CBZ incubations, red circles represent CBZE incubations, 
horizontal line represents mean expression).  
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Figure 6.8 Relative expression levels of top 5 CBZ/CBZE-specific miRNA generated 
from comparison analyses in IPA. (Expression normalised to HSA-miR-92a-3p, black 
circles represent CBZ incubations, red circles represent CBZE incubations, horizontal 
line represents mean expression). 
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6.4 Discussion 
Gene expression profiles were generated from PBMCs of 7 patients with a known 
history of CBZ hypersensitivity. The PBMCs were incubated with CBZ, CBZE, TT 
(positive control) or cell culture medium (negative control) in vitro. Differential 
expression of mRNA and miRNA between different incubation conditions was used 
to further investigate the molecular mechanisms of these reactions with IPA 
network analyses and GSEA. 
 
When comparing differential gene expression using unadjusted p-value < 0.05 and 
Log2-fold change <-1 or >1 there is very limited overlap in mRNA and miRNA 
between CBZ and CBZE incubations (Figure 6.2). This finding suggests that CBZ and 
CBZE activate different molecular pathways when incubated with PBMCs from CBZ 
hypersensitive patients in vitro. This was also borne out in IPA pathway analyses 
where the top canonical pathways for CBZ and CBZE incubations were different 
(Figure 6.3). Canonical pathways involving antiviral responses, apoptosis/death 
receptor signalling and pyrimidine processing were the most significant pathways 
when PBMCs were incubated with CBZ. In contrast, the most significant canonical 
pathways in PBMCs incubated with CBZE were involved with eicosanoid synthesis 
and signalling, synthesis of multiple glycosaminoglycans (GAGs) and pathways 
involved in regulation of the immune system. 
 
The role of immune responses to viruses has been implicated in both HLA-restricted 
and non-HLA associated hypersensitivity reactions (Picard et al. 2010; Lucas et al. 
2015). A prospective assessment of a cohort of 40 patients diagnosed with DRESS to 
CBZ, allopurinol and sulphamethoxazole identified reactivation of EBV, HHV-6, or 
HHV-7 reactivation in 76% of the patients. The authors propose that the culprit 
drug(s) induce viral reactivation and antigenic presentation of quiescent forms of 
EBV or other herpes viruses which trigger a multi-organ immune response (Picard et 
al. 2010). Abacavir-reactive memory T cells have been identified in drug-naive 
individuals who are HLA-B*57:01 positive. T cell responses to persistent viral 
infections (e.g. HHV) have been shown to mediate allogenic organ rejection via TCR 
cross reactivity and a similar heterologous immunity model may explain the 
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existence of drug-reactive T cells in absence of prior exposure to the culprit drug 
(Lucas et al. 2015). In SJS/TEN, cytotoxic CD8+ T cells and the cytotoxic molecules 
FasL (Fas ligand) and granulysin lead to disseminated keratinocyte apoptosis (Viard 
et al. 1998; Chung et al. 2008). Activation of canonical pathways involved in 
apoptosis and death receptor signalling in PBMCs activated by CBZ is therefore 
consistent with the pathogenesis of SJS/TEN. Interestingly, retinoic acid mediated 
apoptosis signalling is the second most significant canonical pathway activated by 
CBZ in PBMCs. It has been hypothesised that medications implicated in SJS/TEN 
synergise with endogenous retinoids leading to accumulation of retinoids in the 
liver and cholestatic dysfunction (Mawson et al. 2015). This leads to toxic retinoid 
compounds that are normally stored in the liver and excreted harmlessly into the 
intestinal tract to be spilled into the circulation inducing cytotoxicity and apoptosis 
via granulysin with manifestation of clinical symptoms similar to SJS/TEN (Mawson 
et al. 2015). 
 
Eicosanoids, which include prostaglandins (PG), are locally acting bioactive 
signalling lipids derived from arachidonic acid which regulate a diverse set of 
homeostatic and inflammatory processes (Funk 2001). In PBMCs treated with CBZE 
there is a reduction in the expression of the gene PTGES. PTGES encodes for the 
enzyme PGE synthase which catalyses the formation of PGE2 (Jegerschold et al. 
2008). PGE2 has been shown to compromise immunity to influenza A virus through 
inhibition of macrophage antigen presentation and T cell immunity (Coulombe et al. 
2014). Reduced expression of PTGES in PBMCs exposed to CBZE may be in response 
to activation of antiviral pathways in order to enhance antiviral immunity. 
Dermatan sulphate, chondroitin sulphate and heparan sulphate are GAGs (Esko et 
al. 2009). GAGs have been shown to play important roles in the immune system 
which includes modulation of cytokine function, detection of tissue injury, 
activation of inflammation and as potential targets for bacterial and viral virulence 
factors that contribute to immune system evasion (Trowbridge and Gallo 2002; 
Davis and Parish 2013). CBZE leads to reduced expression of the gene CHST15 in 
PBMCs which encodes for a sulfotransferase protein important in synthesis of 
dermatan sulphate, chondroitin sulphate and heparan sulphate (Wu et al. 2011). 
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CBZE therefore reduces GAG synthesis in PBMCs but the effect on hypersensitivity 
reactions is unclear as GAGs have both pro-inflammatory and anti-inflammatory 
effects (Davis and Parish 2013). Patients prescribed CBZ will be exposed to both the 
parent drug and CBZE in vivo as CBZE is the major metabolite of CBZ metabolism 
(Kerr et al. 1994). These data suggest that exposure to both CBZ and CBZE could 
contribute to hypersensitivity via multiple molecular pathways and may explain the 
diverse clinical phenotypes observed in CBZ hypersensitivity reactions.  
 
Comparison analyses were undertaken between PBMCs incubated with CBZ/CBZE 
and TT using IPA to identify canonical pathways and genes significant in CBZ/CBZE 
treated samples only. Nine drug-specific genes were identified and a network 
involving all nine genes was created. Viral infection was the most significant 
disease/function associated with the CBZ/CBZE-specific pathway providing further 
evidence to support the role of heterologous immunity in pathogenesis of CBZ 
hypersensitivity reactions. Heterologous immunity proposes that effector memory 
T cells are generated when viral peptides (e.g. HHV) are presented with risk HLA 
alleles (e.g. HLA-A*31:01). When a patient is subsequently exposed to the culprit 
drug/metabolite (e.g. CBZ or CBZE) it is presented with the risk HLA and the effector 
memory T cells originally primed against viral pathogens are cross-reactive to the 
drug/metabolite leading to hypersensitivity (White et al. 2015). Psoriasis was the 
second most significant disease associated with the CBZ/CBZE-specific network. 
Psoriasis is a chronic inflammatory autoimmune disease characterised by aberrant 
hyperproliferation of keratinocytes. The pathogenesis of psoriasis shares similarities 
with hypersensitivity reactions and involves a complex interplay of immune cell 
functions, cytokines and T cell responses (Deng et al. 2016).  
 
Gene set analysis aims to overcome the problems associated with individual gene 
analysis methods where selection of significant genes is typically based upon 
arbitrarily chosen threshold values (Nam and Kim 2008). Alteration of the chosen 
thresholds can result in alternative biological conclusions and the omission of genes 
with moderate but meaningful expression changes if the thresholds selected are 
too strict reducing statistical power (Pan et al. 2005). GSEA evaluates the entire 
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microarray dataset at the level of gene sets (Subramanian et al. 2005). The gene 
sets are defined based on existing biological knowledge and enable the 
identification of sets of genes with subtle but coordinated expression changes that 
would not be detectable using individual gene analysis (Nam and Kim 2008). In 
contrast to individual gene and canonical pathway analysis above where there was 
little overlap between different incubation conditions, GSEA demonstrated 
considerable overlap in enriched gene sets of PBMCs from the same subjects that 
were incubated with CBZ or CBZE when compared with TT.  Lack of overlap in 
statistically significant genes when different groups study the same biological 
systems is a problem frequently encountered with individual gene analysis 
(Fortunel et al. 2003).  
 
Fifty one gene sets were significantly enriched in CBZ or CBZE treated PBMCs only. 
Gene sets involved in collagen binding, positive regulation of T cell activation and 
caspase activation were significantly enriched in drug treated cells and are 
consistent with the known pathogenesis of hypersensitivity reactions to CBZ, with 
identification of drug-specific T cells and keratinocyte apoptosis in SJS/TEN (Naisbitt 
et al. 2003; Chung et al. 2008). Other gene sets that were significantly enriched 
involved regulation of cell cycle and processes pertaining to synthesis of DNA and 
protein complexes (Table 6.10). Cyclins and cyclin-dependent kinases (CDKs) are 
important regulators in the control of the cell cycle (Malumbres 2014). Owing to 
their role in cell proliferation and other diverse processes (e.g. apoptosis and 
regulation of transcription), development of drugs that target CDK have been 
developed for cancer and other therapeutic areas (Roskoski 2016). Current 
management options for drug-induced hypersensitivity reactions are limited and 
include withdrawal of the suspected culprit drug and systemic corticosteroids 
(Shiohara et al. 2012). CDK inhibitor drugs have been demonstrated experimentally 
to have anti-inflammatory and pro-resolution properties through promotion of 
neutrophil and lymphocyte apoptosis (Leitch et al. 2009). These findings raise the 
possibility that CDK inhibitors could be used to treat acute hypersensitivity 
reactions in the future. 
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Five CBZ/CBZE-specific miRNAs were found by network analysis in IPA to interact 
with the CBZ/CBZE-specific gene network. The top 5 functions of the CBZ/CBZE-
specific miRNA and mRNA network was similar to the network involving only the 
mRNA with viral infection and psoriasis incorporating the most number of mRNA 
and miRNA transcripts. However, addition of miRNA has also highlighted 
inflammation as being an important function regulated by the network. This is 
unsurprising as the clinical manifestation of CBZ hypersensitivity reactions involves 
inflammation of multiple organs (Yip et al. 2015a). Inspection of the CBZ/CBZE-
specific network reveals that PARP9 is the gene that is most highly regulated. 
PARP9 [poly (ADP-ribose) polymerase] has recently been shown to enhance cellular 
responses to interferon which markedly improved antiviral function in transgenic 
mice and transduced human cells (Zhang et al. 2015). In these studies PARP9 
formed a complex with DTX3L to promote interferon-stimulated gene expression by 
interaction with STAT1 and degradation of viral proteases through ubiquitin ligase 
functionality. These functions share similarities with the CBZ/CBZE-specific 
canonical pathways that were identified in IPA analysis where interferon signalling 
and protein ubiquitination were upregulated in CBZ treated PBMCs. Small molecule 
interferon signal-enhancer compounds have been identified using high throughput 
screening as possible candidates for new antiviral therapy (Patel et al. 2014). It may 
be possible that these new antiviral agents could also be used to treat CBZ 
hypersensitivity reactions.   
 
There have been a very limited number of studies that have studied transcriptomic 
profiles in drug hypersensitivity (Bellon et al. 2010; Ichihara et al. 2014). Bellon et 
al. (2010) isolated PBMCs from 23 patients during an acute hypersensitivity reaction 
with a repeat sample upon resolution of the symptoms. Eighty-five genes were 
differentially expressed during the acute phase of hypersensitivity reactions with 
the majority involved in apoptosis, the cell cycle and the immune response. 
Although the functions of the genes that were differentially expressed are similar to 
the results observed in this chapter there is very little overlap in individual mRNA 
transcripts. These discrepancies could be explained by different experimental 
design. Bellon et al. (2010) recruited patients with hypersensitivity to multiple drugs 
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(including 2 cases of CBZ), PBMCs were exposed to the suspected culprit 
drug/metabolite in vivo rather than in vitro and analysis of gene expression was 
undertaken only at the individual gene level with arbitrarily defined significance 
levels (1.5-fold change and unadjusted p < 0.005). Upregulation of miR-18a-5p was 
detected in skin and serum samples from patients with acute TEN (Ichihara et al. 
2014). The miR-18a-5p was found to mediate keratinocyte apoptosis through 
downregulation of the expression of B-cell lymphoma/leukaemia-2-like protein 10, 
an anti-intrinsic apoptotic molecule. The authors concluded that serum miR-18a-5p 
levels could be a useful disease marker for drug eruptions. Significant upregulation 
of miR-18a-5p was also observed in our experiments when PBMCs were incubated 
with CBZE implying that it may also have a role in CBZ hypersensitivity. However, it 
was also detected in TT incubations suggesting that it may not be drug-specific in 
vitro. 
 
Diagnosis of drug hypersensitivity is complex and dependent on patient history and 
clinical judgement. In vitro tests (e.g. LTT) are time-consuming, lack sufficient 
sensitivity and specificity; whilst in vivo tests (e.g. patch testing or drug 
provocation) are not applicable in all cases of hypersensitivity (Schrijvers et al. 
2015). In this chapter, 9 CBZ/CBZE-specific mRNA and 39 CBZ/CBZE-specific miRNA 
have been identified. Analysis of expression profiles of these transcripts was unable 
to identify any that were specific to CBZ or CBZE in vitro as expression was also 
elevated in TT incubations (Figure 6.5, Figure 6.7 and Figure 6.8).  However, they 
may demonstrate utility in vivo, during the acute hypersensitivity reaction, as 
outlined above with miR-18a-5p (Ichihara et al. 2014).  
 
The limitations of this study include the small number of patients analysed and the 
lack of validation of gene expression with RT-PCR due to time constraints. Also, 
PBMCs were incubated with CBZ or CBZE and it is unknown if the parent drug or 
major metabolite are responsible for hypersensitivity in vivo.  
 
In conclusion, gene expression profiles were generated using PBMCs obtained from 
5 patients with a history of CBZ hypersensitivity. A list of CBZ/CBZE-specific mRNA 
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and miRNA were generated that may serve as biomarkers for diagnosis of CBZ 
hypersensitivity in future. The differential gene expression profiles have provided 
further evidence for involvement of the immune system in CBZ hypersensitivity 
reactions and identified specific therapies, such as CDK inhibitors or interferon 
signal enhancers, which could be treatment options for CBZ hypersensitivity 
reactions in the future. 
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Chapter 7  
Final Discussion 
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The overall aim of this thesis was to identify and connect the metabolic and 
immunological risk factors that are associated with the development of CBZ 
hypersensitivity reactions. Despite extensive research into CBZ hypersensitivity, the 
exact pathophysiological mechanism(s) of these reactions is still not fully 
understood but is likely to involve a combination of genetic, immunological and 
metabolic factors. Predisposition to CBZ hypersensitivity is thought to be genetic 
because of cases reported in families and monozygotic twins (Edwards et al. 1999). 
The clinical features of CBZ hypersensitivity and discovery of CBZ-specific T cells 
provide evidence that the reactions are mediated by the immune system (Naisbitt 
et al. 2003; Wu et al. 2006; Wu et al. 2007). Specific HLAs, HLA-B*15:02 and HLA-
A*31:01, have been strongly associated with susceptibility to CBZ hypersensitivity 
(Chung et al. 2004; McCormack et al. 2011). However, the HLA associations are 
both phenotype- and ethnicity-specific and carriage of the risk HLA allele alone is 
insufficient to trigger a hypersensitivity reaction when exposed to CBZ (Yip et al. 
2012). These findings imply the involvement of other as yet unidentified factors.  
 
The metabolism of CBZ is complex and leads to the formation of greater than 30 
metabolites (Lertratanangkoon and Horning 1982). Several reactive metabolites 
have been proposed to be responsible for CBZ hypersensitivity and include an arene 
oxide (Pirmohamed et al. 1992), 9-acridine carboxaldehyde (Furst et al. 1995), an 
iminostilbene (Ju and Uetrecht 1999), an o-quinone (Lillibridge et al. 1996) and 
CBZE (Bu et al. 2005). Taken together, these studies provide some evidence that 
CBZ hypersensitivity reactions involve both metabolic and immunological risk 
factors. 
 
The exact chemical identity of the antigen that triggers hypersensitivity to CBZ is 
unknown – of course, it may be that multiple antigens are involved, and the antigen 
profile may vary from patient to patient. CBZ is metabolised by multiple CYP450 
isoforms but the major route of metabolism is conversion to CBZE (Pearce et al. 
2008). CBZE has been demonstrated to be chemically reactive through the 
spontaneous formation of two isomeric adducts with GSH in vitro (Bu et al. 2005). 
In chapter 2 of this thesis, CBZE was demonstrated to form protein-adducts not only 
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with GSH but also with HSA. HSA is the most abundant plasma protein constituting 
around 60% of total body proteins and is able to circulate freely throughout the 
body. It has thus been extensively used in vitro as a model protein to study the 
formation of active drug metabolites because it contains many nucleophilic amino 
acid residues (Osaki et al. 2014). CBZE was found to modify HSA at his146 
(145RH([O]CBZ)PYFYAPELLFFAK159) in a concentration- and time-dependent manner 
in vitro. The same CBZE-modified HSA adduct was also identified in vivo from 20 
patients with epilepsy who had been taking CBZ at a stable dose for at least 4 
weeks. However, it is important to note that these patients were tolerant of CBZ and 
did not have any symptoms of hypersensitivity. Despite this, it remains possible that 
the CBZE-modified HSA adduct is one of the antigens responsible for 
hypersensitivity. Other, as yet unidentified risk factors, such as immune system 
variation (e.g. HLA, TCR subtype) or polymorphisms in drug metabolising enzymes 
(e.g. reduced clearance of CBZE) may influence susceptibility. Indeed, there was 16-
fold variation in the relative quantity of CBZE-modified adduct identified in patients 
and only moderate correlation with measured plasma levels of CBZ (r2 = 0.4387, p = 
0.0015) and CBZE (r2 =0.3545, p = 0.0056) suggesting that variability in exposure will 
occur between patients and consequently may be a factor in determining 
susceptibility. Adducts between beta-lactam antibiotics (flucloxacillin, piperacillin 
and amoxicillin) and HSA have been isolated from patients and demonstrated to 
activate T cells isolated from hypersensitive individuals in vitro (Jenkins et al. 2013; 
Yaseen et al. 2015). A strategy to determine whether the CBZE-modified HSA 
adduct is able to stimulate T cell responses would involve chemical synthesis of the 
CBZE-modified peptide and incubation with T cells isolated from patients with CBZ 
hypersensitivity in experiments similar to those described in chapter 5.   
 
The second quantitatively most important metabolic pathway for CBZ involves the 
formation of several phenolic products (e.g. 2OH-CBZ and 3OH-CBZ) by 
hydroxylation at different positions of the six-membered aromatic rings (Spina 
2002). These reactions are catalysed by various CYP450 isoforms including CYP3A4, 
CYP2E1 and CYP2B6 (Pearce et al. 2002). There is indirect evidence that formation 
of these phenolic compounds proceeds through a highly reactive arene oxide 
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intermediate (Madden et al. 1996; Bu et al. 2007). In chapter 2, relative formation 
of the presumed arene oxide conjugate with GSH was positively correlated with the 
aromatic hydroxylase activity of specific CYP isoforms. Mass spectrometric evidence 
for the existence of the arene oxide intermediate was generated by incubation of 
CBZ with microsomes/supersomes and HSA. The arene oxide modified HSA at 
his146 which is consistent with the amino acid residue modified by CBZE. These 
results provide the first chemical evidence for the existence of an arene oxide 
intermediate and its ability to escape the immediate microsomal environment and 
modify proteins. The clinical manifestations of CBZ hypersensitivity are highly 
variable affecting multiple organ systems including the skin and liver (Yip et al. 
2012). It is possible that localised metabolism of CBZ, for example in the skin, to a 
highly reactive arene oxide intermediate may overcome the limited detoxification 
pathways leading to keratinocyte death. Incubation of CBZ with HaCaT cells (an 
immortalised keratinocyte line) led to the generation of low levels of CBZE, 2OH-
CBZ and 3OH-CBZ as detected by mass spectrometry (Yip, unpublished data). This 
provides evidence for the generation of reactive metabolites in keratinocytes in 
vitro but detection of drug metabolites in skin biopsy from patients with an acute 
hypersensitivity reaction in vivo using techniques such as mass spectrometric 
imaging (Cobice et al. 2015) or Raman spectroscopy (Franzen and Windbergs 2015) 
would provide direct evidence for such a mechanism.  
 
Based on the identification of the CBZE and arene oxide intermediates, it was 
hypothesised that bioactivation of CBZ to greater amounts of the two reactive 
metabolites may increase susceptibility to CBZ hypersensitivity reactions through 
formation of protein adducts. A HPLC-MS/MS assay was set up and validated in 
chapter 3 to measure plasma levels of CBZ, CBZE, 2OH-CBZ, 3OH-CBZ and DiOH-CBZ 
in patient plasma. CBZE is metabolised to DiOH-CBZ (Thorn et al. 2011) and 2OH-
CBZ and 3OH-CBZ act as surrogates for arene oxide formation (Madden et al. 1996). 
Variation in plasma levels of CBZ and metabolites of CBZ may be secondary to 
genetic variation in drug metabolising enzymes and transporters known to be 
involved in the disposition of CBZ (Table 1.4). However, there are numerous 
conflicting reports regarding the effect of genetic variation on the metabolism of 
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CBZ and this is likely to be secondary to inadequate sample sizes and analysis of the 
parent compound alone in the majority of studies. Healthy volunteers (n=8) and 
patients with epilepsy who were prescribed CBZ (n=72) were recruited into two 
clinical studies. A mixture of rich and sparse PK samples, blood for genotyping and 
medical history for each patient were collected. All patients were genotyped for 20 
SNPs in drug metabolising enzymes and transporters known to be involved in CBZ 
disposition. The data showed that there was 14-fold variation in levels of CBZ and 
approximately 30-fold variation for each of the metabolites.  
 
Population PK is the study of the sources and correlates of variability in drug 
concentrations among individuals who are the target patient population receiving 
clinically relevant doses of the drug of interest (Aarons 1991). It was the original 
intention to set up a population PK model using NONMEM to describe the PK of CBZ 
and its metabolites and to examine the effects of the clinical demographics and 
genotypes as covariates. Unfortunately, the final population PK model did not 
include metabolites as it was too complex, with simulations that were very time-
consuming and which ultimately did not describe the data accurately. Due to time 
constraints, a population PK model examining CBZ alone was developed in chapter 
4 although work on the multiple metabolite PK model is ongoing. The population PK 
model for CBZ reported that completion of autoinduction, total daily dosage and 
concomitant medication with phenytoin significantly influenced the clearance of 
CBZ which is consistent with covariates reported in other studies (Table 1.6). None 
of the SNPs in metabolising enzymes were reported as significant in the current 
population PK model. This is possibly secondary to small population size meaning 
the study was underpowered to detect significant differences or the genotypes 
exert their influence on the metabolism of specific metabolites that were not part 
of the current population PK model. Alternatively, in order to influence the PK of 
CBZ it may require a combination of SNPs in metabolising enzymes and the 
presence of specific clinical factors. For example, one study found that SNPs in the 
drug transporter ABCB1 influenced the CBZ/CBZE ratio only in patients receiving 
concomitant phenytoin or phenobarbital therapy and no effect was seen with the 
SNPs alone (Wang et al. 2015). Another study reported that patients required 
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higher dosages of CBZ only if they possessed a combination of SNPs in both UGT2B7 
and ABCC2 (Ma et al. 2015). 
 
ADRs represent a significant clinical problem accounting for 6.5% of UK hospital 
admissions and cost the NHS £466 million each year  (Pirmohamed et al. 2004). 
ADRs also lead to withdrawal of medications after licensing at great cost to the drug 
industry (FDA Centre for Drug Evaluation and Research 2005). Hypersensitivity to 
CBZ affects up to 10% of patients that are prescribed the drug and clinical 
presentation includes MPE, HSS, SJS and TEN. CBZ hypersensitivity is a type B ADR 
that is unpredictable from the known pharmacology of the drug and is (probably) 
dose-independent (Edwards and Aronson 2000). These reactions are T cell 
mediated, and represent type IV hypersensitivity reactions (Demoly et al. 2014), as 
CBZ-specific T cells have been isolated from patients with a history of 
hypersensitivity to CBZ (Naisbitt et al. 2003; Wu et al. 2006; Wu et al. 2007). HLA 
also play an important role in hypersensitivity to CBZ with carriage of HLA-B*15:02 
or HLA-A*31:01 being associated with significantly increased susceptibility to CBZ 
hypersensitivity reactions (Chung et al. 2004; McCormack et al. 2011). However, a 
significant number of patients that possess the risk HLA alleles do not develop 
hypersensitivity when prescribed CBZ indicating other factors that affect 
susceptibility (Yip et al. 2012). Three mechanisms have been proposed to explain 
how drugs or reactive metabolites activate T cells: the hapten hypothesis 
(Landsteiner and Jacobs 1935), the direct PI concept (Pichler et al. 2006) and the 
altered peptide repertoire model (Ostrov et al. 2012; Illing et al. 2012; Norcross et 
al. 2012). There is evidence to suggest that CBZ can activate T cells through multiple 
mechanisms including direct interaction (Naisbitt et al. 2003; Zhou et al. 2015), 
altered peptide repertoire (Illing et al. 2012) and formation of haptens (Chapter 2). 
 
In chapter 5, TCCs were generated from patients with a known history of 
hypersensitivity to CBZ to further investigate the pathophysiological mechanisms in 
CBZ hypersensitivity. TCCs were successfully generated to CBZ and CBZE from two 
subjects who reported hypersensitivity reactions to CBZ more than 25 years ago. 
Seventeen clones were generated to CBZ and 11 clones to CBZE all of which were 
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CD4+ phenotype. The TCCs secreted the cytokines IFN-γ, IL-13, granzyme B and 
perforin. These cytokines have been detected in skin biopsy, blood samples and 
biopsy fluid from subjects with MPE, SJS and TEN (Posadas et al. 2002; Caproni et al. 
2006). A significant number of TCCs generated were cross reactive to CBZ or CBZE. 
Previous experiments have shown in vitro lymphocyte proliferation to CBZ, CBZE, 
10-hydroxycarbamazepine and oxcarbazepine, but lack of proliferation to the 
metabolites 2OH-CBZ, 3OH-CBZ and DiOH-CBZ (Wu et al. 2006). The antigen pulsing 
assay provides indirect evidence for the hapten mechanism of hypersensitivity. The 
drug is incubated with APCs for 16h before washing to remove excess drug followed 
by incubation with drug specific TCCs. All TCCs responded when incubated with 
fresh drug supporting the PI concept for T cell activation. Interestingly, a single TCC 
also responded in the incubation containing only washed APCs implying a hapten 
mechanism of activation. The identity of the proposed hapten could not be 
determined, and it is not possible to exclude metabolism of CBZ in the T cell culture 
medium which also contained abundant HSA.  
 
Two HLA class I alleles, HLA-B*15:02 (Chung et al. 2004) and HLA-A*31:01 
(McCormack et al. 2011), have been associated with susceptibility to CBZ 
hypersensitivity. However, all of the TCCs generated in this study were CD4+ and as 
expected TCC activation was blocked by MHC class II antibody but not by an 
antibody to MHC class I. These results suggest that CD4+ lymphocytes also play a 
role in the pathogenesis of CBZ hypersensitivity. This is further supported by the 
generation of CBZ-specific CD4+ TCCs from a patient positive for HLA-A*31:01; the 
CD4+ TCCs were activated in a HLA-DBRB1*04:04 restricted manner (Lichtenfels et 
al. 2014). The pathogenesis and phenotype of nevirapine hypersensitivity reactions 
has been associated with specific combinations of class I and class II HLA alleles 
(Keane et al. 2014) and a similar pathophysiological mechanism may be applicable 
to CBZ hypersensitivity reactions. T cells that are responsive to CBZ and or its 
metabolites persist in the circulation of patients for many years (25 years in this 
study). It has been proposed that these long lasting T cells are maintained by 
heterologous immune responses to other antigens such as viruses (e.g. HHV and 
EBV) (White et al. 2015). There is significant overlap in the clinical presentation of 
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drug hypersensitivity and viral illness (e.g. exanthema and liver inflammation) and 
reactivation of HHV6 in CBZ induced HSS is associated with slower recovery (Aihara 
et al. 2003). Taken together these data demonstrate that CBZ hypersensitivity is 
characterised by plurality of T cell responses reacting with multiple antigens using 
different mechanistic pathways.    
 
The diagnosis of hypersensitivity to CBZ and other drugs is very difficult as there is 
significant heterogeneity in clinical presentation and clinical history can be limited 
with many patients taking multiple medications. Incorrect diagnosis leads to the 
inappropriate exclusion of effective treatments and switching to suboptimal 
therapies (Demoly et al. 2014). There are a variety of in vivo (skin testing and drug 
provocation testing) and in vitro tests (LTT, ELISpot and flow cytometry) available 
but none are routinely used in clinical practice (Schrijvers et al. 2015). In vivo testing 
involves re-administration of the suspected drug to the patient but is associated 
with risk of serious ADR and cannot be used in patients who have experienced 
severe forms of hypersensitivity (e.g. SJS/TEN) (Demoly et al. 2014). In vitro tests 
are more acceptable to patients but are time-consuming, involve radiation in the 
case of LTT, require specialised cell culture laboratories and cannot be used during 
the acute hypersensitivity reaction (Naisbitt et al. 2014). If the identity of the culprit 
antigen is unknown or it is a reactive metabolite, then it is not possible to test 
hypersensitivity in vitro at present. Pre-treatment HLA genotyping for HLA-B*57:01 
has demonstrated clinical utility and cost effectiveness in abacavir therapy (Hughes 
et al. 2004). Currently, pre-treatment screening for HLA-A*31:01 is not mandated 
for CBZ but HLA-B*15:02 screening is recommended in patients of South East Asian 
origin (Ferrell and McLeod 2008). There is an urgent clinical need for diagnostic 
tests for drug hypersensitivity. It is likely that a combination of tests will be 
necessary with rapid in vivo biomarkers able to confirm drug hypersensitivity in the 
acutely unwell patient whilst longer term in vitro tests enable the mechanisms of 
hypersensitivity to be unravelled and to allow structurally similar compounds to the 
culprit drug to be tested and avoided in the patient if they test positive.  
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In chapter 6, gene expression profiles and transcriptomic analyses were undertaken 
using PBMCs from patients with known CBZ hypersensitivity in order to investigate 
the pathophysiological mechanisms of hypersensitivity to CBZ and to explore the 
possibility of using mRNA or miRNA as biomarkers for diagnosis. Using IPA, 9 mRNA 
and 39 miRNA molecules were identified to be differentially expressed in CBZ/CBZE 
incubated cells when compared with negative controls and TT incubations. A 
network analysis incorporating the CBZ/CBZE specific mRNA and miRNA was 
generated in IPA and the top 5 functions associated with the network were viral 
infection, psoriasis, inflammation of body region/organ and antiviral response. 
These functions are consistent with the clinical presentation of CBZ hypersensitivity 
(Yip et al. 2012) and provide further evidence for the association between CBZ 
hypersensitivity and viral reactivation (White et al. 2015). Interestingly, psoriasis 
was also a function reported to be associated with the CBZ/CBZE specific mRNA and 
miRNA network. There is evidence to suggest overlap of disease mechanisms 
between autoimmune diseases, such as psoriasis, and drug mediated 
hypersensitivity reactions. Both autoimmune disease and drug hypersensitivity are 
associated with dysregulation of the immune system and increased susceptibility 
with carriage of specific HLA alleles (Michels and Ostrov 2015). In psoriasis, T cells 
are directed against the dermis (Liu et al. 2008) and dysregulation of T cells may 
impair the immune system’s ability to correctly self-regulate (Soler et al. 2016). 
Susceptibility to psoriasis has also been associated with carriage of specific HLA 
alleles (Indhumathi et al. 2016) and response to treatment may also be predicted by 
carriage of the same HLA-C*06 allele (Talamonti et al. 2016).  
 
MicroRNAs are small noncoding RNAs that are 22 nucleotides on average and 
regulate mRNA expression in a large variety of cellular processes including immune 
system regulation, cell development and apoptosis (Bartel 2004). MicroRNAs are 
attractive biomarkers for diagnosis because they are likely to play an important role 
in onset of disease and progression and are easily measureable in biofluids and 
biological samples (Aziz 2016). MicroRNAs have been explored for the diagnosis of 
acute coronary syndrome (Ahlin et al. 2016), drug-induced kidney injury (Pavkovic 
and Vaidya 2016) and cancer (Shi 2016). Elevated levels of the miR-18a-5p were 
 307 
 
reported in the serum and skin biopsy samples of patients with hypersensitivity to 
multiple medications (including 2 cases of CBZ) (Ichihara et al. 2014). The 
association was strongest with TEN and serum concentrations demonstrated a 
positive correlation with severity of hypersensitivity. The miR-18a-5p was also 
detected in chapter 6 but expression was elevated in both CBZE and TT incubated 
PBMCs suggesting that it may not be drug specific in vitro. Further investigation of 
miR-18a-5p levels in patients with viral or bacterial infections is necessary to 
determine if it is an acceptable diagnostic biomarker in vivo. The list of 9 mRNA and 
39 miRNA moelcules identified in chapter 6 represent a collection of potential 
diagnostic biomarkers but requires validation in a larger cohort of patients with 
hypersensitivity to CBZ. It would also be worth investigating if the mRNA and 
miRNA are applicable biomarkers in hypersensitivity to other drugs. In the future, it 
will be important to obtain skin biopsy and blood samples from patients with acute 
hypersensitivity to determine if the mRNA and miRNA transcripts are applicable for 
acute in vivo diagnosis.   
 
The current management for hypersensitivity reactions to CBZ and other 
medications is withdrawal of the suspected culprit drug, supportive therapy and 
corticosteroid therapy (Shiohara et al. 2012). There is limited evidence for the 
benefits of corticosteroids and no specific treatments have yet been identified (Lee 
et al. 2012). GSEA was undertaken using the entire gene list generated from the in 
vitro gene expression experiments irrespective of fold change or p value 
(Subramanian et al. 2005). Fifty one gene sets were identified as significantly 
enriched in CBZ or CBZE treated PBMCs only. Multiple gene sets related to the cell 
cycle including regulation of cyclins and CDKs were significantly enriched. 
Identification of the involvement of CDKs in hypersensitivity to CBZ raises the 
possibility that CDK inhibitors, which are currently in development for cancer 
(Roskoski 2016), may be useful to treat acute hypersensitivity reactions, but of 
course, this will require well-designed prospective trials. CDK inhibitors have been 
reported to have anti-inflammatory and pro-resolution properties through 
promotion of neutrophil and lymphocyte apoptosis (Leitch et al. 2009). The PARP9 
gene was identified as being the most regulated gene in the CBZ/CBZE specific 
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mRNA and miRNA network. PARP9 functions to promote interferon-stimulated 
gene expression to enhance antiviral function (Zhang et al. 2015). Interferon signal 
enhancing small molecules are currently in development as novel antiviral agents 
(Patel et al. 2014) and identification of the importance of the interferon signalling in 
CBZ hypersensitivity raises the possibility that these compounds could also be used 
for the treatment of acute hypersensitivity reactions.  
 
There are a number of outstanding questions that arise from this research. There is 
significant in vitro evidence to suggest that CBZ is able to directly activate T cells 
through a PI mechanism (Naisbitt et al. 2003; Zhou et al. 2015).  However, the 
identification of two [O]CBZ-HSA protein conjugates suggest that alternative T cell 
activation pathways including those consistent with the hapten hypothesis need to 
be considered. CBZE modified HSA conjugates were also detected in patients 
tolerant of CBZ. Similarly, abacavir-HSA conjugates have also been detected in 
patients tolerant to abacavir (Meng et al. 2014a). Piperacillin modified HSA was 
found to stimulate T cells in vitro (Whitaker et al. 2011) but whether all drug 
modified HSA conjugates are immunogenic is unknown. Synthesis of the [O]CBZ 
modified peptides for testing in vitro would provide direct evidence as to whether 
[O]CBZ-HSA conjugates are immunogenic. If the [O]CBZ-HSA conjugates are 
immunogenic, then further work should focus on identification of other 
susceptibility factors as the CBZE modified HSA adduct was detected in CBZ tolerant 
patients. These could include carriage of the risk HLA allele, specific TCR clonotype 
or formation of excessive amounts of reactive metabolites that overcome 
detoxification processes. Animal models of CBZ induced liver injury have 
demonstrated that CYP3A- mediated metabolism and GSH depletion in rats 
contribute to CBZ induced liver injury (Iida et al. 2015) in conjunction with 
activation and stimulation of immune responses (Higuchi et al. 2012).  However, 
these results have to be treated with caution, because it is unclear how well these 
animal models reflect the situation in man. 
 
It has been hypothesised that reactive metabolites of CBZ are responsible for 
triggering hypersensitivity reactions (Furst and Uetrecht 1995; Pearce et al. 2002) 
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and that genetic polymorphisms in CBZ metabolism enzymes contribute to risk (He 
et al. 2014). None of the 19 SNPs implicated in CBZ metabolism or transport 
significantly affected the PK of CBZ as described by population PK modelling using 
NONMEM. This may be secondary to insufficient sample size. Although the levels of 
other metabolites including CBZE, DiOH-CBZ, 2OH-CBZ and 3OH-CBZ were also 
measured in these patients it was not possible to develop a PK model that included 
all of the metabolites due to its complex nature and time constraints on the project.  
 
However, two SNPS in ABCB1 (c.1236T>C and c.2677G>T) and a single SNP in EPHX1 
(c.416A>G) were found to be significantly associated with dose-adjusted plasma 
CBZE concentrations by ANOVA. Patients who were heterozygous or homozygous 
mutants for ABCB1 c.1236T>C demonstrated lower plasma levels of dose-adjusted 
CBZE compared with wild-type patients. Patients who were homozygous mutants 
for ABCB1 c.2677G>T were found to have higher dose-adjusted plasma 
concentrations of CBZE compared with heterozygous and wild-type patients. 
Homozygous mutants for EPHX1 c.416A>G demonstrated higher levels of dose-
adjusted plasma CBZE concentrations compared with heterozygous and wild-type 
patients, which is consistent with reduced activity of the mutant mEH as 
demonstrated in earlier studies (Nakajima et al. 2005). These results demonstrate 
that genetic variation in CBZ metabolising enzymes can affect the plasma 
concentrations of CBZE. Elevated concentrations of plasma CBZE could trigger 
hypersensitivity through increased formation of the CBZE-modified HSA identified 
earlier in chapter 2. However, this hypothesis would require further study and proof 
that CBZE-modified HSA can act as an antigen. 
 
Transcriptome analysis of PBMCs incubated with CBZ or CBZE identified 9 mRNA 
and 39 miRNA molecules that are specific for CBZ and CBZE. Validation of these 
markers is required in a larger number of patients and their applicability to other 
drugs that can cause hypersensitivity also needs to be investigated. To determine if 
any mRNA or miRNA are applicable in vivo, then skin biopsies and blood samples 
should be taken from patients with acute hypersensitivity reactions. The ideal 
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biomarker for diagnosis should be applicable in both the acute hypersensitivity 
reaction but also as an outcome measure in post hypersensitivity in vitro testing. 
 
Because hypersensitivity reactions are relatively rare, a recurring problem in studies 
of drug hypersensitivity is inadequate sample size. In addition, patients present 
with clinically heterogeneous signs and symptoms that mimic many other 
conditions and there is currently no diagnostic test meaning diagnosis is complex. 
Patients may also be prescribed multiple medications making it harder for the 
clinician to be sure of the culprit medication. Correct diagnosis is very important as 
some pharmacogenetic associations (e.g. HLA-B*15:02 and CBZ induced SJS/TEN) 
are applicable only to one phenotype of hypersensitivity (Chung et al. 2004). 
Inadequate diagnosis and phenotyping of patients with hypersensitivity will reduce 
the power of any study to detect a true association. The phenotype standardisation 
project for drug induced skin injury outlines clear diagnostic criteria and 
investigations to be undertaken for suspected drug hypersensitivity which will 
hopefully standardise the clinical information collected for these patients in future 
(Pirmohamed et al. 2011). To ensure sufficient numbers of patients are recruited 
for clinical studies repositories such as the RegiSCAR (Kardaun et al. 2013) and the 
international serious adverse event consortium (http://www.saeconsortium.org/) 
have been established where clinical samples are collected and stored. 
 
In conclusion, this thesis has investigated the links between metabolism and 
immunological mechanisms in CBZ hypersensitivity. Two novel [O]CBZ-HSA adducts 
were identified both in vitro and in vivo although their ability to stimulate the 
immune system requires further investigation. A novel HPLC-MS/MS analysis was 
developed to measure CBZ and four of its metabolites in healthy volunteers and 
patients prescribed CBZ for epilepsy. A population PK model was developed to 
investigate the role of genetic polymorphisms in metabolising enzymes on the PK of 
CBZ although none were found to be significant. In vitro experiments demonstrated 
that CBZ-specific T cells are activated by multiple mechanisms and several antigens. 
Transcriptomic analysis provided further evidence to support involvement of viral 
infection processes and revealed novel pathways that may be targets for treatment 
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such as CDK inhibitors and interferon signalling enhancers. A selection of CBZ/CBZE 
specific mRNA and miRNA has the potential to act as diagnostic biomarkers, but 
requires validation in larger cohorts of patients. The results in this thesis provide 
further evidence for the role of immunological and metabolic factors in the 
susceptibility and pathogenesis of CBZ hypersensitivity reactions. Future research 
into drug induced hypersensitivity reactions requires the establishment of 
infrastructure and guidelines for the diagnosis and investigation of suspected 
patients with joint working between clinicians, scientists, government, industry and 
patient advocates. 
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1. INVESTIGATIONAL SITE 
The study will be conducted at the Clinical Research Facility in the Royal Liverpool 
University Hospital, Prescot Street, Liverpool, L7 8XP, UK 
Dr Amitava Ganguli will be the principal investigator responsible for the conduct of 
the study. 
Prof Munir Pirmohamed will act as the chief investigator for the study. 
 
2.  LABORATORIES 
The Department of Molecular and Clinical Pharmacology, University of Liverpool, 
Liverpool, L69 3BX, UK will conduct the relevant analyses required for the study 
 
3.  ETHICS 
The trial will be performed in compliance with the guidelines of the Declaration of 
Helsinki on biomedical research involving human volunteers (Hong Kong revision, 
1989 and the 48th General Assembly, Somerset West, Republic of South Africa, 
October 1996, updated in October 2000), ICH-GCP guidelines, relevant regulatory 
guidelines, and the study protocol. The protocol and relevant substantive data will 
be submitted for consideration by the Local Research Ethics Committee and written 
approval from the Chair of the Ethics Committee is required before the study is 
initiated and clinical activities of the study can commence. 
 
Any major changes to the protocol will be made by means of a formal written 
protocol amendment and submitted for approval by the Research Ethics 
Committee. The committee will also be kept informed of the study progress and 
will receive a copy of the final study report. 
 
On completion of the study, subjects will be paid £250. This compensation is based 
on an assessment of the loss of time and inconvenience as a result of participation 
in this study. Subjects who are withdrawn from the study by the Investigator for 
medical reasons (either due to study medication or procedures) will receive 
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payment for the visits completed. Subjects who do not complete the study for 
other bona fide reasons (e.g. intercurrent illness, major unexpected change in 
personal circumstances) will be compensated pro rata. Withdrawal of consent 
without any reason or violation of the protocol may, however, result in partial or 
complete forfeiture of compensation. Protocol violation is defined as the 
disobeying of instructions communicated verbally or in writing. 
 
4. BACKGROUND 
 
Carbamazepine (CBZ) is an important drug that is used in the treatment of epilepsy, 
trigeminal neuralgia and bipolar disorder (1, 2). Although generally well tolerated, it 
can cause cutaneous adverse drug reactions (ADR) in up to 10% of patients (1). 
These reactions can range from mild maculopapular exanthema (MPE) to severe life 
threatening conditions such as the hypersensitivity syndrome (HSS), Stevens-
Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) (3). MPE consists of 
diffuse cutaneous erythema with areas of skin elevation that may evolve to vesicles 
or papules but usually resolve once the offending agent is stopped (4). HSS is a 
severe adverse reaction that typically occurs within three months of the start of 
drug treatment and is characterised by fever, eosinophilia, lymphadenopathy, 
cutaneous exanthematous eruption and involvement of extracutaneous organs (5). 
The most severe phenotypes, SJS and TEN, are associated with significant mortality 
(up to 30%) and long-term morbidity. SJS and TEN are characterised by a blistering 
rash affecting a variable percentage of the body surface area, erosion of mucous 
membranes, fever, malaise and systemic involvement. SJS and TEN represent a 
spectrum of the same disease with skin detachment of 1-10% in SJS, 10-30% in the 
overlap syndrome and >30% in TEN (5, 6).  
 
The pathophysiology of these CBZ hypersensitivity reactions is not well understood 
but predisposition is thought to be genetic because of cases reported in families 
and monozygotic twins (7).  One of the presently accepted mechanisms of drug 
hypersensitivity is based on the hapten hypothesis. This hypothesis suggests that 
drugs and/or their metabolites can act as haptens binding and irreversibly 
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modifying carrier proteins in patients. These drug-protein conjugate are then able 
to stimulate the immune system via T-cells in susceptible hypersensitive patients 
(8). The clinical features of CBZ hypersensitivity suggest an immune-based aetiology 
and the discovery of CBZ specific T-cells in hypersensitive individuals is consistent 
with this hypothesis (9). Human leukocyte antigens (HLA) play a central role in the 
immune response to antigens and it has been hypothesised that specific HLA 
molecules may present a drug or its metabolites to specific T-cells which 
subsequently triggers an immune response. This has been borne out by studies 
which have demonstrated strong associations between CBZ hypersensitivity and 
two HLA alleles in particular HLA-B*1502, which was first reported in Han Chinese 
patients and HLA-A*3101 which has been reported in Japanese and Caucasian 
patients (10-12). 
 
Whitaker et al have used mass spectrometry to identify and characterise the 
identity of two haptens formed by piperacillin and its metabolites with human 
serum albumin; these haptens were also detected in plasma isolated from patients 
receiving piperacillin therapy. The antigenicity of these haptens was confirmed by 
stimulation of piperacillin-specific T-cells in vitro from patients with known 
penicillin allergy using synthetic conjugates (13). Similar studies and drug haptens 
have been identified with benzylpenicillin and flucloxacillin (14, 15). The identity of 
the CBZ metabolites and CBZ-protein conjugates responsible for CBZ 
hypersensitivity reactions are currently not known. 
 
Hapten formation and susceptibility to drug hypersensitivity reactions is also 
dependent upon drug metabolism. CBZ is metabolised primarily in the liver by 
CYP3A4 to form the major metabolite CBZ-10,11-epoxide (16). Other metabolites 
include 2-OH-CBZ and 3-OH-CBZ which are formed by ring hydroxylation via 
chemically reactive arene oxide intermediates which have the potential to cause 
cellular damage if not detoxified (17, 18). Secondary oxidation of 2-OH-CBZ and 3-
OH-CBZ by CYP3A4 leads to the formation of thiol-reactive metabolites via 
iminoquinone intermediates that are capable of inactivating CYP3A4 and formation 
of protein adducts (19, 20). Genetic variation in CBZ metabolising and detoxification 
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enzymes has been hypothesised to contribute to susceptibility of CBZ 
hypersensitivity reactions.  Most studies have focused on polymorphisms in the 
microsomal epoxide hydrolase enzyme which is responsible for the detoxification of 
chemically reactive arene oxide metabolites but researchers did not find a 
significant association (21, 22). The role of genetic polymorphisms in CYP450 
enzymes, transporter proteins and other detoxification pathways have not been 
fully characterised in relation to CBZ metabolism or susceptibility to CBZ 
hypersensitivity reactions. 
 
Our current understanding of how CBZ triggers hypersensitivity reactions in 
genetically susceptible individuals is lacking. Further research is needed to link CBZ 
metabolism, CBZ hapten formation and activation of the immune system to enable 
better diagnostic tests and safer drug design in future.  
 
5. STUDY RATIONALE, OBJECTIVES AND DESIGN 
 
5.1   Rationale 
An improved mechanistic understanding of CBZ hypersensitivity is crucial because 
CBZ is an effective and widely prescribed medication. However, a significant 
number of patients (up to 10%) develop hypersensitivity reactions that if severe 
are associated with significant mortality and long-term morbidity. Current methods 
for the diagnosis of CBZ hypersensitivity are time consuming, have low sensitivity 
and low specificity and would not be applicable in clinical practice. Although 
pharmacogenetic tests for HLA exist that can identify patients at risk of 
hypersensitivity they are not employed routinely in clinical practice. The 
mechanistic studies described herein will link CBZ metabolism which leads to 
antigen formation to the immune response and individual susceptibility. This will 
improve our understanding of the relationship between antigenicity and 
immunogenicity which will help in future drug design; and how individuals with 
specific genetic biomarkers respond to CBZ in-vivo and in-vitro which will improve 
the basis for developing predictive tests. The lessons from this research will also 
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provide valuable information for other drugs that are known to cause 
hypersensitivity reactions. 
 
5.2   Aims and Objectives 
 To obtain rich pharmacokinetic (PK) data from plasma and urine of healthy 
volunteers following a single dose of CBZ to improve our understanding of 
CBZ metabolism and CBZ-protein adduct formation. 
 To study the effect of genetic polymorphisms in drug metabolising enzymes 
and transporter proteins on metabolism and adduct formation following 
CBZ therapy. 
 Data from this study will subsequently be incorporated into a larger 
population PK model for CBZ. 
 
5.3   Study Design 
It is intended that 8 healthy male volunteers will complete the study. Subjects will 
attend an initial screening visit within 14 days prior to Day 1. Subjects will then be 
admitted to the Clinical Research Facility at the Royal Liverpool University Hospital 
on day 1. Subjects will be requested to fast from midnight prior to admission. 
Subjects will have an intravenous cannula inserted into the forearm and blood 
samples will be collected from the cannula and venepuncture at regular intervals 
over the next 72 hours 
 
5.4   Statistical Considerations 
The number of subjects planned for this study is consistent with other studies of a 
similar nature (23-25). As this is a novel exploratory study to characterise 
metabolite and hapten formation it is difficult to provide an accurate sample size in 
advance. 
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6.   SUBJECTS AND SCREENING 
6.1   Source of Subjects 
The study population will consist of healthy male volunteers between the ages of 
18-55 years inclusive and will be recruited from a variety of sources. These will 
include the Royal Liverpool University Hospital clinical research facility volunteer 
panel, the University of Liverpool volunteer research database and new 
recruitment through advertising in the Royal Liverpool Hospital and the University 
of Liverpool. Prospective volunteers will be contacted in writing and telephone. 
Subjects will be assigned the numbers CBZ1, CBZ2, etc, in the order of their 
inclusion in the study which will be defined as the time they consent to 
participation. 
 
6.2   Inclusion Criteria 
 Subject is willing and able to give written informed consent 
 Healthy male subjects between 18 and 55 years of age inclusive 
 Subject’s body weight is between 50 and 100 kg 
 Subject’s body mass index is between 18 and 32 kg/m2 
 
6.3   Exclusion Criteria 
 Subject is not willing to take part or unable to give written informed consent 
 Subject has clinically significant abnormal medical history or physical exam 
 Subject has history of febrile illness within 4 weeks prior to admission 
 Subject has clinically significant abnormal laboratory test at screening 
including HBV/HCV/HIV 
 Subject has taken any interacting prescription or non-prescription drug, or 
dietary supplements within 2 weeks prior to study admission. Herbal 
supplements must be discontinued at least 4 weeks prior to admission to 
the clinical research facility 
 Subject possesses either the HLA-B*1502 or HLA-A*3101 genotype 
 Subject has a clinically significant ECG abnormality – prolonged corrected 
QT>450ms, 2nd or 3rd degree atrioventricular conduction block 
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 Subject has known hypersensitivity to carbamazepine or structurally related 
drugs (e.g. tricyclic antidepressants) or any other component of the 
formulation 
 Subject with history of bone marrow depression 
 Subject with history of hepatic porphyrias (e.g. intermittent porphyria, 
variegate porphyria, porphyria cutanea tarda) 
 Subject has taken part on another research study within 90 days of 
commencement 
 Subject has any condition which in the opinion of the investigator will 
interfere with the study 
 
6.4   Screening Procedures 
The first clinic visit will be the pre-study (screening) visit. Subjects will be invited to 
attend this visit up to 14 days before the start of the study. This visit will take 
approximately 60 minutes in total and further details can be found in section 7.1.1. 
 
6.5   Subject Informed Consent Form 
Voluntary written informed consent will be obtained from each subject prior to 
performing any trial-related procedures. Each subject will be given both verbal and 
written information describing the nature and duration of the clinical trial. The 
informed consent process will take place under conditions where the subject has 
adequate time to consider the risks associated with his participation in the clinical 
trial. Subjects will not be screened until they have signed an approved informed 
consent form (ICF) written in a language that is understandable to the subject. 
 
The investigator’s local research and ethics committee (REC)-approved ICF will be 
personally signed and dated by the subject and the investigator or designee who 
conducted the informed consent discussion. Each subject will receive a copy of the 
signed and dated written ICF along with any other written information provided to 
the subject. 
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The investigator is responsible for ensuring that informed consent is obtained from 
each subject in accordance with all applicable regulations and guidelines. The 
original signed ICF will be retained within the subject’s source documents. 
 
7.   STUDY CONDUCT 
7.1   Study Schedule 
Blood sampling of patients will take place at the clinical research facility in the Royal 
Liverpool Hospital as part of a planned 12 hour admission with subsequent blood 
sampling at 24, 48 and 72 hours as ambulatory visits. 
 
7.1.1   Screening Visit 
The first clinic visit will be the pre-study (screening) visit. Subjects will be invited to 
attend this visit up to 14 days before the start of the study. The visit will take 
approximately 60 minutes and proceed accordingly: 
1. Consent Written and verbal consent for inclusion into study 
2. Interview (a) Past medical history 
(b) Concomitant medications 
(c) Social history – smoking, alcohol, caffeine, diet, physical 
activity 
(d) Contact details – GP 
3. Physical 
Examination 
(a) Height and Weight 
(b) Blood Pressure 
(c) Temperature 
(d) Cardiovascular, respiratory and abdominal examination 
(e) ECG 
4. Blood Sampling (a) 2 x 9ml EDTA monovette tube (FBC, HLA genotyping) 
(b) 1 x 9ml Serum gel monovette tube (U&E, LFTs) 
(c) 1 x 9ml Serum Z gel monovette tube (Hep B&C and HIV 
screen) 
5. Administration (a) Screen subject against over-volunteering using the TOPS 
(The Over-volunteering Protection System) database 
(b) GP questionnaire to confirm subject’s past medical 
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history 
 
7.1.2   Visit 1 
Subjects will be admitted in at 0700 on day 1 and undergo routine observations 
(temperature, blood pressure and pulse rate). Blood sampling will commence 
following insertion of a cannula into the arm at approximately 0800. Samples will 
be obtained by an appropriately qualified person from the clinical research facility. 
If the cannula becomes blocked a new one will be sited or samples taken by 
standard venepuncture. Blood will be collected for analysis in EDTA and Li-heparin 
monovette tubes and 24 hour urine collected. Subjects will receive a single dose of 
oral CBZ 400mg after cannula insertion and first blood sample. Subsequent blood 
sampling will be according to the timeline below. A standard operating procedure 
for blood sampling including aseptic technique will be utilised by all practitioners 
involved in the study. The following timeline will be followed for all subjects: 
 
1. Consent Ensure patient still happy to continue with study 
2. Case Note 
Review 
(a) Review laboratory 
results 
FBC, U&E, LFTs, Hep B&C, 
HIV 
(b) Review HLA genotype  
(c) Review ECG  
(d) Review GP 
questionnaire 
 
3. Interview (a) Ensure that patient well 
(b) New medications since screening visit 
4. Physical 
Examination 
(a) Temperature 
(b) Blood Pressure 
(c) Pulse 
5. Inclusion/Exclusi
on Criteria 
Review and update inclusion/exclusion criteria 
If all inclusion and exclusion criteria are satisfied then continue 
6. Cannulate and 
Blood Sampling 
(Time=0) 
(a) 1x 9ml EDTA monovette (genetic polymorphisms) 
(b) 1x 5ml Li Heparin monovette 
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7. Carbamazepine Single oral dose 400mg Carbamazepine administered at 0800 
8. Blood Sampling Blood sampling from cannula into 1x9ml Li Heparin 
monovette at the following times: 
 0815 (15 minute sample) 
 0830 (30 minute sample) 
 0900 (1 hour blood sample) 
 1000 (2 hour blood sample) 
 1200 (4 hour blood sample) 
 1400 (6 hour blood sample) 
 1600 (8 hour blood sample) 
 2000 (12 hour blood sample) 
9. Urine Collection Commence 1st 24 hour urine collection 
10. Discharge Removal of cannula and discharge from clinical research 
facility following 12 hour blood sample at 2000 
 
Subjects will be discharged following the 12 hour blood sample at 2000 hours. 
Blood and urine samples will be analysed for CBZ metabolites and CBZ protein 
adducts. Blood taken pre-carbamazepine at time 0 will also be analysed for genetic 
polymorphisms in drug metabolising enzymes and transporter proteins.  
 
7.1.3   Visit 2 
Visit 2 will take place at 0800 on day 2 and subjects will undergo the following 
consultation: 
1. Interview (a) Ensure patient happy to continue with study 
(b) Monitor for adverse 
events 
Complete AE and SAE forms 
as necessary 
2. Physical 
Examination 
(a) Temperature 
(b) Pulse 
(c) Blood pressure 
3. Blood Sampling 1x 5ml Li Heparin monovette at 
 0800 (24 hour blood sample) 
4. Urine Collection Completion of 1st 24 hour urine collection 
Commence 2nd 24 hour urine collection 
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7.1.4   Visit 3 
Visit 3 will take place at 0800 on day 3 and subjects will undergo the following 
consultation: 
1. Interview (a) Ensure patient happy to continue with study 
(b) Monitor for adverse 
events 
Complete AE and SAE forms 
as necessary 
2. Physical 
Examination 
(a) Temperature 
(b) Pulse 
(c) Blood pressure 
3. Blood Sampling 1x 5ml Li Heparin monovette at 
 2000 (48 hour blood sample) 
4. Urine Collection Completion of 2nd 24 hour urine collection 
Commence 3rd 24 hour urine collection 
 
7.1.5   Visit 4 
Visit 4 will take place at 0800 on day 4 and is the final study visit. 
1. Interview (a) Ensure patient happy to continue with study 
(b) Monitor for adverse 
events 
Complete AE and SAE forms 
as necessary 
2. Physical 
Examination 
(d) Temperature 
(e) Pulse 
(f) Blood pressure 
3. Blood Sampling 1x 5ml Li Heparin monovette at 
 0800 (72 hour blood sample) 
4. Urine Collection Completion of 3rd 24 hour urine sample 
 
In total approximately 100mls of blood will be drawn over the whole study period. 
A summary of study visits and interventions are provided in appendix A. 
 
7.2   Study Restrictions 
7.2.1   Concurrent Medication 
Subjects must refrain from taking any interacting prescription or non-prescription 
drug, or dietary supplements within 2 weeks of admission to the clinical unit. Herbal 
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supplements must be discontinued at least 4 weeks prior to admission to the 
clinical research facility. This is because other medications and herbal supplements 
may induce or inhibit cytochrome P450 enzyme function. 
 
7.2.2   Diet 
Seville oranges, grapefruits and grapefruit juice are known inhibitors of CYP3A4, the 
principal CYP450 enzyme responsible for CBZ metabolism, subjects will be asked to 
avoid consuming pomelo oranges, grapefruits or grapefruit juice for at least 48 
hours prior to day 1 of the clinical trial. 
 
7.2.3   Alcohol 
Subjects must refrain from alcohol consumption from 48 hours prior to admission 
to the clinical research facility until all blood and urine sampling is completed. 
 
7.2.4   Caffeine 
Subjects must refrain from caffeine and caffeine-containing products from 48 hours 
prior to admission to the clinical research facility and until blood and urine sampling 
is completed. 
 
7.2.5   Smoking 
Subjects must have refrained from smoking for at least 6 months prior to the 
screening visit and should not smoke until the end of the study. 
 
7.2.6   Physical Activity 
Subjects should not perform excess strenuous exercise beyond his/her normal 
exercise routine. 
 
7.2.7   Sexual Intercourse 
Subjects should utilise single barrier contraception (such as condoms) if they 
engage in sexual intercourse until the end of the study. 
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7.2.8   Blood Donation 
Subjects must refrain from blood donation for one month prior to screening visit, 
during the study and 2 months after completion of the study. 
 
7.3   Methods for Clinical Procedures 
 
7.3.1   Blood Sampling 
This study will be conducted with close attention to patient safety. Venepuncture 
poses minimal risk of bruising or bleeding. This procedure will be carried out by 
trained, competent health professionals. 
 
Blood samples for determination of CBZ metabolites, CBZ-protein conjugates and 
genetic polymorphisms will be collected via a cannula or direct venepuncture. Prior 
to each sample being taken from the cannula 0.5mls of blood will be drawn and 
discarded. The cannula will be flushed with 2mls of 0.9% saline each time a sample 
is taken. At each designated time point 5mls of blood will be taken into lithium 
heparin tubes. Blood sampling at time 0 will include a further 9ml sample taken into 
an ethylene-diamine-tetra-acetic-acid (EDTA) monovette tube for metabolising 
enzyme and transporter protein genetic polymorphism analysis. Blood samples will 
be centrifuged within 15 minutes of collection or stored overnight at 4oC for 
centrifuge the following day. 1mL and 100µL aliquots will then be transferred to 
appropriate tubes and stored at approximately -80oC prior to bioanalysis. 
 
No more than 20mls of blood will be extracted at time 0 and no more than 10mls 
for each subsequent sampling. Over a 24 hour period no more than 60mls of blood 
will be sampled. Total volume of blood sampled for the study will be approximately 
100mls. 
 
7.3.2   Urine Sampling 
Three 24 hour urine bottles for each subject will be collected. Total volume of each 
bottle will be measured and a 50mls sample stored at -20oC for metabolite and 
carbamazepine-protein conjugate analysis. 
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7.4   Laboratory Evaluations 
7.4.1   Haematology 
Blood samples will be taken into an EDTA monovette for full blood count. 
 
7.4.2    Biochemistry 
Blood samples will be taken into a serum gel monovette for urea and electrolytes 
and liver function tests. 
 
7.4.3   Virology 
Blood samples will be taken into a serum Z monovette for hepatitis B and C and HIV 
serology. 
 
7.4.4   Analysis of Genetic Polymorphisms 
Blood samples will be taken into EDTA monovette tubes for HLA-A*3101 and HLA-
B*1502 genotyping and for identification of polymorphisms in drug metabolising 
enzymes and drug transporter proteins. 
 
7.5   CBZ Metabolite and CBZ-Protein Conjugate Analysis 
High sensitivity mass spectrometry techniques already in use at the MRC Centre for 
Drug Safety Science at the University of Liverpool will be utilised to characterise and 
quantify CBZ metabolites and CBZ-protein conjugates. 
 
7.6   Sample storage  
All samples will be transferred/delivered in appropriate packaging in dry ice (solid 
carbon dioxide) to the University of Liverpool, Department of Pharmacology 
Laboratories. Samples will be stored securely as described above and the University 
will act as custodian. 
 
7.7   End of Study 
The end of study is defined as the last scheduled protocol activity of the last subject 
in the study. The conclusion of the study will be notified by the University of 
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Liverpool to the Ethics Committee within the required timelines. All research data 
will be archived at the University of Liverpool for at least 15 years. 
 
7.8   Criteria for Termination of the Study 
There are no criteria for termination of the study. Details regarding the withdrawal 
of subjects are given in section 10. 
 
8.   CASE REPORT FORMS 
Paper case report forms (CRFs) will be used for recording all data collected during 
the study. All CRFs are to be completely filled out by personnel administering the 
study procedures and reviewed and signed by the chief investigator or nominated 
designee. All CRFs are to be completed in a clear and legible manner. Black ink must 
be used to ensure accurate interpretation of data. Any changes or corrections must 
be made by drawing a line through the data to be changed, entering corrected 
information, and signing (or initialling) and dating the change. Erasing, overwriting, 
or the use of “liquid paper” is not permitted on CRFs. Every effort should be made 
to have the CRFs completed as soon as possible following a subject’s study visit. All 
data from the recruited patients will be transcribed onto an electronic spreadsheet. 
All study documentation as defined above will be made available to the Ethics 
Committee and to regulatory authorities for inspection on request. 
 
9.   ADVERSE EVENTS AND SAFETY REPORTING 
An adverse event (AE) is defined as any undesirable event occurring to a subject 
during a clinical study. All adverse events will be coded and reported as follows: 
 Mild:  Awareness of sign or symptom but easily tolerated 
 Moderate: Discomfort enough to cause interference with usual activity 
 Severe:  Incapacitating with inability to work or do usual 
activity 
Laboratory results that are outside the normal range will be recorded as an adverse 
event. If patients are found to be HIV or hepatitis positive then the investigator will 
invite the patient to the CRF to explain the results and refer them to the infectious 
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diseases team at the Royal Liverpool University Hospital. The severity of each event 
will be assessed by the investigator. When recording the outcome of the adverse 
event its maximum severity will also be recorded. Adverse events, if any, not 
resolved by the end of the study, will be followed up by the investigator.  
 
Serious adverse events (SAE) or suspected unexpected serious adverse reactions 
(SUSAR) are defined as any adverse event that results in death, is life-threatening, 
requires hospitalisation, results in persistent or significant disability or incapacity 
and consists of a congenital anomaly or birth defect. All SAEs have to be reported, 
whether or not considered causally related to the investigational product, or to the 
study procedure(s). If any SAE occurs in the course of the study, the investigator 
must inform the Sponsor within 24 hours of when he or she becomes aware of it. 
The investigator must inform the Sponsor of any follow-up information on a 
previously reported SAE immediately, or no later than 24 hours of when he or she 
becomes aware of it. SUSARs that are fatal or life-threatening will be reported to 
the MHRA as soon as possible but no later than 7 days. SUSARs which are not fatal 
or life-threatening will be reported to the MHRA as soon as possible but no later 
than 15 days. Causality for SAEs and SUSARs will be checked against the SmPc. All 
SAE and SUSAR will be managed according to the Royal Liverpool University 
Hospital research and development standard operating procedures. 
 
10.   WITHDRAWAL OF SUBJECTS 
Subjects will be informed that they are free to withdraw from the study at any time. 
The investigator may remove a subject if, in his opinion, it is in the best interest of 
the subject. Although a subject is not obliged to give his reason for premature 
withdrawal, the investigator will make a reasonable effort to obtain the reason 
while fully respecting the subject’s rights. If there is a medical reason for 
withdrawal of the subject then this will be reported as an adverse event and 
followed up by the investigator. If in the opinion of the investigator it is considered 
necessary, the subject’s GP will be informed of the medical reason for the 
withdrawal. The subject’s consent will be obtained prior to informing the GP. 
Subjects that withdraw consent or are withdrawn at the discretion of the 
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investigator prior to completion of study procedures may be replaced to ensure 
that there are 8 evaluable subjects. 
 
11.   DATA ANALYSIS 
As this is an exploratory/pilot study it is most likely that only descriptive statistics 
will be required. 
 
12.   RECORDS AND CONFIDENTIALITY 
12.1   Records 
Adequate records as required by ICH GCP will be maintained for the study. This 
includes medical records, case report forms, laboratory reports, signed consent 
forms, and worksheets. All records from the study will be kept for 15 years. 
 
12.2   Confidentiality 
To maintain subject privacy, all case report forms, study reports and 
communications will identify the subject by initials where permitted and/or by the 
assigned subject number. The subject’s confidentiality will be maintained and will 
not be made publicly available to the extent permitted by the applicable laws and 
regulations. 
 
12.3   Report and Publication 
The results of the study will be incorporated into scientific papers for publication. 
All identifiable patient information will be removed. Appropriate precautions will be 
taken to maintain confidentiality of medical records and personal information. 
  
 359 
 
13.   APPENDIX A 
13.1   Summary of Study Visits 
  Day 1 Day 2 Day 3 Day 4 
 Screening Visit 1 Visit 2 Visit 3 Visit 4 
Informed Consent X     
Medical History X     
Clinical Examination X     
Height and Weight X     
Vital Signs X X X X X 
FBC,U&E, LFT X     
Hepatitis 
B & C test 
X     
HIV test X     
HLA Genotyping X     
Genetic 
polymorphisms in drug 
metabolising enzymes 
 X    
Carbamazepine blood 
tests over 12 hours 
 X    
Single Carbamazepine 
blood tests 
  X X X 
AE Monitoring  X X X X 
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A PHARMACOKINETIC INVESTIGATION INTO THE FORMATION OF 
CARBAMAZEPINE METABOLITES AND CARBAMAZEPINE-PROTEIN CONJUGATES IN 
HEALTHY VOLUNTEERS 
Participation Information Sheet 
Invitation 
You are being invited to participate in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read this sheet carefully and discuss it with relatives, 
friends and the study team. You may also wish to discuss this with your GP. Ask us 
about anything that is not clear and take time to decide whether or not you wish to 
take part. 
 
What is the purpose of the study? 
This study is looking at the formation of breakdown products produced by the body 
following carbamazepine ingestion and how genetic variation affects this process. 
Carbamazepine is a medication that is used to treat epilepsy, trigeminal neuralgia 
and some psychiatric conditions. We know that some patients develop adverse 
reactions, which are termed hypersensitivity reactions, to carbamazepine. These 
hypersensitivity reactions include skin rash, fever and lethargy, and usually occur 
with multiple doses. At the moment we do not know what causes these 
hypersensitivity reactions but we believe that they are caused by the way the body 
handles carbamazepine and forms breakdown products.  These breakdown 
products (also called metabolites) then cause hypersensitivity reactions in 
genetically susceptible patients. The main purpose of this study is to find out how 
genetic variation can affect the formation of carbamazepine metabolites. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part in the study. Participation is 
entirely voluntary. If you do decide to participate you will be given this information 
sheet to keep and be asked to sign a consent form. You will receive a copy of this 
signed consent form to keep. If you decide to take part you are still free to 
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withdraw at any time and without giving a reason. This will not affect the standard 
of care you receive. 
 
What will happen to me if I take part? 
You will be given sufficient time to consider whether or not you wanted to take 
part. If you agree to take part in the study you will be participating for a maximum 
of 5 days. Over this period of time you will be asked to visit the clinical research 
facility 5 times. On one of these visits you will have to stay for 12 hours. 
 
During the study you will be asked to take a single 400mg tablet of 
carbamazepine.Your partner should not become pregnant whilst taking part in the 
study. You will need to use one of the following methods of contraception until you 
have finished the study. 
 
 Complete abstinence from intercourse from 24 hours prior to taking study 
medication, throughout the study and for at least 1 week after stopping 
study medication 
 Single barrier method (male condom, diaphragm) 
 Any intrauterine device (IUD) with published data showing the expected 
failure rate is <1% per year 
 Any other method with published data showing that the expected failure 
rate is <1% per year 
 Hormonal contraception plus a barrier method. Hormonal contraception 
alone cannot be used 
 
During the study you will not be able to eat grapefruit or pommello oranges or any 
product that contains grapefruit or pommello oranges. 
 
If you need to take any other medication you should contact the study team before 
taking it. You are not allowed to take any interacting prescription or non-
prescription drug, recreational drugs (such as St John’s wort, cannabis, cocaine), or 
dietary supplements. You are allowed to take paracetamol and multi-vitamins. 
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During the study we will ask you to refrain from alcohol consumption and caffeine 
products from 48 hours prior to admission to the clinical research facility until the 
end of the study. 
 
We will ask you not to perform any extra physical exercise during the study. It is ok 
to carry on with your normal exercise routine. 
 
Screening Visit 
You will need to bring a form of photographic identification and your National 
Insurance number with you. This visit will be used to see if you are suitable to take 
part. Details about yourself will be taken such as your age, ethnic group, past 
medical problems and details of any medication you are taking. A clinical 
examination will be undertaken. We will also take some blood samples to see if you 
can take part in the study. This blood will also be tested for HIV and hepatitis. If you 
want further information or to discuss these tests please ask the study doctor or 
nurse who can give you more information. If we find out that you have HIV or 
hepatitis we will make sure you receive the right care. If you are suitable to take 
part in the study we will arrange for you to attend the study days. 
 
Visit 1 
You will be asked to attend the clinical research facility at 0730 and be required to 
stay until 2000. You will be required to fast from midnight before this visit. On this 
visit we check your temperature, pulse and blood pressure. We will ask you about 
any medication you may be taking and about your general health. We will insert a 
small tube (cannula) into a blood vessel and we will take two blood samples at this 
time (time=0). Following this you will be given a single 400mg tablet of 
carbamazepine. We will use the cannula to take blood samples at 15mins, 30mins, 
1hr, 2hrs, 4hrs, 6hrs, 8hrs and 12hrs after you took the tablet. The total amount of 
blood taken will be approximately 54 mls. We will also request that you collect your 
urine for the next 72 hours using three 24 hour urine collection bottles. You will be 
allowed home following the 12 hour blood sample and cannula will be removed.  
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Visit 2 
You will be asked to return to the clinical research facility at 0730 the day following 
visit 1. At this visit we will check your temperature, pulse and blood pressure. We 
will ask if you had any problems with the medication. We will require a blood test 
and return of the first 24 hour urine sample bottle. 
 
Visit 3 
On day 3, 48 hours since you took the carbamazepine tablet, we will ask you to 
return to the clinical research facility at 0730. We will check your temperature, 
pulse and blood pressure. We will ask if you had any problems with the medication. 
We will require a blood test and return of the second 24 hour urine sample bottle. 
 
Visit 4 
This is the final study visit and will take place at 0730 at the clinical research facility 
one day after visit 3. We will check your temperature, pulse and blood pressure. We 
will ask if you had any problems with the medication. We will require a blood test 
and return of the third 24 hour urine sample bottle. 
 
Withdrawal Visit 
If you decide to stop the study before the end you will need to attend for a final 
visit. We will check your blood pressure, pulse, temperature and urine. 
 
What are the possible side effects/risks of taking part? 
You may have side effects whilst taking part in this study. However, we will monitor 
everyone in the study for side effects. If you are worried about your symptoms then 
you can contact the study team at any time. You will be given contact numbers of 
the study team. 
 
Carbamazepine side effects 
Dizziness, ataxia (loss of co-ordination), double vision, drowsiness, and nausea and 
vomiting may occur with single doses in about 10% of people.  However, these are 
usually short lasting. Other side effects which have been reported with 
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carbamazepine occur with multiple doses, which you will not be receiving.  These 
include low platelets, fluid retention, dry mouth, elevated liver enzymes and skin 
rashes.  
 
Abnormal blood test results 
If any blood tests taken during your participation in the study are abnormal then we 
will invite you back to the clinical research facility to explain the results to you. We 
will also ensure that you are referred to the appropriate clinician for further 
management. 
 
Other possible risks 
When you give blood you may feel faint or experience bruising or tenderness at the 
site of the needle puncture. You will be required to remain in hospital for most of 
the day on day 1 of the clinical trial which may cause inconvenience. 
 
What are the benefits of taking part? 
There are unlikely to be any direct benefits to you by taking part in the study. 
However, in the long-term, the information we get from this study may help 
improve the treatment of people with carbamazepine. 
 
What happens if something goes wrong? 
If you are unhappy with any aspect of the study then complaints should be made to 
the chief investigator in the first instance. There are no special compensation 
arrangements. If you are harmed because of negligence then you may have grounds 
for legal action but you may have to pay for it. Regardless of this, if you have any 
cause to complain about any aspect of the way you have been approached or 
treated during the course of the study, the normal National Health Service 
complaints mechanisms are available to you. 
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Will my taking part in this study be kept confidential? 
All the information collected about you during the course of the study will be kept 
strictly confidential. Any information about you which leaves the clinic will have 
your name and address removed so that you cannot be recognised from it. All 
samples will be coded and anonymised. All identifying details (e.g. name, address, 
date of birth) will be removed, but the sample will remain linked to data collected 
from this study (e.g. weight, age). Your medical records may be inspected by 
research staff for the purposes of checking that the information we have is accurate 
and complete. We will seek your consent to notify your GP about your participation 
in this study. 
 
What will happen to my samples? 
Your blood and urine samples will be analysed for levels of carbamazepine and its 
breakdown products.  We will look at genes in your DNA samples to see how this 
determines the way your body handles carbamazepine. 
 
What happens when the research study stops? 
You will be asked if we can store the samples from this study for use in other 
projects. The samples will be kept in a locked freezer in the University of Liverpool. 
ALL THESE SAMPLES WILL BE CODED (but will be linked to details that we will collect 
about your drug levels). We will keep your sample until all of it is used up. The 
samples will be considered a gift to the University of Liverpool, which will act as a 
custodian of all the samples obtained as part of this project. Rarely, a small amount 
of your sample may be provided to other researchers in the UK or other parts of the 
world. However, it is important to remember that this will only be identified by a 
unique code, and your name will not be given out. 
We are asking for your permission to store your samples and linked details for 
these future studies. Your samples will not be sold for profit. (It is not the purpose 
of this study to produce commercial gain, and in any case, any commercial value in 
the future will only come from findings in groups of people rather than from 
samples from a single person). 
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Once the studies are completed your anonymised data will be kept for a minimum 
of 15 years. 
 
What will happen to the results of the study? 
We will combine all the results from the subjects taking part in the study, and 
publish any important results in medical journals. Results may also be presented at 
scientific meetings. No individuals will be specifically identified in any publication. 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the area that is being studied. We will share this information with 
you right away if it is important to your health. If you have any concerns about it 
you should discuss this with the research team. 
 
Prevention of over volunteering (TOPs database) 
You must not take part in too many studies because it is not good for you. We and 
other units like ours in the UK keep a database of healthy volunteers and when they 
take part in studies. We will enter into the database: 
 Your National Insurance number (if you’re a UK citizen); or  
 Your passport number and country of origin (if you’re not a UK citizen); and  
 The date of your last dose of study medicine 
If you withdraw from the study before you receive any study medicine, the 
database will show that you never received a dose. Only staff at the Royal Liverpool 
NHS Hospital and other medicines research units can use the database. We may call 
other units, or they may call us, to check your details. We will keep your details for 
at least 2 years. If we need to contact you about the study after you have finished 
it, but we can’t because you have moved or lost contact with your GP, we might be 
able to trace you through the information in the database. 
 
Who is funding the research? 
This study is funded by the Medical Research Council. 
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Who has reviewed the study? 
This study has been reviewed by the National Research Ethics Service Committee 
North West – Greater Manchester Central 
 
Reimbursement 
You will be reimbursed a total of £250 for participating in this study. This payment 
includes travel expenses. If you withdraw before completion of the study you will 
be reimbursed for the time you participated. Screening visit £40; visit 1- 12 hour 
blood sampling £90; visit 2- blood sampling £40; visit 3- blood sampling £40; final 
visit- blood sampling £40. Withdrawal of consent without any reason or violation of 
the protocol may, however, result in partial or complete forfeiture of 
compensation. Protocol violation is defined as the disobeying of instructions 
communicated verbally or in writing. You will be asked to provide details of your 
bank account so this payment can be made. You will be responsible for paying tax 
on any payment received. 
 
Involvement of your General Practitioner 
With your permission, your general practitioner will be contacted to confirm your 
past medical history. Your signature on the consent form will authorise the study 
team to do this. 
 
For further information on this study please contact: 
Dr Vincent Yip, MRC Clinical Fellow in Clinical Pharmacology and Therapeutics, 
Department of Molecular and Clinical Pharmacology, The Wolfson Centre for 
Personalised Medicine, The University of Liverpool, L69 3GL 
Email:  vyip@liv.ac.uk 
Tel: 0151 795 5407 
Study Investigator ______________________________ 
Tel Number  ______________________________ 
E-mail   ______________________________ 
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Summary of Study Visits 
  Day 1 Day 2 Day 3 Day 4 
 Screening Visit 1 Visit 2 Visit 3 Visit 4 
Informed Consent X     
Medical History X     
Clinical Examination X     
Height and Weight X     
Vital Signs X X X X X 
FBC,U&E, LFT X     
Hepatitis 
B & C test 
X     
HIV test X     
HLA Genotyping X     
Genetic polymorphisms in 
drug metabolising enzymes 
 X    
Carbamazepine blood tests 
over 12 hours 
 X    
Single Carbamazepine 
blood tests 
  X X X 
AE Monitoring  X X X X 
 
Thank you for reading this. This sheet (and a copy of the consent form) should be 
retained by you if you decide to participate. 
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A PHARMACOKINETIC INVESTIGATION INTO THE FORMATION OF 
CARBAMAZEPINE METABOLITES AND CARBAMAZEPINE-PROTEIN CONJUGATES IN 
HEALTHY VOLUNTEERS 
Participant Consent Form 
The volunteer should complete the whole of this sheet himself/herself 
Thank you for reading the information about our research project. If you would 
like to take part, please read and sign this form. 
Participant identification number:  _______________________ 
Name of Researcher:   _______________________ 
Contact Details for Research Team: _______________________ 
 
PART 1                     Please initial boxes 
1. I confirm that I have read and understand the information sheet dated 
26/11/12 (version 3) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
2. I agree to give blood samples for research in this project. I understand 
how the samples will be collected, that giving samples for this research is 
voluntary and that I am free to withdraw at any time without giving any 
reason, without medical care or legal rights being affected. 
 
3. I understand that once the study has ended the samples will be fully 
anonymised and once gifted to the University of Liverpool cannot be 
withdrawn. 
 
4. I understand that relevant sections of my study records and data collected 
during the study may be looked at by individuals from regulatory 
authorities or from the NHS Trust, where it is relevant to my taking part in 
this research. I give permission for these individuals to have access to my 
records.  
 
5. I understand that I will not benefit financially if this research leads to the 
development of a new medical test. 
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6. I agree to my GP being informed of my participation in the study and I 
understand that the GP will be required to complete a questionnaire 
about my past medical history before I can participate in the study. 
 
7. I know how to contact the research team if I need to, and how to get 
information about the results of the research. 
 
8. I agree to take part in the above study 
 
9. I understand that I will receive up to £250 for participating in this study. 
 
10. I agree to my details being entered into the TOPS database. 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept 
in medical notes. 
 
 
________________ 
Name of patient 
(BLOCK CAPITALS) 
 
 
________________ 
Date 
 
 
_________________ 
Signature 
 
 
_________________ 
Name of person 
taking consent (if 
different from 
researcher) 
 
 
________________ 
Date 
 
 
_________________ 
Signature 
 
 
______________ 
Name of Researcher 
 
 
 
_______________ 
Date 
 
 
________________ 
Signature 
 
 
Please see overleaf for part 2 of the consent form. 
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PART 2 
11. Consent for storage and use in possible future research projects 
I agree that the samples I have given and the information gathered 
about me can be stored by the University of Liverpool for possible use in 
future projects as described in the attached information sheet. I 
understand that some of these projects may be carried out by 
researchers other than the Liverpool Pharmacology who ran the first 
project. 
 
 
_________________ 
Name of patient 
(BLOCK CAPITALS) 
 
 
________________ 
Date 
 
 
________________ 
Signature 
 
 
_________________ 
Name of person 
taking consent (if 
different from 
researcher) 
 
 
_________________ 
Date 
 
 
_________________ 
Signature 
 
 
______________ 
Name of Researcher 
 
 
 
________________ 
Date 
 
 
_________________ 
Signature 
 
Thank you for agreeing to participate in this research. 
Prof M Pirmohamed, Department of Molecular and Clinical Pharmacology, 
University of Liverpool, Liverpool L69 3GL 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept 
in medical notes 
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1. INVESTIGATIONAL SITE 
The study will be conducted at the Walton Centre NHS Foundation Trust, Lower 
Lane, Fazakerley, Liverpool, L9 7LJ, UK. 
Dr Vincent Yip will be the principal investigator responsible for the conduct of the 
study. 
Prof A Marson will act as the chief investigator for the study. 
 
2. LABORATORIES 
The department of Molecular and Clinical Pharmacology, University of Liverpool, 
Liverpool, L69 3BX, UK, will conduct the relevant analyses required for the study. 
 
3. ETHICS 
The trial will be performed in compliance with the guidelines of the Declaration of 
Helsinki on biomedical research involving human volunteers (Hong Kong revision, 
1989 and the 48th General Assembly, Somerset West, Republic of South Africa, 
October 1996, updated in October 2000), ICH-GCP guidelines, relevant regulatory 
guidelines, and the study protocol. The protocol and relevant substantive data will 
be submitted for consideration by the Local Research Ethics Committee and written 
approval from the Chair of the Ethics Committee is required before the study is 
initiated and clinical activities of the study can commence. 
 
Any major changes to the protocol will be made by means of a formal written 
protocol amendment and submitted for approval by the Research Ethics 
Committee. The committee will also be kept informed of the study progress and 
will receive a copy of the final study report. 
 
On completion of the study, only subjects in the autoinduction group will be paid 
£200 (£40 per visit). This compensation is based on an assessment of the loss of 
time and inconvenience as a result of participation in this study. All participants will 
have their travel costs reimbursed. Subjects who are withdrawn from the study by 
the Investigator for medical reasons (either due to study medication or procedures) 
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will receive payment for the visits completed. Subjects who do not complete the 
study for other bona fide reasons (e.g. intercurrent illness, major unexpected 
change in personal circumstances) will be compensated pro rata. Withdrawal of 
consent without any reason or violation of the protocol may, however, result in 
partial or complete forfeiture of compensation. Protocol violation is defined as 
disobeying of instructions communicated verbally or in writing. 
 
4. BACKGROUND 
Carbamazepine (CBZ) is an important drug that is used in the treatment of epilepsy, 
trigeminal neuralgia and bipolar disorder.1,2 Although generally well tolerated, it 
can cause cutaneous adverse drug reactions (ADR) in up to 10% of patients.1 These 
reactions can range from mild maculopapular exanthema (MPE) to severe life 
threatening conditions such as  the hypersensitivity syndrome (HSS), Stevens-
Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).3 MPE consists of 
diffuse vesicles or papules but usually resolve once the offending agent is stopped.4 
HSS is a severe adverse reaction that typically occurs within three months of the 
start of drug treatment and is characterised by fever, eosinophilia, 
lymphadenopathy, cutaneous exanthematous eruption and involvement of 
extracutaneous organs.5 The most severe phenotypes, SJS and TEN, are associated 
with significant mortality (up to 30%) and long term morbidity. SJS and TEN are 
characterised by a blistering rash affecting a variable percentage of the body 
surface area, erosion of mucous membranes, fever, malaise and systemic 
involvement. SJS and TEN represent a spectrum of the same disease with skin 
detachment of 1-10% in SJS, 10-30% in the overlap syndrome and >30% in TEN.5,6 
The pathophysiology of these CBZ hypersensitivity reactions is not well understood 
but predisposition is thought to be genetic because of cases reported in families 
and monozygotic twins.7  One of the presently accepted mechanisms of drug 
hypersensitivity is based on the hapten hypothesis. This hypothesis suggests that 
drugs and/or their metabolites can act as haptens binding and irreversibly 
modifying carrier proteins in patients. These drug-protein conjugates are then able 
to stimulate the immune system via T-cells in susceptible hypersensitive patients.8 
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The clinical features of CBZ hypersensitivity suggest an immune-based aetiology 
and the discovery of CBZ specific T-cells in hypersensitive individuals is consistent 
with this hypothesis.9 Human leukocyte antigens (HLA) play a central role in the 
immune response to antigens and it has been hypothesised that specific HLA 
molecules may present a drug or its metabolites to specific T-cells which 
subsequently triggers an immune response. This has been borne out by studies 
which have demonstrated strong associations between CBZ hypersensitivity and 
two HLA alleles in particular HLA-B*1502, which was first reported in Han Chinese 
patients and HLA-A*3101 which has been reported in Japanese and Caucasian 
patients.10-12 
 
Whitaker et al have used mass spectrometry to identify and characterise the 
identity of two haptens formed by piperacillin and its metabolites with human 
serum albumin; these haptens were also detected in plasma isolated from patients 
receiving piperacillin therapy. The antigenicity of these haptens was confirmed by 
stimulation of piperacillin-specific T-cells in vitro from patients with known 
penicillin allergy using synthetic conjugates.13 Similar studies and drug haptens have 
been identified with benzylpenicillin and flucloxacillin.14,15 The identity of the CBZ 
metabolites and CBZ-protein conjugates responsible for CBZ hypersensitivity 
reactions are currently not known. 
 
Hapten formation and susceptibility to drug hypersensitivity reactions is also 
dependent upon drug metabolism. CBZ is metabolised primarily in the liver by 
CYP3A4 to form the major metabolite CBZ-10,11-epoxide.16 Other metabolites 
include 2-OH-CBZ and 3-OH-CBZ which are formed by ring hydroxylation via 
chemically reactive arene oxide intermediates which have the potential to cause 
cellular damage if not detoxified.17,18 Secondary oxidation of 2-OH-CBZ and 3-OH-
CBZ by CYP3A4 leads to the formation of thiol-reactive metabolites via 
iminoquinone intermediates that are capable of inactivating CYP3A4 and formation 
of protein adducts.19,20 The metabolism of CBZ is unique because it undergoes 
autoinduction which takes between one week and one month.21-23 Genetic 
variation in CBZ metabolising and detoxification enzymes has been hypothesised to 
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contribute to susceptibility of CBZ hypersensitivity reactions.  Most studies have 
focused on polymorphisms in the microsomal epoxide hydrolase enzyme which is 
responsible for the detoxification of chemically reactive arene oxide metabolites 
but researchers did not find a significant association.24,25 The role of genetic 
polymorphisms and autoinduction in CYP450 enzymes, transporter proteins and 
other detoxification pathways have not been fully characterised in relation to CBZ 
metabolism or susceptibility to CBZ hypersensitivity reactions. 
 
Our current understanding of how CBZ triggers hypersensitivity reactions in 
genetically susceptible individuals is lacking. Further research is needed to link CBZ 
metabolism, CBZ hapten formation and activation of the immune system to enable 
better diagnostic tests and safer drug design in future.  
 
5. STUDY RATIONALE, OBJECTIVES AND DESIGN 
5.1. Rationale 
An improved mechanistic understanding of CBZ hypersensitivity is crucial because 
CBZ is an effective and widely prescribed medication. However, a significant 
number of patients (up to 10%) develop hypersensitivity reactions, which if severe, 
are associated with significant mortality and long-term morbidity. Current methods 
for diagnosis of CBZ hypersensitivity are time consuming, have low sensitivity and 
low specificity and would not be applicable in clinical practice. Although 
pharmacogenetic tests for HLA exist that can identify patients at risk of 
hypersensitivity they are not employed routinely in clinical practice. The 
mechanistic studies described herein will link CBZ metabolism which leads to 
antigen formation to the immune response and individual susceptibility. This will 
improve our understanding of the relationship between antigenicity and 
immunogenicity which will help in future drug design; and how individuals with 
specific genetic biomarkers respond to CBZ in-vivo and in-vitro which will improve 
the basis for developing predictive tests. The lessons from this research will also 
provide valuable information for other drugs that are known to cause 
hypersensitivity reactions. 
 386 
 
5.2. Aims and Objectives 
 To obtain pharmacokinetic (PK) data from plasma and urine of patients who 
have been newly prescribed CBZ to improve our understanding of the role 
of auto-induction in CBZ metabolism and CBZ protein adduct formation. 
 To obtain sparse pharmacokinetic (PK) data from plasma and urine of 
patients who have been on maintenance CBZ treatment to improve our 
understanding of CBZ metabolism and CBZ-protein adduct formation. 
 To study the effects of genetic polymorphisms in drug metabolising enzymes 
and transporter proteins on metabolism and adduct formation in patients 
receiving CBZ therapy. 
 Data from this study will subsequently be incorporated into a larger 
population PK model for CBZ. 
 
5.3.  Study Design 
The study will consist of two groups: 
Autoinduction group: 
It is intended that 8 patients with epilepsy who are newly commenced on CBZ 
therapy will complete the study. Subjects will be identified from the Walton Centre 
NHS Foundation Trust. Subjects will be required to attend the clinical research 
facility at the Walton Centre for blood and urine sampling. 
 
Maintenance group: 
It is intended that 150 plasma samples will be obtained from patients who have 
been receiving maintenance CBZ therapy at the same dosage for at least 4 weeks. 
Subjects will be identified from outpatient clinics at the Walton Centre NHS 
Foundation Trust. If a subject consents to participation then a blood sample will be 
taken by venepuncture and a spot urine sample collected.  
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5.4. Statistical Considerations 
The number of patients planned for this study is consistent with other studies of a 
similar nature.22,23 As this is a novel exploratory study to characterise metabolite 
and drug-protein conjugate formation it is difficult to provide an accurate sample 
size in advance. 
 
6. SUBJECTS AND SCREENING 
6.1. Source of Subjects 
The study population will consist of male or female patients age 18 or over and will 
be recruited from the Walton Centre NHS Foundation Trust. Subjects will be 
assigned trial numbers, in the order of their inclusion in the study which will be 
defined as the time they consent to participation. 
 
6.2. Inclusion Criteria  
Autoinduction group: 
 Subject is willing and able to give written informed consent 
 Subject is aged 18 or over 
 Subject is newly prescribed CBZ by their attending physician 
Maintenance group: 
 Subject is willing and able to give written informed consent 
 Subject is aged 18 or over 
 Subject has received CBZ therapy at the same dosage for at least 4 weeks 
 
6.3. Exclusion Criteria  
Autoinduction group: 
 Subject is not willing to take part or unable to give written informed consent 
 Subject has in the past 4 weeks received other medication that is a CYP3A4 
inducer or inhibitor (see study restrictions- section 7.2) 
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 Subject has any condition which in the opinion of the investigator will 
interfere with the study 
Maintenance group: 
 Subject is not willing to take part or unable to give written informed consent 
 Subject has any condition which in the opinion of the investigator will 
interfere with the study 
 
6.4. Screening Procedures 
Subjects will be identified from neurology clinics at the Walton Centre NHS 
Foundation Trust. Subjects will be asked if they are willing to take part following 
their clinic appointments. 
 
6.5. Subject Informed Consent Form 
Voluntary written informed consent will be obtained from each subject prior to 
performing any trial-related procedures. Each subject will be given both verbal and 
written information describing the nature and duration of the clinical trial. The 
informed consent process will take place under conditions where the subject has 
adequate time to consider the risks associated with his/her participation in the 
clinical trial. No trial procedures will be undertaken until subjects have signed an 
approved informed consent form (ICF) written in a language that is understandable 
to the subject. 
The Investigator’s local research and ethics committee (REC) - approved ICF will be 
personally signed and dated by the subject and the investigator or designee who 
conducted the informed consent discussion. Each subject will receive a copy of the 
signed and dated written ICF along with any other written information provided to 
the subject. 
The investigator is responsible for ensuring that informed consent is obtained from 
each subject in accordance with all applicable regulations and guidelines. The 
original signed ICF will be retained within the subject’s source documents. 
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7. STUDY CONDUCT 
7.1. Study Schedule 
Blood sampling of patients will take place at the clinical research facility at the 
Walton Centre NHS Foundation Trust. 
 
7.1.1. Patient Recruitment and Consent 
Autoinduction Group: 
Patients that are issued with a new prescription for carbamazepine will be 
identified and invited for a short consultation where the study will be explained and 
they will be provided with the patient information leaflet and consent form. If the 
patient is happy to consent at this time then this will be allowed. Otherwise, 
patients will be given at least 24 hours to decide and a member of the study team 
will contact the patient to determine if the patient is willing to participate. In the 
meantime the patient should be advised not to start CBZ therapy. Delaying CBZ 
therapy by up to 5 days will have no negative effects for patient care. 
 
Maintenance Group: 
Patients who have received carbamazepine treatment at the same dosage for at 
least 4 weeks will be identified and invited for a short consultation where the study 
will be explained and they will be provided with the patient information leaflet and 
consent form. If the patient is happy to consent at this time then this will be 
allowed because the study does not interfere with patient care and consists of 
venepuncture only. 
 
7.1.2. Autoinduction Group Visit Schedule 
7.1.2.1. Visit 1 
All potential participants will be asked to the clinical research facility at the Walton 
Centre NHS Foundation Trust at approximately 0800 on the first day that they are 
due to start CBZ treatment. During this visit subjects will be consented (if not 
already completed). They will also undertake a brief interview with physical 
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examination and blood and urine sampling according to the timeline below. Blood 
samples will be sent for full blood count (FBC), urea & electrolytes (U&E), liver 
function tests (LFT) and analysis of genetic polymorphisms in drug metabolism and 
transporter proteins. Patients will be allowed to leave the unit after the 8 hour 
blood sample and return the following morning for the 24 hour blood sample. 
Patients will also be asked to provide a 24 hour urine sample. After this visit 
subjects will be advised to continue carbamazepine as prescribed by their physician 
and will be given the date to return for their next blood sampling appointment. 
1. Consent Written and verbal consent for inclusion into study 
2. Interview (a) Past medical history 
(b) Concomitant medications 
(c) Carbamazepine – dosage, frequency, formulation, 
time of last dosage 
(d) Social history – smoking, alcohol and ethnicity 
(including parents) 
(e) Contact details - GP 
3. Physical 
Examination 
(a) Height and Weight 
(b) Body mass index 
4. Cannulate and 
blood sampling 
at time=0 
(a) 2 x 9ml EDTA tube (FBC, Genetic polymorphisms) 
(b) 1 x 9ml serum gel tube (U&E, LFT) 
(c) 1 x 5ml Li Heparin tube (CBZ, metabolite and adducts) 
5. CBZ 
administration 
(a) Administer CBZ 
4. Blood Sampling Blood sampling from cannula into 1 x 5ml Li heparin tube 
at the following times: 
 1 hour post dose 
 2 hours post dose 
 4 hours post dose 
 6 hours post dose 
 8 hours post dose 
5. Urine Sampling (a) 1 x 24 hour urine sample 
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7.1.2.2. Visit 2 
Subjects will be asked to return to the Walton Centre on day 2 following 
commencement of CBZ when they will undergo the following consultation: 
1. Interview (a) Ensure patient happy to continue with study 
(b) Concomitant medications 
(c) Carbamazepine – dosage, frequency and formulation 
2. Blood Sampling Blood sampling by venepuncture into 1 x 5ml Li heparin 
tube prior to administration of CBZ (pre dose) 
3. Urine Sampling (a) 1 x 24 hour urine sample 
 
7.1.2.3. Visit 3 
Subjects will be asked to return to the Walton Centre on day 14 after starting CBZ 
when the following consultation will take place: 
1. Interview (a) Ensure patient happy to continue with study 
(b) Concomitant medications 
(c) Carbamazepine – dosage, frequency and formulation 
2. Cannulation 
and Blood 
Sampling 
Blood sampling from cannula into 1x 5ml Li heparin tube at 
the following times 
 0 hours (pre dose) then administer CBZ 
 1 hour post dose 
 2 hours post dose 
 4 hours post dose 
 6 hours post dose 
 8 hours post dose 
3. Urine Sampling (a) 1 x 24 hour urine sample 
 
7.1.2.4. Visit 4 
Subjects will be asked to return to the Walton Centre on day 28 after starting CBZ 
when the following consultation will take place.  
1. Interview (a) Ensure patient happy to continue with study 
(b) Concomitant medications 
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(c) Carbamazepine – dosage, frequency and formulation 
2. Cannulation 
and Blood 
Sampling 
Blood sampling from cannula into 1x 5ml Li heparin tube at 
the following times 
 0 hours (pre dose) then administer CBZ 
 1 hour post dose 
 2 hours post dose 
 4 hours post dose 
 6 hours post dose 
 8 hours post dose 
3. Urine Sampling (a) 1 x 24 hour urine sample 
 
 
7.1.2.5. Visit 5 
Subjects will be asked to return to the Walton Centre on day 42 since starting CBZ 
for the following consultation.  
 
7.1.2.6. Visit Schedule Variations 
If subjects are not able to attend on the exact dates outlined above then they will 
be allowed to reschedule appointments up to 48 hours before and after the 
specified date. 
1. Interview (a) Ensure patient happy to continue with study 
(b) Concomitant medications 
(c) Carbamazepine – dosage, frequency and formulation 
2. Cannulation 
and Blood 
Sampling 
Blood sampling from cannula into 1 x 5ml Li heparin tube at 
the following times: 
 0 hours (pre dose) then administer CBZ 
 1 hour post dose 
 2 hours post dose 
 4 hours post dose 
 6 hours post dose 
 8 hours post dose 
3. Urine Sampling (a) 1 x 24 hour urine sample 
 393 
 
7.1.3 Maintenance Group Visit Schedule 
7.1.3.1 Visit 1 
Once a patient has consented for the study two blood samples will be taken by 
venepuncture and a spot urine sample collected. A short interview will be 
conducted to ascertain patient demographics, past medical history, concurrent 
medications and social history. A brief physical examination will also be undertaken 
to determine the subject’s height and weight. 
1. Consent Written and verbal consent for inclusion into study 
2. Interview (a) Past medical history 
(b) Concomitant medications 
(c) Carbamazepine – dosage, frequency, formulation, 
time of last dosage 
(d) Social history – smoking, alcohol and ethnicity 
(including parents) 
3. Physical 
Examination 
(a) Height and Weight 
(b) Body mass index 
4. Venepuncture (a) 1 x 9ml EDTA tube (Genetic polymorphisms) 
(b) 1 x 5ml Li Heparin tube (CBZ, metabolite and 
adducts) 
(c) 1 x 5ml serum gel tube (U&E, LFTs) 
5. Urine Sampling (b) 1 x spot urine sample 
 
7.1.3.2 Subsequent Visits 
If the same subject presents to the Walton Centre for further clinic visits then they 
will be allowed to donate further blood and urine samples as long as they are happy 
to do so. The original consent will be valid for one year. If a patient presents more 
than one year after their initial consent then they will be re-consented for the 
study. 
 
7.2  Study Restrictions (applicable only to autoinduction group) 
7.2.1   Concurrent Medication  
Participants will be expected to complete all 5 visits for blood and urine sampling. 
CBZ is metabolised by CYP3A4 and other drugs may influence its metabolism 
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through induction or inhibition of CYP3A426. Therefore, patients will be excluded 
from the study if they have taken any of the following list of medications in the past 
4 weeks: 
Inducers Inhibitors   
Rifampicin Amiodarone Fluvoxamine Saquinavir 
Rifampin Amprenavir Indinavir S-Verapamil 
Isoniazid Atazanavir Lopinavir Verapamil 
Phenytoin Azithromycin Mifepristone  
Phenobarbital Grapefruit juice Nelfinavir  
Omeprazole Clarithromycin Norverapamil  
Clotrimazole Cyclosporine A Ritonavir  
HMG-CoA reductase 
inhibitors 
Delavirdine N-
desmethylerythromycin 
 
Cyclophosphamide Erythromycin Roxithromycin  
Spironolactone Fluoxetine R-Verapamil  
 
7.2.2    Diet 
Seville oranges, grapefruits and grapefruit juice are known inhibitors of CYP3A4. 
Subjects will be asked to avoid consuming these substances for the study period. 
 
7.2.3 Alcohol 
Subjects will be advised to adhere to the government recommendations for alcohol 
intake for the duration of the study. For men that is 3-4 units per day and women 2-
3 units per day.  
 
7.3 Methods for Clinical Procedures 
7.3.1 Blood Sampling 
This study will be conducted with close attention to patient safety. Venepuncture 
and cannulation poses minimal risk of bruising or bleeding. This procedure will be 
carried out by trained, competent health professionals. 
Blood samples for determination of CBZ, CBZ metabolites and CBZ-protein 
conjugates and genetic polymorphisms will be collected via a cannula or direct 
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venepuncture. Prior to each sample being taken from the cannula 0.5mls of blood 
will be drawn and discarded. The cannula will be flushed with 2mls of 0.9% saline 
each time a sample is taken. Blood samples will be centrifuged within 15 minutes of 
collection or stored overnight at 4oC for centrifuge the following day. 1ml and 
350µL aliquots will then be transferred to appropriate tubes and stored at 
approximately -80oC prior to bioanalysis. 
In the autoinduction group no more than 35mls of blood will be extracted at time 0 
on day one and no more than 5mls for each subsequent sampling on day one. Over 
a 24 hour period no more than 65mls of blood will be sampled. Total volume of 
blood sampled for the autoinduction group will be approximately 155mls. 
In the maintenance group no more than 20mls of blood will be extracted at each 
visit. 
 
7.3.2 Urine Sampling 
Subjects in the autoinduction group will be asked to provide a 24 hour urine sample 
at each visit. The samples will be stored at -20oC for metabolite and carbamazepine-
protein conjugate analysis. 
Subjects in the maintenance group will be asked to provide a spot urine sample at 
each visit. The samples will be stored at -20oC for metabolite and carbamazepine-
protein conjugate analysis. 
 
7.4 Laboratory Evaluations 
7.4.1 Haematology 
Blood samples will be taken into EDTA tube for full blood count. 
7.4.2 Biochemistry 
Blood samples will be taken into serum gel tube for urea and electrolytes and liver 
function tests.  
7.4.3 Analysis of Genetic Polymorphisms 
Blood samples will be taken into EDTA tube for identification of polymorphisms in 
drug metabolising enzymes and drug transporter proteins. 
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7.5 CBZ Metabolite and CBZ-Protein Conjugate Analysis 
High sensitivity mass spectrometry techniques already in use at the MRC Centre for 
Drug Safety Science at the University of Liverpool will be utilised to characterise and 
quantify CBZ metabolites and CBZ-protein conjugates. 
7.6 Sample Storage 
All samples will be transferred/delivered in appropriate packaging in dry ice (solid 
carbon dioxide) to the University of Liverpool, Department of Pharmacology 
Laboratories. Samples will be stored securely as described above and the University 
will act as custodian. 
7.7 End of Study 
The end of study is defined as the last scheduled protocol activity of the last subject 
in the study. The conclusion of the study will be notified by the University of 
Liverpool to the Ethics Committee within the required timelines. All research data 
will be archived at the University of Liverpool for at least 15 years. 
 
7.8 Criteria for Termination of the Study 
There are no criteria for termination of the study. Details regarding the withdrawal 
of subjects are given in section 10. 
 
8. CASE REPORT FORMS 
Paper case report forms (CRFs) will be used for recording all data collected during 
the study. All CRFs are to be completely filled out by personnel administering the 
study procedures and reviewed and signed by the chief investigator or nominated 
designee. All CRFs are to be completed in a clear and legible manner. Black ink must 
be used to ensure accurate interpretation of data. Any changes or corrections must 
be made by drawing a line through the data to be changed, entering corrected 
information, and signing (or initialling) and dating the change. Erasing, overwriting, 
or the use of “liquid paper” is not permitted on CRFs. Every effort should be made 
to have the CRFs completed as soon as possible following a subject’s study visit. All 
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data from the recruited patients will be transcribed onto an electronic spreadsheet. 
All study documentation as defined above will be made available to the Ethics 
Committee and to regulatory authorities for inspection on request. 
 
9. SAFETY ASSESSMENT AND ADVERSE EVENT REPORTING 
An adverse event (AE) is defined as any undesirable event occurring to a subject 
during a clinical study. All adverse events will be coded and reported as follows: 
 Mild:  Awareness of sign or symptom but easily tolerated 
 Moderate: Discomfort enough to cause interference with usual activity 
 Severe:  Incapacitating with inability to work or do usual 
activity 
Laboratory results that are outside the normal range will be recorded as an adverse 
event. The severity of each event will be assessed by the investigator. When 
recording the outcome of the adverse event its maximum severity will also be 
recorded. Adverse events, if any, not resolved by the end of the study, will be 
followed up by the investigator.  
 
Serious adverse events (SAE) or suspected unexpected serious adverse reactions 
(SUSAR) are defined as any adverse event that results in death, is life-threatening, 
requires hospitalisation, results in persistent or significant disability or incapacity 
and consists of a congenital anomaly or birth defect. . All SAEs possibly or probably 
definitely related to CBZ or to the study procedure(s) will be reported by the 
investigator to the Sponsor within 24 hours of when he or she becomes aware of it. 
The investigator must inform the Sponsor of any follow-up information on a 
previously reported SAE immediately, or no later than 24 hours of when he or she 
becomes aware of it. SUSARs that are fatal or life-threatening will be reported to 
the MHRA as soon as possible but no later than 7 days. SUSARs which are not fatal 
or life-threatening will be reported to the MHRA as soon as possible but no later 
than 15 days. Causality for SAEs and SUSARs will be checked against the SmPc. All 
SAE and SUSAR will be managed according to the Royal Liverpool University 
Hospital research and development standard operating procedures. 
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10. WITHDRAWAL OF SUBJECTS 
Subjects will be informed that they are free to withdraw from the study at any time. 
The investigator may remove a subject if, in his opinion, it is in the best interest of 
the subject. Although a subject is not obliged to give his reason for premature 
withdrawal, the investigator will make a reasonable effort to obtain the reason 
while fully respecting the subject’s rights. If there is a medical reason for 
withdrawal of the subject then this will be reported as an adverse event and 
followed up by the investigator. If in the opinion of the investigator it is considered 
necessary, the subject’s GP will be informed of the medical reason for the 
withdrawal. The subject’s consent will be obtained prior to informing the GP. 
Subjects that withdraw consent or are withdrawn at the discretion of the 
investigator prior to completion of study procedures may be replaced to ensure 
that there are 8 evaluable subjects. 
 
11. DATA ANALYSIS 
Initially descriptive statistics will be used to analyse the data. Subsequently a 
population pharmacokinetic model will be generated using the software NONMEM 
(non-linear mixed effects modelling). 
 
12. RECORDS AND CONFIDENTIALITY 
12.1 Records 
Adequate records as required as required by ICH GCP will be maintained for the 
study. This includes medical records, case report forms, laboratory reports, signed 
consent forms, and worksheets. All records from the study will be kept for 15 years. 
12.2 Confidentiality 
To maintain subject privacy, all case report forms, study reports and 
communications will identify the subject by initials where permitted and/or by the 
assigned subject number. The subject’s confidentiality will be maintained and will 
not be made publicly available to the extent permitted by the applicable laws and 
regulations. 
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12.3 Publication 
The results of the study will be incorporated into scientific papers for publication. 
All identifiable patient information will be removed.  Appropriate precautions will 
be taken to maintain confidentiality of medical records and personal information. 
 
APPENDIX A 
13.1 Summary of Study Visits for Autoinduction Group 
 Day 1 Day 2 Day 14 Day 28 Day 42 
 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 
Informed consent X     
Interview X X X X X 
Medication review X X X X X 
Physical examination X     
Cannulation X  X X X 
Safety bloods X     
Bloods for genetic 
variation 
X     
Carbamazepine blood 
test 
X X X X X 
24 hour urine sample  X X X X 
Adverse event 
monitoring 
X X X X X 
 
13.2  Summary of Study Visits for Maintenance Group 
 Visit 1 Subsequent Visits  
Informed consent X Not necessary if within 1 year 
Interview X X 
Medication review X X 
Physical examination X X 
Blood test for genetic variation X  
Carbamazepine blood test X X 
Spot urine sample X X 
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A PHARMACOKINETIC INVESTIGATION INTO THE FORMATION OF 
CARBAMAZEPINE METABOLITES AND CARBAMAZEPINE-PROTEIN CONJUGATES IN 
EPILEPSY PATIENTS 
Participation Information Sheet (Auto-Induction Group) 
Invitation 
You are being invited to participate in a research study because you have been 
newly prescribed carbamazepine by your doctor. Before you decide it is important 
for you to understand why the research is being done and what it will involve. 
Please take time to read this sheet carefully and discuss it with relatives, friends 
and the study team. You may also wish to discuss this with your GP. Ask us about 
anything that is not clear and take time to decide whether or not you wish to take 
part. 
 
What is the purpose of the study? 
This study is looking at the formation of breakdown products produced by the body 
following carbamazepine ingestion and how genetic variation affects this process. 
Carbamazepine is a medication that is used to treat epilepsy, trigeminal neuralgia 
and some psychiatric conditions. We know that some patients develop adverse 
reactions, which are termed hypersensitivity reactions, to carbamazepine. These 
hypersensitivity reactions include skin rash, fever and lethargy, and usually occur 
with multiple doses. At the moment we do not know what causes these 
hypersensitivity reactions but we believe that they are caused by the way the body 
handles carbamazepine and forms breakdown products.  These breakdown 
products (also called metabolites) then cause hypersensitivity reactions in 
genetically susceptible patients. The main purpose of this study is to find out how 
genetic variation can affect the formation of carbamazepine metabolites. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part in the study. Participation is 
entirely voluntary. If you do decide to participate you will be given this information 
sheet to keep and be asked to sign a consent form. You will receive a copy of this 
signed consent form to keep. If you decide to take part you are still free to 
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withdraw at any time and without giving a reason. This will not affect the standard 
of care you receive. 
 
What will happen to me if I take part? 
You will be given sufficient time to consider whether or not you wanted to take 
part. If you agree to take part in the study you will be required to make 5 visits to 
the Walton Centre. For each visit you will be asked to donate blood and urine 
samples. Each visit will take at least 8 hours. During the study you will be asked to 
take your carbamazepine as prescribed by your doctor. The first visit will take place 
on the same day as you take your first tablet of carbamazepine. Subsequent visits 
will take place on days 2, 14, 28 and 42 following commencement of treatment. 
 
During the study you will not be able to eat grapefruit or pommello oranges or any 
product that contains grapefruit or pommello oranges. 
If you need to take any other medication you should contact the study team before 
taking it. You are not allowed to take any interacting prescription or non-
prescription drug, recreational drugs (cannabis, cocaine), or dietary supplements. 
You are allowed to take paracetamol and multi-vitamins. 
During the study we will ask you to adhere to the governments recommendations 
with regards to alcohol consumption. For men that is 3-4 units per day and women 
2-3 units per day. 
 
During the study visits you will be studying in the clinical research unit at the 
Walton Centre. You will have your own room and bed. There is also a common 
room where a TV is available. Wi-Fi is available throughout the unit and you are 
free to bring laptops or tablets. Breakfast and lunch are provided with unlimited 
tea and coffee throughout the day. 
 
Visit 1 
Please do not take your first dose of carbamazepine before your first visit. Your 
details will be checked against your clinical notes and we will record your age, 
ethnic group, past medical problems and details of any medication you are taking. A 
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clinical examination will be undertaken. If you are suitable to take part in the study 
we will insert a small tube (cannula) into a blood vessel and take blood samples for 
full blood count, kidney and liver function and genetic variation in the proteins 
responsible for metabolism of carbamazepine. We will then ask you to take your 
first carbamazepine tablet. Blood will be taken from the cannula at regular intervals 
following the carbamazepine dose at 1 hour, 2 hours, 4 hours, 6 hours and 8 hours. 
We will also ask you to keep a 24 hour urine collection. The total amount of blood 
taken will be approximately 65mls. You will be allowed home following the 8 hour 
blood sample and the cannula will be removed. 
 
Visit 2 
You will be asked to return to the clinical research facility the following morning, 24 
hours after taking your first carbamazepine tablet. Please do not take the 2nd dose 
of carbamazepine before this visit. We will undertake a brief interview, take a single 
blood sample and ask you to return your first 24 hour urine sample bottle. You will 
be given a new 24 hour urine bottle to collect urine on the day before (day 6) you 
are due for the next visit. Visit 2 will last approximately 30 minutes. 
 
Visit 3 
Visit 3 will take place on day 14 after starting carbamazepine therapy. You will be 
asked to omit your carbamazepine tablet that morning and to return to the clinical 
research facility with your completed 24 hour urine collection bottle.  A brief 
interview will be undertaken and a cannula will be inserted and a blood sample 
taken from it. Following this you will be given your carbamazepine tablet and blood 
will be taken at 1 hour, 2 hours, 4 hours, 6 hours and 8 hours from the cannula. The 
total amount of blood taken will be approximately 30mls. We will provide you with 
a 24 hour urine sample bottle to complete the day before (day 20) you are due to 
return for your next visit.  
 
Visit 4 
Visit 4 will take place on day 28 after starting carbamazepine therapy. You will be 
asked to omit your carbamazepine tablet that morning and to return to the clinical 
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research facility with your completed 24 hour urine collection bottle.  A brief 
interview will be undertaken and a cannula will be inserted and a blood sample 
taken from it. Following this you will be given your carbamazepine tablet and blood 
will be taken at 1 hour, 2 hours, 4 hours, 6 hours and 8 hours from the cannula. The 
total amount of blood taken will be approximately 30mls. We will provide you with 
a 24 hour urine sample bottle to complete the day before (day 27) you are due to 
return for your next visit. 
 
Visit 5 
This is the final study visit and will take place on day 42 after starting 
carbamazepine therapy. You will be asked to omit your carbamazepine tablet that 
morning and to return to the clinical research facility with your completed 24 hour 
urine collection bottle.  A brief interview will be undertaken and a cannula will be 
inserted and a blood sample taken from it. Following this you will be given your 
carbamazepine tablet and blood will be taken at 1 hour, 2 hours, 4 hours, 6 hours 
and 8 hours from the cannula. The total amount of blood taken will be 
approximately 30mls.  
 
Visit Schedule Variations 
If you are unable to attend appointments on the dates outlined above then you will 
be allowed to reschedule them up to 48 hours before the specified date. 
 
Withdrawal Visit 
If you decide to stop the study before the end you will need to attend for a final 
visit. We will check your pulse, blood pressure and temperature. 
 
What are the possible side effects/risks of taking part? 
You may have side effects whilst taking part in this study. However, we will monitor 
everyone in the study for side effects. If you are worried about your symptoms then 
you can contact the study team at any time. You will be given contact numbers of 
the study team. 
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Carbamazepine side effects 
Dizziness, ataxia (loss of co-ordination), double vision, drowsiness, and nausea and 
vomiting may occur with single doses in about 10% of people.  However, these are 
usually short lasting. Other side effects which have been reported with 
carbamazepine include low platelets, fluid retention, dry mouth, elevated liver 
enzymes and skin rashes.  
 
Abnormal blood test results 
If any blood tests taken during your participation in the study are abnormal then we 
will invite you back to the clinical research facility to explain the results to you. We 
will also ensure that you are referred to the appropriate clinician for further 
management. 
 
Other possible risks 
When you give blood you may feel faint or experience bruising or tenderness at the 
site of the needle puncture. You will be required to remain in hospital for 8 hours 
during study visits 1, 3, 4 and 5 which may cause inconvenience. 
 
What are the benefits of taking part? 
There will  be no direct benefits to you by taking part in the study. However, in the 
long-term, the information we get from this study may help improve the treatment 
of people with carbamazepine. 
 
What happens if something goes wrong? 
If you are unhappy with any aspect of the study then complaints should be made to 
the chief investigator in the first instance. There are no special compensation 
arrangements. If you are harmed because of negligence then you may have grounds 
for legal action but you may have to pay for it. Regardless of this, if you have any 
cause to complain about any aspect of the way you have been approached or 
treated during the course of the study, the normal National Health Service 
complaints mechanisms are available to you. 
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Will my taking part in this study be kept confidential? 
All the information collected about you during the course of the study will be kept 
strictly confidential. Any information about you which leaves the clinic will have 
your name and address removed so that you cannot be recognised from it. All 
samples will be coded and anonymised. All identifying details (e.g. name, address, 
date of birth) will be removed, but the sample will remain linked to data collected 
from this study (e.g. weight, age). Your medical records may be inspected by 
research staff for the purposes of checking that the information we have is accurate 
and complete. We will seek your consent to notify your GP about your participation 
in this study. 
 
What will happen to my samples? 
Your blood and urine samples will be analysed for levels of carbamazepine and its 
breakdown products.  We will look at genes in your DNA samples to see how this 
determines the way your body handles carbamazepine. If during the study you lose 
capacity then any samples we have collected will still be analysed but no further 
samples will be taken. 
 
What happens when the research study stops? 
You will be asked if we can store the samples from this study for use in other 
research projects. The samples will be kept in a locked freezer in the University of 
Liverpool. ALL THESE SAMPLES WILL BE CODED (but will be linked to details that we 
will collect about your drug levels). We will keep your sample until all of it is used 
up. The samples will be considered a gift to the University of Liverpool, which will 
act as a custodian of all the samples obtained as part of this project. Rarely, a small 
amount of your sample may be provided to other researchers in the UK or other 
parts of the world. However, it is important to remember that this will only be 
identified by a unique code, and your name will not be given out. 
We are asking for your permission to store your samples and linked details for 
these future studies. Your samples will not be sold for profit. (It is not the purpose 
of this study to produce commercial gain, and in any case, any commercial value in 
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the future will only come from findings in groups of people rather than from 
samples from a single person). 
Once the studies are completed your anonymised data will be kept for a minimum 
of 15 years. 
 
What will happen to the results of the study? 
We will combine all the results from the subjects taking part in the study, and 
publish any important results in medical journals. Results may also be presented at 
scientific meetings. No individuals will be specifically identified in any publication. 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the area that is being studied. We will share this information with 
you right away if it is important to your health. If you have any concerns about it 
you should discuss this with the research team. 
 
Who is funding the research? 
This study is funded by the Medical Research Council. 
 
Who has reviewed the study? 
This study has been reviewed by the National Research Ethics Service Committee 
North West – Haydock 
 
Reimbursement 
You will be reimbursed a total of £200 on completion of the study. In addition, 
travel arrangements will also be reimbursed. If required travel arrangements can 
be organised with the Walton Centre NHS Foundation Trust. If you withdraw 
before completion of the study you will be reimbursed for the time you 
participated. You will be reimbursed £40 for each visit. Withdrawal of consent or 
violation of the protocol may, however, result in partial or complete forfeiture of 
compensation. Protocol violation is defined as the disobeying of instructions 
communicated verbally or in writing. You will be asked to provide details of your 
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bank account so this payment can be made. You will be responsible for paying tax 
on any payment received. 
 
Involvement of your General Practitioner 
With your permission, your general practitioner will be informed that you are taking 
part in the study and may be contacted to confirm your past medical history. Your 
signature on the consent form will authorise the study team to do this. 
 
For further information on this study please contact: 
Dr Vincent Yip, MRC Clinical Fellow in Clinical Pharmacology and Therapeutics, 
Department of Molecular and Clinical Pharmacology, The Wolfson Centre for 
Personalised Medicine, The University of Liverpool, L69 3GL 
0151 795 5407 
vyip@liv.ac.uk 
Study Investigator ______________________________ 
Tel Number  ______________________________ 
E-mail   ______________________________ 
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Summary of Study Visits 
 Day 1 Day 2 Day 14 Day 28 Day 42 
 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 
Informed consent X     
Interview X X X X X 
Medication review X X X X X 
Physical examination X     
Cannula X  X X X 
Safety blood tests X     
 Blood tests for 
genetic variation 
X     
Carbamazepine 
blood test 
X X X X X 
24 hour urine sample  X X X X 
Adverse event 
monitoring 
X X X X X 
 
Thank you for reading this. This sheet (and a copy of the consent form) should be 
retained by you if you decide to participate. 
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A PHARMACOKINETIC INVESTIGATION INTO THE FORMATION OF 
CARBAMAZEPINE METABOLITES AND CARBAMAZEPINE-PROTEIN CONJUGATES IN 
EPILEPSY PATIENTS 
Participant Consent Form (Autoinduction Group) 
The volunteer should complete the whole of this sheet himself/herself 
Thank you for reading the information about our research project. If you would 
like to take part, please read and sign this form. 
Participant identification number:  _______________________ 
Name of Researcher:   _______________________ 
Contact Details for Research Team: _______________________ 
 
PART 1        Please initial boxes 
1. I confirm that I have read and understand the information sheet dated 
________________for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
2. I agree to give blood samples for research in this project. I understand 
how the samples will be collected, that giving samples for this research is 
voluntary and that I am free to withdraw at any time without giving any 
reason, without medical care or legal rights being affected. 
 
3. In the (unlikely) event that I lose capacity to consent during the study I 
understand that I will be withdrawn from the study. The samples that I 
have provided for the study up to this point will be retained and used for 
research as outlined in the study information sheet. 
 
4. I understand that once the study has ended the samples will be fully 
anonymised and once gifted to the University of Liverpool cannot be 
withdrawn. 
 
5. I understand that relevant sections of my study records and data 
collected during the study may be looked at by individuals from 
regulatory authorities or from the NHS Trust, where it is relevant to my 
taking part in this research. I give permission for these individuals to have 
access to my records.  
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I understand that I will not benefit financially if this research leads to the 
development of a new medical test. 
 
6. I agree to my GP being informed of my participation in the study and I 
understand that the GP may be contacted to confirm my past medical 
history. 
 
7. I know how to contact the research team if I need to, and how to get 
information about the results of the research. 
 
8. I  agree to take part in the above study 
 
10. I understand that I will receive up to £280 for participating in this study. 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept 
in medical notes. 
 
 
 
________________ 
Name of patient 
(BLOCK CAPITALS) 
 
 
________________ 
Date 
 
 
_________________ 
Signature 
 
 
_________________ 
Name of person 
taking consent (if 
different from 
researcher) 
 
 
_________________ 
Date 
 
 
_________________ 
Signature 
 
 
_______________ 
Name of Researcher 
 
 
 
________________ 
Date 
 
 
_________________ 
Signature 
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PART 2 
9. Consent for storage and use in possible future research projects 
I agree that the samples I have given and the information gathered 
about me can be stored by the University of Liverpool for possible use in 
future projects as described in the attached information sheet. I 
understand that some of these projects may be carried out by 
researchers other than the University of Liverpool Pharmacology 
department who ran the first project. 
 
 
_________________ 
Name of patient 
(BLOCK CAPITALS) 
 
 
_________________ 
Date 
 
 
_________________ 
Signature 
 
 
_________________ 
Name of person 
taking consent (if 
different from 
researcher) 
 
 
_________________ 
Date 
 
 
_________________ 
Signature 
 
 
_______________ 
Name of Researcher 
 
 
 
________________ 
Date 
 
 
__________________ 
Signature 
 
Thank you for agreeing to participate in this research. 
Prof A Marson, Department of Molecular and Clinical Pharmacology, Block 
A: Wolfson Centre for Personalised Medicine, University of Liverpool, 
Liverpool L69 3GL 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to 
be kept in medical notes 
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A PHARMACOKINETIC INVESTIGATION INTO THE FORMATION OF 
CARBAMAZEPINE METABOLITES AND CARBAMAZEPINE-PROTEIN CONJUGATES IN 
EPILEPSY PATIENTS 
Participation Information Sheet (Maintenance Group) 
Invitation 
You are being invited to participate in a research study because you are prescribed 
carbamazepine by your doctor. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take 
time to read this sheet carefully and discuss it with relatives, friends and the study 
team. You may also wish to discuss this with your GP. Ask us about anything that is 
not clear and take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
This study is looking at the formation of breakdown products produced by the body 
following carbamazepine ingestion and how genetic variation affects this process. 
Carbamazepine is a medication that is used to treat epilepsy, trigeminal neuralgia 
and some psychiatric conditions. We know that some patients develop adverse 
reactions, which are termed hypersensitivity reactions, to carbamazepine. These 
hypersensitivity reactions include skin rash, fever and lethargy, and usually occur 
with multiple doses. At the moment we do not know what causes these 
hypersensitivity reactions but we believe that they are caused by the way the body 
handles carbamazepine and forms breakdown products.  These breakdown 
products (also called metabolites) then cause hypersensitivity reactions in 
genetically susceptible patients. The main purpose of this study is to find out how 
genetic variation can affect the formation of carbamazepine metabolites. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part in the study. Participation is 
entirely voluntary. If you do decide to participate you will be given this information 
sheet to keep and be asked to sign a consent form. You will receive a copy of this 
signed consent form to keep. If you decide to take part you are still free to 
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withdraw at any time and without giving a reason. This will not affect the standard 
of care you receive. 
 
What will happen to me if I take part? 
You will be given sufficient time to consider whether or not you wanted to take 
part. If you agree to take part in the study you will be required to donate 2 blood 
samples and one urine sample.  
 
Visit 1 
If you agree to take part in the study immediately then we will collect a blood and 
urine sample on straight after your clinic appointment. The total amount of blood 
taken will be approximately 20mls. 
 
Subsequent Visits 
You may be asked to donate further blood samples for this study if you are 
attending the Walton Centre for other clinic appointments. We will ask your 
permission and if it is within 1 year of your first blood sample donation then we 
will not need to obtain consent again. 
 
What are the possible side effects/risks of taking part? 
When you give blood you may feel faint or experience bruising or tenderness at the 
site of the needle puncture. However, these risks will be minimised because only 
trained health professionals will be permitted to take your blood. 
 
What are the benefits of taking part? 
There will be no direct benefits to you by taking part in the study. However, in the 
long-term, the information we get from this study may help improve the treatment 
of people with carbamazepine. 
 
What happens if something goes wrong? 
If you are unhappy with any aspect of the study then complaints should be made to 
the chief investigator in the first instance. There are no special compensation 
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arrangements. If you are harmed because of negligence then you may have grounds 
for legal action but you may have to pay for it. Regardless of this, if you have any 
cause to complain about any aspect of the way you have been approached or 
treated during the course of the study, the normal National Health Service 
complaints mechanisms are available to you. 
 
Will my taking part in this study be kept confidential? 
All the information collected about you during the course of the study will be kept 
strictly confidential. Any information about you which leaves the clinic will have 
your name and address removed so that you cannot be recognised from it. All 
samples will be coded and anonymised. All identifying details (e.g. name, address, 
date of birth) will be removed, but the sample will remain linked to data collected 
from this study (e.g. weight, age). Your medical records may be inspected by 
research staff for the purposes of checking that the information we have is accurate 
and complete. We will seek your consent to notify your GP about your participation 
in this study. 
 
What will happen to my samples? 
Your blood and urine samples will be analysed for levels of carbamazepine and its 
breakdown products.  We will look at genes in your DNA samples to see how this 
determines the way your body handles carbamazepine. If during the study you lose 
capacity then any samples we have collected will still be analysed but no further 
samples will be taken. 
 
What happens when the research study stops? 
You will be asked if we can store the samples from this study for use in other 
research projects. The samples will be kept in a locked freezer in the University of 
Liverpool. ALL THESE SAMPLES WILL BE CODED (but will be linked to details that we 
will collect about your drug levels). We will keep your sample until all of it is used 
up. The samples will be considered a gift to the University of Liverpool, which will 
act as a custodian of all the samples obtained as part of this project. Rarely, a small 
amount of your sample may be provided to other researchers in the UK or other 
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parts of the world. However, it is important to remember that this will only be 
identified by a unique code, and your name will not be given out. 
 
We are asking for your permission to store your samples and linked details for 
these future studies. Your samples will not be sold for profit. (It is not the purpose 
of this study to produce commercial gain, and in any case, any commercial value in 
the future will only come from findings in groups of people rather than from 
samples from a single person). 
 
Once the studies are completed your anonymised data will be kept for a minimum 
of 15 years. 
 
What will happen to the results of the study? 
We will combine all the results from the subjects taking part in the study, and 
publish any important results in medical journals. Results may also be presented at 
scientific meetings. No individuals will be specifically identified in any publication. 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the area that is being studied. We will share this information with 
you right away if it is important to your health. If you have any concerns about it 
you should discuss this with the research team. 
 
Who is funding the research? 
This study is funded by the Medical Research Council. 
 
Who has reviewed the study? 
This study has been reviewed by the National Research Ethics Service Committee 
North West – Haydock 
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Involvement of your General Practitioner 
With your permission, your general practitioner will be informed that you are taking 
part in the study and may be contacted to confirm your past medical history. Your 
signature on the consent form will authorise the study team to do this. 
 
For further information on this study please contact: 
Dr Vincent Yip, MRC Clinical Fellow in Clinical Pharmacology and Therapeutics, 
Department of Molecular and Clinical Pharmacology, The Wolfson Centre for 
Personalised Medicine, The University of Liverpool, L69 3GL 
0151 795 5407 
vyip@liv.ac.uk 
Study Investigator ______________________________ 
Tel Number  ______________________________ 
E-mail   ______________________________ 
 
Summary of Study Visits 
 Visit 1 Subsequent Visits  
Informed consent X Not necessary to re-consent if within 1 year 
Interview X X 
Medication review X X 
Physical examination X X 
 Blood tests for 
genetic variation 
X X 
Carbamazepine blood 
test 
X X 
Spot urine sample X X 
 
Thank you for reading this. This sheet (and a copy of the consent form) should be 
retained by you if you decide to participate. 
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A PHARMACOKINETIC INVESTIGATION INTO THE FORMATION OF 
CARBAMAZEPINE METABOLITES AND CARBAMAZEPINE-PROTEIN CONJUGATES IN 
EPILEPSY PATIENTS 
Participant Consent Form (Maintenance Group) 
The volunteer should complete the whole of this sheet himself/herself 
Thank you for reading the information about our research project. If you would 
like to take part, please read and sign this form. 
Participant identification number:  _______________________ 
Name of Researcher:   _______________________ 
Contact Details for Research Team: _______________________ 
 
PART 1         Please initial boxes 
1. I confirm that I have read and understand the information sheet dated 
________________ for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
2. I agree to give blood samples for research in this project. I understand 
how the samples will be collected, that giving samples for this research is 
voluntary and that I am free to withdraw at any time without giving any 
reason, without medical care or legal rights being affected. 
 
3. In the (unlikely) event that I lose capacity to consent during the study I 
understand that I will be withdrawn from the study. The samples that I 
have provided for the study up to this point will be retained and used for 
research as outlined in the study information sheet. 
 
4. I understand that once the study has ended the samples will be fully 
anonymised and once gifted to the University of Liverpool cannot be 
withdrawn. 
 
5. I understand that relevant sections of my study records and data 
collected during the study may be looked at by individuals from 
regulatory authorities or from the NHS Trust, where it is relevant to my 
taking part in this research. I give permission for these individuals to have 
access to my records.  
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6. I understand that I will not benefit financially if this research leads to the 
development of a new medical test. 
 
7. I agree to my GP being informed of my participation in the study and I 
understand that the GP may be contacted to confirm my past medical 
history. 
 
8. I know how to contact the research team if I need to, and how to get 
information about the results of the research. 
 
9. I  agree to take part in the above study 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept 
in medical notes. 
 
 
________________ 
Name of patient 
(BLOCK CAPITALS) 
 
 
_________________ 
Date 
 
 
_________________ 
Signature 
 
 
_________________ 
Name of person 
taking consent (if 
different from 
researcher) 
 
 
_________________ 
Date 
 
 
_________________ 
Signature 
 
 
_______________ 
Name of Researcher 
 
 
 
________________ 
Date 
 
 
_________________ 
Signature 
 
Please see overleaf for part 2 of the consent form. 
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PART 2 
10. Consent for storage and use in possible future research projects 
I agree that the samples I have given and the information gathered 
about me can be stored by the University of Liverpool for possible use in 
future projects as described in the attached information sheet. I 
understand that some of these projects may be carried out by 
researchers other than the University of Liverpool Pharmacology 
Department who ran the first project. 
 
 
 
________________ 
Name of patient 
(BLOCK CAPITALS) 
 
 
_________________ 
Date 
 
 
_________________ 
Signature 
 
 
_________________ 
Name of person 
taking consent (if 
different from 
researcher) 
 
 
_________________ 
Date 
 
 
_________________ 
Signature 
 
 
_______________ 
Name of Researcher 
 
 
 
________________ 
Date 
 
 
_________________ 
Signature 
 
Thank you for agreeing to participate in this research. 
Prof A Marson, Department of Molecular and Clinical Pharmacology, Block 
A: Wolfson Centre for Personalised Medicine, University of Liverpool, 
Liverpool L69 3GL 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept 
in medical notes 
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HYPERSENSITIVITY STUDY – A MECHANISTIC INVESTIGATION INTO DRUG AND 
CHEMICAL INDUCED HYPERSENSITIVITY 
PATIENT INFORMATION SHEET 
 
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with friends, relatives and your GP if you wish. If there is anything that is not clear, 
or if you would like more information, please ask. This is a voluntary project, and if, 
when you have heard about the study, you would prefer not to take part, your 
decision will be accepted without question and will not affect the standard of care 
you receive.  
 
What is the purpose of the study? 
The purpose of this study is to investigate drug induced hypersensitivity reactions. 
Most diseases and/or disorders require treatment by drugs, which may either cure 
the disease or reduce its symptoms. Unfortunately, drugs and chemicals can also 
cause side effects such as hypersensitivity reactions. These are unexpected 
reactions produced by the normal immune system, for example allergies. These 
reactions may be uncomfortable, damaging, or occasionally fatal. This study aims to 
look at the metabolism (breakdown in the human body) of certain drugs in order to 
gain appreciation of the quality and intensity of drug specific immune responses. It 
is hoped that this will pave the way for increased drug safety. 
 
Why have I been chosen? 
You have been asked to participate in this study because you have experienced a 
hypersensitive reaction to one of the drugs we are investigating.  Although, this 
drug is normally considered to be safe a small number of patients have been found 
to have developed a hypersensitive reaction.  
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Do I have to take part? 
It is up to you to decide whether or not to take part in this study. If you do decide to 
take part you will be given a copy of this information and be asked to sign a consent 
form. You are free to withdraw from this study at anytime without giving a reason. 
The standard of your care will not be affected in any way. 
 
What will happen to me if I take part? 
If you do decide to take part in this study it will not affect your usual clinical care in 
any way. That is; you will continue to take all current medications or continue with 
any planned treatments, as perscribed by your clinician/GP. If you do decide to take 
part you will be seen by a research nurse or other health professional who will:  
 
1) Take some details including your height, weight, date of birth, past medical 
history, current medications, alcohol and smoking history.  
2) Details will be obtained from your case notes regarding the drug(s) that caused 
the reaction(s), other drugs that were taken at that time and also details of the 
reaction that you suffered.  
3) A blood sample will be collected (40mL – approximately 4 tablespoons). This 
sample will be analysed in order to further understand why an individual may 
respond is such a way. 
 
After this initial visit you may be recalled for further visits. At any additional visit a 
research nurse or other health profession will verbally confirm that you consent to 
continue in the study, and a blood sample (up to 60mL) will be collected.  
You may be recalled several times over the duration of the study, up to a total of 
180mL per year may be collected for a maximum of 3 years. If after 3 years it is 
thought the data from your blood sample(s) warrant further investigation you may 
be approached for further blood donation, this will not exceed 180mL per year. 
If you have to attend hospital or clinic especially for the study, we will pay you 
reasonable travel expenses. 
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What are the possible disadvantages and risks of taking part?  
There may be some minor but short-lasting discomfort from having a blood test. 
Taking part in the study will not affect your current treatment, nor will it affect 
your ability to obtain insurance for health purposes. 
 
What are the possible benefits of taking part?  
It is unlikely that the study will be of direct benefit to you. However the study 
results will in the future hopefully aid patients who have had a hypersensitive 
reaction to drugs.  
 
What will happen to my blood test? 
Your blood sample will be stored at the University of Liverpool. A number of 
experiments will be performed on your sample including body cell and protein 
based experiments to determine how you respond to the drug which caused your 
hypersensitivity reaction. 
 
It is important to note that all blood samples received by the University will be 
identified by a code number only. All coded sample will be held, securely, within the 
Department of Pharmacology within the University of Liverpool. Once the study has 
been completed we will irreversibly anonymise your clinical details and your blood 
sample(s), therefore, it will not be possible to trace your sample back to you. After 
anonymisation, it will also not be possible to withdraw your blood sample(s). Once 
anonymised, your sample(s) may be used for other research, but as this cannot be 
traced back to you, it will have no impact on your clinical care. Further approval will 
be sought from the ethics committee for any future studies. 
 
Your blood sample(s) will be considered a gift to the University of Liverpool, which 
will act as custodian for all samples obtained as part of this project.  
 
In the short-term, it is unlikely that the sample(s) will be of any commercial value to 
the University or the hospital. However, it is possible that there may be some 
commercial value in the future, although it is important to note that any 
commercial value is likely to be due to the findings in a group of patients rather 
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than from samples from a single patient. You will not be paid for taking part in this 
study, nor will you derive financial benefit from future discoveries. 
 
Will my taking part in this study be kept confidential? 
As stated above, all samples will be coded and anonymised. Any information 
obtained from your blood sample(s) will be kept strictly confidential and will not be 
disclosed to anyone. All information collected about you during the course of the 
research will also remain strictly confidential. Any information about you that 
leaves the research centers taking part in this study will have your name and 
address removed so that you cannot be recognised from it. 
 
What will happen to the results of the research study? 
Results from the project will be published in leading, international medical journals.  
 
Who is organising and funding the research? 
The study has been designed as a collaborative project between the University of 
Liverpool and the Royal Liverpool and Broadgreen University Hospital NHS trust, 
and has been funded by the Medical Research Council. 
 
Who has reviewed the study? 
The study has been reviewed by the North West – North Research Ethics 
Committee. 
 
Contact for further information 
If you need further information or are worried about any aspect of the study, 
please do not hesitate to contact the research nurse working on the study, [NAME], 
on [TELEPHONE NUMBER] 
 
If you are unhappy and wish to complain formally, you can do this through the 
NHS Complaints Procedure by contacting your local NHS Trust on (TELEPHONE 
NUMBER) 
 
THANK YOU FOR READING THIS INFORMATION LEAFLET 
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HYPERSENSITIVITY STUDY – A MECHANISTIC INVESTIGATION INTO DRUG AND 
CHEMICAL INDUCED HYPERSENSITIVITY 
CONSENT FORM 
 
PLEASE INITIAL EACH BOX BEFORE SIGNING THE FORM 
1 I confirm that I have read and understood the information sheet 
dated………………………………………  Version number…………………………for the above study. 
 
 
2 I have had the opportunity to discuss the research and ask questions.  
 
3 I understand that my participation is voluntary and that I may withdraw at any time 
without giving a reason up until the time that my biological sample can still be identified, 
without my medical care or legal rights being affected. 
 
 
4 I understand that relevant sections of my medical notes and data collected during the 
study, may be looked at by authorised responsible individuals from regulatory 
authorities and/or from the NHS Trust, where it is relevant to my taking part in the 
research. I give permission for these individuals/bodies to have access to my records to 
access information relevant to this study 
 
 
5 I agree to have a blood sample(s) taken for tests that determine how people react to 
drugs  
 
 
6 I agree for my sample(s) to be stored for future use in this research study 
 
 
 
7 I agree to gift my blood sample(s) for future research and further tests as there are more 
scientific advances and understand that my sample(s) will be anonymised and it will not 
be possible to trace the sample(s) back to me  
 
 
8 I understand that the results will not be added to my medical records   
 
9 I give permission for a copy of my consent form to be sent to the Sponsor of this study   
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 10      I agree to participate in the study  
 
Name of Patient: Date: Signature: 
 [DD/MM/YYYY]  
Name of person taking 
consent: 
Date: Signature: 
 [DD/MM/YYYY]  
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Figure 9.1 Differential equations describing the semi-mechanistic CBZ metabolite 
model 
$MODEL 
 
       COMPARTMENT=(CBZ_DEP)   ;1 PO CBZ depot 
       COMPARTMENT=(CBZ_CENT)   ;2 CBZ plasma 
       COMPARTMENT=(CBZE)   ;3 CBZE plasma 
       COMPARTMENT=(CBZ_DiOH)   ;4 CBZ_DiOH plasma 
       COMPARTMENT=(CBZ_2OH)     ;5 CBZ_2OH 
       COMPARTMENT=(CBZ_3OH)     ;6 CBZ_3OH 
 
$PK 
;metabolite formation clearances 
TVCLtot=THETA(1) 
CLtot=TVCLtot*EXP(ETA(1)) 
 
TVFM1=THETA(2) 
FM1=TVFM1*EXP(ETA(2)) 
 
TVFM2=THETA(3) 
FM2=TVFM2*EXP(ETA(3)) 
 
;metabolite elimination clearances 
TVCL2=THETA(4) 
CL2=TVCL2*EXP(ETA(4)) 
 
TVCL2E=THETA(5) 
CL2E=TVCL2E*EXP(ETA(5)) 
 
TVCL3E=THETA(6) 
CL3E=TVCL3E*EXP(ETA(6)) 
 
TVCL4E=THETA(7) 
CL4E=TVCL4E*EXP(ETA(7)) 
 
TVKA_star=THETA(8) 
KA_star=TVKA_star*EXP(ETA(8)) 
 
TVV1=THETA(9) 
V1=TVV1*EXP(ETA(9)) 
 
TVV2=THETA(10) 
V2=TVV2*EXP(ETA(10)) 
 
TVV3=THETA(11) 
V3=TVV3*EXP(ETA(11)) 
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;TVKEL_rest=THETA(10) 
;KEL_rest==TVV3*EXP(ETA(10)) 
 
;reparameterisation 
 
;if you want to constrain the volumes 
;V2=V1/V2_diff 
;V3=V2/V3_diff 
 
KEL=CLtot/V1 
KA=KEL+KA_star ; fix KA to be faster than KEL 
 
KEL1=FM1*KEL ; constrained to 70% total clearance based on prior paper 
KEL2=CL2/V2 
 
KEL3=FM2*KEL 
KEL4=(1-FM1-FM2)*KEL 
 
;KEL_rest=CL_rest/V1 ; assumed 100% routes accounted for 
 
;KEL1E dropped i.e. 100% CBZE is converted to CBZ-DiOH 
KEL2E=CL2E/V3  
KEL3E=CL3E/V2 ; assume approx. V2 = V4 = V5 as physchem is similar 
KEL4E=CL4E/V2 ; assume elimination rate is equal to the other mono-hydroxy 
 
;scaling 
S2=V1 ; CBZ parent 
S3=V2 ; CBZE 
S4=V3 ; CBZ-DiOH  
S5=V2 ; CBZ-2-OH 
S6=V2 ; CBZ-3-OH 
 
D1=THETA(12)*EXP(ETA(12)) 
 
$DES 
 
DADT(1) = -KA*A(1) 
DADT(2)=KA*A(1)-KEL1*A(2)-KEL3*A(2)-KEL4*A(2);CBZ plasma 
DADT(3)=KEL1*A(2)-KEL2*A(3); CBZE plasma 
DADT(4)=KEL2*A(3)-KEL2E*A(4); DiOH plasma 
DADT(5)=KEL3*A(2)-KEL3E*A(5) ;2-OH plasma 
DADT(6)=KEL4*A(2)-KEL4E*A(6) ; 3-OH plasma 
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Table 9.1 Gene expression profile in patients with positive response on LTT to CBZ incubated with CBZ 
ID Exp Log Ratio Exp p-value Entrez Gene Name Type(s) 
CCL8 3.031 5.91E-03 chemokine (C-C motif) ligand 8 cytokine 
RSAD2 2.825 3.04E-02 radical S-adenosyl methionine domain containing 2 enzyme 
IFIT3 2.419 4.45E-02 interferon-induced protein with tetratricopeptide repeats 3 other 
CMPK2 2.007 2.69E-02 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial kinase 
USP18 1.882 3.32E-02 ubiquitin specific peptidase 18 peptidase 
DDX60 1.710 2.30E-02 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 enzyme 
HERC6 1.684 4.92E-02 HECT and RLD domain containing E3 ubiquitin protein ligase family 
member 6 
enzyme 
PLSCR1 1.662 2.71E-02 phospholipid scramblase 1 enzyme 
EIF2AK2 1.576 4.23E-02 eukaryotic translation initiation factor 2-alpha kinase 2 kinase 
RTP4 1.503 2.94E-02 receptor (chemosensory) transporter protein 4 other 
SAMD9L 1.494 4.57E-02 sterile alpha motif domain containing 9-like other 
PARP9 1.424 3.52E-02 poly (ADP-ribose) polymerase family, member 9 enzyme 
MX2 1.310 4.13E-02 MX dynamin-like GTPase 2 enzyme 
LAMP3 1.303 2.34E-02 lysosomal-associated membrane protein 3 other 
PNPT1 1.261 2.76E-02 polyribonucleotide nucleotidyltransferase 1 enzyme 
USP41 1.259 4.98E-02 ubiquitin specific peptidase 41 other 
TRIM25 1.164 4.82E-02 tripartite motif containing 25 transcription 
regulator 
DDX60L 1.146 3.64E-02 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like other 
IFI35 1.142 4.60E-02 interferon-induced protein 35 other 
DTX3L 1.100 3.87E-02 deltex 3 like, E3 ubiquitin ligase enzyme 
PARP12 1.091 4.08E-02 poly (ADP-ribose) polymerase family, member 12 other 
OR56B1 1.051 2.82E-02 olfactory receptor, family 56, subfamily B, member 1 G-protein coupled 
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receptor 
SAMD9 1.005 3.52E-02 sterile alpha motif domain containing 9 other 
MIR181B1 -1.031 3.13E-02 microRNA 181a-1 microRNA 
 
 
Table 9.2 Gene expression profile in patients with positive response on LTT to CBZ and incubated with tetanus toxoid 
ID Exp Log Ratio Exp p-value Entrez Gene Name Type(s) 
IL1B 7.992 2.22E-03 interleukin 1, beta cytokine 
IL1A 7.161 1.16E-02 interleukin 1, alpha cytokine 
CCL20 6.991 1.70E-02 chemokine (C-C motif) ligand 20 cytokine 
PTGS2 6.781 2.88E-02 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase 
and cyclooxygenase) 
enzyme 
CXCL5 6.114 7.38E-03 chemokine (C-X-C motif) ligand 5 cytokine 
CXCL8 5.849 1.96E-03 chemokine (C-X-C motif) ligand 8 cytokine 
CXCL1 5.668 1.72E-02 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating 
activity, alpha) 
cytokine 
TNFAIP6 4.977 1.78E-02 tumor necrosis factor, alpha-induced protein 6 other 
IL6 4.856 2.00E-02 interleukin 6 cytokine 
CXCL2 3.486 1.73E-02 chemokine (C-X-C motif) ligand 2 cytokine 
NAMPT 3.458 6.92E-03 nicotinamide phosphoribosyltransferase cytokine 
MMP14 3.334 3.87E-02 matrix metallopeptidase 14 (membrane-inserted) peptidase 
NAMPTL 3.301 1.73E-02 nicotinamide phosphoribosyltransferase pseudogene 1 other 
PLAUR 3.207 3.10E-02 plasminogen activator, urokinase receptor transmembrane 
receptor 
EREG 2.976 3.49E-02 epiregulin growth factor 
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RN7SKP283 2.945 3.33E-02   other 
CXCL3 2.931 2.78E-02 chemokine (C-X-C motif) ligand 3 cytokine 
TREM1 2.709 4.84E-02 triggering receptor expressed on myeloid cells 1 transmembrane 
receptor 
ITGB8 2.659 2.02E-02 integrin, beta 8 other 
GPR84 2.624 3.87E-02 G protein-coupled receptor 84 G-protein coupled 
receptor 
IL2RA 2.566 7.06E-03 interleukin 2 receptor, alpha transmembrane 
receptor 
SOD2 2.461 1.43E-02 superoxide dismutase 2, mitochondrial enzyme 
C3 2.335 3.46E-02   chemical - 
endogenous 
mammalian 
FLT1 2.329 4.63E-02 fms-related tyrosine kinase 1 kinase 
SOCS3 2.143 5.41E-03 suppressor of cytokine signaling 3 phosphatase 
ACSL1 2.132 2.75E-02 acyl-CoA synthetase long-chain family member 1 enzyme 
TLR2 2.112 3.85E-02 toll-like receptor 2 transmembrane 
receptor 
LOC541472 1.977 4.77E-02 uncharacterized LOC541472 other 
SERPINB2 1.969 3.66E-02 serpin peptidase inhibitor, clade B (ovalbumin), member 2 other 
MT1G 1.928 3.65E-02 metallothionein 1G other 
RGS1 1.925 6.58E-03 regulator of G-protein signaling 1 other 
ETS2 1.842 3.07E-02 v-ets avian erythroblastosis virus E26 oncogene homolog 2 transcription 
regulator 
MT1H 1.825 3.68E-02 metallothionein 1H other 
CCL22 1.720 4.21E-02 chemokine (C-C motif) ligand 22 cytokine 
PFKFB3 1.697 3.14E-02 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 kinase 
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SLC41A2 1.682 4.97E-02 solute carrier family 41 (magnesium transporter), member 2 transporter 
NFKBIA 1.665 1.57E-03 nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha 
transcription 
regulator 
NFKBIZ 1.637 1.15E-04 nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, zeta 
transcription 
regulator 
RNF144B 1.525 4.08E-02 ring finger protein 144B enzyme 
SAMSN1 1.519 4.86E-02 SAM domain, SH3 domain and nuclear localization signals 1 other 
SLC7A5 1.375 3.91E-02 solute carrier family 7 (amino acid transporter light chain, L system), 
member 5 
transporter 
BHLHE40 1.368 3.23E-02 basic helix-loop-helix family, member e40 transcription 
regulator 
TNIP1 1.238 2.82E-02 TNFAIP3 interacting protein 1 other 
MT1M 1.237 2.34E-02 metallothionein 1M other 
PIM1 1.212 3.07E-02 Pim-1 proto-oncogene, serine/threonine kinase kinase 
CHST15 1.209 3.11E-02 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 enzyme 
BCL6 1.197 3.06E-02 B-cell CLL/lymphoma 6 transcription 
regulator 
MT1B 1.131 3.70E-02 metallothionein 1B other 
NFKB1 1.097 5.51E-03 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 transcription 
regulator 
JUNB 1.093 4.26E-02 jun B proto-oncogene transcription 
regulator 
HDGFRP3 1.078 5.75E-03 hepatoma-derived growth factor, related protein 3 other 
CTAGE6 1.070 1.25E-02 CTAGE family, member 4 other 
HIF1A 1.055 2.79E-03 hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor) 
transcription 
regulator 
MT1E 1.029 4.21E-02 metallothionein 1E other 
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LDHA 1.014 3.63E-02 lactate dehydrogenase A enzyme 
FAIM3 -1.012 4.63E-02 Fc fragment of IgM receptor other 
MIR16-2 -1.014 4.58E-04 microRNA 15a microRNA 
AK5 -1.016 2.75E-02 adenylate kinase 5 kinase 
TRAV8-3 -1.029 1.33E-02 T cell receptor alpha variable 8-3 other 
RNU7-125P -1.073 2.96E-03   other 
MIR3671 -1.082 4.45E-03 microRNA 3671 microRNA 
CD84 -1.114 1.05E-02 CD84 molecule other 
C1orf162 -1.237 2.32E-02 chromosome 1 open reading frame 162 transporter 
MIR181B1 -1.244 1.21E-02 microRNA 181a-1 microRNA 
CD52 -1.256 5.10E-03 CD52 molecule other 
MIR580 -1.269 8.05E-04 microRNA 580 microRNA 
MPEG1 -1.485 4.38E-02 macrophage expressed 1 other 
FABP5 -1.504 3.78E-02 fatty acid binding protein 5 (psoriasis-associated) transporter 
FABP5P1 -2.261 3.38E-02 fatty acid binding protein 5 pseudogene 1 other 
FABP5P7 -2.330 4.44E-02 fatty acid binding protein 5 pseudogene 7 other 
CD36 -2.712 4.22E-02 CD36 molecule (thrombospondin receptor) transmembrane 
receptor 
FABP4 -5.016 1.64E-02 fatty acid binding protein 4, adipocyte transporter 
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Table 9.3 Gene expression profile in subjects with negative response to LTT with CBZ and incubated with CBZ 
ID Exp Log 
Ratio 
Exp p-value Entrez Gene Name Type(s) 
MIR4795 -1.068 9.34E-04 microRNA 4795 microRNA 
 
 
Table 9.4 Gene expression profile in subjects with negative response to LTT with CBZ and incubated with tetanus toxoid 
ID Exp Log 
Ratio 
Exp p-value Entrez Gene Name Type(s) 
MRC1 4.596 1.61E-02 mannose receptor, C type 1 transmembrane 
receptor 
STEAP4 4.386 9.66E-04 STEAP family member 4 enzyme 
CXCL10 4.028 3.51E-02 chemokine (C-X-C motif) ligand 10 cytokine 
ANKRD22 2.752 4.42E-03 ankyrin repeat domain 22 transcription 
regulator 
CXCL9 2.672 2.60E-03 chemokine (C-X-C motif) ligand 9 cytokine 
IL2RA 2.562 7.14E-03 interleukin 2 receptor, alpha transmembrane 
receptor 
CXCL11 2.416 3.95E-02 chemokine (C-X-C motif) ligand 11 cytokine 
CCL8 2.190 3.39E-02 chemokine (C-C motif) ligand 8 cytokine 
ENPP2 2.049 1.73E-03 ectonucleotide pyrophosphatase/phosphodiesterase 2 enzyme 
SLAMF8 1.963 1.04E-02 SLAM family member 8 other 
IGSF6 1.939 3.36E-02 immunoglobulin superfamily, member 6 transmembrane 
receptor 
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CD80 1.856 3.14E-03 CD80 molecule transmembrane 
receptor 
GBP1P1 1.775 2.27E-02 guanylate binding protein 1, interferon-inducible pseudogene 1 other 
WARS 1.751 3.49E-03 tryptophanyl-tRNA synthetase enzyme 
MYOF 1.738 1.95E-02 myoferlin other 
CD274 1.734 3.26E-02 CD274 molecule enzyme 
FBP1 1.709 3.56E-02 fructose-1,6-bisphosphatase 1 phosphatase 
CXCR2P1 1.640 1.13E-02 chemokine (C-X-C motif) receptor 2 pseudogene 1 other 
PSME2P2 1.597 7.08E-03 proteasome activator subunit 2 pseudogene 2 other 
SUCNR1 1.576 7.21E-04 succinate receptor 1 G-protein 
coupled receptor 
GBP4 1.562 4.70E-02 guanylate binding protein 4 enzyme 
FCER2 1.558 4.79E-02 Fc fragment of IgE, low affinity II, receptor for (CD23) transmembrane 
receptor 
PSTPIP2 1.505 4.75E-03 proline-serine-threonine phosphatase interacting protein 2 other 
BCL2 1.499 7.72E-03 B-cell CLL/lymphoma 2 transporter 
SNX10 1.483 1.93E-03 sorting nexin 10 transporter 
SPRED1 1.479 7.59E-03 sprouty-related, EVH1 domain containing 1 other 
KMO 1.474 3.25E-02 kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) enzyme 
ARHGAP31 1.461 8.18E-03 Rho GTPase activating protein 31 other 
PSME2 1.431 6.40E-03 proteasome activator subunit 2 peptidase 
EMP1 1.404 2.92E-02 epithelial membrane protein 1 other 
TXN 1.352 2.05E-02 thioredoxin enzyme 
CLEC6A 1.298 1.38E-02 C-type lectin domain family 6, member A transmembrane 
receptor 
DRAM1 1.295 3.62E-02 DNA-damage regulated autophagy modulator 1 other 
PIM1 1.289 2.30E-02 Pim-1 proto-oncogene, serine/threonine kinase kinase 
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CTSC 1.284 3.37E-02 cathepsin C peptidase 
CLEC4A 1.238 2.55E-02 C-type lectin domain family 4, member A transmembrane 
receptor 
FLVCR2 1.237 4.19E-02 feline leukemia virus subgroup C cellular receptor family, member 2 transporter 
PDCD1LG2 1.234 3.38E-02 programmed cell death 1 ligand 2 enzyme 
CCL13 1.212 1.68E-03 chemokine (C-C motif) ligand 13 cytokine 
CISH 1.207 5.44E-03 cytokine inducible SH2-containing protein other 
PRRG4 1.189 1.97E-02 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) other 
CD209 1.176 2.77E-02 CD209 molecule other 
TNFAIP2 1.172 3.21E-02 tumor necrosis factor, alpha-induced protein 2 other 
ARNTL2 1.162 1.66E-02 aryl hydrocarbon receptor nuclear translocator-like 2 transcription 
regulator 
ITGAM 1.161 1.20E-02 integrin, alpha M (complement component 3 receptor 3 subunit) transmembrane 
receptor 
MTHFD2 1.153 1.69E-02 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
enzyme 
MB21D2 1.136 1.65E-02 Mab-21 domain containing 2 other 
LMNB1 1.109 2.74E-02 lamin B1 other 
BST2 1.106 3.16E-02 bone marrow stromal cell antigen 2 other 
PTGER2 1.093 1.24E-02 prostaglandin E receptor 2 (subtype EP2), 53kDa G-protein 
coupled receptor 
MOB3B 1.090 7.83E-03 MOB kinase activator 3B other 
P2RY14 1.029 2.06E-02 purinergic receptor P2Y, G-protein coupled, 14 G-protein 
coupled receptor 
NFKBIA 1.011 3.14E-02 nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha 
transcription 
regulator 
MIR663A -1.023 3.63E-03 microRNA 663a microRNA 
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NFXL1 -1.083 1.04E-02 nuclear transcription factor, X-box binding-like 1 transcription 
regulator 
MIR4766 -1.093 5.31E-04 microRNA 4766 microRNA 
MIR548AL -1.094 8.00E-03 microRNA 570 microRNA 
SEPP1 -1.715 2.81E-03 selenoprotein P, plasma, 1 other 
 
 
Table 9.5 Gene expression profile in patients with positive response on LTT to CBZE incubated with CBZE 
ID Exp Log Ratio Exp p-value Entrez Gene Name Type(s) 
COX8A 1.133 1.56E-02 cytochrome c oxidase subunit VIIIA (ubiquitous) enzyme 
RNU6-267P -1.004 2.37E-02   other 
RNU6-162P -1.024 2.44E-02   other 
MIR4441 -1.030 3.00E-03 microRNA 4441 microRNA 
RNU7-38P -1.033 4.97E-02 RNA, U7 small nuclear 38 pseudogene other 
RNU7-123P -1.063 4.41E-05 RNU7-123P snRNA other 
AF178030.2 -1.129 3.05E-03 trichorhinophalangeal syndrome I transcription 
regulator 
PTGES -1.147 2.86E-02 prostaglandin E synthase enzyme 
RNA5SP237 -1.169 8.15E-03 RNA, 5S ribosomal pseudogene 237 other 
CHST15 -1.176 3.52E-02 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 enzyme 
BACH1-IT2 -1.182 2.13E-02 BACH1 intronic transcript 2 other 
NAMPT -2.367 4.74E-02 nicotinamide phosphoribosyltransferase cytokine 
RN7SKP283 -2.735 4.56E-02   other 
PTGS2 -6.122 4.50E-02 prostaglandin-endoperoxide synthase 2 enzyme 
Table 9.6 Gene expression profile in patients with positive response on LTT to CBZE incubated with tetanus toxoid 
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ID Exp Log Ratio Exp p-value Entrez Gene Name Type(s) 
STAT1 1.870 1.64E-02 signal transducer and activator of transcription 1, 91kDa transcription 
regulator 
RNU4-1 1.098 3.01E-02 RNA, U4 small nuclear 1 other 
RNU6-151P -1.036 2.13E-02 RNU6-151P snRNA other 
LOC644090 -1.043 3.55E-02 uncharacterized LOC644090 other 
AF178030.2 -1.140 2.84E-03 trichorhinophalangeal syndrome I transcription 
regulator 
MIR4307 -1.241 5.22E-03 microRNA 4307 microRNA 
RN7SKP283 -2.706 4.77E-02   other 
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Table 9.7 Gene expression profile in patients with negative response on LTT to CBZE incubated with CBZE 
ID Exp Log Ratio Exp p-value Entrez Gene Name Type(s) 
MIR302F 1.493 2.65E-03 microRNA 302c microRNA 
MIR4317 1.272 1.79E-02 microRNA 4317 microRNA 
DOCK4-AS1 1.204 4.37E-03 DOCK4 antisense RNA 1 other 
RNU6-1006P 1.182 3.28E-02 RNU6-1006P snRNA other 
RNA5SP201 1.060 6.20E-05 RNA, 5S ribosomal pseudogene 201 other 
MIR4308 1.052 1.03E-02 microRNA 4308 microRNA 
MIR548M 1.044 2.58E-02 microRNA 570 microRNA 
RNU6-1176P 1.031 2.58E-02 RNU6-1176P snRNA other 
RNU6-395P 1.004 4.10E-02 RNU6-395P snRNA other 
MYCBP2-AS2 -1.027 4.18E-02 MYCBP2 antisense RNA 2 other 
RNU6-1045P -1.044 4.69E-02   other 
MIR1302-5 -1.153 1.31E-02 microRNA 1302-5 microRNA 
MIR4307 -1.214 3.76E-02 microRNA 4307 microRNA 
MIR15B -1.216 3.78E-02 microRNA 15a microRNA 
OR11H12 -1.224 3.66E-05 olfactory receptor, family 11, subfamily H, member 12 other 
MIR4679-1 -1.261 3.19E-02 microRNA 4679-2 microRNA 
RNU5E-3P -1.318 9.77E-03 RNA, U5E small nuclear 3, pseudogene other 
MIR548C -1.498 2.94E-02 microRNA 570 microRNA 
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Table 9.8 Gene expression profile in patients with negative response on LTT to CBZE incubated with tetanus toxoid 
ID Exp Log Ratio Exp p-value Entrez Gene Name Type(s) 
MIR627 1.574 5.83E-03 microRNA 627 microRNA 
MIR302F 1.572 1.83E-03 microRNA 302c microRNA 
RNU6-1289P 1.265 9.55E-03 RNU6-1289P snRNA other 
DCSTAMP 1.098 8.13E-03 dendrocyte expressed seven transmembrane protein other 
MIR3145 1.094 2.41E-02 microRNA 3145 microRNA 
PCDH9-AS3 1.079 2.34E-03 PCDH9 antisense RNA 3 other 
RNU6-699P 1.059 9.13E-03 RNU6-699P snRNA other 
RNU6-989P 1.056 1.12E-03 RNU6-989P snRNA other 
LINC00392 1.035 1.21E-04 long intergenic non-protein coding RNA 392 other 
MIR3910-1 1.023 1.54E-02 microRNA 3910-2 microRNA 
MIR548M 1.012 2.99E-02 microRNA 570 microRNA 
CTD-2201E9.1 1.006 1.98E-05 uncharacterized LOC101929338 other 
PFN1P2 -1.015 6.30E-03 profilin 1 pseudogene 2 other 
LOC100287934 -1.029 2.65E-02 uncharacterized LOC100287934 other 
RNU6-396P -1.046 4.42E-02 RNU6-396P snRNA other 
MIR125B2 -1.080 7.94E-04 microRNA 100 microRNA 
MIR4719 -1.116 2.27E-02 microRNA 4719 microRNA 
RNU6-1214P -1.122 6.46E-03   other 
TAS2R7 -1.137 5.39E-04 taste receptor, type 2, member 7 G-protein 
coupled 
receptor 
MIR548O -1.243 2.86E-05 microRNA 548o microRNA 
RNU7-147P -1.254 1.29E-02   other 
RNU5E-3P -1.265 1.24E-02 RNA, U5E small nuclear 3, pseudogene other 
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MIR15B -1.439 1.69E-02 microRNA 15a microRNA 
LOC644172 -1.562 4.98E-05 mitogen-activated protein kinase 8 interacting protein 1 pseudogene other 
MIR1255A -1.865 2.06E-04 microRNA 1255b-1 microRNA 
IGHD3-22 -2.503 3.40E-02 immunoglobulin heavy diversity 3-22 other 
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Table 9.9 CBZ/CBZE-specific mRNA normalised expression levels (Normalised according to GAPDH) 
 
RSAD2   PARP9   PARP12   PTGES   IFIT3   COX8A   IFI35   USP18   USP41   
RLH001 CBZ 0 1.65 1.85 1.75 1.11 1.59 2.08 1.39 1.33 1.32 
RLH001 CBZ 25 2.32 2.18 2.01 1.07 2.16 2.17 1.66 1.85 1.65 
RLH001 CBZ TT 2.05 2.12 1.95 1.13 1.94 2.09 1.51 1.53 1.46 
RLH002 CBZ 0 2.01 1.94 1.84 1.11 1.90 2.10 1.51 1.51 1.43 
RLH002 CBZ 25 2.10 2.03 1.89 1.11 1.96 2.26 1.56 1.58 1.51 
RLH002 CBZ TT 2.06 2.00 1.90 1.09 1.90 2.32 1.56 1.57 1.48 
RLH007 CBZ 0 1.71 1.76 1.73 1.09 1.69 2.23 1.44 1.35 1.30 
RLH007 CBZ 25 1.99 1.90 1.82 1.11 1.94 2.14 1.55 1.47 1.39 
RLH007 CBZ TT 1.67 1.73 1.64 1.39 1.66 2.00 1.38 1.29 1.25 
RLH007 CBZE 0 1.44 1.71 1.69 1.43 1.49 2.27 1.38 1.29 1.27 
RLH007 CBZE 25 1.88 1.90 1.84 1.11 1.80 2.29 1.50 1.47 1.41 
RLH007 CBZE TT 2.05 1.96 1.89 1.11 1.99 2.34 1.56 1.52 1.44 
RLH010 CBZE 0 1.39 1.71 1.67 1.11 1.40 2.27 1.36 1.25 1.23 
RLH010 CBZE 25 1.47 1.76 1.67 1.14 1.53 2.16 1.40 1.29 1.27 
RLH010 CBZE TT 1.36 1.69 1.64 1.07 1.42 2.30 1.37 1.22 1.18 
WAL004 CBZ 0 2.35 2.09 1.97 1.08 2.15 2.23 1.68 1.69 1.56 
WAL004 CBZ 50 2.03 1.92 1.82 1.10 1.93 2.27 1.57 1.49 1.40 
WAL004 CBZ TT 2.69 2.35 2.17 1.12 2.55 2.36 2.00 2.03 1.83 
WAL004 CBZE 0 1.32 1.73 1.65 1.21 1.38 1.96 1.33 1.18 1.20 
WAL004 CBZE 25 1.55 1.81 1.71 1.14 1.43 2.40 1.42 1.25 1.25 
WAL004 CBZE TT 1.54 1.93 1.82 1.28 1.51 2.27 1.48 1.26 1.26 
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Table 9.10 Significant gene sets identified by GSEA (FDR<0.05) in subjects with positive response on LTT to CBZ incubated with CBZ (size: 
number of genes in gene set, NES: normalised enrichment score, FDR: false discovery rate) 
Gene Set (Functional Category) Size NES FDR (q value) 
CHEMOKINE_RECEPTOR_BINDING 41 2.89 0.00 
CHEMOKINE_ACTIVITY 40 2.87 0.00 
G_PROTEIN_COUPLED_RECEPTOR_BINDING 51 2.86 0.00 
CYTOKINE_ACTIVITY 108 2.76 0.00 
STRUCTURAL_CONSTITUENT_OF_RIBOSOME 77 2.74 0.00 
LOCOMOTORY_BEHAVIOR 89 2.66 0.00 
RESPONSE_TO_VIRUS 42 2.56 0.00 
BEHAVIOR 139 2.54 0.00 
RESPONSE_TO_EXTERNAL_STIMULUS 296 2.35 0.00 
INFLAMMATORY_RESPONSE 124 2.34 0.00 
RNA_BINDING 240 2.30 0.00 
RESPONSE_TO_CHEMICAL_STIMULUS 297 2.26 0.00 
RIBONUCLEOPROTEIN_COMPLEX 135 2.24 0.00 
RESPONSE_TO_OTHER_ORGANISM 73 2.24 0.00 
CELL_CELL_SIGNALING 386 2.20 0.00 
JAK_STAT_CASCADE 30 2.16 0.00 
TRANSLATION 167 2.16 0.00 
EXTRACELLULAR_SPACE 230 2.16 0.00 
RESPONSE_TO_BIOTIC_STIMULUS 109 2.13 0.00 
DEFENSE_RESPONSE 253 2.12 0.00 
EXOCYTOSIS 23 2.12 0.00 
NUCLEOLUS 115 2.10 0.00 
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VIRAL_GENOME_REPLICATION 18 2.08 0.00 
RESPONSE_TO_WOUNDING 182 2.08 0.00 
PROTEASOME_COMPLEX 22 2.06 0.00 
RECEPTOR_BINDING 357 2.05 0.00 
RIBOSOME 35 2.01 0.01 
CATION_HOMEOSTASIS 101 1.98 0.01 
CELLULAR_CATION_HOMEOSTASIS 99 1.98 0.01 
VIRAL_INFECTIOUS_CYCLE 28 1.96 0.02 
ION_HOMEOSTASIS 121 1.96 0.02 
EXTRACELLULAR_REGION_PART 320 1.96 0.02 
RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY 80 1.95 0.02 
ORGANELLE_LUMEN 428 1.95 0.02 
MEMBRANE_ENCLOSED_LUMEN 428 1.94 0.02 
NEGATIVE_REGULATION_OF_CELL_PROLIFERATION 148 1.92 0.03 
COLLAGEN_BINDING 14 1.89 0.04 
PROTEIN_FOLDING 55 1.89 0.04 
MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS 45 1.88 0.04 
CHEMICAL_HOMEOSTASIS 147 1.89 0.04 
CELLULAR_HOMEOSTASIS 138 1.89 0.04 
STRUCTURAL_MOLECULE_ACTIVITY 232 1.89 0.04 
METALLOENDOPEPTIDASE_ACTIVITY 26 1.88 0.04 
MULTI_ORGANISM_PROCESS 153 1.88 0.04 
DEFENSE_RESPONSE_TO_VIRUS 8 1.87 0.04 
CASPASE_ACTIVATION 26 1.87 0.04 
PROTEIN_TARGETING_TO_MEMBRANE 11 1.86 0.04 
CELLULAR_BIOSYNTHETIC_PROCESS 297 1.86 0.04 
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PROTEIN_KINASE_REGULATOR_ACTIVITY 36 1.85 0.04 
VIRAL_REPRODUCTIVE_PROCESS 32 1.85 0.04 
REGULATION_OF_CELL_PROLIFERATION 296 1.85 0.04 
ENDOPLASMIC_RETICULUM_LUMEN 13 1.84 0.05 
APOPTOSIS_GO 417 1.84 0.05 
PROGRAMMED_CELL_DEATH 418 1.84 0.05 
NUCLEAR_PART 537 1.84 0.05 
VIRAL_REPRODUCTION 37 1.83 0.05 
IMMUNE_RESPONSE 217 1.83 0.05 
REGULATION_OF_APOPTOSIS 330 1.83 0.05 
REGULATION_OF_CYCLIN_DEPENDENT_PROTEIN_KINASE_ACTIVITY 42 1.83 0.05 
REGULATION_OF_PROGRAMMED_CELL_DEATH 331 1.82 0.05 
HOMEOSTATIC_PROCESS 196 1.82 0.05 
TRNA_METABOLIC_PROCESS 19 1.82 0.05 
 
 
Table 9.11 Significant gene sets identified by GSEA (FDR<0.05) in subjects with negative response on LTT to CBZ incubated with CBZ (size: 
number of genes in gene set, NES: normalised enrichment score, FDR: false discovery rate) 
Gene Set (Functional Category) SIZE NES FDR.q.val 
STRUCTURAL_CONSTITUENT_OF_RIBOSOME 77 2.30 0 
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Table 9.12 Significant gene sets identified by GSEA (FDR<0.05) in subjects with positive response on LTT to CBZ incubated with TT (size: 
number of genes in gene set, NES: normalised enrichment score, FDR: false discovery rate) 
Gene Set (Functional Category) SIZE NES FDR.q.val 
CYTOKINE_ACTIVITY 108 2.93 0.00 
EXTRACELLULAR_SPACE 230 2.84 0.00 
EXTRACELLULAR_REGION_PART 320 2.82 0.00 
G_PROTEIN_COUPLED_RECEPTOR_BINDING 51 2.75 0.00 
CHEMOKINE_RECEPTOR_BINDING 41 2.75 0.00 
CHEMOKINE_ACTIVITY 40 2.69 0.00 
RESPONSE_TO_EXTERNAL_STIMULUS 296 2.68 0.00 
INFLAMMATORY_RESPONSE 124 2.62 0.00 
LOCOMOTORY_BEHAVIOR 89 2.61 0.00 
NEGATIVE_REGULATION_OF_CELL_PROLIFERATION 148 2.60 0.00 
RECEPTOR_BINDING 357 2.58 0.00 
RESPONSE_TO_CHEMICAL_STIMULUS 297 2.54 0.00 
BEHAVIOR 139 2.54 0.00 
RESPONSE_TO_WOUNDING 182 2.54 0.00 
REGULATION_OF_CELL_PROLIFERATION 296 2.50 0.00 
EXTRACELLULAR_REGION 424 2.50 0.00 
CELL_CELL_SIGNALING 386 2.50 0.00 
RESPONSE_TO_VIRUS 42 2.48 0.00 
NEGATIVE_REGULATION_OF_APOPTOSIS 146 2.40 0.00 
NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 192 2.41 0.00 
PATTERN_BINDING 44 2.42 0.00 
DEFENSE_RESPONSE 253 2.42 0.00 
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RESPONSE_TO_STRESS 484 2.35 0.00 
APOPTOSIS_GO 417 2.33 0.00 
PROGRAMMED_CELL_DEATH 418 2.33 0.00 
NEGATIVE_REGULATION_OF_PROGRAMMED_CELL_DEATH 147 2.32 0.00 
CELL_PROLIFERATION_GO_0008283 483 2.32 0.00 
POLYSACCHARIDE_BINDING 35 2.32 0.00 
GLYCOSAMINOGLYCAN_BINDING 33 2.31 0.00 
REGULATION_OF_PROGRAMMED_CELL_DEATH 331 2.30 0.00 
REGULATION_OF_APOPTOSIS 330 2.28 0.00 
POSITIVE_REGULATION_OF_CELL_PROLIFERATION 145 2.27 0.00 
JAK_STAT_CASCADE 30 2.26 0.00 
NEGATIVE_REGULATION_OF_CELLULAR_PROCESS 615 2.23 0.00 
METALLOENDOPEPTIDASE_ACTIVITY 26 2.22 0.00 
VIRAL_GENOME_REPLICATION 18 2.21 0.00 
NEGATIVE_REGULATION_OF_BIOLOGICAL_PROCESS 645 2.21 0.00 
REGULATION_OF_BLOOD_PRESSURE 18 2.20 0.01 
RESPONSE_TO_OTHER_ORGANISM 73 2.20 0.01 
RESPONSE_TO_BIOTIC_STIMULUS 109 2.20 0.01 
REGULATION_OF_DEVELOPMENTAL_PROCESS 426 2.19 0.01 
ANTI_APOPTOSIS 114 2.17 0.01 
CELL_DEVELOPMENT 559 2.17 0.01 
CARBOHYDRATE_TRANSPORT 18 2.16 0.01 
METALLOPEPTIDASE_ACTIVITY 48 2.14 0.01 
NEGATIVE_REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS 11 2.10 0.02 
HOMEOSTASIS_OF_NUMBER_OF_CELLS 19 2.10 0.02 
VIRAL_INFECTIOUS_CYCLE 28 2.09 0.02 
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NEGATIVE_REGULATION_OF_CELLULAR_BIOSYNTHETIC_PROCESS 26 2.07 0.03 
NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 27 2.06 0.03 
NEGATIVE_REGULATION_OF_TRANSLATION 21 2.05 0.03 
CYTOKINE_PRODUCTION 66 2.05 0.03 
CYTOKINE_METABOLIC_PROCESS 38 2.04 0.04 
RESPONSE_TO_HYPOXIA 26 2.04 0.04 
VIRAL_REPRODUCTIVE_PROCESS 32 2.03 0.04 
INTEGRIN_COMPLEX 19 2.03 0.04 
MONOSACCHARIDE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY 10 2.03 0.04 
HOMEOSTATIC_PROCESS 196 2.03 0.04 
NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 27 2.02 0.04 
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Table 9.13 Significant gene sets identified by GSEA (FDR<0.05) in subjects with negative response on LTT to CBZ incubated with TT (size: 
number of genes in gene set, NES: normalised enrichment score, FDR: false discovery rate) 
Gene Set (Functional Category) SIZE NES FDR.q.val 
CYTOKINE_ACTIVITY 108 3.01 0.00 
G_PROTEIN_COUPLED_RECEPTOR_BINDING 51 2.96 0.00 
LOCOMOTORY_BEHAVIOR 89 2.91 0.00 
CHEMOKINE_RECEPTOR_BINDING 41 2.89 0.00 
BEHAVIOR 139 2.88 0.00 
CHEMOKINE_ACTIVITY 40 2.86 0.00 
INFLAMMATORY_RESPONSE 124 2.83 0.00 
RESPONSE_TO_EXTERNAL_STIMULUS 296 2.77 0.00 
IMMUNE_RESPONSE 217 2.76 0.00 
RESPONSE_TO_WOUNDING 182 2.72 0.00 
DEFENSE_RESPONSE 253 2.72 0.00 
RESPONSE_TO_CHEMICAL_STIMULUS 297 2.67 0.00 
CELL_CELL_SIGNALING 386 2.66 0.00 
IMMUNE_SYSTEM_PROCESS 307 2.61 0.00 
RECEPTOR_BINDING 357 2.60 0.00 
CELLULAR_CATION_HOMEOSTASIS 99 2.49 0.00 
CARBOHYDRATE_BINDING 70 2.47 0.00 
CATION_HOMEOSTASIS 101 2.45 0.00 
RESPONSE_TO_VIRUS 42 2.42 0.00 
NEGATIVE_REGULATION_OF_APOPTOSIS 146 2.41 0.00 
ION_HOMEOSTASIS 121 2.41 0.00 
RESPONSE_TO_BIOTIC_STIMULUS 109 2.40 0.00 
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PATTERN_BINDING 44 2.40 0.00 
APOPTOSIS_GO 417 2.38 0.00 
NEGATIVE_REGULATION_OF_PROGRAMMED_CELL_DEATH 147 2.38 0.00 
CHEMICAL_HOMEOSTASIS 147 2.37 0.00 
PROGRAMMED_CELL_DEATH 418 2.36 0.00 
REGULATION_OF_PROGRAMMED_CELL_DEATH 331 2.36 0.00 
REGULATION_OF_APOPTOSIS 330 2.35 0.00 
JAK_STAT_CASCADE 30 2.32 0.00 
CELLULAR_HOMEOSTASIS 138 2.33 0.00 
EXTRACELLULAR_SPACE 230 2.33 0.00 
TRANSLATION 167 2.29 0.00 
EXTRACELLULAR_REGION_PART 320 2.30 0.00 
VIRAL_REPRODUCTIVE_PROCESS 32 2.30 0.00 
ANTI_APOPTOSIS 114 2.31 0.00 
SIGNAL_TRANSDUCTION 1547 2.26 0.00 
VIRAL_INFECTIOUS_CYCLE 28 2.27 0.00 
STRUCTURAL_CONSTITUENT_OF_RIBOSOME 77 2.28 0.00 
RESPONSE_TO_STRESS 484 2.28 0.00 
NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 192 2.28 0.00 
VIRAL_GENOME_REPLICATION 18 2.25 0.00 
VIRAL_REPRODUCTION 37 2.24 0.00 
REGULATION_OF_DEVELOPMENTAL_PROCESS 426 2.23 0.00 
PROTEASOME_COMPLEX 22 2.21 0.00 
CELL_DEVELOPMENT 559 2.23 0.00 
SOLUBLE_FRACTION 153 2.21 0.00 
HOMEOSTATIC_PROCESS 196 2.21 0.00 
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ELECTRON_CARRIER_ACTIVITY 75 2.22 0.00 
SUGAR_BINDING 33 2.22 0.00 
RESPONSE_TO_OTHER_ORGANISM 73 2.20 0.00 
PROTEIN_FOLDING 55 2.20 0.00 
CELL_PROLIFERATION_GO_0008283 483 2.19 0.00 
REGULATION_OF_CELL_PROLIFERATION 296 2.18 0.00 
CELLULAR_BIOSYNTHETIC_PROCESS 297 2.16 0.00 
CYTOPLASM 1982 2.16 0.00 
INTRACELLULAR_TRANSPORT 271 2.16 0.00 
PYROPHOSPHATASE_ACTIVITY 211 2.15 0.00 
HUMORAL_IMMUNE_RESPONSE 32 2.15 0.00 
EXTRACELLULAR_REGION 424 2.15 0.00 
RECEPTOR_SIGNALING_PROTEIN_ACTIVITY 81 2.15 0.00 
MULTI_ORGANISM_PROCESS 153 2.14 0.00 
CELL_FRACTION 471 2.14 0.00 
HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES 213 2.12 0.00 
CELLULAR_PROTEIN_METABOLIC_PROCESS 1059 2.12 0.00 
ESTABLISHMENT_OF_CELLULAR_LOCALIZATION 340 2.11 0.00 
RIBONUCLEOPROTEIN_COMPLEX 135 2.11 0.00 
ENDOPLASMIC_RETICULUM_LUMEN 13 2.11 0.00 
GLYCOSAMINOGLYCAN_BINDING 33 2.11 0.00 
CELLULAR_MACROMOLECULE_METABOLIC_PROCESS 1072 2.10 0.00 
PROTEIN_METABOLIC_PROCESS 1164 2.09 0.00 
POSITIVE_REGULATION_OF_CELL_PROLIFERATION 145 2.07 0.01 
ENDOPLASMIC_RETICULUM 275 2.07 0.01 
CELLULAR_LOCALIZATION 357 2.06 0.01 
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PROTEIN_KINASE_CASCADE 278 2.06 0.01 
SERINE_TYPE_ENDOPEPTIDASE_INHIBITOR_ACTIVITY 22 2.06 0.01 
MACROMOLECULE_BIOSYNTHETIC_PROCESS 298 2.06 0.01 
MEMBRANE_ORGANIZATION_AND_BIOGENESIS 132 2.05 0.01 
NUCLEOSIDE_TRIPHOSPHATASE_ACTIVITY 199 2.05 0.01 
REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 43 2.05 0.01 
ENVELOPE 153 2.05 0.01 
POLYSACCHARIDE_BINDING 35 2.05 0.01 
NUCLEOLUS 115 2.05 0.01 
RESPONSE_TO_ORGANIC_SUBSTANCE 29 2.05 0.01 
HYDROLASE_ACTIVITY_ACTING_ON_CARBON 
NITROGEN_NOT_PEPTIDEBONDSIN_CYCLIC_AMIDINES 16 2.05 0.01 
REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 89 2.05 0.01 
OXIDOREDUCTASE_ACTIVITY 274 2.04 0.01 
I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 107 2.04 0.01 
ORGANELLE_MEMBRANE 280 2.04 0.01 
UNFOLDED_PROTEIN_BINDING 41 2.04 0.01 
RESPONSE_TO_CARBOHYDRATE_STIMULUS 11 2.04 0.01 
NEGATIVE_REGULATION_OF_CELLULAR_PROCESS 615 2.04 0.01 
POSITIVE_REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 83 2.04 0.01 
ENDOPLASMIC_RETICULUM_PART 91 2.03 0.01 
MONOSACCHARIDE_BINDING 11 2.03 0.01 
ENZYME_REGULATOR_ACTIVITY 304 2.03 0.01 
BIOSYNTHETIC_PROCESS 435 2.02 0.01 
MACROMOLECULAR_COMPLEX 886 2.01 0.01 
ORGANELLE_ENVELOPE 153 2.01 0.01 
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RNA_BINDING 240 2.01 0.01 
GTP_BINDING 42 2.01 0.01 
HETEROCYCLE_METABOLIC_PROCESS 23 2.00 0.01 
REGULATION_OF_BIOLOGICAL_QUALITY 392 2.00 0.01 
NEGATIVE_REGULATION_OF_BIOLOGICAL_PROCESS 645 2.00 0.01 
TRNA_METABOLIC_PROCESS 19 2.00 0.01 
GUANYL_NUCLEOTIDE_BINDING 43 1.99 0.01 
PEPTIDYL_TYROSINE_MODIFICATION 28 1.99 0.01 
MICROVILLUS 10 1.99 0.01 
MITOCHONDRIAL_PART 129 1.99 0.01 
VESICLE_MEDIATED_TRANSPORT 190 1.98 0.01 
CYTOPLASMIC_PART 1292 1.98 0.01 
MYELOID_CELL_DIFFERENTIATION 35 1.98 0.01 
PHAGOCYTOSIS 17 1.97 0.01 
MEMBRANE 1860 1.97 0.01 
POSITIVE_REGULATION_OF_SIGNAL_TRANSDUCTION 120 1.97 0.01 
NUCLEAR_ENVELOPE 67 1.97 0.01 
PEPTIDYL_TYROSINE_PHOSPHORYLATION 26 1.97 0.01 
CELLULAR_DEFENSE_RESPONSE 54 1.96 0.01 
PROTEOLYSIS 184 1.95 0.01 
RESPONSE_TO_TOXIN 10 1.95 0.01 
POST_TRANSLATIONAL_PROTEIN_MODIFICATION 458 1.95 0.01 
MITOCHONDRIAL_OUTER_MEMBRANE 18 1.95 0.01 
IMMUNE_EFFECTOR_PROCESS 32 1.95 0.01 
TRANSPORT 760 1.95 0.01 
INTRACELLULAR_PROTEIN_TRANSPORT 139 1.95 0.01 
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NEGATIVE_REGULATION_OF_CELL_PROLIFERATION 148 1.95 0.01 
PROTEIN_TRANSPORT 150 1.94 0.02 
PHOSPHORIC_ESTER_HYDROLASE_ACTIVITY 147 1.94 0.02 
INACTIVATION_OF_MAPK_ACTIVITY 12 1.94 0.02 
GTPASE_ACTIVITY 91 1.94 0.02 
RUFFLE 30 1.94 0.02 
BIOPOLYMER_MODIFICATION 620 1.93 0.02 
PLASMA_MEMBRANE 1326 1.93 0.02 
PROTON_TRANSPORTING_TWO_SECTOR_ATPASE_COMPLEX 14 1.93 0.02 
RIBOSOME 35 1.93 0.02 
RECEPTOR_ACTIVITY 553 1.93 0.02 
ORGANELLE_OUTER_MEMBRANE 23 1.93 0.02 
PROTEIN_MODIFICATION_PROCESS 602 1.93 0.02 
PROTEIN_COMPLEX 764 1.93 0.02 
MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS 45 1.93 0.02 
MONOOXYGENASE_ACTIVITY 30 1.93 0.02 
REGULATION_OF_CELLULAR_PROTEIN_METABOLIC_PROCESS 151 1.92 0.02 
NUCLEAR_MEMBRANE_PART 40 1.92 0.02 
POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 28 1.92 0.02 
POSITIVE_REGULATION_OF_CELLULAR_PROCESS 639 1.91 0.02 
PROTEIN_AMINO_ACID_PHOSPHORYLATION 266 1.91 0.02 
NUCLEAR_MEMBRANE 48 1.91 0.02 
POSITIVE_REGULATION_OF_BIOLOGICAL_PROCESS 676 1.91 0.02 
ESTABLISHMENT_OF_LOCALIZATION 831 1.91 0.02 
RAS_GTPASE_BINDING 25 1.91 0.02 
ENDOMEMBRANE_SYSTEM 206 1.91 0.02 
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PHOSPHORYLATION 297 1.91 0.02 
PROTEIN_KINASE_REGULATOR_ACTIVITY 36 1.91 0.02 
INTRACELLULAR_NON_MEMBRANE_BOUND_ORGANELLE 579 1.90 0.02 
NON_MEMBRANE_BOUND_ORGANELLE 579 1.90 0.02 
ENZYME_BINDING 168 1.90 0.02 
MITOCHONDRIAL_MEMBRANE 77 1.89 0.02 
INTRACELLULAR_SIGNALING_CASCADE 631 1.89 0.02 
CYTOKINE_BINDING 43 1.89 0.02 
PEPTIDYL_AMINO_ACID_MODIFICATION 60 1.89 0.02 
RHO_GTPASE_ACTIVATOR_ACTIVITY 17 1.88 0.02 
INTRACELLULAR_ORGANELLE_PART 1110 1.88 0.02 
MITOCHONDRION 314 1.88 0.02 
CELL_PROJECTION 104 1.88 0.02 
PROTEIN_KINASE_ACTIVITY 271 1.88 0.02 
MITOCHONDRIAL_ENVELOPE 87 1.88 0.02 
MESODERM_DEVELOPMENT 20 1.88 0.02 
SECRETORY_PATHWAY 82 1.88 0.02 
ORGANELLE_PART 1115 1.88 0.02 
SMALL_GTPASE_BINDING 32 1.87 0.02 
REGULATION_OF_PROTEIN_METABOLIC_PROCESS 160 1.87 0.02 
REGULATION_OF_CELL_MIGRATION 27 1.87 0.02 
MEMBRANE_PART 1562 1.87 0.02 
CELLULAR_COMPONENT_DISASSEMBLY 31 1.86 0.03 
PHOSPHORIC_MONOESTER_HYDROLASE_ACTIVITY 106 1.86 0.03 
DEFENSE_RESPONSE_TO_VIRUS 8 1.85 0.03 
PROTEASE_INHIBITOR_ACTIVITY 35 1.85 0.03 
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ENZYME_INHIBITOR_ACTIVITY 110 1.85 0.03 
MACROMOLECULE_LOCALIZATION 223 1.85 0.03 
INTERLEUKIN_BINDING 21 1.85 0.03 
LEADING_EDGE 45 1.84 0.03 
NUCLEAR_PORE 30 1.84 0.03 
REGULATION_OF_PHOSPHORYLATION 47 1.83 0.03 
ATPASE_ACTIVITY 107 1.83 0.03 
INTEGRAL_TO_PLASMA_MEMBRANE 906 1.83 0.03 
PATTERN_RECOGNITION_RECEPTOR_ACTIVITY 10 1.83 0.03 
ESTABLISHMENT_OF_PROTEIN_LOCALIZATION 182 1.83 0.03 
VACUOLAR_MEMBRANE 10 1.83 0.03 
REGULATION_OF_PROTEIN_AMINO_ACID_PHOSPHORYLATION 29 1.83 0.03 
MITOCHONDRIAL_TRANSPORT 20 1.83 0.03 
INTEGRAL_TO_MEMBRANE 1243 1.83 0.03 
INTRINSIC_TO_MEMBRANE 1260 1.82 0.03 
OUTER_MEMBRANE 24 1.82 0.04 
ISOMERASE_ACTIVITY 34 1.81 0.04 
NUCLEOLAR_PART 18 1.81 0.04 
COFACTOR_METABOLIC_PROCESS 50 1.81 0.04 
INTRINSIC_TO_PLASMA_MEMBRANE 919 1.82 0.04 
REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION 17 1.81 0.04 
PHOSPHOTRANSFERASE_ACTIVITY_ALCOHOL_GROUP_AS_ACCEPTOR 317 1.81 0.04 
NEGATIVE_REGULATION_OF_MAP_KINASE_ACTIVITY 15 1.82 0.04 
MEMBRANE_FRACTION 325 1.81 0.04 
SIGNAL_SEQUENCE_BINDING 15 1.81 0.04 
TYROSINE_PHOSPHORYLATION_OF_STAT_PROTEIN 12 1.81 0.04 
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TRANSLATION_INITIATION_FACTOR_ACTIVITY 22 1.81 0.04 
INTEGRIN_COMPLEX 19 1.81 0.04 
PROTEIN_LOCALIZATION 203 1.81 0.04 
PROTEIN_AMINO_ACID_DEPHOSPHORYLATION 60 1.81 0.04 
LIGASE_ACTIVITY_FORMING_CARBON_OXYGEN_BONDS 14 1.80 0.04 
PROTEIN_DOMAIN_SPECIFIC_BINDING 70 1.80 0.04 
MONOVALENT_INORGANIC_CATION_TRANSMEMBRANE 
TRANSPORTER_ACTIVITY 30 1.80 0.04 
CATION_BINDING 204 1.80 0.04 
POSITIVE_REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION 12 1.80 0.04 
CYTOSKELETON_DEPENDENT_INTRACELLULAR_TRANSPORT 24 1.80 0.04 
REGULATION_OF_VIRAL_REPRODUCTION 11 1.79 0.04 
PROTEIN_TYROSINE_PHOSPHATASE_ACTIVITY 53 1.79 0.04 
POSITIVE_REGULATION_OF_PHOSPHATE_METABOLIC_PROCESS 27 1.79 0.04 
AMINE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY 40 1.79 0.04 
TRANSLATIONAL_INITIATION 35 1.79 0.04 
HEPARIN_BINDING 22 1.79 0.04 
PORE_COMPLEX 35 1.78 0.04 
SECRETION_BY_CELL 113 1.78 0.04 
REPRODUCTIVE_PROCESS 149 1.78 0.04 
KINASE_ACTIVITY 347 1.78 0.04 
POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 70 1.78 0.04 
TRANSFERASE_ACTIVITY_TRANSFERRING_PHOSPHORUS 
CONTAINING_GROUPS 399 1.79 0.04 
GTPASE_BINDING 33 1.78 0.04 
L_AMINO_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITY 17 1.78 0.04 
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BIOPOLYMER_METABOLIC_PROCESS 1595 1.78 0.04 
MUSCLE_DEVELOPMENT 88 1.78 0.04 
ION_BINDING 261 1.78 0.04 
PERIPHERAL_NERVOUS_SYSTEM_DEVELOPMENT 11 1.78 0.04 
ORGANELLAR_SMALL_RIBOSOMAL_SUBUNIT 10 1.77 0.04 
POSITIVE_REGULATION_OF_CELLULAR_PROTEIN_METABOLIC_PROCESS 68 1.77 0.04 
KINASE_REGULATOR_ACTIVITY 43 1.77 0.04 
ORGANELLE_LUMEN 428 1.77 0.04 
MEMBRANE_ENCLOSED_LUMEN 428 1.77 0.05 
STRUCTURAL_MOLECULE_ACTIVITY 232 1.77 0.05 
CALCIUM_ION_TRANSPORT 26 1.76 0.05 
REGULATION_OF_PH 12 1.76 0.05 
VACUOLAR_PART 11 1.76 0.05 
CYTOSOL 192 1.76 0.05 
MONOVALENT_INORGANIC_CATION_HOMEOSTASIS 13 1.76 0.05 
ATP_DEPENDENT_HELICASE_ACTIVITY 26 1.76 0.05 
NEGATIVE_REGULATION_OF_CELL_MIGRATION 15 1.75 0.05 
FATTY_ACID_BIOSYNTHETIC_PROCESS 14 1.75 0.05 
PLASMA_MEMBRANE_PART 1076 1.75 0.05 
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Table 9.14 Significant gene sets identified by GSEA (FDR<0.05) in subjects with positive response on LTT to CBZE incubated with CBZE (size: 
number of genes in gene set, NES: normalised enrichment score, FDR: false discovery rate) 
Gene Set (Functional Category) SIZE NES FDR.q.val 
STRUCTURAL_CONSTITUENT_OF_RIBOSOME 77 3.05 0.00 
RNA_BINDING 240 2.95 0.00 
RIBONUCLEOPROTEIN_COMPLEX 135 2.77 0.00 
RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY 80 2.63 0.00 
NUCLEOLUS 115 2.63 0.00 
RNA_PROCESSING 164 2.62 0.00 
MITOCHONDRION 314 2.56 0.00 
ORGANELLE_MEMBRANE 280 2.56 0.00 
MITOCHONDRIAL_INNER_MEMBRANE 58 2.54 0.00 
INTRACELLULAR_ORGANELLE_PART 1110 2.51 0.00 
PROTEIN_RNA_COMPLEX_ASSEMBLY 63 2.50 0.00 
ORGANELLE_INNER_MEMBRANE 66 2.49 0.00 
ORGANELLE_PART 1115 2.48 0.00 
COFACTOR_METABOLIC_PROCESS 50 2.47 0.00 
MITOCHONDRIAL_PART 129 2.46 0.00 
MEMBRANE_ENCLOSED_LUMEN 428 2.44 0.00 
ENDOPLASMIC_RETICULUM_PART 91 2.42 0.00 
ORGANELLE_LUMEN 428 2.41 0.00 
MITOCHONDRIAL_ENVELOPE 87 2.40 0.00 
NUCLEAR_PART 537 2.38 0.00 
MACROMOLECULAR_COMPLEX 886 2.37 0.00 
RIBOSOME 35 2.35 0.00 
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NUCLEAR_ENVELOPE_ENDOPLASMIC_RETICULUM_NETWORK 88 2.35 0.00 
MITOCHONDRIAL_MEMBRANE 77 2.35 0.00 
ENDOPLASMIC_RETICULUM_MEMBRANE 80 2.34 0.00 
NUCLEAR_LUMEN 361 2.34 0.00 
TRANSLATIONAL_INITIATION 35 2.33 0.00 
MRNA_PROCESSING_GO_0006397 70 2.32 0.00 
CYTOKINE_ACTIVITY 108 -2.33 0.00 
EXTRACELLULAR_REGION_PART 320 -2.33 0.00 
PATTERN_BINDING 44 -2.34 0.00 
EXTRACELLULAR_SPACE 230 -2.36 0.00 
CYTOPLASMIC_PART 1292 2.22 0.00 
COENZYME_METABOLIC_PROCESS 35 2.23 0.00 
MITOCHONDRIAL_MEMBRANE_PART 47 2.23 0.00 
RNA_SPLICING 88 2.24 0.00 
HELICASE_ACTIVITY 48 2.25 0.00 
SPLICEOSOME 50 2.26 0.00 
MRNA_METABOLIC_PROCESS 81 2.26 0.00 
ORGANELLE_ENVELOPE 153 2.28 0.00 
PROTEASOME_COMPLEX 22 2.28 0.00 
GOLGI_VESICLE_TRANSPORT 48 2.28 0.00 
ENVELOPE 153 2.29 0.00 
REGULATION_OF_TRANSLATIONAL_INITIATION 29 2.20 0.00 
PROTON_TRANSPORTING_TWO_SECTOR_ATPASE_COMPLEX 14 2.20 0.00 
DNA_DIRECTED_RNA_POLYMERASEII_HOLOENZYME 62 2.21 0.00 
TRANSLATION_REGULATOR_ACTIVITY 37 2.18 0.00 
TRANSLATION_FACTOR_ACTIVITY_NUCLEIC_ACID_BINDING 35 2.18 0.00 
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STRUCTURE_SPECIFIC_DNA_BINDING 50 2.19 0.00 
LYSOSOME 56 2.17 0.00 
STRUCTURAL_MOLECULE_ACTIVITY 232 2.17 0.00 
CYSTEINE_TYPE_ENDOPEPTIDASE_ACTIVITY 34 2.16 0.00 
DNA_REPAIR 119 2.15 0.00 
LYTIC_VACUOLE 56 2.13 0.00 
PROTEIN_COMPLEX 764 2.13 0.00 
GLYCEROPHOSPHOLIPID_BIOSYNTHETIC_PROCESS 28 2.12 0.00 
HYDROGEN_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY 24 2.11 0.00 
TRANSLATION_INITIATION_FACTOR_ACTIVITY 22 2.12 0.00 
SINGLE_STRANDED_DNA_BINDING 32 2.11 0.00 
MITOCHONDRIAL_RESPIRATORY_CHAIN 21 2.11 0.00 
RIBOSOME_BIOGENESIS_AND_ASSEMBLY 17 2.11 0.00 
VACUOLE 64 2.10 0.00 
MONOOXYGENASE_ACTIVITY 30 2.10 0.00 
SMALL_NUCLEAR_RIBONUCLEOPROTEIN_COMPLEX 22 2.10 0.00 
ENDOMEMBRANE_SYSTEM 206 2.09 0.00 
ORGANELLAR_RIBOSOME 21 2.08 0.00 
CYTOPLASM 1982 2.09 0.00 
RNA_HELICASE_ACTIVITY 23 2.08 0.00 
PROTEIN_SERINE_THREONINE_PHOSPHATASE_ACTIVITY 22 2.09 0.00 
MITOCHONDRIAL_RIBOSOME 21 2.08 0.00 
MITOCHONDRIAL_LUMEN 43 2.06 0.00 
MITOCHONDRIAL_MATRIX 43 2.06 0.00 
SUGAR_BINDING 33 2.04 0.00 
RIBOSOMAL_SUBUNIT 19 2.04 0.00 
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MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS 45 2.05 0.00 
CYSTEINE_TYPE_PEPTIDASE_ACTIVITY 46 2.03 0.00 
PHOSPHOINOSITIDE_BIOSYNTHETIC_PROCESS 23 2.03 0.00 
RNA_SPLICINGVIA_TRANSESTERIFICATION_REACTIONS 34 2.03 0.00 
NUCLEOLAR_PART 18 2.02 0.00 
CELLULAR_RESPIRATION 18 2.02 0.00 
INTRACELLULAR_NON_MEMBRANE_BOUND_ORGANELLE 579 2.02 0.00 
ENDONUCLEASE_ACTIVITY_GO_0016893 11 2.01 0.00 
NON_MEMBRANE_BOUND_ORGANELLE 579 2.01 0.00 
TRICARBOXYLIC_ACID_CYCLE_INTERMEDIATE_METABOLIC_PROCESS 11 2.00 0.00 
UNFOLDED_PROTEIN_BINDING 41 2.00 0.00 
PERINUCLEAR_REGION_OF_CYTOPLASM 51 2.00 0.00 
RNA_DEPENDENT_ATPASE_ACTIVITY 17 1.98 0.00 
NUCLEUS 1313 1.98 0.00 
TRANSLATION 167 1.98 0.00 
ENDODEOXYRIBONUCLEASE_ACTIVITY 11 1.97 0.00 
NUCLEASE_ACTIVITY 53 1.96 0.01 
LIPID_BINDING 83 1.96 0.01 
GLYCEROPHOSPHOLIPID_METABOLIC_PROCESS 42 1.96 0.01 
ATP_DEPENDENT_RNA_HELICASE_ACTIVITY 16 1.96 0.01 
RRNA_PROCESSING 14 1.96 0.01 
GLYCOSAMINOGLYCAN_BINDING 33 -2.16 0.01 
EXONUCLEASE_ACTIVITY 18 1.95 0.01 
G_PROTEIN_COUPLED_RECEPTOR_BINDING 51 -2.14 0.01 
MONOVALENT_INORGANIC_CATION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY 30 1.95 0.01 
INTRINSIC_TO_ENDOPLASMIC_RETICULUM_MEMBRANE 23 1.95 0.01 
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INTEGRAL_TO_ENDOPLASMIC_RETICULUM_MEMBRANE 23 1.95 0.01 
AEROBIC_RESPIRATION 14 1.94 0.01 
LIGASE_ACTIVITY_FORMING_CARBON_OXYGEN_BONDS 14 1.94 0.01 
OLIGOSACCHARYL_TRANSFERASE_COMPLEX 9 1.94 0.01 
POLYSACCHARIDE_BINDING 35 -2.14 0.01 
RRNA_METABOLIC_PROCESS 15 1.93 0.01 
ATP_DEPENDENT_HELICASE_ACTIVITY 26 1.93 0.01 
INTRACELLULAR_TRANSPORT 271 1.93 0.01 
NEGATIVE_REGULATION_OF_DNA_METABOLIC_PROCESS 17 1.93 0.01 
PROTEIN_FOLDING 55 1.93 0.01 
COATED_MEMBRANE 16 1.92 0.01 
PROTEIN_EXPORT_FROM_NUCLEUS 12 1.92 0.01 
RNA_SPLICING_FACTOR_ACTIVITYTRANSESTERIFICATION_MECHANISM 19 1.92 0.01 
INTRACELLULAR_PROTEIN_TRANSPORT 139 1.92 0.01 
MEMBRANE_COAT 16 1.92 0.01 
TRNA_METABOLIC_PROCESS 19 1.91 0.01 
NUCLEAR_PORE 30 1.92 0.01 
ESTABLISHMENT_OF_VESICLE_LOCALIZATION 8 1.92 0.01 
SECRETORY_PATHWAY 82 1.92 0.01 
NUCLEOPLASM_PART 198 1.91 0.01 
ELECTRON_CARRIER_ACTIVITY 75 1.92 0.01 
PHOSPHOINOSITIDE_METABOLIC_PROCESS 30 1.91 0.01 
CHEMOKINE_ACTIVITY 40 -2.11 0.01 
NUCLEOPLASM 260 1.90 0.01 
CELLULAR_COMPONENT_ASSEMBLY 278 1.90 0.01 
MICROTUBULE_ORGANIZING_CENTER 63 1.90 0.01 
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MACROMOLECULAR_COMPLEX_ASSEMBLY 260 1.90 0.01 
CHEMOKINE_RECEPTOR_BINDING 41 -2.09 0.01 
MACROMOLECULE_BIOSYNTHETIC_PROCESS 298 1.90 0.01 
ELECTRON_TRANSPORT_GO_0006118 47 1.90 0.01 
INFLAMMATORY_RESPONSE 124 -2.10 0.01 
DOUBLE_STRANDED_DNA_BINDING 29 1.89 0.01 
NUCLEAR_MEMBRANE_PART 40 1.89 0.01 
NUCLEAR_MEMBRANE 48 1.89 0.01 
MITOCHONDRIAL_SMALL_RIBOSOMAL_SUBUNIT 10 1.89 0.01 
VESICLE_COAT 15 1.88 0.01 
PROTEIN_AMINO_ACID_N_LINKED_GLYCOSYLATION 28 1.88 0.01 
VESICLE_LOCALIZATION 9 1.88 0.01 
RESPONSE_TO_DNA_DAMAGE_STIMULUS 152 1.88 0.01 
ORGANELLE_LOCALIZATION 23 1.87 0.01 
CENTROSOME 54 1.87 0.01 
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS 1175 1.87 0.01 
ORGANELLAR_SMALL_RIBOSOMAL_SUBUNIT 10 1.87 0.01 
CELLULAR_PROTEIN_COMPLEX_DISASSEMBLY 12 1.87 0.01 
COATED_VESICLE_MEMBRANE 16 1.87 0.01 
ENDOPLASMIC_RETICULUM_LUMEN 13 1.87 0.01 
VESICLE_MEMBRANE 28 1.87 0.01 
SMALL_RIBOSOMAL_SUBUNIT 10 1.87 0.01 
ENDOPLASMIC_RETICULUM 275 1.86 0.01 
METALLOEXOPEPTIDASE_ACTIVITY 12 1.86 0.01 
CELLULAR_LOCALIZATION 357 1.86 0.01 
DEOXYRIBONUCLEASE_ACTIVITY 20 1.86 0.01 
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DAMAGED_DNA_BINDING 21 1.85 0.01 
EXTRACELLULAR_REGION 424 -2.06 0.01 
LIGASE_ACTIVITY 92 1.85 0.01 
MICROBODY 47 1.85 0.01 
DNA_HELICASE_ACTIVITY 24 1.85 0.01 
COFACTOR_BIOSYNTHETIC_PROCESS 20 1.84 0.01 
HEME_METABOLIC_PROCESS 10 1.84 0.01 
CYTOPLASMIC_VESICLE_MEMBRANE 26 1.84 0.01 
TRANSCRIPTION_FACTOR_TFIID_COMPLEX 12 1.84 0.01 
REGULATION_OF_CELLULAR_PH 10 1.83 0.02 
RESPONSE_TO_WOUNDING 182 -2.03 0.02 
ESTABLISHMENT_OF_CELLULAR_LOCALIZATION 340 1.83 0.02 
RNA_METABOLIC_PROCESS 793 1.83 0.02 
OXIDOREDUCTASE_ACTIVITY_GO_0016616 54 1.83 0.02 
T_CELL_ACTIVATION 41 1.83 0.02 
CYTOCHROME_C_OXIDASE_ACTIVITY 12 1.83 0.02 
RESPONSE_TO_EXTERNAL_STIMULUS 296 -2.03 0.02 
REGULATION_OF_HOMEOSTATIC_PROCESS 13 1.82 0.02 
BIOSYNTHETIC_PROCESS 435 1.82 0.02 
CELLULAR_PROTEIN_CATABOLIC_PROCESS 56 1.82 0.02 
PEROXISOME 47 1.82 0.02 
IMMUNOLOGICAL_SYNAPSE 11 1.82 0.02 
LOCOMOTORY_BEHAVIOR 89 -2.04 0.02 
UBIQUITIN_LIGASE_COMPLEX 24 1.82 0.02 
PROTEIN_TRANSPORT 150 1.82 0.02 
POSITIVE_REGULATION_OF_T_CELL_ACTIVATION 20 1.82 0.02 
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GOLGI_ASSOCIATED_VESICLE 26 1.81 0.02 
COENZYME_BINDING 16 1.81 0.02 
APOPTOTIC_MITOCHONDRIAL_CHANGES 11 1.82 0.02 
MEMBRANE_LIPID_METABOLIC_PROCESS 95 1.81 0.02 
CYTOPLASMIC_VESICLE_PART 26 1.81 0.02 
NEGATIVE_REGULATION_OF_CELL_PROLIFERATION 148 -2.01 0.02 
RESPONSE_TO_HYPOXIA 26 -2.02 0.02 
DNA_RECOMBINATION 45 1.81 0.02 
CHROMATIN_ASSEMBLY_OR_DISASSEMBLY 23 1.80 0.02 
INTRA_GOLGI_VESICLE_MEDIATED_TRANSPORT 12 1.80 0.02 
OXIDOREDUCTASE_ACTIVITY 274 1.80 0.02 
CYTOKINE_METABOLIC_PROCESS 38 -2.00 0.02 
ONE_CARBON_COMPOUND_METABOLIC_PROCESS 25 1.80 0.02 
DNA_METABOLIC_PROCESS 245 1.80 0.02 
PROTEIN_N_TERMINUS_BINDING 38 1.80 0.02 
CELLULAR_PROTEIN_COMPLEX_ASSEMBLY 31 1.79 0.02 
POSITIVE_REGULATION_OF_LYMPHOCYTE_ACTIVATION 23 1.80 0.02 
ESTABLISHMENT_OF_ORGANELLE_LOCALIZATION 16 1.79 0.02 
DNA_REPLICATION 97 1.79 0.02 
PYRIMIDINE_NUCLEOTIDE_METABOLIC_PROCESS 9 1.78 0.02 
MEDIATOR_COMPLEX 16 1.78 0.02 
REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 89 1.78 0.02 
BEHAVIOR 139 -1.98 0.02 
NUCLEOBASENUCLEOSIDENUCLEOTIDE_KINASE_ACTIVITY 23 1.78 0.02 
BIOPOLYMER_METABOLIC_PROCESS 1595 1.77 0.02 
OXIDOREDUCTASE_ACTIVITY_ACTING_ON_CH_OH_GROUP_OF_DONORS 60 1.77 0.02 
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RNA_POLYMERASE_II_TRANSCRIPTION_MEDIATOR_ACTIVITY 11 1.77 0.02 
REGULATION_OF_PH 12 1.77 0.02 
PROTEIN_TARGETING_TO_MEMBRANE 11 1.77 0.02 
RIBONUCLEOPROTEIN_BINDING 11 1.77 0.02 
PHOSPHOLIPID_BIOSYNTHETIC_PROCESS 37 1.77 0.02 
EUKARYOTIC_TRANSLATION_INITIATION_FACTOR_3_COMPLEX 10 1.77 0.02 
3_5_EXONUCLEASE_ACTIVITY 12 1.77 0.02 
PROTEIN_AMINO_ACID_LIPIDATION 21 1.77 0.02 
REGULATION_OF_BLOOD_PRESSURE 18 -1.98 0.02 
CHROMATIN_ASSEMBLY 14 1.77 0.02 
NADH_DEHYDROGENASE_COMPLEX 12 1.76 0.02 
INTEGRIN_COMPLEX 19 -1.98 0.02 
MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_I 12 1.76 0.03 
TRNA_PROCESSING 10 1.76 0.03 
ATPASE_ACTIVITY 107 1.76 0.03 
MONOSACCHARIDE_BINDING 11 1.75 0.03 
ER_TO_GOLGI_VESICLE_MEDIATED_TRANSPORT 18 1.75 0.03 
LIPOPROTEIN_METABOLIC_PROCESS 30 1.75 0.03 
POSITIVE_REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 83 1.75 0.03 
BASE_EXCISION_REPAIR 16 1.75 0.03 
LIGASE_ACTIVITY_FORMING_CARBON_NITROGEN_BONDS 65 1.75 0.03 
RESPIRATORY_CHAIN_COMPLEX_I 12 1.75 0.03 
THIOLESTER_HYDROLASE_ACTIVITY 15 1.74 0.03 
MANNOSYLTRANSFERASE_ACTIVITY 10 1.74 0.03 
ORGANELLE_ORGANIZATION_AND_BIOGENESIS 443 1.74 0.03 
PROTEIN_DNA_COMPLEX_ASSEMBLY 44 1.74 0.03 
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CELLULAR_CATABOLIC_PROCESS 204 1.73 0.03 
POST_GOLGI_VESICLE_MEDIATED_TRANSPORT 14 1.73 0.03 
CHROMOSOME 112 1.73 0.03 
SPHINGOID_METABOLIC_PROCESS 11 1.73 0.03 
CATABOLIC_PROCESS 217 1.73 0.03 
ACID_AMINO_ACID_LIGASE_ACTIVITY 56 1.72 0.03 
CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS 100 1.72 0.03 
MICROTUBULE_ORGANIZING_CENTER_ORGANIZATION_AND_BIOGENESIS 15 1.73 0.03 
CELLULAR_MONOVALENT_INORGANIC_CATION_HOMEOSTASIS 11 1.72 0.03 
CERAMIDE_METABOLIC_PROCESS 10 1.72 0.03 
GENERAL_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY 29 1.72 0.03 
DOUBLE_STRAND_BREAK_REPAIR 22 1.72 0.03 
RESPONSE_TO_ENDOGENOUS_STIMULUS 188 1.71 0.03 
ANTIOXIDANT_ACTIVITY 16 1.71 0.03 
PROTEIN_CATABOLIC_PROCESS 67 1.71 0.03 
CENTROSOME_ORGANIZATION_AND_BIOGENESIS 14 1.71 0.03 
REGULATION_OF_GENE_EXPRESSION_EPIGENETIC 28 1.71 0.03 
CHROMOSOMAL_PART 90 1.71 0.03 
LIPOPROTEIN_BIOSYNTHETIC_PROCESS 23 1.71 0.04 
PYROPHOSPHATASE_ACTIVITY 211 1.70 0.04 
REGULATION_OF_CELL_PROLIFERATION 296 -1.92 0.04 
PIGMENT_METABOLIC_PROCESS 16 1.70 0.04 
PATTERN_RECOGNITION_RECEPTOR_ACTIVITY 10 -1.93 0.04 
HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES 213 1.70 0.04 
OXIDOREDUCTASE_ACTIVITY_GO_0016706 10 -1.93 0.04 
TUBULIN_BINDING 43 1.69 0.04 
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AMINO_ACID_DERIVATIVE_METABOLIC_PROCESS 21 1.69 0.04 
MEMBRANE_LIPID_BIOSYNTHETIC_PROCESS 46 1.69 0.04 
BIOPOLYMER_CATABOLIC_PROCESS 114 1.69 0.04 
PORE_COMPLEX 35 1.69 0.04 
PHOSPHOLIPID_BINDING 45 1.69 0.04 
COFACTOR_CATABOLIC_PROCESS 10 1.68 0.04 
DNA_DEPENDENT_ATPASE_ACTIVITY 21 1.68 0.04 
MEMBRANE_FUSION 28 1.68 0.04 
BIOGENIC_AMINE_METABOLIC_PROCESS 14 1.68 0.04 
OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_CH_GROUP_OF_DONORS 23 1.67 0.04 
APOPTOTIC_PROGRAM 57 1.67 0.04 
RIBONUCLEASE_ACTIVITY 25 1.67 0.04 
SPLICEOSOME_ASSEMBLY 21 1.67 0.04 
MACROMOLECULE_LOCALIZATION 223 1.66 0.05 
POSITIVE_REGULATION_OF_CELL_PROLIFERATION 145 -1.89 0.05 
CELLULAR_BIOSYNTHETIC_PROCESS 297 1.66 0.05 
OXIDOREDUCTASE_ACTIVITY_GO_0016705 36 -1.87 0.05 
PROTEIN_TARGETING 106 1.66 0.05 
CYTOKINE_PRODUCTION 66 -1.87 0.05 
CYTOKINE_BIOSYNTHETIC_PROCESS 37 -1.88 0.05 
CARBOHYDRATE_TRANSPORT 18 -1.88 0.05 
RESPONSE_TO_TOXIN 10 1.66 0.05 
MICROTUBULE_ORGANIZING_CENTER_PART 18 1.66 0.05 
MITOTIC_CELL_CYCLE_CHECKPOINT 20 1.66 0.05 
POSITIVE_REGULATION_OF_DNA_METABOLIC_PROCESS 11 -1.89 0.05 
GENE_SILENCING 10 1.65 0.05 
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CELLULAR_LIPID_CATABOLIC_PROCESS 32 1.65 0.05 
TRANSCRIPTION_COACTIVATOR_ACTIVITY 118 1.65 0.05 
CELLULAR_MACROMOLECULE_METABOLIC_PROCESS 1072 1.65 0.05 
PROTEIN_METABOLIC_PROCESS 1164 1.65 0.05 
LATE_ENDOSOME 9 1.65 0.05 
MONOVALENT_INORGANIC_CATION_HOMEOSTASIS 13 1.65 0.05 
NUCLEAR_EXPORT 32 1.65 0.05 
HEME_BIOSYNTHETIC_PROCESS 9 1.65 0.05 
RNA_3END_PROCESSING 9 1.65 0.05 
CELLULAR_PROTEIN_METABOLIC_PROCESS 1059 1.65 0.05 
MONOSACCHARIDE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY 10 -1.89 0.05 
DNA_REPLICATION_INITIATION 14 1.65 0.05 
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Table 9.15 Significant gene sets identified by GSEA (FDR<0.05) in subjects with positive response on LTT to CBZE incubated with TT (size: 
number of genes in gene set, NES: normalised enrichment score, FDR: false discovery rate) 
Gene Set (Functional Category) SIZE NES FDR.q.val 
STRUCTURAL_CONSTITUENT_OF_RIBOSOME 77 3.00 0.00 
RNA_BINDING 240 2.87 0.00 
RIBONUCLEOPROTEIN_COMPLEX 135 2.78 0.00 
ORGANELLE_MEMBRANE 280 2.67 0.00 
RNA_PROCESSING 164 2.66 0.00 
ORGANELLE_PART 1115 2.61 0.00 
INTRACELLULAR_ORGANELLE_PART 1110 2.60 0.00 
RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY 80 2.59 0.00 
ENDOPLASMIC_RETICULUM_PART 91 2.56 0.00 
NUCLEOLUS 115 2.49 0.00 
ORGANELLE_ENVELOPE 153 2.46 0.00 
NUCLEAR_PART 537 2.45 0.00 
ENDOPLASMIC_RETICULUM_MEMBRANE 80 2.45 0.00 
PROTEIN_RNA_COMPLEX_ASSEMBLY 63 2.44 0.00 
MACROMOLECULAR_COMPLEX 886 2.44 0.00 
MRNA_METABOLIC_PROCESS 81 2.43 0.00 
MITOCHONDRIAL_PART 129 2.43 0.00 
ENVELOPE 153 2.43 0.00 
RIBOSOME 35 2.42 0.00 
NUCLEAR_ENVELOPE_ENDOPLASMIC_RETICULUM_NETWORK 88 2.41 0.00 
PROTEASOME_COMPLEX 22 2.39 0.00 
MITOCHONDRION 314 2.38 0.00 
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MITOCHONDRIAL_INNER_MEMBRANE 58 2.37 0.00 
CYSTEINE_TYPE_ENDOPEPTIDASE_ACTIVITY 34 2.28 0.00 
RNA_SPLICING 88 2.29 0.00 
SPLICEOSOME 50 2.29 0.00 
CYSTEINE_TYPE_PEPTIDASE_ACTIVITY 46 2.31 0.00 
MRNA_PROCESSING_GO_0006397 70 2.31 0.00 
MITOCHONDRIAL_ENVELOPE 87 2.35 0.00 
ORGANELLE_INNER_MEMBRANE 66 2.35 0.00 
ORGANELLE_LUMEN 428 2.35 0.00 
MEMBRANE_ENCLOSED_LUMEN 428 2.36 0.00 
VACUOLE 64 2.25 0.00 
NUCLEAR_LUMEN 361 2.25 0.00 
NUCLEAR_MEMBRANE 48 2.26 0.00 
SECRETORY_PATHWAY 82 2.26 0.00 
ENDOMEMBRANE_SYSTEM 206 2.27 0.00 
MITOCHONDRIAL_MEMBRANE 77 2.27 0.00 
SMALL_NUCLEAR_RIBONUCLEOPROTEIN_COMPLEX 22 2.21 0.00 
LYSOSOME 56 2.21 0.00 
COFACTOR_METABOLIC_PROCESS 50 2.21 0.00 
PROTEIN_COMPLEX 764 2.21 0.00 
CYTOPLASM 1982 2.22 0.00 
TRANSLATIONAL_INITIATION 35 2.22 0.00 
NUCLEUS 1313 2.22 0.00 
CYTOPLASMIC_PART 1292 2.22 0.00 
TRANSLATION_REGULATOR_ACTIVITY 37 2.22 0.00 
DNA_REPAIR 119 2.23 0.00 
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PROTON_TRANSPORTING_TWO_SECTOR_ATPASE_COMPLEX 14 2.24 0.00 
LYTIC_VACUOLE 56 2.20 0.00 
TRANSLATION_FACTOR_ACTIVITY_NUCLEIC_ACID_BINDING 35 2.20 0.00 
REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 89 2.18 0.00 
DNA_DIRECTED_RNA_POLYMERASEII_HOLOENZYME 62 2.18 0.00 
REGULATION_OF_TRANSLATIONAL_INITIATION 29 2.19 0.00 
INTRACELLULAR_NON_MEMBRANE_BOUND_ORGANELLE 579 2.18 0.00 
GOLGI_VESICLE_TRANSPORT 48 2.18 0.00 
NON_MEMBRANE_BOUND_ORGANELLE 579 2.17 0.00 
TRANSLATION_INITIATION_FACTOR_ACTIVITY 22 2.16 0.00 
STRUCTURAL_MOLECULE_ACTIVITY 232 2.16 0.00 
HELICASE_ACTIVITY 48 2.13 0.00 
INTRACELLULAR_TRANSPORT 271 2.13 0.00 
CELLULAR_LOCALIZATION 357 2.13 0.00 
GLYCEROPHOSPHOLIPID_BIOSYNTHETIC_PROCESS 28 2.14 0.00 
MITOCHONDRIAL_RESPIRATORY_CHAIN 21 2.15 0.00 
RNA_DEPENDENT_ATPASE_ACTIVITY 17 2.12 0.00 
ENDOPLASMIC_RETICULUM 275 2.12 0.00 
TRICARBOXYLIC_ACID_CYCLE_INTERMEDIATE_METABOLIC_PROCESS 11 2.11 0.00 
PROTEIN_SERINE_THREONINE_PHOSPHATASE_ACTIVITY 22 2.12 0.00 
ENDOPLASMIC_RETICULUM_LUMEN 13 2.11 0.00 
INTEGRAL_TO_ENDOPLASMIC_RETICULUM_MEMBRANE 23 2.11 0.00 
NUCLEAR_PORE 30 2.11 0.00 
ESTABLISHMENT_OF_CELLULAR_LOCALIZATION 340 2.11 0.00 
TRANSLATION 167 2.11 0.00 
GTP_BINDING 42 2.11 0.00 
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POSITIVE_REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 83 2.10 0.00 
TRNA_METABOLIC_PROCESS 19 2.09 0.00 
RNA_HELICASE_ACTIVITY 23 2.09 0.00 
MITOCHONDRIAL_MEMBRANE_PART 47 2.08 0.00 
PHOSPHOINOSITIDE_BIOSYNTHETIC_PROCESS 23 2.08 0.00 
INTRINSIC_TO_ENDOPLASMIC_RETICULUM_MEMBRANE 23 2.07 0.00 
MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS 45 2.07 0.00 
ATP_DEPENDENT_RNA_HELICASE_ACTIVITY 16 2.06 0.00 
UNFOLDED_PROTEIN_BINDING 41 2.07 0.00 
PHOSPHOINOSITIDE_METABOLIC_PROCESS 30 2.06 0.00 
RNA_SPLICINGVIA_TRANSESTERIFICATION_REACTIONS 34 2.05 0.00 
VIRAL_REPRODUCTION 37 2.04 0.00 
GUANYL_NUCLEOTIDE_BINDING 43 2.04 0.00 
RNA_METABOLIC_PROCESS 793 2.04 0.00 
CYTOKINE_BINDING 43 2.04 0.00 
ATP_DEPENDENT_HELICASE_ACTIVITY 26 2.04 0.00 
INTRACELLULAR_PROTEIN_TRANSPORT 139 2.03 0.00 
VESICLE_COAT 15 2.03 0.00 
PATTERN_BINDING 44 -2.19 0.00 
TRNA_PROCESSING 10 2.03 0.00 
CELLULAR_COMPONENT_ASSEMBLY 278 2.02 0.00 
NUCLEAR_MEMBRANE_PART 40 2.02 0.00 
RIBOSOME_BIOGENESIS_AND_ASSEMBLY 17 2.01 0.00 
RESPONSE_TO_DNA_DAMAGE_STIMULUS 152 2.01 0.00 
MACROMOLECULAR_COMPLEX_ASSEMBLY 260 2.01 0.00 
JAK_STAT_CASCADE 30 2.00 0.00 
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GLYCEROPHOSPHOLIPID_METABOLIC_PROCESS 42 1.99 0.00 
MACROMOLECULE_BIOSYNTHETIC_PROCESS 298 1.99 0.00 
STRUCTURE_SPECIFIC_DNA_BINDING 50 1.99 0.00 
INTRA_GOLGI_VESICLE_MEDIATED_TRANSPORT 12 1.98 0.01 
BIOPOLYMER_METABOLIC_PROCESS 1595 1.98 0.01 
COATED_MEMBRANE 16 1.98 0.01 
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS 1175 1.98 0.01 
IMMUNE_SYSTEM_PROCESS 307 1.97 0.01 
PROTEIN_TRANSPORT 150 1.98 0.01 
ORGANELLE_ORGANIZATION_AND_BIOGENESIS 443 1.97 0.01 
COENZYME_METABOLIC_PROCESS 35 1.97 0.01 
SINGLE_STRANDED_DNA_BINDING 32 1.97 0.01 
PORE_COMPLEX 35 1.97 0.01 
IMMUNOLOGICAL_SYNAPSE 11 1.97 0.01 
EXTRACELLULAR_SPACE 230 -2.08 0.01 
RNA_POLYMERASE_ACTIVITY 15 1.96 0.01 
INTERLEUKIN_BINDING 21 1.96 0.01 
MITOCHONDRIAL_LUMEN 43 1.96 0.01 
MEMBRANE_COAT 16 1.95 0.01 
RNA_SPLICING_FACTOR_ACTIVITYTRANSESTERIFICATION_MECHANISM 19 1.95 0.01 
PROTEIN_EXPORT_FROM_NUCLEUS 12 1.95 0.01 
GLYCOSAMINOGLYCAN_BINDING 33 -2.09 0.01 
NUCLEAR_EXPORT 32 1.94 0.01 
RESPONSE_TO_VIRUS 42 1.94 0.01 
IMMUNE_RESPONSE 217 1.94 0.01 
PEPTIDYL_AMINO_ACID_MODIFICATION 60 1.93 0.01 
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EXTRACELLULAR_REGION_PART 320 -2.06 0.01 
POLYSACCHARIDE_BINDING 35 -2.09 0.01 
AEROBIC_RESPIRATION 14 1.93 0.01 
MITOCHONDRIAL_MATRIX 43 1.92 0.01 
RIBOSOMAL_SUBUNIT 19 1.92 0.01 
ESTABLISHMENT_OF_ORGANELLE_LOCALIZATION 16 1.92 0.01 
LATE_ENDOSOME 9 1.91 0.01 
REGULATION_OF_PH 12 1.91 0.01 
CELLULAR_RESPIRATION 18 1.90 0.01 
REGULATION_OF_HOMEOSTATIC_PROCESS 13 1.90 0.01 
PYROPHOSPHATASE_ACTIVITY 211 1.90 0.01 
VIRAL_REPRODUCTIVE_PROCESS 32 1.90 0.01 
REGULATION_OF_CELLULAR_PH 10 1.90 0.01 
EXONUCLEASE_ACTIVITY 18 1.90 0.01 
NUCLEOPLASM_PART 198 1.90 0.01 
NUCLEOPLASM 260 1.89 0.01 
MONOVALENT_INORGANIC_CATION_HOMEOSTASIS 13 1.89 0.01 
CELLULAR_MONOVALENT_INORGANIC_CATION_HOMEOSTASIS 11 1.89 0.01 
COATED_VESICLE_MEMBRANE 16 1.89 0.01 
HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES 213 1.89 0.01 
VESICLE_MEMBRANE 28 1.89 0.01 
CYTOPLASMIC_VESICLE_PART 26 1.89 0.01 
CELLULAR_DEFENSE_RESPONSE 54 1.88 0.01 
HETEROGENEOUS_NUCLEAR_RIBONUCLEOPROTEIN_COMPLEX 12 1.88 0.01 
UBIQUITIN_LIGASE_COMPLEX 24 1.87 0.01 
INTERLEUKIN_RECEPTOR_ACTIVITY 16 1.87 0.01 
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PEPTIDYL_TYROSINE_PHOSPHORYLATION 26 1.87 0.01 
MITOCHONDRIAL_RIBOSOME 21 1.87 0.01 
PIGMENT_METABOLIC_PROCESS 16 1.87 0.01 
CYTOPLASMIC_VESICLE_MEMBRANE 26 1.87 0.01 
CHROMOSOME 112 1.87 0.01 
VACUOLAR_PART 11 1.86 0.01 
RESPONSE_TO_ENDOGENOUS_STIMULUS 188 1.86 0.01 
RESPONSE_TO_BIOTIC_STIMULUS 109 1.86 0.01 
DOUBLE_STRAND_BREAK_REPAIR 22 1.85 0.02 
MEMBRANE_LIPID_METABOLIC_PROCESS 95 1.85 0.02 
PERINUCLEAR_REGION_OF_CYTOPLASM 51 1.85 0.02 
ESTABLISHMENT_OF_VESICLE_LOCALIZATION 8 1.85 0.02 
LIPID_BINDING 83 1.85 0.02 
LIGASE_ACTIVITY_FORMING_CARBON_OXYGEN_BONDS 14 1.85 0.02 
ORGANELLAR_RIBOSOME 21 1.85 0.02 
CATION_HOMEOSTASIS 101 1.85 0.02 
CELLULAR_CATION_HOMEOSTASIS 99 1.84 0.02 
COENZYME_BINDING 16 1.84 0.02 
GOLGI_ASSOCIATED_VESICLE 26 1.84 0.02 
MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_I 12 1.84 0.02 
CHROMOSOMEPERICENTRIC_REGION 28 1.84 0.02 
NUCLEOTIDE_EXCISION_REPAIR 20 1.84 0.02 
NUCLEOSIDE_TRIPHOSPHATASE_ACTIVITY 199 1.84 0.02 
VESICLE_MEDIATED_TRANSPORT 190 1.83 0.02 
PHOSPHORIC_DIESTER_HYDROLASE_ACTIVITY 40 1.83 0.02 
PHOSPHOLIPASE_ACTIVITY 41 1.83 0.02 
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DOUBLE_STRANDED_RNA_BINDING 15 1.83 0.02 
PROTEIN_METABOLIC_PROCESS 1164 1.82 0.02 
CELLULAR_MACROMOLECULE_METABOLIC_PROCESS 1072 1.82 0.02 
DOUBLE_STRANDED_DNA_BINDING 29 1.82 0.02 
PATTERN_RECOGNITION_RECEPTOR_ACTIVITY 10 -1.99 0.02 
EUKARYOTIC_TRANSLATION_INITIATION_FACTOR_3_COMPLEX 10 1.81 0.02 
RRNA_PROCESSING 14 1.81 0.02 
DNA_DAMAGE_RESPONSESIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR 12 1.81 0.02 
I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 107 1.81 0.02 
RNA_EXPORT_FROM_NUCLEUS 19 1.81 0.02 
ATPASE_ACTIVITY 107 1.81 0.02 
HYDROGEN_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY 24 1.81 0.02 
BIOSYNTHETIC_PROCESS 435 1.81 0.02 
ORGANELLE_LOCALIZATION 23 1.81 0.02 
CHROMATIN_ASSEMBLY_OR_DISASSEMBLY 23 1.81 0.02 
MACROMOLECULE_LOCALIZATION 223 1.80 0.02 
RESPIRATORY_CHAIN_COMPLEX_I 12 1.80 0.02 
MICROTUBULE_CYTOSKELETON 140 1.80 0.02 
ADAPTIVE_IMMUNE_RESPONSE_GO_0002460 21 1.80 0.02 
MULTI_ORGANISM_PROCESS 153 1.80 0.02 
CHROMOSOMAL_PART 90 1.80 0.02 
PROTEIN_FOLDING 55 1.80 0.02 
PROTEIN_CATABOLIC_PROCESS 67 1.79 0.02 
HEME_METABOLIC_PROCESS 10 1.79 0.02 
ACTIN_BINDING 72 1.79 0.02 
INTERACTION_WITH_HOST 16 1.79 0.02 
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ENDOSOME 62 1.79 0.02 
TRANSFERASE_ACTIVITY_TRANSFERRING_GROUPS_OTHER_THAN_AMINO_ACYL_GROUPS 45 1.79 0.02 
CELLULAR_PROTEIN_CATABOLIC_PROCESS 56 1.79 0.02 
LYSOSOMAL_MEMBRANE 9 1.79 0.02 
3_5_EXONUCLEASE_ACTIVITY 12 1.79 0.02 
CELLULAR_HOMEOSTASIS 138 1.79 0.02 
PROTEIN_PHOSPHATASE_TYPE_2A_REGULATOR_ACTIVITY 12 1.79 0.02 
MICROBODY 47 1.79 0.02 
CELLULAR_PROTEIN_METABOLIC_PROCESS 1059 1.79 0.02 
MONOSACCHARIDE_BINDING 11 1.79 0.02 
ADAPTIVE_IMMUNE_RESPONSE 22 1.78 0.03 
EXOCYTOSIS 23 1.78 0.03 
ION_HOMEOSTASIS 121 1.78 0.03 
TRANSCRIPTION_ACTIVATOR_ACTIVITY 167 1.77 0.03 
SPINDLE 38 1.77 0.03 
PROTEIN_TARGETING 106 1.77 0.03 
TRANSCRIPTION_FACTOR_TFIID_COMPLEX 12 1.77 0.03 
TRANSCRIPTION_COACTIVATOR_ACTIVITY 118 1.77 0.03 
PEROXISOME 47 1.77 0.03 
DAMAGED_DNA_BINDING 21 1.77 0.03 
INOSITOL_OR_PHOSPHATIDYLINOSITOL_PHOSPHATASE_ACTIVITY 11 1.77 0.03 
PROTEIN_TARGETING_TO_MEMBRANE 11 1.77 0.03 
NUCLEAR_ENVELOPE 67 1.77 0.03 
OXIDOREDUCTASE_ACTIVITY_GO_0016616 54 1.77 0.03 
NADH_DEHYDROGENASE_COMPLEX 12 1.76 0.03 
VESICLE_LOCALIZATION 9 1.76 0.03 
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RESPONSE_TO_OTHER_ORGANISM 73 1.76 0.03 
RRNA_METABOLIC_PROCESS 15 1.76 0.03 
METALLOEXOPEPTIDASE_ACTIVITY 12 1.75 0.03 
VACUOLAR_MEMBRANE 10 1.76 0.03 
CELLULAR_BIOSYNTHETIC_PROCESS 297 1.75 0.03 
N_TERMINAL_PROTEIN_AMINO_ACID_MODIFICATION 10 1.75 0.03 
HISTONE_ACETYLTRANSFERASE_ACTIVITY 15 1.75 0.03 
LIGASE_ACTIVITY 92 1.75 0.03 
CELLULAR_PROTEIN_COMPLEX_ASSEMBLY 31 1.75 0.03 
RIBONUCLEOPROTEIN_BINDING 11 1.75 0.03 
CYTOSKELETAL_PART 220 1.75 0.03 
T_CELL_ACTIVATION 41 1.75 0.03 
OLIGOSACCHARYL_TRANSFERASE_COMPLEX 9 1.74 0.03 
RESPONSE_TO_HYPOXIA 26 -1.96 0.03 
PROTEIN_DNA_COMPLEX_ASSEMBLY 44 1.74 0.03 
ENDODEOXYRIBONUCLEASE_ACTIVITY 11 1.74 0.03 
DNA_METABOLIC_PROCESS 245 1.74 0.03 
TYROSINE_PHOSPHORYLATION_OF_STAT_PROTEIN 12 1.74 0.03 
RECEPTOR_MEDIATED_ENDOCYTOSIS 33 1.74 0.03 
LIPASE_ACTIVITY 49 1.74 0.03 
SIGNAL_SEQUENCE_BINDING 15 1.74 0.03 
ACTIN_FILAMENT_BINDING 22 1.73 0.03 
COATED_VESICLE 44 1.73 0.03 
PROTEIN_AMINO_ACID_N_LINKED_GLYCOSYLATION 28 1.73 0.03 
GROWTH_FACTOR_BINDING 29 1.73 0.03 
PROTEIN_LOCALIZATION 203 1.73 0.03 
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NUCLEOLAR_PART 18 1.72 0.04 
DNA_RECOMBINATION 45 1.72 0.04 
MRNA_BINDING 21 1.72 0.04 
OXIDOREDUCTASE_ACTIVITY_ACTING_ON_CH_OH_GROUP_OF_DONORS 60 1.72 0.04 
MICROTUBULE_BASED_PROCESS 75 1.72 0.04 
NEUTRAL_AMINO_ACID_TRANSPORT 10 1.72 0.04 
COFACTOR_BIOSYNTHETIC_PROCESS 20 1.72 0.04 
MEMBRANE_ORGANIZATION_AND_BIOGENESIS 132 1.72 0.04 
CHROMOSOME_ORGANIZATION_AND_BIOGENESIS 116 1.72 0.04 
PML_BODY 13 1.71 0.04 
PIGMENT_BIOSYNTHETIC_PROCESS 15 1.71 0.04 
PROTEIN_AMINO_ACID_LIPIDATION 21 1.71 0.04 
NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION_AND_BIOGENESIS 26 1.71 0.04 
ONE_CARBON_COMPOUND_METABOLIC_PROCESS 25 1.71 0.04 
DEOXYRIBONUCLEASE_ACTIVITY 20 1.71 0.04 
U12_DEPENDENT_SPLICEOSOME 10 1.71 0.04 
MITOTIC_CELL_CYCLE_CHECKPOINT 20 1.71 0.04 
BASE_EXCISION_REPAIR 16 1.71 0.04 
ESTABLISHMENT_OF_PROTEIN_LOCALIZATION 182 1.71 0.04 
DNA_BINDING 566 1.70 0.04 
PHOSPHOLIPID_METABOLIC_PROCESS 70 1.70 0.04 
KINETOCHORE 22 1.70 0.04 
MICROTUBULE_ORGANIZING_CENTER 63 1.70 0.04 
ENZYME_REGULATOR_ACTIVITY 304 1.70 0.04 
CALCIUM_MEDIATED_SIGNALING 13 1.70 0.04 
REGULATION_OF_IMMUNE_EFFECTOR_PROCESS 13 1.70 0.04 
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BIOPOLYMER_CATABOLIC_PROCESS 114 1.69 0.04 
LEUKOCYTE_ACTIVATION 64 1.69 0.04 
IMMUNE_EFFECTOR_PROCESS 32 1.69 0.04 
INACTIVATION_OF_MAPK_ACTIVITY 12 1.69 0.04 
CYTOCHROME_C_OXIDASE_ACTIVITY 12 1.69 0.04 
RNA_POLYMERASE_COMPLEX 17 1.69 0.04 
TUBULIN_BINDING 43 1.69 0.04 
INSOLUBLE_FRACTION 15 1.68 0.04 
PHOSPHOLIPASE_C_ACTIVITY 15 1.68 0.04 
MONOSACCHARIDE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY 10 -1.91 0.04 
ACTIN_FILAMENT 16 1.68 0.04 
LYMPHOCYTE_ACTIVATION 57 1.68 0.04 
ELECTRON_TRANSPORT_GO_0006118 47 1.68 0.04 
ER_TO_GOLGI_VESICLE_MEDIATED_TRANSPORT 18 1.68 0.04 
CARBOXYLIC_ACID_METABOLIC_PROCESS 172 1.68 0.04 
SMALL_RIBOSOMAL_SUBUNIT 10 1.68 0.04 
DNA_HELICASE_ACTIVITY 24 1.68 0.05 
REGULATION_OF_GENE_EXPRESSION_EPIGENETIC 28 1.68 0.05 
OXIDOREDUCTASE_ACTIVITY_GO_0016705 36 -1.92 0.05 
SECRETION_BY_CELL 113 1.67 0.05 
VIRAL_INFECTIOUS_CYCLE 28 1.67 0.05 
NEGATIVE_REGULATION_OF_CELL_PROLIFERATION 148 -1.90 0.05 
SUGAR_BINDING 33 1.67 0.05 
COFACTOR_BINDING 22 1.67 0.05 
CHROMATIN_REMODELING_COMPLEX 15 1.67 0.05 
APOPTOTIC_MITOCHONDRIAL_CHANGES 11 1.66 0.05 
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APOPTOTIC_PROGRAM 57 1.66 0.05 
ENDOPEPTIDASE_ACTIVITY 109 1.66 0.05 
OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_CH_GROUP_OF_DONORS 23 1.66 0.05 
ENDONUCLEASE_ACTIVITY_GO_0016893 11 1.66 0.05 
RECEPTOR_SIGNALING_PROTEIN_ACTIVITY 81 1.66 0.05 
MANNOSYLTRANSFERASE_ACTIVITY 10 1.66 0.05 
GTPASE_REGULATOR_ACTIVITY 119 1.66 0.05 
 
 
Table 9.16 Significant gene sets identified by GSEA (FDR<0.05) in subjects with negative response on LTT to CBZE incubated with TT (size: 
number of genes in gene set, NES: normalised enrichment score, FDR: false discovery rate) 
Gene Set (Functional Category) SIZE NES FDR.q.val 
CHEMOKINE_RECEPTOR_BINDING 41 2.43 0.00 
CHEMOKINE_ACTIVITY 40 2.42 0.00 
G_PROTEIN_COUPLED_RECEPTOR_BINDING 51 2.41 0.00 
LOCOMOTORY_BEHAVIOR 89 2.18 0.00 
CYTOKINE_ACTIVITY 108 1.98 0.04 
CELLULAR_CATION_HOMEOSTASIS 99 1.96 0.04 
PATTERN_BINDING 44 1.94 0.05 
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Table 9.17 CBZ/CBZE-specific gene sets identified by GSEA (FDR<0.05) (size: number of genes in gene set, NES: normalised enrichment score, 
FDR: false discovery rate) 
Gene Set (Functional Category) SIZE NES FDR.q.val 
NUCLEASE_ACTIVITY 53 1.96 0.01 
NEGATIVE_REGULATION_OF_DNA_METABOLIC_PROCESS 17 1.93 0.01 
COLLAGEN_BINDING 14 1.89 0.04 
MITOCHONDRIAL_SMALL_RIBOSOMAL_SUBUNIT 10 1.89 0.01 
CENTROSOME 54 1.87 0.01 
CELLULAR_PROTEIN_COMPLEX_DISASSEMBLY 12 1.87 0.01 
CASPASE_ACTIVATION 26 1.87 0.04 
REGULATION_OF_CYCLIN_DEPENDENT_PROTEIN_KINASE_ACTIVITY 42 1.83 0.05 
POSITIVE_REGULATION_OF_T_CELL_ACTIVATION 20 1.82 0.02 
POSITIVE_REGULATION_OF_LYMPHOCYTE_ACTIVATION 23 1.80 0.02 
PROTEIN_N_TERMINUS_BINDING 38 1.80 0.02 
DNA_REPLICATION 97 1.79 0.02 
PYRIMIDINE_NUCLEOTIDE_METABOLIC_PROCESS 9 1.78 0.02 
MEDIATOR_COMPLEX 16 1.78 0.02 
NUCLEOBASENUCLEOSIDENUCLEOTIDE_KINASE_ACTIVITY 23 1.78 0.02 
PHOSPHOLIPID_BIOSYNTHETIC_PROCESS 37 1.77 0.02 
RNA_POLYMERASE_II_TRANSCRIPTION_MEDIATOR_ACTIVITY 11 1.77 0.02 
CHROMATIN_ASSEMBLY 14 1.77 0.02 
LIGASE_ACTIVITY_FORMING_CARBON_NITROGEN_BONDS 65 1.75 0.03 
LIPOPROTEIN_METABOLIC_PROCESS 30 1.75 0.03 
THIOLESTER_HYDROLASE_ACTIVITY 15 1.74 0.03 
POST_GOLGI_VESICLE_MEDIATED_TRANSPORT 14 1.73 0.03 
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CELLULAR_CATABOLIC_PROCESS 204 1.73 0.03 
CATABOLIC_PROCESS 217 1.73 0.03 
SPHINGOID_METABOLIC_PROCESS 11 1.73 0.03 
MICROTUBULE_ORGANIZING_CENTER_ORGANIZATION_AND_BIOGENESIS 15 1.73 0.03 
CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS 100 1.72 0.03 
ACID_AMINO_ACID_LIGASE_ACTIVITY 56 1.72 0.03 
CERAMIDE_METABOLIC_PROCESS 10 1.72 0.03 
GENERAL_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY 29 1.72 0.03 
ANTIOXIDANT_ACTIVITY 16 1.71 0.03 
CENTROSOME_ORGANIZATION_AND_BIOGENESIS 14 1.71 0.03 
LIPOPROTEIN_BIOSYNTHETIC_PROCESS 23 1.71 0.04 
AMINO_ACID_DERIVATIVE_METABOLIC_PROCESS 21 1.69 0.04 
MEMBRANE_LIPID_BIOSYNTHETIC_PROCESS 46 1.69 0.04 
PHOSPHOLIPID_BINDING 45 1.69 0.04 
COFACTOR_CATABOLIC_PROCESS 10 1.68 0.04 
DNA_DEPENDENT_ATPASE_ACTIVITY 21 1.68 0.04 
MEMBRANE_FUSION 28 1.68 0.04 
BIOGENIC_AMINE_METABOLIC_PROCESS 14 1.68 0.04 
RIBONUCLEASE_ACTIVITY 25 1.67 0.04 
SPLICEOSOME_ASSEMBLY 21 1.67 0.04 
MICROTUBULE_ORGANIZING_CENTER_PART 18 1.66 0.05 
GENE_SILENCING 10 1.65 0.05 
HEME_BIOSYNTHETIC_PROCESS 9 1.65 0.05 
CELLULAR_LIPID_CATABOLIC_PROCESS 32 1.65 0.05 
DNA_REPLICATION_INITIATION 14 1.65 0.05 
RNA_3END_PROCESSING 9 1.65 0.05 
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CYTOKINE_BIOSYNTHETIC_PROCESS 37 -1.88 0.05 
POSITIVE_REGULATION_OF_DNA_METABOLIC_PROCESS 11 -1.89 0.05 
OXIDOREDUCTASE_ACTIVITY_GO_0016706 10 -1.93 0.04 
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Table 9.18 MicroRNA expression profile in patients with positive response on LTT 
to CBZ incubated with CBZ 
ID Exp Log Ratio Exp p-value Location Type(s) 
hsa-mir-711 2.18 2.76E-02 Cytoplasm microRNA 
hsa-miR-4430 -1.005 3.16E-02 Other microRNA 
hsa-miR-637 -1.023 2.60E-02 Cytoplasm microRNA 
hsa-miR-7112-5p -1.111 1.87E-02 Cytoplasm mature microRNA 
hsa-miR-6840-3p -1.111 3.05E-02 Cytoplasm mature microRNA 
hsa-miR-27a-3p -1.171 1.33E-02 Cytoplasm mature microRNA 
hsa-miR-181c-5p -1.198 2.99E-02 Cytoplasm mature microRNA 
hsa-miR-6861-5p -1.257 2.17E-02 Cytoplasm mature microRNA 
hsa-miR-6847-5p -1.262 4.24E-03 Cytoplasm mature microRNA 
hsa-miR-3619-5p -1.311 1.63E-02 Cytoplasm mature microRNA 
hsa-miR-1224-5p -1.347 1.49E-02 Cytoplasm mature microRNA 
hsa-miR-30c-5p -1.369 3.68E-02 Cytoplasm mature microRNA 
hsa-miR-29c-3p -1.421 2.70E-02 Cytoplasm mature microRNA 
hsa-miR-30e-3p -1.53 4.04E-04 Cytoplasm mature microRNA 
hsa-miR-501-3p -1.585 3.20E-02 Cytoplasm mature microRNA 
hsa-miR-128-3p -1.685 2.82E-02 Cytoplasm mature microRNA 
hsa-miR-28-5p -1.724 3.52E-02 Cytoplasm mature microRNA 
hsa-miR-6723-5p -1.812 9.05E-03 Cytoplasm mature microRNA 
hsa-miR-6124 -1.83 1.71E-02 Other microRNA 
hsa-miR-574-3p -1.863 2.98E-02 Cytoplasm mature microRNA 
hsa-miR-92b-3p -1.92 3.19E-03 Cytoplasm mature microRNA 
hsa-miR-30e-5p -1.99 1.95E-02 Cytoplasm mature microRNA 
hsa-miR-27b-3p -2.023 5.29E-03 Cytoplasm mature microRNA 
hsa-miR-21-5p -2.139 1.75E-02 Cytoplasm mature microRNA 
hsa-let-7d-3p -2.221 2.49E-02 Cytoplasm mature microRNA 
hsa-miR-199a-3p -2.36 3.24E-02 Cytoplasm mature microRNA 
hsa-miR-199b-3p -2.36 3.24E-02 Cytoplasm mature microRNA 
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Table 9.19 MicroRNA expression profile in patients with positive response on LTT 
to CBZ and incubated with tetanus toxoid 
ID Exp Log Ratio Exp p-value Location Type(s) 
hsa-miR-6887-5p 1.065 3.05E-02 Cytoplasm mature microRNA 
hsa-miR-6840-3p -1.01 4.61E-02 Cytoplasm mature microRNA 
hsa-miR-4788 -1.072 5.63E-03 Cytoplasm microRNA 
hsa-miR-6847-5p -1.109 9.64E-03 Cytoplasm mature microRNA 
hsa-miR-30e-3p -1.166 3.40E-03 Cytoplasm mature microRNA 
hsa-miR-6768-5p -1.288 3.79E-02 Cytoplasm mature microRNA 
hsa-miR-29c-3p -1.301 4.02E-02 Cytoplasm mature microRNA 
hsa-miR-363-3p -1.431 4.17E-02 Cytoplasm mature microRNA 
hsa-miR-128-3p -1.478 4.99E-02 Cytoplasm mature microRNA 
hsa-miR-1224-5p -1.516 7.48E-03 Cytoplasm mature microRNA 
hsa-miR-6861-5p -1.568 6.16E-03 Cytoplasm mature microRNA 
hsa-miR-152-3p -1.61 3.53E-02 Cytoplasm mature microRNA 
hsa-miR-501-3p -1.763 1.91E-02 Cytoplasm mature microRNA 
 
 
Table 9.20 MicroRNA expression profile in subjects with negative response to LTT 
with CBZ and incubated with CBZ 
ID Exp Log Ratio Exp p-value Location Type(s) 
hsa-miR-455-3p 1.779 4.58E-02 Cytoplasm mature microRNA 
hsa-miR-8060 1.549 6.84E-03 Other microRNA 
hsa-miR-4717-3p 1.309 2.39E-03 Cytoplasm mature microRNA 
hsa-miR-6815-5p -1.040 1.30E-02 Cytoplasm mature microRNA 
hsa-miR-1292-5p -1.054 1.49E-02 Cytoplasm mature microRNA 
hsa-miR-7112-5p -1.085 2.10E-02 Cytoplasm mature microRNA 
hsa-miR-433-3p -1.087 1.96E-02 Cytoplasm mature microRNA 
hsa-miR-6829-5p -1.126 8.97E-03 Cytoplasm mature microRNA 
hsa-miR-212-3p -1.199 3.51E-03 Cytoplasm mature microRNA 
hsa-miR-30e-3p -1.232 2.30E-03 Cytoplasm mature microRNA 
hsa-miR-675-5p -1.367 1.07E-02 Cytoplasm mature microRNA 
hsa-miR-128-3p -1.524 4.40E-02 Cytoplasm mature microRNA 
hsa-miR-7111-5p -1.786 4.69E-02 Cytoplasm mature microRNA 
hsa-miR-642a-3p -1.800 6.31E-04 Cytoplasm mature microRNA 
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Table 9.21 MicroRNA expression profile in subjects with negative response to LTT 
with CBZ and incubated with tetanus toxoid 
ID Exp Log Ratio Exp p-value Location Type(s) 
hsa-miR-6732-5p 1.251 3.15E-03 Cytoplasm mature microRNA 
hsa-miR-4499 1.002 1.70E-02 Cytoplasm microRNA 
hsa-miR-6772-5p -1.069 7.21E-04 Cytoplasm mature microRNA 
hsa-mir-142 -1.078 2.76E-02 Cytoplasm microRNA 
hsa-miR-211-3p -1.089 1.81E-03 Other mature microRNA 
hsa-miR-675-5p -1.091 3.39E-02 Cytoplasm mature microRNA 
SNORD126 -1.096 2.99E-03 Other other 
hsa-miR-182-5p -1.181 7.06E-03 Cytoplasm mature microRNA 
hsa-miR-193b-5p -1.201 8.92E-03 Cytoplasm mature microRNA 
hsa-miR-30a-5p -1.244 5.74E-03 Cytoplasm mature microRNA 
hsa-miR-7112-5p -1.254 9.52E-03 Cytoplasm mature microRNA 
hsa-miR-6829-5p -1.3 3.54E-03 Cytoplasm mature microRNA 
hsa-miR-8073 -1.321 3.70E-02 Other microRNA 
hsa-miR-25-5p -1.338 4.33E-02 Cytoplasm mature microRNA 
hsa-miR-29c-3p -1.372 3.18E-02 Cytoplasm mature microRNA 
hsa-mir-484 -1.449 4.62E-02 Cytoplasm microRNA 
hsa-miR-2392 -1.465 4.06E-02 Cytoplasm microRNA 
hsa-miR-941 -1.473 2.73E-02 Cytoplasm mature microRNA 
hsa-miR-193b-3p -1.531 1.96E-02 Cytoplasm mature microRNA 
hsa-miR-6795-5p -1.554 1.17E-02 Cytoplasm mature microRNA 
hsa-miR-363-3p -1.559 2.85E-02 Cytoplasm mature microRNA 
hsa-miR-874-3p -1.628 2.60E-02 Cytoplasm mature microRNA 
hsa-miR-1307-3p -1.728 3.39E-02 Cytoplasm mature microRNA 
hsa-miR-484 -1.785 2.00E-02 Cytoplasm microRNA 
hsa-miR-130a-3p -1.795 2.49E-03 Cytoplasm mature microRNA 
hsa-miR-128-3p -1.808 2.00E-02 Cytoplasm mature microRNA 
hsa-miR-1231 -1.813 4.35E-02 Cytoplasm microRNA 
hsa-miR-1247-3p -1.886 1.43E-02 Other mature microRNA 
hsa-miR-30e-3p -2.206 1.11E-05 Cytoplasm mature microRNA 
hsa-miR-3651 -2.22 1.53E-02 Cytoplasm microRNA 
hsa-miR-1909-3p -2.28 2.91E-02 Cytoplasm mature microRNA 
hsa-miR-7977 -2.289 1.31E-02 Other microRNA 
hsa-miR-1260b -2.456 1.70E-03 Cytoplasm microRNA 
hsa-miR-7641 -3.421 1.42E-02 Cytoplasm mature microRNA 
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Table 9.22 MicroRNA expression profile in patients with positive response on LTT 
to CBZE incubated with CBZE 
ID Exp Log Ratio Exp p-value Location Type(s) 
hsa-miR-28-3p 1.665 4.77E-02 Cytoplasm mature microRNA 
hsa-miR-505-5p 1.638 2.17E-03 Cytoplasm mature microRNA 
hsa-miR-6782-5p 1.631 2.23E-02 Cytoplasm mature microRNA 
hsa-miR-200c-3p 1.482 4.91E-02 Cytoplasm mature microRNA 
hsa-miR-6124 1.480 4.62E-02 Other microRNA 
hsa-miR-3648 1.429 4.78E-02 Cytoplasm mature microRNA 
hsa-miR-486-3p 1.365 4.05E-02 Cytoplasm mature microRNA 
hsa-miR-6785-5p 1.292 9.74E-03 Cytoplasm mature microRNA 
hsa-miR-744-5p 1.008 3.59E-02 Cytoplasm mature microRNA 
hsa-miR-6780a-5p -1.012 1.10E-02 Cytoplasm mature microRNA 
hsa-miR-1224-3p -1.089 5.15E-03 Cytoplasm mature microRNA 
hsa-miR-4750-3p -1.579 1.98E-02 Cytoplasm mature microRNA 
hsa-miR-1281 -1.777 2.38E-02 Cytoplasm microRNA 
 
 
Table 9.23 MicroRNA expression profile in patients with positive response on LTT 
to CBZE and incubated with tetanus toxoid 
ID Exp Log Ratio Exp p-value Location Type(s) 
hsa-miR-150-3p 2.452 1.63E-03 Cytoplasm mature microRNA 
hsa-miR-4651 2.356 3.29E-02 Cytoplasm microRNA 
hsa-miR-1307-3p 2.280 7.82E-03 Cytoplasm mature microRNA 
hsa-miR-339-3p 1.967 2.36E-02 Cytoplasm mature microRNA 
hsa-miR-671-5p 1.903 4.09E-03 Cytoplasm mature microRNA 
hsa-miR-3188 1.796 4.39E-02 Cytoplasm microRNA 
hsa-miR-4734 1.756 4.86E-02 Cytoplasm microRNA 
hsa-miR-92a-1-5p 1.744 3.19E-02 Cytoplasm mature microRNA 
hsa-miR-28-3p 1.733 4.04E-02 Cytoplasm mature microRNA 
hsa-miR-6821-5p 1.691 1.79E-02 Cytoplasm mature microRNA 
hsa-miR-6724-5p 1.685 4.05E-02 Cytoplasm mature microRNA 
hsa-miR-4758-5p 1.670 2.22E-02 Cytoplasm mature microRNA 
hsa-miR-505-5p 1.661 1.96E-03 Cytoplasm mature microRNA 
hsa-miR-25-5p 1.650 1.60E-02 Cytoplasm mature microRNA 
hsa-miR-6789-5p 1.647 4.70E-02 Cytoplasm mature microRNA 
hsa-mir-3656 1.612 1.42E-02 Cytoplasm microRNA 
hsa-miR-642a-3p 1.572 1.86E-03 Cytoplasm mature microRNA 
hsa-miR-3648 1.571 3.18E-02 Cytoplasm mature microRNA 
hsa-miR-200c-3p 1.537 4.23E-02 Cytoplasm mature microRNA 
hsa-miR-6785-5p 1.442 4.90E-03 Cytoplasm mature microRNA 
hsa-miR-6850-5p 1.422 2.17E-02 Cytoplasm mature microRNA 
hsa-miR-378a-3p 1.419 3.76E-02 Cytoplasm mature microRNA 
hsa-miR-6723-5p 1.293 4.85E-02 Cytoplasm mature microRNA 
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hsa-miR-6510-5p 1.197 4.94E-02 Cytoplasm mature microRNA 
hsa-miR-3679-5p 1.193 2.78E-02 Cytoplasm mature microRNA 
hsa-miR-423-3p 1.169 4.56E-02 Cytoplasm mature microRNA 
hsa-miR-744-5p 1.141 1.99E-02 Cytoplasm mature microRNA 
hsa-miR-4667-5p 1.101 8.69E-04 Cytoplasm mature microRNA 
hsa-mir-4537 1.095 2.30E-02 Cytoplasm microRNA 
hsa-miR-181b-5p 1.020 2.56E-02 Cytoplasm mature microRNA 
hsa-miR-7855-5p -1.056 2.51E-02 Cytoplasm mature microRNA 
hsa-miR-6790-3p -1.082 7.47E-03 Cytoplasm mature microRNA 
hsa-mir-320e -1.100 4.59E-02 Cytoplasm microRNA 
hsa-let-7f-5p -1.241 3.98E-02 Cytoplasm mature microRNA 
hsa-mir-6776 -1.295 2.53E-02 Other microRNA 
hsa-miR-378h -1.472 2.83E-02 Cytoplasm microRNA 
hsa-miR-4706 -1.769 1.39E-02 Cytoplasm microRNA 
hsa-miR-4722-3p -2.080 2.34E-02 Cytoplasm mature microRNA 
hsa-miR-3613-5p -2.840 2.70E-02 Cytoplasm mature microRNA 
hsa-miR-4720-5p -3.936 2.14E-02 Cytoplasm mature microRNA 
 
 
Table 9.24 MicroRNA expression profile in subjects with negative response to LTT 
with CBZE and incubated with CBZE 
ID Exp Log Ratio Exp p-value Location Type(s) 
hsa-miR-548a-3p 3.052 2.44E-04 Cytoplasm mature microRNA 
hsa-miR-4433-3p 2.726 9.12E-04 Cytoplasm mature microRNA 
hsa-miR-6831-5p 2.707 5.84E-03 Cytoplasm mature microRNA 
hsa-miR-328-3p 2.508 4.75E-02 Cytoplasm mature microRNA 
hsa-miR-130b-3p 2.496 3.05E-02 Cytoplasm mature microRNA 
hsa-miR-197-5p 2.174 1.08E-02 Cytoplasm mature microRNA 
hsa-miR-4758-5p 2.064 4.12E-02 Cytoplasm mature microRNA 
hsa-miR-532-3p 1.921 1.55E-02 Cytoplasm mature microRNA 
hsa-miR-18a-5p 1.727 4.75E-02 Cytoplasm mature microRNA 
hsa-miR-378c 1.667 7.12E-03 Cytoplasm microRNA 
hsa-miR-130a-3p 1.563 3.98E-02 Cytoplasm mature microRNA 
hsa-miR-6133 1.476 3.87E-02 Other microRNA 
hsa-miR-6769a-5p 1.405 3.07E-02 Cytoplasm mature microRNA 
hsa-miR-6076 1.264 4.67E-02 Other microRNA 
hsa-miR-3154 1.207 2.95E-02 Cytoplasm microRNA 
hsa-mir-4454 1.039 4.69E-03 Cytoplasm microRNA 
hsa-miR-1976 1.013 1.09E-02 Cytoplasm microRNA 
hsa-mir-4648 -1.013 3.37E-02 Cytoplasm microRNA 
hsa-miR-4783-3p -1.033 2.01E-02 Cytoplasm mature microRNA 
hsa-miR-6753-3p -1.035 4.82E-02 Cytoplasm mature microRNA 
hsa-mir-4296 -1.047 7.87E-03 Cytoplasm microRNA 
hsa-miR-6784-3p -1.080 5.62E-03 Cytoplasm mature microRNA 
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hsa-miR-3194-5p -1.106 9.34E-03 Cytoplasm mature microRNA 
hsa-miR-6735-5p -1.114 2.82E-02 Cytoplasm mature microRNA 
hsa-miR-6890-5p -1.126 3.60E-02 Cytoplasm mature microRNA 
hsa-miR-6746-3p -1.148 2.09E-02 Cytoplasm mature microRNA 
hsa-mir-6887 -1.315 1.45E-02 Other microRNA 
hsa-miR-1273h-5p -1.491 1.38E-02 Cytoplasm mature microRNA 
hsa-miR-181c-5p -1.558 4.32E-02 Cytoplasm mature microRNA 
hsa-miR-4462 -2.244 1.64E-02 Cytoplasm microRNA 
hsa-miR-6782-5p -2.683 9.82E-03 Cytoplasm mature microRNA 
 
 
Table 9.25 MicroRNA expression profile in subjects with negative response to LTT 
with CBZE and incubated with tetanus toxoid 
ID Exp Log Ratio Exp p-value Location Type(s) 
hsa-let-7d-3p 3.622 1.17E-02 Cytoplasm mature microRNA 
hsa-miR-328-3p 2.786 3.01E-02 Cytoplasm mature microRNA 
hsa-miR-18a-5p 2.494 7.30E-03 Cytoplasm mature microRNA 
hsa-miR-8089 2.088 4.92E-02 Other microRNA 
hsa-miR-4668-5p 2.072 3.08E-02 Cytoplasm mature microRNA 
hsa-miR-130a-3p 1.767 2.26E-02 Cytoplasm mature microRNA 
hsa-miR-30e-3p 1.657 3.29E-03 Cytoplasm mature microRNA 
hsa-miR-422a 1.566 1.37E-02 Cytoplasm microRNA 
hsa-miR-6133 1.520 3.40E-02 Other microRNA 
hsa-miR-6769a-5p 1.466 2.51E-02 Cytoplasm mature microRNA 
hsa-miR-3147 1.395 4.68E-02 Cytoplasm microRNA 
hsa-miR-4265 1.342 1.93E-03 Cytoplasm microRNA 
hsa-miR-4667-3p 1.216 2.48E-03 Cytoplasm mature microRNA 
hsa-miR-4433-5p 1.158 1.01E-02 Other mature microRNA 
hsa-miR-4767 1.156 1.20E-02 Cytoplasm microRNA 
hsa-miR-380-3p 1.032 4.76E-03 Cytoplasm mature microRNA 
hsa-miR-4687-5p 1.000 1.38E-02 Cytoplasm mature microRNA 
hsa-mir-18b -1.006 9.45E-03 Cytoplasm microRNA 
hsa-mir-4474 -1.055 1.26E-03 Cytoplasm microRNA 
hsa-miR-127-3p -1.266 3.30E-02 Cytoplasm mature microRNA 
hsa-miR-6730-3p -1.296 1.81E-03 Cytoplasm mature microRNA 
hsa-miR-877-5p -1.356 2.34E-02 Cytoplasm mature microRNA 
hsa-miR-1273h-5p -1.410 1.86E-02 Cytoplasm mature microRNA 
hsa-miR-1268a -1.526 4.42E-02 Cytoplasm microRNA 
hsa-mir-4417 -1.584 1.48E-02 Cytoplasm microRNA 
hsa-miR-181c-5p -1.771 2.42E-02 Cytoplasm mature microRNA 
hsa-miR-3162-5p -1.984 1.36E-02 Cytoplasm mature microRNA 
hsa-miR-8071 -2.622 1.55E-02 Cytoplasm mature microRNA 
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Table 9.26 CBZ/CBZE-specific miRNA identified by comparison analyses in IPA 
miRNA Exp Log Ratio Exp P-Val Drug 
hsa-miR-548f-3p 3.052 2.44E-04 CBZE 
hsa-miR-711 2.184 2.76E-02 CBZ 
hsa-miR-197-5p 2.174 1.08E-02 CBZE 
hsa-miR-532-3p  1.921 1.55E-02 CBZE 
hsa-miR-455-3p  1.779 4.58E-02 CBZ 
hsa-MIR378C 1.667 7.12E-03 CBZE 
hsa-miR-6782-5p  1.631 2.23E-02 CBZE 
hsa-MIR8060 1.549 6.84E-03 CBZ 
hsa-miR-486-3p  1.365 4.05E-02 CBZE 
hsa-miR-4717-3p  1.309 2.39E-03 CBZ 
hsa-MIR6076 1.264 4.67E-02 CBZE 
hsa-miR-3154 1.207 2.95E-02 CBZE 
hsa-MIR4454 1.039 4.69E-03 CBZE 
hsa-miR-1976 1.013 1.09E-02 CBZE 
hsa-miR-4430 -1.005 3.16E-02 CBZ 
hsa-mir-4648 -1.013 3.37E-02 CBZE 
hsa-miR-637 -1.023 2.60E-02 CBZ 
hsa-miR-4783-3p  -1.033 2.01E-02 CBZE 
hsa-miR-5106  -1.035 4.82E-02 CBZE 
hsa-miR-6815-5p -1.040 1.30E-02 CBZ 
hsa-mir-4296 -1.047 7.87E-03 CBZE 
hsa-miR-1247-3p  -1.054 1.49E-02 CBZ 
hsa-miR-6862-3p  -1.08 5.62E-03 CBZE 
hsa-miR-433-3p -1.087 1.96E-02 CBZ 
hsa-miR-1224-3p  -1.089 5.15E-03 CBZE 
hsa-miR-3194-5p  -1.106 9.34E-03 CBZE 
hsa-miR-4436b-3p  -1.114 2.82E-02 CBZE 
hsa-miR-6890-5p -1.126 3.60E-02 CBZE 
hsa-miR-6746-3p  -1.148 2.09E-02 CBZE 
hsa-miR-132-3p  -1.199 3.51E-03 CBZ 
hsa-miR-214-3p  -1.311 1.63E-02 CBZ 
hsa-mir-6887 -1.315 1.45E-02 CBZE 
hsa-miR-345-5p  -1.579 1.98E-02 CBZE 
hsa-miR-708-5p  -1.724 3.52E-02 CBZ 
hsa-miR-1281 -1.777 2.38E-02 CBZE 
hsa-miR-4723-5p -1.786 4.69E-02 CBZ 
hsa-miR-6124 -1.830 1.71E-02 CBZ 
hsa-miR-574-3p  -1.863 2.98E-02 CBZ 
hsa-miR-27a-3p  -2.023 5.29E-03 CBZ 
hsa-miR-21-5p  -2.139 1.75E-02 CBZ 
hsa-miR-4462 -2.244 1.64E-02 CBZE 
hsa-miR-199a-3p  -2.360 3.24E-02 CBZ 
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Table 9.27 CBZ/CBZE-specific miRNA normalised expression levels (normalised 
according to HSA-miR-92a-3p) 
 
Hsa-miR- 
433-3p 
Hsa-miR- 
3194-5p   
Hsa-miR- 
455-3p   
Hsa-miR- 
4723-5p   
Hsa-miR- 
345-5p   
RLH001 CBZ 0 0.147 0.081 0.460 0.087 0.157 
RLH001 CBZ 25 0.095 0.126 0.584 0.094 0.156 
RLH001 CBZ TT 0.062 0.094 0.555 0.084 0.213 
RLH002 CBZ 0 0.160 0.130 0.448 0.073 0.242 
RLH002 CBZ 25 0.070 0.074 0.630 0.051 0.142 
RLH002 CBZ TT 0.132 0.152 0.630 0.078 0.195 
RLH007 CBZ 0 0.098 0.078 0.619 0.069 0.211 
RLH007 CBZ 25 0.040 0.078 0.591 0.096 0.118 
RLH007 CBZ TT 0.111 0.096 0.522 0.100 0.241 
RLH007 CBZE 0 0.074 0.113 0.533 0.067 0.175 
RLH007 CBZE 25 0.069 0.142 0.461 0.119 0.144 
RLH007 CBZE TT 0.073 0.085 0.533 0.109 0.212 
RLH010 CBZE 0 0.120 0.157 0.606 0.094 0.103 
RLH010 CBZE 25 0.076 0.061 0.720 0.114 0.143 
RLH010 CBZE TT 0.106 0.097 0.579 0.074 0.199 
WAL004 CBZ 0 0.186 0.117 0.458 0.083 0.363 
WAL004 CBZ 50 0.173 0.106 0.601 0.046 0.236 
WAL004 CBZ TT 0.105 0.117 0.584 0.103 0.348 
WAL004 CBZE 0 0.063 0.113 0.755 0.067 0.089 
WAL004 CBZE 25 0.097 0.086 0.585 0.075 0.331 
WAL004 CBZE TT 0.187 0.137 0.597 0.055 0.181 
 
